New None None O
functions None None O
of None None O
epidermal None None O
growth None None O
factor None None O
: None None O
stimulation None None O
of None None O
capillary None None O
endothelial None None O
cell None None O
migration None None O
and None None O
matrix None None O
dependent None None O
proliferation None None O
. None None O

The None None O
proliferative None None O
response None None O
of None None O
bovine None None O
retinal None None O
capillary None None O
endothelial None None O
cells None None O
to None None O
EGF None None O
is None None O
dependent None None O
upon None None O
attaching None None O
the None None O
cells None None O
to None None O
a None None O
matrix None None O
of None None O
fibronectin None None O
. None None O

Bovine None None O
capillary None None O
endothelial None None O
cells None None O
are None None O
also None None O
stimulated None None O
to None None O
actively None None O
migrate None None O
when None None O
exposed None None O
to None None O
EGF None None O
in None None O
vitro None None O
. None None O

These None None O
activities None None O
provide None None O
an None None O
explanation None None O
for None None O
the None None O
angiogenic None None O
properties None None O
of None None O
EGF None None O
in None None O
vivo None None O
. None None O

Capillary None None O
cell None None O
migration None None O
and None None O
proliferation None None O
are None None O
proposed None None O
as None None O
sensitive None None O
quantifiable None None O
bioassays None None O
to None None O
explore None None O
the None None O
functional None None O
domains None None O
of None None O
the None None O
EGF None None O
molecule None None O
. None None O

Studies None None O
on None None O
the None None O
inactivation None None O
of None None O
these None None O
properties None None O
of None None O
EGF None None O
by None None O
specific None None O
cleavage None None O
of None None O
the None None O
molecule None None O
with None None O
CNBr None None O
or None None O
proteases None None O
suggest None None O
that None None O
an None None O
intact None None O
loop None None O
composed None None O
in None None O
part None None O
by None None O
amino None None O
acid None None O
residues None None O
20 None None O
to None None O
31 None None O
is None None O
essential None None O
for None None O
at None None O
least None None O
some None None O
functions None None O
. None None O

Phase None None O
II None None O
trial None None O
with None None O
D None None O
- None None O
Trp None None O
- None None O
6 None None O
- None None O
LH None None O
- None None O
RH None None O
in None None O
prostatic None None O
carcinoma None None O
: None None O
comparison None None O
with None None O
other None None O
hormonal None None O
agents None None O
. None None O

Various None None O
approaches None None O
to None None O
hormonal None None O
treatment None None O
of None None O
prostate None None O
carcinoma None None O
are None None O
discussed None None O
. None None O

Eighty None None O
- None None O
one None None O
patients None None O
with None None O
prostatic None None O
carcinoma None None O
, None None O
eight None None O
with None None O
stage None None O
B None None O
, None None O
nine None None O
with None None O
stage None None O
C None None O
, None None O
and None None O
64 None None O
with None None O
stage None None O
D None None O
disease None None O
, None None O
were None None O
treated None None O
subcutaneously None None O
daily None None O
for None None O
3 None None O
months None None O
with None None O
the None None O
LH None None O
- None None O
RH None None O
agonist None None O
D None None O
- None None O
Trp None None O
- None None O
6 None None O
- None None O
LH None None O
- None None O
RH None None O
( None None O
Decapeptyl None None O
) None None O
in None None O
order None None O
to None None O
evaluate None None O
the None None O
incidence None None O
of None None O
remissions None None O
according None None O
to None None O
WHO None None O
recommendations None None O
for None None O
oncologic None None O
trials None None O
. None None O

The None None O
findings None None O
were None None O
compared None None O
to None None O
those None None O
obtained None None O
with None None O
other None None O
hormonal None None O
therapies None None O
of None None O
prostatic None None O
carcinoma None None O
according None None O
to None None O
the None None O
statistical None None O
method None None O
of None None O
" None None O
expected None None O
response None None O
rate None None O
" None None O
as None None O
adapted None None O
by None None O
Lee None None O
and None None O
Wesley None None O
for None None O
phase None None O
II None None O
trials None None O
. None None O

Treatment None None O
with None None O
D None None O
- None None O
Trp None None O
- None None O
6 None None O
- None None O
LH None None O
- None None O
RH None None O
greatly None None O
reduced None None O
serum None None O
LH None None O
and None None O
testosterone None None O
levels None None O
without None None O
raising None None O
serum None None O
prolactin None None O
. None None O

After None None O
1 None None O
- None None O
2 None None O
weeks None None O
of None None O
therapy None None O
, None None O
there None None O
was None None O
relief None None O
of None None O
subjective None None O
symptoms None None O
and None None O
a None None O
reversal None None O
of None None O
the None None O
signs None None O
of None None O
prostatism None None O
as None None O
well None None O
as None None O
a None None O
marked None None O
decrease None None O
in None None O
bone None None O
pain None None O
. None None O

At None None O
90 None None O
days None None O
52 None None O
patients None None O
had None None O
complete None None O
relief None None O
of None None O
prostatism None None O
and None None O
21 None None O
had None None O
only None None O
mild None None O
signs None None O
and None None O
symptoms None None O
. None None O

Seventy None None O
patients None None O
were None None O
experiencing None None O
no None None O
bone None None O
pain None None O
and None None O
an None None O
additional None None O
six None None O
had None None O
only None None O
mild None None O
pain None None O
. None None O

Prostatic None None O
size None None O
, None None O
evaluated None None O
by None None O
rectal None None O
examination None None O
and None None O
transabdominal None None O
ultrasonography None None O
, None None O
reverted None None O
to None None O
normal None None O
in None None O
26 None None O
. None None O
4 None None O
% None None O
of None None O
patients None None O
( None None O
complete None None O
remission None None O
) None None O
and None None O
was None None O
reduced None None O
by None None O
more None None O
than None None O
50 None None O
% None None O
in None None O
an None None O
additional None None O
17 None None O
. None None O
6 None None O
% None None O
( None None O
partial None None O
remission None None O
) None None O
, None None O
the None None O
overall None None O
rate None None O
of None None O
complete None None O
plus None None O
partial None None O
regression None None O
of None None O
prostatic None None O
enlargement None None O
being None None O
44 None None O
% None None O
. None None O

Scans None None O
showed None None O
a None None O
major None None O
improvement None None O
of None None O
bone None None O
lesions None None O
in None None O
14 None None O
. None None O
8 None None O
% None None O
of None None O
cases None None O
. None None O

This None None O
response None None O
increased None None O
to None None O
37 None None O
% None None O
after None None O
more None None O
than None None O
6 None None O
months None None O
of None None O
follow None None O
- None None O
up None None O
. None None O

Prostatic None None O
acid None None O
phosphatase None None O
levels None None O
were None None O
decreased None None O
by None None O
more None None O
than None None O
50 None None O
% None None O
in None None O
61 None None O
% None None O
of None None O
the None None O
patients None None O
, None None O
but None None O
this None None O
test None None O
appears None None O
to None None O
be None None O
a None None O
less None None O
valid None None O
marker None None O
than None None O
the None None O
lipid None None O
- None None O
associated None None O
sialic None None O
acid None None O
( None None O
LASA None None O
) None None O
. None None O

The None None O
increase None None O
in None None O
LASA None None O
before None None O
treatment None None O
and None None O
a None None O
reduction None None O
after None None O
treatment None None O
can None None O
frequently None None O
be None None O
correlated None None O
with None None O
the None None O
objective None None O
volume None None O
of None None O
the None None O
neoplasms None None O
. None None O

No None None O
flare None None O
- None None O
up None None O
of None None O
the None None O
disease None None O
was None None O
encountered None None O
, None None O
and None None O
there None None O
were None None O
no None None O
side None None O
effects None None O
except None None O
for None None O
impotence None None O
. None None O

Statistical None None O
analyses None None O
of None None O
results None None O
by None None O
the None None O
method None None O
of None None O
Lee None None O
and None None O
Wesley None None O
indicated None None O
that None None O
the None None O
incidence None None O
of None None O
complete None None O
and None None O
partial None None O
regression None None O
( None None O
CR None None O
and None None O
PR None None O
) None None O
observed None None O
with None None O
D None None O
- None None O
Trp None None O
- None None O
6 None None O
- None None O
LH None None O
- None None O
RH None None O
was None None O
not None None O
significantly None None O
different None None O
from None None O
that None None O
recorded None None O
in None None O
previous None None O
studies None None O
for None None O
another None None O
LH None None O
- None None O
RH None None O
analog None None O
, None None O
Buserelin None None O
. None None O

However None None O
, None None O
CR None None O
and None None O
PR None None O
obtained None None O
with None None O
D None None O
- None None O
Trp None None O
- None None O
6 None None O
- None None O
LH None None O
- None None O
RH None None O
( None None O
44 None None O
% None None O
) None None O
were None None O
significantly None None O
higher None None O
than None None O
with None None O
subcapsular None None O
orchiectomy None None O
( None None O
22 None None O
% None None O
) None None O
. None None O

Hormonal None None O
effects None None O
and None None O
some None None O
other None None O
actions None None O
of None None O
D None None O
- None None O
Trp None None O
- None None O
6 None None O
- None None O
LH None None O
- None None O
RH None None O
were None None O
compared None None O
and None None O
contrasted None None O
with None None O
those None None O
produced None None O
by None None O
castration None None O
, None None O
estrogens None None O
, None None O
antiandrogens None None O
, None None O
and None None O
progestogens None None O
. None None O
( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Conjunctival None None O
hypoxia None None O
in None None O
diabetes None None O
mellitus None None O
. None None O

A None None O
frequently None None O
cited None None O
theory None None O
for None None O
the None None O
pathogenesis None None O
of None None O
neovascularization None None O
in None None O
diabetic None None O
retinopathy None None O
is None None O
that None None O
retinal None None O
hypoxia None None O
and None None O
/ None None O
or None None O
ischemia None None O
release None None O
a None None O
factor None None O
which None None O
stimulates None None O
neovascularization None None O
. None None O

To None None O
the None None O
authors None None O
' None None O
knowledge None None O
, None None O
there None None O
is None None O
no None None O
direct None None O
in None None O
vivo None None O
evidence None None O
in None None O
the None None O
human None None O
proving None None O
this None None O
theory None None O
. None None O

One None None O
hundred None None O
and None None O
twenty None None O
- None None O
two None None O
diabetic None None O
subjects None None O
were None None O
studied None None O
to None None O
see None None O
whether None None O
worsening None None O
retinopathy None None O
was None None O
associated None None O
with None None O
changes None None O
in None None O
conjunctival None None O
oxygen None None O
tension None None O
( None None O
pO2 None None O
) None None O
. None None O

Diabetics None None O
without None None O
retinopathy None None O
had None None O
a None None O
conjunctival None None O
pO2 None None O
which None None O
was None None O
similar None None O
to None None O
an None None O
age None None O
- None None O
matched None None O
normal None None O
population None None O
. None None O

Diabetics None None O
with None None O
only None None O
background None None O
retinopathy None None O
had None None O
a None None O
significantly None None O
lower None None O
conjunctival None None O
pO2 None None O
than None None O
those None None O
without None None O
retinopathy None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Diabetics None None O
with None None O
proliferative None None O
retinopathy None None O
showed None None O
a None None O
conjunctival None None O
pO2 None None O
that None None O
was None None O
significantly None None O
lower None None O
than None None O
either None None O
of None None O
the None None O
first None None O
two None None O
groups None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
lowest None None O
value None None O
of None None O
all None None O
was None None O
found None None O
in None None O
patients None None O
with None None O
rubeosis None None O
iridis None None O
. None None O

Duration None None O
of None None O
diabetes None None O
alone None None O
did None None O
not None None O
correlate None None O
significantly None None O
to None None O
conjunctival None None O
pO2 None None O
. None None O

These None None O
findings None None O
support None None O
the None None O
hypoxic None None O
theory None None O
of None None O
diabetic None None O
neovascular None None O
retinopathy None None O
. None None O

Laser None None O
treatment None None O
of None None O
eccentric None None O
leaks None None O
in None None O
central None None O
serous None None O
chorioretinopathy None None O
resulting None None O
in None None O
disappearance None None O
of None None O
untreated None None O
juxtafoveal None None O
leaks None None O
. None None O

In None None O
central None None O
serous None None O
chorioretinopathy None None O
( None None O
CSCR None None O
) None None O
laser None None O
treatment None None O
of None None O
leaking None None O
points None None O
close None None O
to None None O
the None None O
macular None None O
center None None O
should None None O
be None None O
avoided None None O
because None None O
of None None O
the None None O
possibility None None O
of None None O
producing None None O
juxtafoveal None None O
scotoma None None O
and None None O
stimulating None None O
choroidal None None O
neovascularization None None O
. None None O

Nine None None O
eyes None None O
of None None O
nine None None O
consecutive None None O
patients None None O
with None None O
CSCR None None O
had None None O
two None None O
or None None O
more None None O
leaking None None O
points None None O
within None None O
a None None O
macular None None O
detachment None None O
, None None O
one None None O
of None None O
which None None O
was None None O
foveal None None O
or None None O
near None None O
to None None O
the None None O
fovea None None O
. None None O

Photocoagulation None None O
with None None O
green None None O
argon None None O
laser None None O
was None None O
performed None None O
in None None O
all None None O
eyes None None O
, None None O
treating None None O
all None None O
the None None O
leaking None None O
points None None O
except None None O
for None None O
the None None O
central None None O
one None None O
. None None O

Visual None None O
symptoms None None O
regressed None None O
after None None O
treatment None None O
, None None O
and None None O
the None None O
serous None None O
detachment None None O
was None None O
resolved None None O
10 None None O
days None None O
to None None O
4 None None O
weeks None None O
after None None O
photocoagulation None None O
in None None O
all None None O
cases None None O
. None None O

Fluorescein None None O
angiography None None O
showed None None O
no None None O
leakage None None O
at None None O
either None None O
the None None O
central None None O
leakage None None O
point None None O
or None None O
the None None O
leakage None None O
point None None O
that None None O
had None None O
been None None O
treated None None O
. None None O

These None None O
results None None O
led None None O
us None None O
to None None O
believe None None O
that None None O
the None None O
central None None O
or None None O
dependent None None O
leak None None O
in None None O
our None None O
cases None None O
was None None O
not None None O
sufficient None None O
to None None O
maintain None None O
the None None O
serous None None O
detachment None None O
by None None O
itself None None O
. None None O

An None None O
alternative None None O
hypothesis None None O
is None None O
that None None O
the None None O
untreated None None O
leak None None O
did None None O
not None None O
represent None None O
real None None O
fluid None None O
movement None None O
but None None O
only None None O
diffusion None None O
of None None O
fluorescein None None O
molecules None None O
, None None O
or None None O
a None None O
false None None O
leak None None O
. None None O

In None None O
cases None None O
of None None O
CSCR None None O
with None None O
multiple None None O
leaks None None O
within None None O
a None None O
single None None O
macular None None O
detachment None None O
, None None O
we None None O
believe None None O
that None None O
a None None O
foveal None None O
leak None None O
may None None O
be None None O
a None None O
dependent None None O
or None None O
false None None O
leak None None O
and None None O
that None None O
direct None None O
treatment None None O
is None None O
not None None O
necessary None None O
. None None O

Carcinogenesis None None O
and None None O
transcriptional None None O
regulation None None O
through None None O
Maf None None O
recognition None None O
elements None None O
. None None O

Many None None O
studies None None O
on None None O
carcinogenesis None None O
carried None None O
out None None O
early None None O
in None None O
the None None O
last None None O
century None None O
are None None O
united None None O
on None None O
the None None O
consensus None None O
that None None O
cancer None None O
is None None O
a None None O
genetic None None O
disease None None O
. None None O

Cancer None None O
cells None None O
typically None None O
display None None O
gene None None O
dysfunction None None O
and None None O
endogenous None None O
or None None O
exogenous None None O
insults None None O
resulting None None O
in None None O
gene None None O
dysfunction None None O
are None None O
often None None O
carcinogenic None None O
. None None O

Recent None None O
advances None None O
in None None O
stem None None O
cell None None O
biology None None O
added None None O
the None None O
new None None O
concept None None O
that None None O
cancer None None O
originates None None O
from None None O
a None None O
single None None O
cancer None None O
- None None O
initiating None None O
cell None None O
. None None O

To None None O
understand None None O
the None None O
molecular None None O
basis None None O
of None None O
carcinogenesis None None O
from None None O
the None None O
beginning None None O
to None None O
the None None O
full None None O
acquirement None None O
of None None O
malignancy None None O
, None None O
factors None None O
concerned None None O
with None None O
carcinogenesis None None O
were None None O
categorized None None O
into None None O
three None None O
groups None None O
: None None O
those None None O
guarding None None O
and None None O
stabilizing None None O
genomes None None O
, None None O
those None None O
regulating None None O
cell None None O
proliferation None None O
, None None O
and None None O
those None None O
conferring None None O
resistance None None O
to None None O
various None None O
micro None None O
- None None O
environmental None None O
stresses None None O
. None None O

One None None O
example None None O
of None None O
particular None None O
interest None None O
is None None O
the None None O
Keap1 None None O
- None None O
Nrf2 None None O
system None None O
since None None O
, None None O
according None None O
to None None O
recent None None O
studies None None O
, None None O
it None None O
has None None O
turned None None O
out None None O
to None None O
be None None O
ambivalent None None O
. None None O

Nrf2 None None O
heterodimerizes None None O
with None None O
small None None O
Maf None None O
protein None None O
to None None O
strongly None None O
activate None None O
transcription None None O
through None None O
the None None O
Maf None None O
recognition None None O
element None None O
( None None O
MARE None None O
) None None O
and None None O
Keap1 None None O
is None None O
an None None O
inhibitory None None O
regulator None None O
of None None O
Nrf2 None None O
. None None O

The None None O
genes None None O
regulated None None O
by None None O
Nrf2 None None O
are None None O
very None None O
important None None O
for None None O
cellular None None O
protection None None O
of None None O
the None None O
genome None None O
from None None O
xenobiotic None None O
and None None O
oxidative None None O
stresses None None O
and None None O
, None None O
consequently None None O
, None None O
for None None O
preventing None None O
carcinogenesis None None O
. None None O

This None None O
implies None None O
that None None O
enhancing None None O
Nrf2 None None O
activity None None O
is None None O
a None None O
promising None None O
method None None O
for None None O
thwarting None None O
cancer None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
the None None O
constitutive None None O
activation None None O
of None None O
Nrf2 None None O
due None None O
to None None O
mutations None None O
in None None O
the None None O
keap1 None None O
gene None None O
is None None O
characteristically None None O
observed None None O
in None None O
lung None None O
cancer None None O
cells None None O
, None None O
suggesting None None O
that None None O
induced None None O
expression None None O
of None None O
Nrf2 None None O
target None None O
genes None None O
favors None None O
the None None O
prevalence None None O
of None None O
cancer None None O
cells None None O
. None None O

Demographic None None O
consequences None None O
of None None O
terrestrial None None O
habitat None None O
loss None None O
for None None O
pool None None O
- None None O
breeding None None O
amphibians None None O
: None None O
predicting None None O
extinction None None O
risks None None O
associated None None O
with None None O
inadequate None None O
size None None O
of None None O
buffer None None O
zones None None O
. None None O

Much None None O
of None None O
the None None O
biodiversity None None O
associated None None O
with None None O
isolated None None O
wetlands None None O
requires None None O
aquatic None None O
and None None O
terrestrial None None O
habitat None None O
to None None O
maintain None None O
viable None None O
populations None None O
. None None O

Current None None O
federal None None O
wetland None None O
regulations None None O
in None None O
the None None O
United None None O
States None None O
do None None O
not None None O
protect None None O
isolated None None O
wetlands None None O
or None None O
extend None None O
protection None None O
to None None O
surrounding None None O
terrestrial None None O
habitat None None O
. None None O

Consequently None None O
, None None O
some None None O
land None None O
managers None None O
, None None O
city None None O
planners None None O
, None None O
and None None O
policy None None O
makers None None O
at None None O
the None None O
state None None O
and None None O
local None None O
levels None None O
are None None O
making None None O
an None None O
effort None None O
to None None O
protect None None O
these None None O
wetland None None O
and None None O
neighboring None None O
upland None None O
habitats None None O
. None None O

Balancing None None O
human None None O
land None None O
- None None O
use None None O
and None None O
habitat None None O
conservation None None O
is None None O
challenging None None O
, None None O
and None None O
well None None O
- None None O
informed None None O
land None None O
- None None O
use None None O
policy None None O
is None None O
hindered None None O
by None None O
a None None O
lack None None O
of None None O
knowledge None None O
of None None O
the None None O
specific None None O
risks None None O
of None None O
varying None None O
amounts None None O
of None None O
habitat None None O
loss None None O
. None None O

Using None None O
projections None None O
of None None O
wood None None O
frog None None O
( None None O
Rana None None O
sylvatica None None O
) None None O
and None None O
spotted None None O
salamander None None O
( None None O
Ambystoma None None O
maculatum None None O
) None None O
populations None None O
, None None O
we None None O
related None None O
the None None O
amount None None O
of None None O
high None None O
- None None O
quality None None O
terrestrial None None O
habitat None None O
surrounding None None O
isolated None None O
wetlands None None O
to None None O
the None None O
decline None None O
and None None O
risk None None O
of None None O
extinction None None O
of None None O
local None None O
amphibian None None O
populations None None O
. None None O

These None None O
simulations None None O
showed None None O
that None None O
current None None O
state None None O
- None None O
level None None O
wetland None None O
regulations None None O
protecting None None O
30 None None O
m None None O
or None None O
less None None O
of None None O
surrounding None None O
terrestrial None None O
habitat None None O
are None None O
inadequate None None O
to None None O
support None None O
viable None None O
populations None None O
of None None O
pool None None O
- None None O
breeding None None O
amphibians None None O
. None None O

We None None O
also None None O
found None None O
that None None O
species None None O
with None None O
different None None O
life None None O
- None None O
history None None O
strategies None None O
responded None None O
differently None None O
to None None O
the None None O
loss None None O
and None None O
degradation None None O
of None None O
terrestrial None None O
habitat None None O
. None None O

The None None O
wood None None O
frog None None O
, None None O
with None None O
a None None O
short None None O
life None None O
span None None O
and None None O
high None None O
fecundity None None O
, None None O
was None None O
most None None O
sensitive None None O
to None None O
habitat None None O
loss None None O
and None None O
isolation None None O
, None None O
whereas None None O
the None None O
longer None None O
- None None O
lived None None O
spotted None None O
salamander None None O
with None None O
lower None None O
fecundity None None O
was None None O
most None None O
sensitive None None O
to None None O
habitat None None O
degradation None None O
that None None O
lowered None None O
adult None None O
survival None None O
rates None None O
. None None O

Our None None O
model None None O
results None None O
demonstrate None None O
that None None O
a None None O
high None None O
probability None None O
of None None O
local None None O
amphibian None None O
population None None O
persistence None None O
requires None None O
sufficient None None O
terrestrial None None O
habitat None None O
, None None O
the None None O
maintenance None None O
of None None O
habitat None None O
quality None None O
, None None O
and None None O
connectivity None None O
among None None O
local None None O
populations None None O
. None None O

Our None None O
results None None O
emphasize None None O
the None None O
essential None None O
role None None O
of None None O
adequate None None O
terrestrial None None O
habitat None None O
to None None O
the None None O
maintenance None None O
of None None O
wetland None None O
biodiversity None None O
and None None O
ecosystem None None O
function None None O
and None None O
offer None None O
a None None O
means None None O
of None None O
quantifying None None O
the None None O
risks None None O
associated None None O
with None None O
terrestrial None None O
habitat None None O
loss None None O
and None None O
degradation None None O
. None None O

Effects None None O
of None None O
spironolactone None None O
on None None O
corneal None None O
allograft None None O
survival None None O
in None None O
the None None O
rat None None O
. None None O

PURPOSE None None O
: None None O
Spironolactone None None O
has None None O
recently None None O
been None None O
shown None None O
to None None O
have None None O
suppressive None None O
effects None None O
on None None O
several None None O
immunoactive None None O
and None None O
proinflammatory None None O
cytokines None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
effects None None O
of None None O
spironolactone None None O
on None None O
the None None O
prevention None None O
of None None O
corneal None None O
allograft None None O
rejection None None O
in None None O
a None None O
MHC None None O
class None None O
I None None O
/ None None O
II None None O
mismatch None None O
rat None None O
corneal None None O
transplant None None O
model None None O
. None None O

METHODS None None O
: None None O
Grafted None None O
animals None None O
for None None O
corneal None None O
survival None None O
analysis None None O
were None None O
assigned None None O
to None None O
receive None None O
either None None O
spironolactone None None O
suspension None None O
( None None O
orally None None O
, None None O
100 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
, None None O
n None None O
= None None O
7 None None O
) None None O
, None None O
phosphate None None O
- None None O
buffered None None O
saline None None O
( None None O
PBS None None O
, None None O
orally None None O
, None None O
same None None O
volume None None O
as None None O
spironolactone None None O
, None None O
n None None O
= None None O
9 None None O
) None None O
or None None O
remained None None O
untreated None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
. None None O

Additional None None O
grafted None None O
rats None None O
treated None None O
with None None O
spironolactone None None O
( None None O
n None None O
= None None O
6 None None O
) None None O
or None None O
PBS None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
were None None O
sacrificed None None O
on None None O
day None None O
12 None None O
for None None O
quantitative None None O
RT None None O
- None None O
PCR None None O
analysis None None O
for None None O
mechanistic None None O
studies None None O
. None None O

RESULTS None None O
: None None O
Mean None None O
( None None O
+ None None O
/ None None O
- None None O
SEM None None O
) None None O
graft None None O
survival None None O
was None None O
significantly None None O
prolonged None None O
in None None O
animals None None O
receiving None None O
spironolactone None None O
( None None O
14 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
0 None None O
days None None O
) None None O
compared None None O
with None None O
both None None O
PBS None None O
- None None O
treated None None O
( None None O
12 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
2 None None O
days None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
007 None None O
) None None O
and None None O
untreated None None O
controls None None O
( None None O
13 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
0 None None O
days None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

We None None O
found None None O
a None None O
decrease None None O
in None None O
corneal None None O
neovascularization None None O
in None None O
spironolactone None None O
- None None O
treated None None O
rats None None O
compared None None O
with None None O
the None None O
PBS None None O
- None None O
treated None None O
group None None O
, None None O
although None None O
the None None O
difference None None O
was None None O
not None None O
statistically None None O
significant None None O
. None None O

Spironolactone None None O
affected None None O
both None None O
systemic None None O
( None None O
down None None O
- None None O
regulation None None O
of None None O
CD25 None None O
+ None None O
cells None None O
in None None O
spleen None None O
) None None O
and None None O
local None None O
immune None None O
response None None O
( None None O
up None None O
- None None O
regulation None None O
of None None O
IL None None O
- None None O
10 None None O
in None None O
cornea None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
We None None O
present None None O
initial None None O
results None None O
demonstrating None None O
anti None None O
- None None O
inflammatory None None O
effects None None O
of None None O
spironolactone None None O
. None None O

Endogenous None None O
thyroid None None O
hormones None None O
modulate None None O
pituitary None None O
somatotroph None None O
differentiation None None O
during None None O
chicken None None O
embryonic None None O
development None None O
. None None O

Growth None None O
hormone None None O
cell None None O
differentiation None None O
normally None None O
occurs None None O
between None None O
day None None O
14 None None O
and None None O
day None None O
16 None None O
of None None O
chicken None None O
embryonic None None O
development None None O
. None None O

We None None O
reported None None O
previously None None O
that None None O
corticosterone None None O
( None None O
CORT None None O
) None None O
could None None O
induce None None O
somatotroph None None O
differentiation None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
and None None O
that None None O
thyroid None None O
hormones None None O
could None None O
act None None O
in None None O
combination None None O
with None None O
CORT None None O
to None None O
further None None O
augment None None O
the None None O
abundance None None O
of None None O
somatotrophs None None O
in None None O
vitro None None O
. None None O

The None None O
objective None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
test None None O
our None None O
hypothesis None None O
that None None O
endogenous None None O
thyroid None None O
hormones None None O
regulate None None O
the None None O
abundance None None O
of None None O
somatotrophs None None O
during None None O
chicken None None O
embryonic None None O
development None None O
. None None O

Plasma None None O
samples None None O
were None None O
collected None None O
on None None O
embryonic None None O
day None None O
( None None O
e None None O
) None None O
9 None None O
- None None O
14 None None O
. None None O

We None None O
found None None O
that None None O
plasma None None O
CORT None None O
and None None O
thyroid None None O
hormone None None O
levels None None O
increased None None O
progressively None None O
in None None O
mid None None O
- None None O
embryogenesis None None O
to None None O
e None None O
13 None None O
or None None O
e None None O
14 None None O
, None None O
immediately None None O
before None None O
normal None None O
somatotroph None None O
differentiation None None O
. None None O

Administration None None O
of None None O
thyroxine None None O
( None None O
T4 None None O
) None None O
and None None O
triiodothyronine None None O
( None None O
T3 None None O
) None None O
into None None O
the None None O
albumen None None O
of None None O
fertile None None O
eggs None None O
on None None O
e None None O
11 None None O
increased None None O
somatotroph None None O
proportions None None O
prematurely None None O
on None None O
e None None O
13 None None O
in None None O
the None None O
developing None None O
chick None None O
embryos None None O
in None None O
vivo None None O
. None None O

Furthermore None None O
, None None O
administration None None O
of None None O
methimazole None None O
, None None O
the None None O
thyroid None None O
hormone None None O
synthesis None None O
inhibitor None None O
, None None O
on None None O
e None None O
9 None None O
inhibited None None O
somatotroph None None O
differentiation None None O
in None None O
vivo None None O
, None None O
as None None O
assessed None None O
on None None O
e None None O
14 None None O
; None None O
this None None O
suppression None None O
was None None O
completely None None O
reversed None None O
by None None O
T3 None None O
replacement None None O
on None None O
e None None O
11 None None O
. None None O

Since None None O
we None None O
reported None None O
that None None O
T3 None None O
alone None None O
was None None O
ineffective None None O
in None None O
vitro None None O
, None None O
we None None O
interpret None None O
these None None O
findings None None O
to None None O
indicate None None O
that None None O
the None None O
effects None None O
of None None O
treatments None None O
in None None O
vivo None None O
were None None O
due None None O
to None None O
interactions None None O
with None None O
endogenous None None O
glucocorticoids None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
treatment None None O
with None None O
exogenous None None O
thyroid None None O
hormones None None O
can None None O
modulate None None O
somatotroph None None O
abundance None None O
and None None O
that None None O
endogenous None None O
thyroid None None O
hormone None None O
synthesis None None O
likely None None O
contributes None None O
to None None O
normal None None O
somatotroph None None O
differentiation None None O
. None None O

Changes None None O
in None None O
plasminogen None None O
activator None None O
inhibitor None None O
- None None O
1 None None O
levels None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
. None None O

Increased None None O
urokinase None None O
plasminogen None None O
activator None None O
( None None O
uPA None None O
) None None O
levels None None O
are None None O
increased None None O
in None None O
a None None O
number None None O
of None None O
malignancies None None O
and None None O
have None None O
been None None O
correlated None None O
with None None O
decreased None None O
disease None None O
- None None O
free None None O
interval None None O
and None None O
decreased None None O
overall None None O
survival None None O
. None None O

We None None O
have None None O
, None None O
therefore None None O
, None None O
examined None None O
components None None O
of None None O
this None None O
plasminogen None None O
activating None None O
system None None O
in None None O
patients None None O
with None None O
Non None None O
- None None O
Small None None O
Cell None None O
Lung None None O
Cancer None None O
( None None O
NSCLC None None O
) None None O
. None None O

Levels None None O
of None None O
uPA None None O
, None None O
urokinase None None O
- None None O
plasminogen None None O
activator None None O
receptor None None O
( None None O
uPAR None None O
) None None O
and None None O
plasminogen None None O
activator None None O
inhibitor None None O
- None None O
1 None None O
( None None O
PAI None None O
- None None O
1 None None O
) None None O
were None None O
measured None None O
semiquantitatively None None O
in None None O
paraffin None None O
sections None None O
of None None O
tumours None None O
from None None O
147 None None O
patients None None O
with None None O
NSCLC None None O
. None None O

Immunohistochemically None None O
stained None None O
sections None None O
of None None O
tumour None None O
were None None O
allocated None None O
a None None O
score None None O
for None None O
stain None None O
intensity None None O
and None None O
results None None O
correlated None None O
to None None O
: None None O
survival None None O
; None None O
tumour None None O
stage None None O
( None None O
T None None O
) None None O
; None None O
nodal None None O
stage None None O
( None None O
N None None O
) None None O
; None None O
stage None None O
grouping None None O
( None None O
I None None O
to None None O
IIIb None None O
) None None O
, None None O
survival None None O
status None None O
and None None O
sex None None O
. None None O

Increased None None O
levels None None O
of None None O
PAI None None O
- None None O
1 None None O
were None None O
associated None None O
with None None O
a None None O
decreased None None O
survival None None O
in None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
SCC None None O
) None None O
X2 None None O
= None None O
5 None None O
. None None O
72 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
017 None None O
( None None O
n None None O
= None None O
74 None None O
) None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
positive None None O
relationship None None O
between None None O
PAI None None O
- None None O
1 None None O
levels None None O
and None None O
N None None O
- None None O
stage None None O
( None None O
p None None O
= None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
presence None None O
of None None O
nodal None None O
metastases None None O
( None None O
p None None O
= None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
stage None None O
grouping None None O
( None None O
p None None O
= None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
and None None O
extent None None O
of None None O
disease None None O
( None None O
p None None O
= None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
in None None O
the None None O
total None None O
group None None O
and None None O
the None None O
SCC None None O
subgroup None None O
, None None O
but None None O
not None None O
adenocarcinoma None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
positive None None O
relationship None None O
between None None O
PAI None None O
- None None O
1 None None O
levels None None O
and None None O
T None None O
- None None O
stage None None O
( None None O
p None None O
= None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
in None None O
the None None O
total None None O
group None None O
, None None O
and None None O
survival None None O
status None None O
( None None O
p None None O
= None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
in None None O
the None None O
SCC None None O
subgroup None None O
alone None None O
. None None O

uPA None None O
and None None O
uPAR None None O
levels None None O
were None None O
not None None O
significantly None None O
associated None None O
with None None O
tumour None None O
staging None None O
or None None O
survival None None O
. None None O

We None None O
conclude None None O
that None None O
increased None None O
PAI None None O
- None None O
1 None None O
antigen None None O
levels None None O
may None None O
be None None O
associated None None O
with None None O
a None None O
decreased None None O
survival None None O
in None None O
patients None None O
with None None O
SCC None None O
. None None O

Angiotensin None None O
II None None O
induces None None O
soluble None None O
fms None None O
- None None O
Like None None O
tyrosine None None O
kinase None None O
- None None O
1 None None O
release None None O
via None None O
calcineurin None None O
signaling None None O
pathway None None O
in None None O
pregnancy None None O
. None None O

Maternal None None O
endothelial None None O
dysfunction None None O
in None None O
preeclampsia None None O
is None None O
associated None None O
with None None O
increased None None O
soluble None None O
fms None None O
- None None O
like None None O
tyrosine None None O
kinase None None O
- None None O
1 None None O
( None None O
sFlt None None O
- None None O
1 None None O
) None None O
, None None O
a None None O
circulating None None O
antagonist None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
and None None O
placental None None O
growth None None O
factor None None O
. None None O

Angiotensin None None O
II None None O
( None None O
Ang None None O
II None None O
) None None O
is None None O
a None None O
potent None None O
vasoconstrictor None None O
that None None O
increases None None O
concomitant None None O
with None None O
sFlt None None O
- None None O
1 None None O
during None None O
pregnancy None None O
. None None O

Therefore None None O
, None None O
we None None O
speculated None None O
that None None O
Ang None None O
II None None O
may None None O
promote None None O
the None None O
expression None None O
of None None O
sFlt None None O
- None None O
1 None None O
in None None O
pregnancy None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
infusion None None O
of None None O
Ang None None O
II None None O
significantly None None O
increases None None O
circulating None None O
levels None None O
of None None O
sFlt None None O
- None None O
1 None None O
in None None O
pregnant None None O
mice None None O
, None None O
thereby None None O
demonstrating None None O
that None None O
Ang None None O
II None None O
is None None O
a None None O
regulator None None O
of None None O
sFlt None None O
- None None O
1 None None O
secretion None None O
in None None O
vivo None None O
. None None O

Furthermore None None O
, None None O
Ang None None O
II None None O
stimulated None None O
sFlt None None O
- None None O
1 None None O
production None None O
in None None O
a None None O
dose None None O
- None None O
and None None O
time None None O
- None None O
dependent None None O
manner None None O
from None None O
human None None O
villous None None O
explants None None O
and None None O
cultured None None O
trophoblasts None None O
but None None O
not None None O
from None None O
endothelial None None O
cells None None O
, None None O
suggesting None None O
that None None O
trophoblasts None None O
are None None O
the None None O
primary None None O
source None None O
of None None O
sFlt None None O
- None None O
1 None None O
during None None O
pregnancy None None O
. None None O

As None None O
expected None None O
, None None O
Ang None None O
II None None O
- None None O
induced None None O
sFlt None None O
- None None O
1 None None O
secretion None None O
resulted None None O
in None None O
the None None O
inhibition None None O
of None None O
endothelial None None O
cell None None O
migration None None O
and None None O
in None None O
vitro None None O
tube None None O
formation None None O
. None None O

In None None O
vitro None None O
and None None O
in None None O
vivo None None O
studies None None O
with None None O
losartan None None O
, None None O
small None None O
interfering None None O
RNA None None O
specific None None O
for None None O
calcineurin None None O
and None None O
FK506 None None O
demonstrated None None O
that None None O
Ang None None O
II None None O
- None None O
mediated None None O
sFlt None None O
- None None O
1 None None O
release None None O
was None None O
via None None O
Ang None None O
II None None O
type None None O
1 None None O
receptor None None O
activation None None O
and None None O
calcineurin None None O
signaling None None O
, None None O
respectively None None O
. None None O

These None None O
findings None None O
reveal None None O
a None None O
previously None None O
unrecognized None None O
regulatory None None O
role None None O
for None None O
Ang None None O
II None None O
on None None O
sFlt None None O
- None None O
1 None None O
expression None None O
in None None O
murine None None O
and None None O
human None None O
pregnancy None None O
and None None O
suggest None None O
that None None O
elevated None None O
sFlt None None O
- None None O
1 None None O
levels None None O
in None None O
preeclampsia None None O
may None None O
be None None O
caused None None O
by None None O
a None None O
dysregulation None None O
of None None O
the None None O
local None None O
renin None None O
/ None None O
angiotensin None None O
system None None O
. None None O

Prognostic None None O
significance None None O
of None None O
TRAIL None None O
signaling None None O
molecules None None O
in None None O
stage None None O
II None None O
and None None O
III None None O
colorectal None None O
cancer None None O
. None None O

PURPOSE None None O
: None None O

We None None O
previously None None O
found None None O
that None None O
cellular None None O
FLICE None None O
- None None O
inhibitory None None O
protein None None O
( None None O
c None None O
- None None O
FLIP None None O
) None None O
, None None O
caspase None None O
8 None None O
, None None O
and None None O
tumor None None O
necrosis None None O
factor None None O
- None None O
related None None O
apoptosis None None O
- None None O
inducing None None O
ligand None None O
( None None O
TRAIL None None O
) None None O
receptor None None O
2 None None O
( None None O
DR5 None None O
) None None O
are None None O
major None None O
regulators None None O
of None None O
cell None None O
viability None None O
and None None O
chemotherapy None None O
- None None O
induced None None O
apoptosis None None O
in None None O
colorectal None None O
cancer None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
determined None None O
the None None O
prognostic None None O
significance None None O
of None None O
c None None O
- None None O
FLIP None None O
, None None O
caspase None None O
8 None None O
, None None O
TRAIL None None O
and None None O
DR5 None None O
expression None None O
in None None O
tissues None None O
from None None O
patients None None O
with None None O
stage None None O
II None None O
and None None O
III None None O
colorectal None None O
cancer None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O

Tissue None None O
microarrays None None O
were None None O
constructed None None O
from None None O
matched None None O
normal None None O
and None None O
tumor None None O
tissue None None O
derived None None O
from None None O
patients None None O
( None None O
n None None O
= None None O
253 None None O
) None None O
enrolled None None O
in None None O
a None None O
phase None None O
III None None O
trial None None O
of None None O
adjuvant None None O
5 None None O
- None None O
fluorouracil None None O
- None None O
based None None O
chemotherapy None None O
versus None None O
postoperative None None O
observation None None O
alone None None O
. None None O

TRAIL None None O
, None None O
DR5 None None O
, None None O
caspase None None O
8 None None O
, None None O
and None None O
c None None O
- None None O
FLIP None None O
expression None None O
levels None None O
were None None O
determined None None O
by None None O
immunohistochemistry None None O
. None None O

RESULTS None None O
: None None O

Colorectal None None O
tumors None None O
displayed None None O
significantly None None O
higher None None O
expression None None O
levels None None O
of None None O
c None None O
- None None O
FLIP None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
caspase None None O
8 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
, None None O
and None None O
DR5 None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
but None None O
lower None None O
levels None None O
of None None O
TRAIL None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
compared None None O
with None None O
matched None None O
normal None None O
tissue None None O
. None None O

In None None O
univariate None None O
analysis None None O
, None None O
higher None None O
TRAIL None None O
expression None None O
in None None O
the None None O
tumor None None O
was None None O
associated None None O
with None None O
worse None None O
overall None None O
survival None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
026 None None O
) None None O
, None None O
with None None O
a None None O
trend None None O
to None None O
decreased None None O
relapse None None O
- None None O
free None None O
survival None None O
( None None O
RFS None None O
; None None O
P None None O
= None None O
0 None None O
. None None O
06 None None O
) None None O
, None None O
and None None O
higher None None O
tumor None None O
c None None O
- None None O
FLIP None None O
expression None None O
was None None O
associated None None O
with None None O
a None None O
significantly None None O
decreased None None O
RFS None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
015 None None O
) None None O
. None None O

Using None None O
multivariate None None O
predictive None None O
modeling None None O
for None None O
RFS None None O
in None None O
all None None O
patients None None O
and None None O
including None None O
all None None O
biomarkers None None O
, None None O
age None None O
, None None O
treatment None None O
, None None O
and None None O
stage None None O
, None None O
we None None O
found None None O
that None None O
the None None O
model None None O
was None None O
significant None None O
when None None O
the None None O
mean None None O
tumor None None O
c None None O
- None None O
FLIP None None O
expression None None O
score None None O
and None None O
disease None None O
stage None None O
were None None O
included None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

As None None O
regards None None O
overall None None O
survival None None O
, None None O
the None None O
overall None None O
model None None O
was None None O
predictive None None O
when None None O
both None None O
TRAIL None None O
expression None None O
and None None O
disease None None O
stage None None O
were None None O
included None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

High None None O
c None None O
- None None O
FLIP None None O
and None None O
TRAIL None None O
expression None None O
may None None O
be None None O
independent None None O
adverse None None O
prognostic None None O
markers None None O
in None None O
stage None None O
II None None O
and None None O
III None None O
colorectal None None O
cancer None None O
and None None O
might None None O
identify None None O
patients None None O
most None None O
at None None O
risk None None O
of None None O
relapse None None O
. None None O

Diallyl None None O
trisulfide None None O
( None None O
DATS None None O
) None None O
inhibits None None O
mouse None None O
colon None None O
tumor None None O
in None None O
mouse None None O
CT None None I-Cell-line-name
- None None I-Cell-line-name
26 None None I-Cell-line-name
cells None None O
allograft None None O
model None None O
in None None O
vivo None None O
. None None O

Our None None O
earlier None None O
studies None None O
showed None None O
that None None O
DATS None None O
induced None None O
apoptosis None None O
in None None O
human None None O
colon None None O
cancer None None O
HT29 None None I-Cell-line-name
and None None O
colo None None I-Cell-line-name
205 None None I-Cell-line-name
cell None None O
lines None None O
in None None O
vitro None None O
. None None O

However None None O
, None None O
there None None O
is None None O
no None None O
report None None O
to None None O
show None None O
that None None O
DATS None None O
induced None None O
apoptosis None None O
in None None O
vitro None None O
and None None O
inhibited None None O
CT26 None None I-Cell-line-name
cancer None None O
cells None None O
in None None O
vivo None None O
on None None O
a None None O
murine None None O
allograft None None O
animal None None O
model None None O
. None None O

In None None O
vitro None None O
studies None None O
, None None O
the None None O
results None None O
indicated None None O
that None None O
DATS None None O
induced None None O
morphological None None O
changes None None O
and None None O
induction None None O
of None None O
apoptosis None None O
in None None O
CT26 None None I-Cell-line-name
cells None None O
. None None O

In None None O
vivo None None O
studies None None O
, None None O
CT26 None None I-Cell-line-name
cancer None None O
cells None None O
were None None O
implanted None None O
into None None O
BALB None None O
/ None None O
c None None O
mice None None O
and None None O
groups None None O
of None None O
mice None None O
were None None O
treated None None O
with None None O
vehicle None None O
, None None O
DATS None None O
( None None O
10 None None O
and None None O
50 None None O
mg None None O
/ None None O
kg None None O
of None None O
body None None O
weight None None O
) None None O
. None None O

DATS None None O
were None None O
injected None None O
once None None O
per None None O
four None None O
days None None O
intraperitoneally None None O
( None None O
i None None O
. None None O
p None None O
. None None O
) None None O
, None None O
with None None O
treatment None None O
starting None None O
4 None None O
weeks None None O
prior None None O
to None None O
cells None None O
inoculation None None O
. None None O

Treatment None None O
with None None O
vehicle None None O
or None None O
with None None O
10 None None O
and None None O
50 None None O
mg None None O
/ None None O
kg None None O
of None None O
DATS None None O
resulted None None O
in None None O
a None None O
reduction None None O
in None None O
tumor None None O
volume None None O
and None None O
weight None None O
. None None O

Tumor None None O
volume None None O
and None None O
total None None O
hemoglobin None None O
in None None O
allograft None None O
mice None None O
treated None None O
with None None O
50 None None O
mg None None O
/ None None O
kg None None O
DATS None None O
were None None O
significantly None None O
smaller None None O
than None None O
that None None O
in None None O
the None None O
control None None O
group None None O
. None None O

These None None O
findings None None O
indicated None None O
that None None O
DATS None None O
inhibits None None O
tumor None None O
growth None None O
in None None O
an None None O
allograft None None O
animal None None O
model None None O
. None None O

Thus None None O
, None None O
DATS None None O
may None None O
represent None None O
a None None O
colon None None O
cancer None None O
preventive None None O
agent None None O
and None None O
can None None O
be None None O
used None None O
in None None O
the None None O
future None None O
. None None O

[ None None O
Epidemiology None None O
of None None O
respiratory None None O
allergy None None O
in None None O
children None None O
] None None O
. None None O

Epidemiology None None O
of None None O
paediatric None None O
respiratory None None O
allergic None None O
disorders None None O
allows None None O
the None None O
approach None None O
to None None O
causal None None O
and None None O
preventive None None O
risk None None O
factors None None O
by None None O
studying None None O
groups None None O
or None None O
sub None None O
groups None None O
of None None O
children None None O
in None None O
different None None O
locations None None O
and None None O
under None None O
different None None O
conditions None None O
. None None O

This None None O
is None None O
, None None O
however None None O
, None None O
complicated None None O
by None None O
the None None O
lack None None O
of None None O
consensus None None O
on None None O
disease None None O
definitions None None O
, None None O
which None None O
renders None None O
comparisons None None O
between None None O
studies None None O
difficult None None O
. None None O

Atopy None None O
is None None O
usually None None O
defined None None O
by None None O
the None None O
presence None None O
of None None O
positive None None O
skin None None O
tests None None O
( None None O
wheal None None O
size None None O
of None None O
at None None O
least None None O
a None None O
mean None None O
diameter None None O
> None None O
or None None O
= None None O
3 None None O
mm None None O
) None None O
, None None O
by None None O
the None None O
presence None None O
of None None O
specific None None O
IgE None None O
, None None O
or None None O
by None None O
the None None O
presence None None O
of None None O
increased None None O
total None None O
IgE None None O
( None None O
> None None O
or None None O
= None None O
100 None None O
UI None None O
/ None None O
mL None None O
) None None O
. None None O

Infantile None None O
asthma None None O
is None None O
not None None O
well None None O
defined None None O
, None None O
complicated None None O
by None None O
the None None O
high None None O
prevalence None None O
of None None O
bronchiolitis None None O
; None None O
one None None O
thus None None O
questions None None O
between None None O
wheezing None None O
or None None O
wheezy None None O
bronchitis None None O
. None None O

Prevalence None None O
is None None O
high None None O
: None None O
among None None O
early None None O
wheezers None None O
, None None O
two None None O
populations None None O
will None None O
be None None O
defined None None O
by None None O
the None None O
medium None None O
term None None O
evolution None None O
: None None O
transient None None O
wheezers None None O
and None None O
persistent None None O
wheezers None None O
. None None O

Risk None None O
factors None None O
for None None O
these None None O
two None None O
conditions None None O
are None None O
different None None O
. None None O

Childhood None None O
asthma None None O
may None None O
be None None O
defined None None O
by None None O
the None None O
diagnosis None None O
of None None O
asthma None None O
( None None O
specific None None O
but None None O
fairly None None O
non None None O
- None None O
sensitive None None O
) None None O
, None None O
by None None O
asthmatic None None O
symptoms None None O
( None None O
wheezing None None O
, None None O
waking None None O
by None None O
an None None O
attack None None O
of None None O
shortness None None O
of None None O
breath None None O
) None None O
( None None O
sensitive None None O
but None None O
not None None O
very None None O
specific None None O
) None None O
, None None O
or None None O
by None None O
the None None O
combination None None O
of None None O
symptoms None None O
and None None O
airway None None O
hyperresponsiveness None None O
. None None O

The None None O
ISAAC None None O
study None None O
has None None O
standardised None None O
a None None O
questionnaire None None O
to None None O
assess None None O
the None None O
prevalence None None O
of None None O
asthma None None O
. None None O

The None None O
preliminary None None O
results None None O
show None None O
that None None O
there None None O
are None None O
wide None None O
variations None None O
across None None O
the None None O
world None None O
. None None O

The None None O
prevalence None None O
is None None O
low None None O
in None None O
Africa None None O
and None None O
Asia None None O
, None None O
intermediate None None O
in None None O
Europe None None O
, None None O
and None None O
high None None O
in None None O
Anglo None None O
- None None O
Saxon None None O
countries None None O
. None None O

The None None O
prevalence None None O
of None None O
asthma None None O
has None None O
gradually None None O
increased None None O
over None None O
the None None O
past None None O
20 None None O
years None None O
in None None O
developed None None O
countries None None O
. None None O

Asthma None None O
and None None O
atopy None None O
are None None O
closely None None O
associated None None O
in None None O
children None None O
. None None O

Risk None None O
factors None None O
are None None O
genetic None None O
, None None O
associated None None O
with None None O
sex None None O
and None None O
environmental None None O
factors None None O
. None None O

Among None None O
these None None O
, None None O
allergic None None O
sensitisation None None O
is None None O
associated None None O
with None None O
the None None O
degree None None O
of None None O
exposure None None O
to None None O
allergens None None O
. None None O

Westernization None None O
of None None O
way None None O
of None None O
life None None O
is None None O
associated None None O
with None None O
increased None None O
prevalence None None O
of None None O
atopy None None O
, None None O
allergic None None O
rhinitis None None O
and None None O
asthma None None O
. None None O

Atopy None None O
seems None None O
inversely None None O
correlated None None O
to None None O
certain None None O
infections None None O
. None None O

Passive None None O
smoking None None O
is None None O
clearly None None O
associated None None O
with None None O
early None None O
wheezing None None O
. None None O

This None None O
and None None O
atmospheric None None O
pollution None None O
aggravate None None O
childhood None None O
asthma None None O
. None None O

However None None O
, None None O
the None None O
inducing None None O
role None None O
of None None O
pollution None None O
on None None O
asthma None None O
is None None O
still None None O
controversial None None O
. None None O

Quantitative None None O
sequencing None None O
of None None O
complex None None O
mixtures None None O
of None None O
heterochitooligosaccharides None None O
by None None O
vMALDI None None O
- None None O
linear None None O
ion None None O
trap None None O
mass None None O
spectrometry None None O
. None None O

Heterochitooligosaccharides None None O
possess None None O
interesting None None O
biological None None O
properties None None O
. None None O

Isobaric None None O
mixtures None None O
of None None O
such None None O
linear None None O
heterochitooligosaccharides None None O
can None None O
be None None O
obtained None None O
by None None O
chemical None None O
or None None O
enzymatic None None O
degradation None None O
of None None O
chitosan None None O
. None None O

However None None O
, None None O
the None None O
separation None None O
of None None O
such None None O
mixtures None None O
is None None O
a None None O
challenging None None O
analytical None None O
problem None None O
which None None O
is None None O
so None None O
far None None O
unresolved None None O
. None None O

It None None O
is None None O
shown None None O
that None None O
these None None O
isobaric None None O
mixtures None None O
can None None O
be None None O
sequenced None None O
and None None O
quantified None None O
simultaneously None None O
using None None O
standard None None O
derivatization None None O
and None None O
multistage None None O
tandem None None O
mass None None O
spectrometric None None O
techniques None None O
. None None O

A None None O
linear None None O
ion None None O
trap None None O
mass None None O
spectrometer None None O
equipped None None O
with None None O
a None None O
vacuum None None O
matrix None None O
- None None O
assisted None None O
laser None None O
desorption None None O
ionization None None O
( None None O
vMALDI None None O
) None None O
source None None O
is None None O
used None None O
to None None O
perform None None O
MS2 None None O
as None None O
well None None O
as None None O
MS3 None None O
experiments None None O
. None None O

Acknowledgements None None O

The None None O
authors None None O
would None None O
like None None O
to None None O
express None None O
their None None O
gratitude None None O
to None None O
Dr None None O
. None None O
Mahasti None None O
Alizadeh None None O
for None None O
her None None O
assistance None None O
in None None O
the None None O
data None None O
analysis None None O
and None None O
designing None None O
the None None O
questionnaire None None O
. None None O

Sciatic None None O
nerve None None O
repair None None O
by None None O
microgrooved None None O
nerve None None O
conduits None None O
made None None O
of None None O
chitosan None None O
- None None O
gold None None O
nanocomposites None None O
. None None O

BACKGROUND None None O
: None None O

To None None O
better None None O
direct None None O
the None None O
repair None None O
of None None O
peripheral None None O
nerve None None O
after None None O
injury None None O
, None None O
an None None O
implant None None O
consisting None None O
of None None O
a None None O
multicomponent None None O
micropatterned None None O
conduit None None O
seeded None None O
with None None O
NSC None None I-Cell-line-name
was None None O
designed None None O
. None None O

METHODS None None O
: None None O

The None None O
mechanical None None O
properties None None O
of None None O
the None None O
chi None None O
- None None O
Au None None O
nanocomposites None None O
were None None O
tested None None O
. None None O

In None None O
vitro None None O
, None None O
the None None O
effect None None O
of None None O
chi None None O
- None None O
Au None None O
on None None O
cell None None O
behavior None None O
( None None O
NSC None None I-Cell-line-name
and None None O
glial None None O
cell None None O
line None None O
C6 None None I-Cell-line-name
) None None O
and None None O
the None None O
influence None None O
of None None O
micropattern None None O
on None None O
cell None None O
alignment None None O
were None None O
evaluated None None O
. None None O

In None None O
vivo None None O
, None None O
the None None O
micropatterned None None O
conduits None None O
with None None O
/ None None O
without None None O
the None None O
preseeded None None O
NSC None None I-Cell-line-name
were None None O
implanted None None O
to None None O
bridge None None O
a None None O
10 None None O
- None None O
mm None None O
- None None O
long None None O
defect None None O
of None None O
the None None O
sciatic None None O
nerve None None O
in None None O
9 None None O
male None None O
Sprague None None O
- None None O
Dawley None None O
rats None None O
. None None O

The None None O
repair None None O
outcome None None O
was None None O
investigated None None O
6 None None O
weeks None None O
after None None O
the None None O
surgery None None O
. None None O

RESULTS None None O
: None None O

Based None None O
on None None O
the None None O
dynamic None None O
modulus None None O
, None None O
chitosan None None O
with None None O
50 None None O
ppm None None O
or None None O
more None None O
gold None None O
was None None O
a None None O
stronger None None O
material None None O
than None None O
others None None O
. None None O

In None None O
vitro None None O
, None None O
gold None None O
at None None O
25 None None O
or None None O
50 None None O
ppm None None O
led None None O
to None None O
better None None O
cell None None O
performance None None O
for None None O
NSC None None I-Cell-line-name
; None None O
and None None O
gold None None O
at None None O
50 None None O
ppm None None O
gave None None O
better None None O
cell None None O
performance None None O
for None None O
C6 None None I-Cell-line-name
. None None O

On None None O
the None None O
microgrooved None None O
substrate None None O
, None None O
the None None O
NSC None None I-Cell-line-name
had None None O
elongated None None O
processes None None O
oriented None None O
parallel None None O
to None None O
the None None O
grooves None None O
, None None O
whereas None None O
the None None O
NSC None None I-Cell-line-name
on None None O
the None None O
nonpatterned None None O
surfaces None None O
did None None O
not None None O
exhibit None None O
a None None O
particular None None O
bias None None O
in None None O
alignment None None O
. None None O

In None None O
vivo None None O
, None None O
the None None O
number None None O
of None None O
regenerated None None O
axons None None O
, None None O
the None None O
regenerated None None O
area None None O
, None None O
and None None O
the None None O
number None None O
of None None O
blood None None O
vessels None None O
were None None O
significantly None None O
higher None None O
in None None O
the None None O
NSC None None I-Cell-line-name
- None None O
preseeded None None O
conduit None None O
. None None O

CONCLUSION None None O
: None None O

Modification None None O
of None None O
the None None O
chitosan None None O
matrix None None O
by None None O
gold None None O
nanoparticles None None O
not None None O
only None None O
provides None None O
the None None O
mechanical None None O
strength None None O
but None None O
also None None O
affects None None O
the None None O
cellular None None O
response None None O
. None None O

The None None O
preliminary None None O
in None None O
vivo None None O
data None None O
demonstrated None None O
that None None O
the None None O
biodegradable None None O
micropatterned None None O
conduits None None O
preseeded None None O
with None None O
NSC None None I-Cell-line-name
provided None None O
a None None O
combination None None O
of None None O
physical None None O
and None None O
biological None None O
guidance None None O
cues None None O
for None None O
regenerating None None O
axons None None O
at None None O
the None None O
cellular None None O
level None None O
and None None O
offered None None O
a None None O
better None None O
alternative None None O
for None None O
repairing None None O
sciatic None None O
nerve None None O
transactions None None O
. None None O

Retrospective None None O
case None None O
series None None O
of None None O
juxtafoveal None None O
choroidal None None O
neovascularization None None O
treated None None O
with None None O
photodynamic None None O
therapy None None O
with None None O
verteporfin None None O
. None None O

PURPOSE None None O
: None None O
To None None O
describe None None O
visual None None O
acuity None None O
and None None O
angiographic None None O
outcomes None None O
of None None O
juxtafoveal None None O
choroidal None None O
neovascularization None None O
( None None O
CNV None None O
) None None O
treated None None O
with None None O
photodynamic None None O
therapy None None O
and None None O
verteporfin None None O
( None None O
PDT None None O
) None None O
. None None O

METHODS None None O
: None None O
Four None None O
hundred None None O
eighty None None O
- None None O
four None None O
consecutive None None O
eyes None None O
of None None O
446 None None O
patients None None O
treated None None O
with None None O
PDT None None O
from None None O
January None None O
1 None None O
, None None O
2001 None None O
, None None O
to None None O
June None None O
30 None None O
, None None O
2002 None None O
, None None O
were None None O
identified None None O
from None None O
billing None None O
records None None O
. None None O

Fluorescein None None O
angiograms None None O
were None None O
reviewed None None O
retrospectively None None O
to None None O
identify None None O
juxtafoveal None None O
CNV None None O
. None None O

Eligible None None O
patients None None O
had None None O
CNV None None O
in None None O
which None None O
the None None O
central None None O
boundary None None O
of None None O
the None None O
lesion None None O
was None None O
between None None O
1 None None O
and None None O
199 None None O
microm None None O
from None None O
the None None O
geometric None None O
center None None O
of None None O
the None None O
foveal None None O
avascular None None O
zone None None O
( None None O
FAZ None None O
) None None O
. None None O

Patient None None O
charts None None O
were None None O
reviewed None None O
for None None O
visual None None O
acuity None None O
of None None O
the None None O
treated None None O
eye None None O
before None None O
PDT None None O
and None None O
at None None O
6 None None O
- None None O
and None None O
12 None None O
- None None O
month None None O
follow None None O
- None None O
up None None O
examinations None None O
. None None O

Presence None None O
of None None O
subfoveal None None O
CNV None None O
at None None O
6 None None O
and None None O
12 None None O
months None None O
of None None O
follow None None O
- None None O
up None None O
was None None O
determined None None O
by None None O
review None None O
of None None O
fluorescein None None O
angiograms None None O
. None None O

A None None O
lesion None None O
was None None O
considered None None O
subfoveal None None O
if None None O
it None None O
extended None None O
underneath None None O
the None None O
geometric None None O
center None None O
of None None O
the None None O
FAZ None None O
. None None O

RESULTS None None O
: None None O
Twenty None None O
- None None O
one None None O
eyes None None O
had None None O
juxtafoveal None None O
CNV None None O
. None None O

Median None None O
change None None O
in None None O
visual None None O
acuity None None O
both None None O
6 None None O
and None None O
12 None None O
months None None O
after None None O
the None None O
initial None None O
PDT None None O
was None None O
0 None None O
lines None None O
( None None O
n None None O
= None None O
18 None None O
at None None O
6 None None O
months None None O
, None None O
range None None O
- None None O
14 None None O
to None None O
+ None None O
8 None None O
lines None None O
; None None O
n None None O
= None None O
17 None None O
at None None O
12 None None O
months None None O
, None None O
range None None O
- None None O
18 None None O
to None None O
+ None None O
7 None None O
lines None None O
) None None O
. None None O

Eleven None None O
lesions None None O
progressed None None O
to None None O
a None None O
subfoveal None None O
location None None O
by None None O
12 None None O
months None None O
. None None O

Visual None None O
acuity None None O
in None None O
eyes None None O
with None None O
progressive None None O
lesions None None O
decreased None None O
a None None O
median None None O
of None None O
4 None None O
lines None None O
of None None O
vision None None O
. None None O

CONCLUSIONS None None O
: None None O
Despite None None O
a None None O
small None None O
sample None None O
size None None O
and None None O
limited None None O
length None None O
of None None O
follow None None O
- None None O
up None None O
, None None O
this None None O
study None None O
shows None None O
that None None O
visual None None O
acuity None None O
on None None O
average None None O
can None None O
remain None None O
stable None None O
for None None O
at None None O
least None None O
12 None None O
months None None O
after None None O
PDT None None O
of None None O
juxtafoveal None None O
lesions None None O
. None None O

Growth None None O
through None None O
the None None O
foveal None None O
center None None O
still None None O
can None None O
occur None None O
, None None O
however None None O
, None None O
and None None O
this None None O
can None None O
be None None O
associated None None O
with None None O
substantial None None O
visual None None O
loss None None O
. None None O

Methods None None O

Thirteen None None O
focus None None O
group None None O
discussions None None O
with None None O
first None None O
- None None O
time None None O
parents None None O
and None None O
female None None O
and None None O
male None None O
informal None None O
supporters None None O
were None None O
analysed None None O
by None None O
discourse None None O
analysis None None O
. None None O

A None None O
new None None O
autosomal None None O
dominant None None O
vascular None None O
retinopathy None None O
syndrome None None O
. None None O

We None None O
describe None None O
a None None O
new None None O
syndrome None None O
with None None O
autosomal None None O
dominant None None O
transmission None None O
whose None None O
most None None O
striking None None O
feature None None O
is None None O
vascular None None O
retinopathy None None O
. None None O

The None None O
retinopathy None None O
is None None O
often None None O
associated None None O
with None None O
migraine None None O
, None None O
Raynaud None None O
' None None O
s None None O
phenomenon None None O
and None None O
mental None None O
changes None None O
, None None O
mainly None None O
forgetfulness None None O
, None None O
aggression None None O
and None None O
depression None None O
. None None O

To None None O
define None None O
this None None O
syndrome None None O
we None None O
collected None None O
medical None None O
data None None O
on None None O
110 None None O
family None None O
members None None O
. None None O

General None None O
ophthalmological None None O
examination None None O
and None None O
fluorescein None None O
angiography None None O
were None None O
performed None None O
in None None O
61 None None O
persons None None O
. None None O

The None None O
retinopathy None None O
, None None O
as None None O
diagnosed None None O
in None None O
22 None None O
persons None None O
, None None O
is None None O
characterized None None O
by None None O
central None None O
and None None O
peripheral None None O
microangiopathy None None O
, None None O
areas None None O
of None None O
capillary None None O
non None None O
- None None O
perfusion None None O
, None None O
haemorrhages None None O
, None None O
cotton None None O
wool None None O
spots None None O
and None None O
, None None O
in None None O
a None None O
more None None O
advanced None None O
stage None None O
, None None O
occlusion None None O
of None None O
large None None O
retinal None None O
vessels None None O
, None None O
which None None O
can None None O
induce None None O
a None None O
neovascular None None O
response None None O
. None None O

A None None O
vascular None None O
occlusive None None O
disorder None None O
may None None O
be None None O
the None None O
common None None O
aetiological None None O
factor None None O
of None None O
the None None O
various None None O
manifestation None None O
of None None O
this None None O
syndrome None None O
. None None O

Dynorphin None None O
is None None O
contained None None O
within None None O
hippocampal None None O
mossy None None O
fibers None None O
: None None O
immunochemical None None O
alterations None None O
after None None O
kainic None None O
acid None None O
administration None None O
and None None O
colchicine None None O
- None None O
induced None None O
neurotoxicity None None O
. None None O

Antisera None None O
raised None None O
against None None O
synthetic None None O
dynorphin None None O
or None None O
[ None None O
Leu5 None None O
] None None O
enkephalin None None O
demonstrate None None O
immunostaining None None O
in None None O
hippocampal None None O
mossy None None O
fibers None None O
and None None O
in None None O
dentate None None O
granule None None O
cells None None O
. None None O

However None None O
, None None O
dynorphin None None O
immunoreactivity None None O
( None None O
ir None None O
) None None O
appears None None O
to None None O
be None None O
denser None None O
in None None O
immunocytochemical None None O
preparations None None O
and None None O
is None None O
quantitatively None None O
greater None None O
by None None O
radioimmunoassay None None O
than None None O
enkephalin None None O
- None None O
ir None None O
. None None O

Immunostaining None None O
with None None O
dynorphin None None O
antisera None None O
is None None O
eliminated None None O
by None None O
adsorption None None O
with None None O
1 None None O
- None None O
100 None None O
microM None None O
dynorphin None None O
- None None O
17 None None O
whereas None None O
immunostaining None None O
with None None O
enkephalin None None O
antisera None None O
is None None O
eliminated None None O
by None None O
adsorption None None O
with None None O
1 None None O
- None None O
100 None None O
microM None None O
[ None None O
Leu5 None None O
] None None O
enkephalin None None O
, None None O
dynorphin None None O
- None None O
17 None None O
, None None O
dynorphin None None O
- None None O
( None None O
1 None None O
- None None O
13 None None O
) None None O
, None None O
or None None O
alpha None None O
- None None O
neo None None O
- None None O
endorphin None None O
. None None O

Intrahippocampal None None O
colchicine None None O
injections None None O
, None None O
which None None O
selectively None None O
destroy None None O
dentate None None O
granule None None O
cells None None O
, None None O
significantly None None O
decrease None None O
the None None O
dynorphin None None O
- None None O
ir None None O
and None None O
enkephalin None None O
- None None O
ir None None O
levels None None O
in None None O
rat None None O
hippocampus None None O
. None None O

Intraventricularly None None O
administered None None O
kainic None None O
acid None None O
, None None O
which None None O
selectively None None O
destroys None None O
CA3 None None O
- None None O
4 None None O
pyramidal None None O
cells None None O
, None None O
results None None O
in None None O
an None None O
increase None None O
of None None O
enkephalin None None O
immunostaining None None O
in None None O
mossy None None O
fibers None None O
and None None O
a None None O
significant None None O
increase None None O
in None None O
enkephalin None None O
- None None O
ir None None O
by None None O
radioimmunoassay None None O
in None None O
whole None None O
hippocampus None None O
. None None O

The None None O
enkephalin None None O
- None None O
ir None None O
cells None None O
and None None O
fibers None None O
in None None O
entorhinal None None O
/ None None O
perirhinal None None O
cortex None None O
, None None O
which None None O
innervate None None O
rat None None O
hippocampus None None O
and None None O
dentate None None O
gyrus None None O
, None None O
do None None O
not None None O
contain None None O
dynorphin None None O
- None None O
ir None None O
. None None O

Maternal None None O
antenatal None None O
anxiety None None O
and None None O
behavioural None None O
/ None None O
emotional None None O
problems None None O
in None None O
children None None O
: None None O
a None None O
test None None O
of None None O
a None None O
programming None None O
hypothesis None None O
. None None O

BACKGROUND None None O
: None None O

Previous None None O
animal None None O
investigations None None O
link None None O
antenatal None None O
stress None None O
with None None O
a None None O
range None None O
of None None O
persistent None None O
behavioural None None O
abnormalities None None O
in None None O
the None None O
offspring None None O
. None None O

The None None O
current None None O
study None None O
examined None None O
if None None O
the None None O
effect None None O
was None None O
also None None O
found None None O
in None None O
humans None None O
through None None O
middle None None O
childhood None None O
. None None O

METHODS None None O
: None None O

The None None O
current None None O
study None None O
is None None O
based None None O
on None None O
the None None O
Avon None None O
Longitudinal None None O
Study None None O
of None None O
Parents None None O
and None None O
Children None None O
( None None O
ALSPAC None None O
) None None O
, None None O
a None None O
prospective None None O
, None None O
community None None O
- None None O
based None None O
study None None O
that None None O
has None None O
followed None None O
a None None O
cohort None None O
of None None O
women None None O
from None None O
pregnancy None None O
. None None O

Self None None O
- None None O
report None None O
measures None None O
of None None O
maternal None None O
anxiety None None O
and None None O
depression None None O
were None None O
assessed None None O
at None None O
repeated None None O
intervals None None O
in None None O
pregnancy None None O
and None None O
the None None O
postnatal None None O
period None None O
. None None O

Children None None O
' None None O
s None None O
behavioural None None O
/ None None O
emotional None None O
problems None None O
were None None O
assessed None None O
by None None O
parent None None O
report None None O
at None None O
age None None O
47 None None O
and None None O
81 None None O
months None None O
. None None O

Information None None O
on None None O
obstetric None None O
and None None O
psychosocial None None O
factors None None O
was None None O
obtained None None O
at None None O
several None None O
points None None O
in None None O
pregnancy None None O
and None None O
the None None O
postnatal None None O
period None None O
. None None O

RESULTS None None O
: None None O

Children None None O
whose None None O
mothers None None O
experienced None None O
high None None O
levels None None O
of None None O
anxiety None None O
in None None O
late None None O
pregnancy None None O
exhibited None None O
higher None None O
rates None None O
of None None O
behavioural None None O
/ None None O
emotional None None O
problems None None O
at None None O
81 None None O
months None None O
of None None O
age None None O
after None None O
controlling None None O
for None None O
obstetric None None O
risks None None O
, None None O
psychosocial None None O
disadvantage None None O
, None None O
and None None O
postnatal None None O
anxiety None None O
and None None O
depression None None O
( None None O
for None None O
girls None None O
, None None O
OR None None O
= None None O
1 None None O
. None None O
91 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
1 None None O
. None None O
26 None None O
- None None O
2 None None O
. None None O
89 None None O
; None None O
for None None O
boys None None O
, None None O
OR None None O
= None None O
2 None None O
. None None O
16 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
1 None None O
. None None O
41 None None O
- None None O
3 None None O
. None None O
30 None None O
) None None O
. None None O

Furthermore None None O
, None None O
the None None O
effect None None O
at None None O
81 None None O
months None None O
was None None O
comparable None None O
to None None O
what None None O
was None None O
previously None None O
obtained None None O
at None None O
47 None None O
months None None O
, None None O
suggesting None None O
the None None O
kind None None O
of None None O
persistent None None O
effect None None O
proposed None None O
in None None O
the None None O
animal None None O
literature None None O
. None None O

CONCLUSIONS None None O
: None None O

There None None O
is None None O
evidence None None O
that None None O
antenatal None None O
stress None None O
/ None None O
anxiety None None O
has None None O
a None None O
programming None None O
effect None None O
on None None O
the None None O
fetus None None O
which None None O
lasts None None O
at None None O
least None None O
until None None O
middle None None O
childhood None None O
. None None O

Thrombospondins None None O
, None None O
metallo None None O
proteases None None O
and None None O
thrombospondin None None O
receptors None None O
messenger None None O
RNA None None O
and None None O
protein None None O
expression None None O
in None None O
different None None O
tumour None None O
sublines None None O
of None None O
the None None O
Dunning None None O
prostate None None O
cancer None None O
model None None O
. None None O

Thrombospondin None None O
is None None O
a None None O
potent None None O
inhibitor None None O
of None None O
angiogenesis None None O
and None None O
might None None O
therefore None None O
be None None O
important None None O
in None None O
controlling None None O
tumour None None O
growth None None O
. None None O

TSP None None O
interacts None None O
with None None O
a None None O
number None None O
of None None O
proteases None None O
and None None O
receptors None None O
and None None O
in None None O
this None None O
way None None O
inhibits None None O
stimulation None None O
of None None O
angiogenesis None None O
. None None O

An None None O
earlier None None O
study None None O
showed None None O
that None None O
thrombospondin None None O
is None None O
expressed None None O
in None None O
benign None None O
prostatic None None O
hyperplasia None None O
( None None O
BPH None None O
) None None O
and None None O
high None None O
- None None O
grade None None O
prostatic None None O
intraepithelial None None O
neoplasia None None O
( None None O
PIN None None O
) None None O
but None None O
is None None O
absent None None O
in None None O
prostate None None O
cancer None None O
. None None O

The None None O
present None None O
study None None O
was None None O
therefore None None O
designed None None O
to None None O
evaluate None None O
the None None O
expression None None O
of None None O
thrombospondin None None O
1 None None O
and None None O
2 None None O
( None None O
TSP None None O
- None None O
1 None None O
, None None O
TSP None None O
- None None O
2 None None O
) None None O
, None None O
TSP None None O
receptors None None O
CD36 None None O
and None None O
CD47 None None O
, None None O
and None None O
matrix None None O
- None None O
metalloproteases None None O
2 None None O
and None None O
9 None None O
( None None O
MMP None None O
- None None O
, None None O
MMP None None O
- None None O
9 None None O
) None None O
in None None O
a None None O
rat None None O
prostate None None O
cancer None None O
model None None O
. None None O

By None None O
using None None O
immunohistochemistry None None O
, None None O
Western None None O
blot None None O
, None None O
and None None O
real None None O
- None None O
time None None O
PCR None None O
the None None O
expression None None O
patterns None None O
of None None O
TSP None None O
- None None O
1 None None O
, None None O
TSP None None O
- None None O
2 None None O
, None None O
CD36 None None O
, None None O
CD47 None None O
, None None O
MMP None None O
- None None O
2 None None O
, None None O
and None None O
MMP None None O
- None None O
9 None None O
were None None O
investigated None None O
in None None O
normal None None O
rat None None O
prostate None None O
tissue None None O
and None None O
five None None O
malignant None None O
Dunning None None O
sublines None None O
tissue None None O
. None None O

TSP None None O
- None None O
1 None None O
mRNA None None O
levels None None O
were None None O
decreased None None O
in None None O
all None None O
tumours None None O
compared None None O
with None None O
normal None None O
prostate None None O
. None None O

However None None O
, None None O
there None None O
was None None O
no None None O
difference None None O
in None None O
expression None None O
of None None O
TSP None None O
- None None O
2 None None O
and None None O
CD36 None None O
mRNA None None O
in None None O
these None None O
samples None None O
. None None O

MMP None None O
- None None O
2 None None O
was None None O
increased None None O
with None None O
malignancy None None O
, None None O
but None None O
no None None O
expression None None O
of None None O
MMP None None O
- None None O
9 None None O
was None None O
seen None None O
. None None O

The None None O
CD47 None None O
receptor None None O
did None None O
slightly None None O
increase None None O
with None None O
malignancy None None O
except None None O
for None None O
H3327 None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
thrombospondin None None O
is None None O
expressed None None O
in None None O
normal None None O
prostate None None O
but None None O
not None None O
in None None O
prostate None None O
tumours None None O
in None None O
a None None O
rat None None O
model None None O
. None None O

Simultaneously None None O
, None None O
MMP None None O
- None None O
2 None None O
expression None None O
increases None None O
with None None O
malignancy None None O
. None None O

Multiple None None O
stages None None O
of None None O
malignant None None O
transformation None None O
of None None O
human None None O
endothelial None None O
cells None None O
modelled None None O
by None None O
co None None O
- None None O
expression None None O
of None None O
telomerase None None O
reverse None None O
transcriptase None None O
, None None O
SV40 None None O
T None None O
antigen None None O
and None None O
oncogenic None None O
N None None O
- None None O
ras None None O
. None None O

We None None O
have None None O
modelled None None O
multiple None None O
stages None None O
of None None O
malignant None None O
transformation None None O
of None None O
human None None O
endothelial None None O
cells None None O
( None None O
ECs None None O
) None None O
by None None O
overexpressing None None O
the None None O
catalytic None None O
subunit None None O
of None None O
human None None O
telomerase None None O
( None None O
hTERT None None O
) None None O
, None None O
together None None O
with None None O
SV40 None None O
T None None O
antigen None None O
( None None O
SV40T None None O
) None None O
and None None O
oncogenic None None O
N None None O
- None None O
ras None None O
. None None O

Transfection None None O
with None None O
hTERT None None O
alone None None O
, None None O
led None None O
to None None O
the None None O
immortalization None None O
of None None O
two None None O
out None None O
of None None O
three None None O
cultures None None O
of None None O
bone None None O
marrow None None O
- None None O
derived None None O
ECs None None O
( None None O
BMECs None None O
) None None O
. None None O

One None None O
hTERT None None O
transduced None None O
BMEC None None O
culture None None O
underwent None None O
a None None O
long None None O
proliferative None None O
lag None None O
before None None O
resuming None None O
proliferation None None O
. None None O

BMECs None None O
transfected None None O
with None None O
hTERT None None O
alone None None O
were None None O
functionally None None O
and None None O
phenotypically None None O
normal None None O
. None None O

BMECs None None O
transfected None None O
with None None O
SV40T None None O
( None None O
BMSVTs None None O
) None None O
had None None O
an None None O
extended None None O
lifespan None None O
, None None O
but None None O
eventually None None O
succumbed None None O
to None None O
crisis None None O
. None None O

BMSVTs None None O
exhibited None None O
a None None O
partially None None O
transformed None None O
phenotype None None O
, None None O
demonstrating None None O
growth None None O
factor None None O
independence None None O
, None None O
altered None None O
antigen None None O
expression None None O
and None None O
forming None None O
tiny None None O
, None None O
infrequent None None O
colonies None None O
in None None O
vitro None None O
. None None O

Transduction None None O
of None None O
BMSVTs None None O
with None None O
hTERT None None O
resulted None None O
in None None O
immortalization None None O
of None None O
4 None None O
out None None O
of None None O
4 None None O
cultures None None O
. None None O

BMSVTs None None O
immortalized None None O
with None None O
hTERT None None O
formed None None O
large None None O
colonies None None O
in None None O
vitro None None O
and None None O
small None None O
transient None None O
tumours None None O
in None None O
vivo None None O
. None None O

BMECs None None O
co None None O
- None None O
expressing None None O
SV40T None None O
, None None O
hTERT None None O
and None None O
N None None O
- None None O
ras None None O
exhibited None None O
an None None O
overtly None None O
transformed None None O
phenotype None None O
; None None O
forming None None O
very None None O
large None None O
colonies None None O
with None None O
an None None O
altered None None O
morphology None None O
and None None O
generating None None O
rapidly None None O
growing None None O
tumours None None O
in None None O
vivo None None O
. None None O

These None None O
investigations None None O
demonstrate None None O
transformation None None O
of None None O
human None None O
ECs None None O
to None None O
an None None O
overtly None None O
malignant None None O
phenotype None None O
. None None O

This None None O
model None None O
will None None O
be None None O
useful None None O
for None None O
understanding None None O
mechanisms None None O
underlying None None O
vascular None None O
and None None O
angiogenic None None O
neoplasias None None O
, None None O
as None None O
well None None O
as None None O
for None None O
testing None None O
drugs None None O
designed None None O
to None None O
curtail None None O
aberrant None None O
EC None None O
growth None None O
. None None O

Differential None None O
reactivity None None O
of None None O
the None None O
functional None None O
sulfhydryl None None O
groups None None O
of None None O
cysteine None None O
- None None O
32 None None O
and None None O
cysteine None None O
- None None O
35 None None O
present None None O
in None None O
the None None O
reduced None None O
form None None O
of None None O
thioredoxin None None O
from None None O
Escherichia None None O
coli None None O
. None None O

Only None None O
one None None O
of None None O
the None None O
sulfhydryl None None O
groups None None O
from None None O
Cys None None O
- None None O
32 None None O
and None None O
Cys None None O
- None None O
35 None None O
in None None O
the None None O
active None None O
center None None O
of None None O
native None None O
Escherichia None None O
coli None None O
thioredoxin None None O
- None None O
( None None O
SH None None O
) None None O
2 None None O
was None None O
alkylated None None O
by None None O
excess None None O
iodoacetic None None O
acid None None O
at None None O
pH None None O
values None None O
below None None O
8 None None O
. None None O
0 None None O
. None None O

Both None None O
groups None None O
reacted None None O
in None None O
the None None O
protein None None O
denatured None None O
with None None O
4 None None O
. None None O
5 None None O
M None None O
guanidine None None O
hydrochloride None None O
. None None O

The None None O
second None None O
order None None O
rate None None O
of None None O
alkylation None None O
of None None O
thioredoxin None None O
- None None O
( None None O
SH None None O
) None None O
2 None None O
with None None O
1 None None O
eq None None O
of None None O
iodoacetic None None O
acid None None O
was None None O
pH None None O
- None None O
dependent None None O
and None None O
showed None None O
independent None None O
initial None None O
reactions None None O
of None None O
one None None O
thiolate None None O
ion None None O
with None None O
a None None O
pK None None O
value None None O
of None None O
6 None None O
. None None O
7 None None O
and None None O
a None None O
second None None O
with None None O
a None None O
pK None None O
value None None O
close None None O
to None None O
9 None None O
. None None O
0 None None O
. None None O

The None None O
same None None O
pH None None O
dependence None None O
was None None O
observed None None O
for None None O
alkylation None None O
with None None O
iodoacetamide None None O
but None None O
the None None O
apparent None None O
rate None None O
constant None None O
, None None O
107 None None O
M None None O
- None None O
1 None None O
S None None O
- None None O
1 None None O
at None None O
pH None None O
7 None None O
. None None O
2 None None O
, None None O
was None None O
about None None O
20 None None O
- None None O
fold None None O
higher None None O
than None None O
the None None O
corresponding None None O
rate None None O
with None None O
iodoacetate None None O
. None None O

The None None O
sulfhydryl None None O
group None None O
with None None O
a None None O
pK None None O
value None None O
of None None O
6 None None O
. None None O
7 None None O
was None None O
shown None None O
to None None O
belong None None O
to None None O
Cys None None O
- None None O
32 None None O
by None None O
labeling None None O
thioredoxin None None O
with None None O
[ None None O
14C None None O
] None None O
iodoacetic None None O
acid None None O
followed None None O
by None None O
complete None None O
alkylation None None O
with None None O
[ None None O
3H None None O
] None None O
iodoacetate None None O
and None None O
amino None None O
acid None None O
sequence None None O
analysis None None O
of None None O
peptides None None O
from None None O
the None None O
active None None O
center None None O
. None None O

The None None O
abnormally None None O
low None None O
pK None None O
value None None O
of None None O
Cys None None O
- None None O
32 None None O
is None None O
suggested None None O
to None None O
arise None None O
by None None O
electrostatic None None O
influence None None O
from None None O
a None None O
positive None None O
charge None None O
on None None O
the None None O
amino None None O
group None None O
of None None O
Lys None None O
- None None O
36 None None O
. None None O

A None None O
mechanism None None O
of None None O
action None None O
for None None O
thioredoxin None None O
- None None O
( None None O
SH None None O
) None None O
2 None None O
as None None O
a None None O
protein None None O
disulfide None None O
reductase None None O
has None None O
been None None O
formulated None None O
. None None O

This None None O
is None None O
based None None O
on None None O
an None None O
initial None None O
nucleophilic None None O
attack None None O
by None None O
the None None O
thiolate None None O
of None None O
Cys None None O
- None None O
32 None None O
with None None O
the None None O
formation None None O
of None None O
an None None O
unstable None None O
transient None None O
mixed None None O
disulfide None None O
involving None None O
Cys None None O
- None None O
32 None None O
and None None O
one None None O
of None None O
the None None O
sulfurs None None O
in None None O
the None None O
substrate None None O
. None None O

This None None O
is None None O
followed None None O
by None None O
a None None O
conformational None None O
change None None O
and None None O
a None None O
nucleophilic None None O
attack None None O
of None None O
Cys None None O
- None None O
35 None None O
to None None O
give None None O
the None None O
14 None None O
- None None O
membered None None O
disulfide None None O
ring None None O
in None None O
thioredoxin None None O
- None None O
S2 None None O
and None None O
the None None O
dithiol None None O
of None None O
the None None O
substrate None None O
. None None O

High None None O
- None None O
Dose None None O
celecoxib None None O
and None None O
metronomic None None O
" None None O
low None None O
- None None O
dose None None O
" None None O
cyclophosphamide None None O
is None None O
an None None O
effective None None O
and None None O
safe None None O
therapy None None O
in None None O
patients None None O
with None None O
relapsed None None O
and None None O
refractory None None O
aggressive None None O
histology None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
. None None O

PURPOSE None None O
: None None O
Angiogenesis None None O
is None None O
increased None None O
in None None O
aggressive None None O
histology None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
and None None O
may None None O
be None None O
a None None O
target None None O
with None None O
selective None None O
cyclooxygenase None None O
- None None O
2 None None O
inhibition None None O
and None None O
metronomic None None O
chemotherapy None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
We None None O
assessed None None O
response None None O
, None None O
toxicity None None O
, None None O
and None None O
biomarkers None None O
of None None O
angiogenesis None None O
to None None O
low None None O
- None None O
dose None None O
cyclophosphamide None None O
( None None O
50 None None O
mg None None O
p None None O
. None None O
o None None O
. None None O
o None None O
. None None O
d None None O
. None None O
) None None O
and None None O
high None None O
- None None O
dose None None O
celecoxib None None O
( None None O
400 None None O
mg None None O
p None None O
. None None O
o None None O
. None None O
b None None O
. None None O
i None None O
. None None O
d None None O
. None None O
) None None O
in None None O
adult None None O
patients None None O
with None None O
relapsed None None O
or None None O
refractory None None O
aggressive None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
in None None O
a None None O
multicenter None None O
phase None None O
II None None O
prospective None None O
study None None O
. None None O

RESULTS None None O
: None None O
Thirty None None O
- None None O
two None None O
of None None O
35 None None O
patients None None O
( None None O
median None None O
age None None O
, None None O
62 None None O
years None None O
) None None O
are None None O
evaluable None None O
for None None O
response None None O
. None None O

Patients None None O
had None None O
primarily None None O
relapsed None None O
diffuse None None O
large None None O
B None None O
- None None O
cell None None O
lymphoma None None O
( None None O
63 None None O
% None None O
) None None O
were None None O
heavily None None O
pretreated None None O
( None None O
median None None O
of None None O
three None None O
regimens None None O
) None None O
and None None O
high None None O
risk None None O
( None None O
79 None None O
% None None O
international None None O
prognostic None None O
index None None O
, None None O
greater None None O
than None None O
or None None O
= None None O
2 None None O
) None None O
and None None O
34 None None O
% None None O
were None None O
relapsed None None O
after None None O
autologous None None O
stem None None O
cell None None O
transplant None None O
. None None O

With None None O
a None None O
median None None O
follow None None O
- None None O
up None None O
of None None O
8 None None O
. None None O
4 None None O
months None None O
, None None O
the None None O
overall None None O
best None None O
response None None O
rate None None O
is None None O
37 None None O
% None None O
( None None O
2 None None O
complete None None O
clinical None None O
response None None O
/ None None O
complete None None O
clinical None None O
response None None O
unconfirmed None None O
and None None O
9 None None O
partial None None O
response None None O
) None None O
, None None O
with None None O
22 None None O
% None None O
achieving None None O
stable None None O
disease None None O
. None None O

Median None None O
overall None None O
and None None O
progression None None O
- None None O
free None None O
survivals None None O
are None None O
14 None None O
. None None O
4 None None O
and None None O
4 None None O
. None None O
7 None None O
months None None O
, None None O
respectively None None O
. None None O

The None None O
median None None O
response None None O
duration None None O
was None None O
8 None None O
. None None O
2 None None O
months None None O
. None None O

The None None O
most None None O
common None None O
toxicity None None O
was None None O
skin None None O
rash None None O
( None None O
40 None None O
% None None O
) None None O
; None None O
myelosuppression None None O
and None None O
gastrointestinal None None O
side None None O
effects None None O
were None None O
uncommon None None O
. None None O

Three None None O
patients None None O
developed None None O
deep None None O
vein None None O
thromboses None None O
and None None O
two None None O
heavily None None O
pretreated None None O
patients None None O
developed None None O
treatment None None O
- None None O
related None None O
acute None None O
myelogenous None None O
leukemia None None O
or None None O
myelodysplasia None None O
after None None O
3 None None O
. None None O
7 None None O
and None None O
12 None None O
months None None O
of None None O
therapy None None O
. None None O

Circulating None None O
endothelial None None O
cells None None O
and None None O
their None None O
precursors None None O
declined None None O
and None None O
remained None None O
low None None O
in None None O
responders None None O
, None None O
whereas None None O
plasma None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
trended None None O
to None None O
decline None None O
in None None O
responding None None O
patients None None O
but None None O
increase None None O
in None None O
nonresponders None None O
. None None O

Trough None None O
celecoxib None None O
levels None None O
achieved None None O
targeted None None O
" None None O
antiangiogenic None None O
" None None O
levels None None O
. None None O

CONCLUSIONS None None O
: None None O
Low None None O
- None None O
dose None None O
cyclophosphamide None None O
and None None O
high None None O
- None None O
dose None None O
celecoxib None None O
is None None O
well None None O
tolerated None None O
and None None O
active None None O
in None None O
pretreated None None O
aggressive None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
. None None O

Close None None O
surveillance None None O
for None None O
arterial None None O
and None None O
venous None None O
thrombotic None None O
events None None O
is None None O
recommended None None O
. None None O

The None None O
decline None None O
in None None O
circulating None None O
endothelial None None O
cells None None O
and None None O
their None None O
precursors None None O
suggests None None O
that None None O
this None None O
combination None None O
may None None O
be None None O
working None None O
by None None O
inhibiting None None O
angiogenesis None None O
but None None O
should None None O
be None None O
validated None None O
in None None O
a None None O
larger None None O
patient None None O
sample None None O
. None None O

[ None None O
Correlation None None O
between None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
C None None O
in None None O
tumor None None O
- None None O
associated None None O
macrophages None None O
and None None O
lymphatic None None O
metastasis None None O
in None None O
oral None None O
cancer None None O
] None None O
. None None O

BACKGROUND None None O
& None None O
# None None O
38 None None O
; None None O
OBJECTIVE None None O
: None None O
Previous None None O
study None None O
shows None None O
that None None O
both None None O
vascular None None O
endothelial None None O
growth None None O
- None None O
C None None O
( None None O
VEGF None None O
- None None O
C None None O
) None None O
and None None O
tumor None None O
- None None O
associated None None O
macrophages None None O
( None None O
TAMs None None O
) None None O
are None None O
related None None O
to None None O
lymphatic None None O
metastasis None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
explore None None O
the None None O
correlation None None O
between None None O
the None None O
expression None None O
of None None O
VEGF None None O
- None None O
C None None O
in None None O
TAMs None None O
and None None O
lymphatic None None O
metastasis None None O
in None None O
human None None O
oral None None O
squamous None None O
- None None O
cell None None O
carcinoma None None O
( None None O
OSCC None None O
) None None O
. None None O

METHODS None None O
: None None O
After None None O
immunohistochemical None None O
staining None None O
, None None O
light None None O
microscope None None O
was None None O
used None None O
for None None O
counting None None O
macrophages None None O
and None None O
automated None None O
image None None O
analysis None None O
quantification None None O
was None None O
used None None O
to None None O
determine None None O
VEGF None None O
- None None O
C None None O
expression None None O
, None None O
which None None O
was None None O
reflected None None O
by None None O
positive None None O
index None None O
( None None O
PI None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
double None None O
staining None None O
was None None O
also None None O
used None None O
to None None O
determine None None O
VEGF None None O
- None None O
C None None O
expression None None O
in None None O
TAMs None None O
. None None O

RESULTS None None O
: None None O
VEGF None None O
- None None O
C None None O
expression None None O
was None None O
higher None None O
in None None O
lymphatic None None O
metastasis None None O
group None None O
( None None O
PI None None O
= None None O
12 None None O
. None None O
169 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
778 None None O
) None None O
than None None O
in None None O
no None None O
- None None O
metastasis None None O
group None None O
( None None O
PI None None O
= None None O
8 None None O
. None None O
498 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
674 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

TAMs None None O
counts None None O
was None None O
related None None O
to None None O
VEGF None None O
- None None O
C None None O
expression None None O
in None None O
OSCC None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
370 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
result None None O
of None None O
double None None O
staining None None O
indicated None None O
that None None O
macrophage None None O
with None None O
positive None None O
VEGF None None O
- None None O
C None None O
expression None None O
accounted None None O
for None None O
about None None O
22 None None O
. None None O
8 None None O
% None None O
of None None O
the None None O
total None None O
. None None O

CONCLUSION None None O
: None None O
Not None None O
only None None O
tumor None None O
cells None None O
but None None O
also None None O
TAMs None None O
secrete None None O
the None None O
VEGF None None O
- None None O
C None None O
in None None O
OSCC None None O
, None None O
and None None O
TAMs None None O
may None None O
play None None O
a None None O
major None None O
role None None O
in None None O
peritumoral None None O
lymphatic None None O
neoangiogenesis None None O
and None None O
lymphatic None None O
metastasis None None O
. None None O

Minimal None None O
contribution None None O
of None None O
marrow None None O
- None None O
derived None None O
endothelial None None O
precursors None None O
to None None O
tumor None None O
vasculature None None O
. None None O

During None None O
embryogenesis None None O
, None None O
vascular None None O
and None None O
hemopoietic None None O
cells None None O
originate None None O
from None None O
a None None O
common None None O
precursor None None O
, None None O
the None None O
hemangioblast None None O
. None None O

Recent None None O
evidence None None O
suggests None None O
the None None O
existence None None O
of None None O
endothelial None None O
precursors None None O
in None None O
adult None None O
bone None None O
marrow None None O
cells None None O
, None None O
but None None O
it None None O
is None None O
unclear None None O
whether None None O
those None None O
precursors None None O
have None None O
a None None O
role None None O
in None None O
tumor None None O
neovascularization None None O
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
demonstrate None None O
that None None O
murine None None O
bone None None O
marrow None None O
contains None None O
endothelial None None O
progenitors None None O
, None None O
which None None O
arise None None O
from None None O
a None None O
cell None None O
with None None O
self None None O
- None None O
renewing None None O
capacity None None O
, None None O
and None None O
can None None O
integrate None None O
into None None O
tumor None None O
microvasculature None None O
, None None O
albeit None None O
at None None O
a None None O
very None None O
low None None O
frequency None None O
. None None O

A None None O
transgenic None None O
double None None O
- None None O
reporter None None O
strategy None None O
allowed None None O
us None None O
to None None O
demonstrate None None O
definitively None None O
that None None O
tumor None None O
bone None None O
marrow None None O
- None None O
derived None None O
endothelial None None O
cells None None O
arise None None O
by None None O
transdifferentiation None None O
of None None O
marrow None None O
progenitors None None O
rather None None O
than None None O
by None None O
cell None None O
fusion None None O
. None None O

Single None None O
cell None None O
transplants None None O
showed None None O
that None None O
a None None O
common None None O
precursor None None O
contributes None None O
to None None O
both None None O
the None None O
hemopoietic None None O
and None None O
endothelial None None O
lineages None None O
, None None O
thus None None O
demonstrating None None O
the None None O
presence None None O
of None None O
an None None O
adult None None O
hemangioblast None None O
. None None O

Furthermore None None O
, None None O
we None None O
demonstrate None None O
that None None O
increased None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
- None None O
A None None O
secretion None None O
by None None O
tumor None None O
cells None None O
, None None O
as None None O
well None None O
as None None O
activation None None O
of None None O
VEGF None None O
receptor None None O
- None None O
2 None None O
in None None O
bone None None O
marrow None None O
cells None None O
does None None O
not None None O
alter None None O
the None None O
mobilization None None O
and None None O
incorporation None None O
of None None O
marrow None None O
- None None O
derived None None O
endothelial None None O
progenitors None None O
into None None O
tumor None None O
vasculature None None O
. None None O

Finally None None O
, None None O
in None None O
human None None O
umbilical None None O
cord None None O
blood None None O
cells None None O
, None None O
we None None O
show None None O
that None None O
endothelial None None O
precursors None None O
make None None O
up None None O
only None None O
approximately None None O
1 None None O
in None None O
10 None None O
( None None O
7 None None O
) None None O
mononuclear None None O
cells None None O
but None None O
are None None O
highly None None O
enriched None None O
in None None O
the None None O
CD133 None None O
+ None None O
cell None None O
population None None O
. None None O

By None None O
ruling None None O
out None None O
cell None None O
fusion None None O
, None None O
we None None O
clearly None None O
demonstrate None None O
the None None O
existence None None O
of None None O
an None None O
adult None None O
hemangioblast None None O
, None None O
but None None O
the None None O
differentiation None None O
of None None O
marrow None None O
stem None None O
cells None None O
toward None None O
the None None O
endothelial None None O
lineage None None O
is None None O
an None None O
extremely None None O
rare None None O
event None None O
. None None O

Furthermore None None O
, None None O
we None None O
show None None O
that None None O
VEGF None None O
- None None O
A None None O
stimulation None None O
of None None O
hemopoietic None None O
cells None None O
does None None O
not None None O
significantly None None O
alter None None O
this None None O
process None None O
. None None O

Glioma None None O
tumor None None O
stem None None O
- None None O
like None None O
cells None None O
promote None None O
tumor None None O
angiogenesis None None O
and None None O
vasculogenesis None None O
via None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
and None None O
stromal None None O
- None None O
derived None None O
factor None None O
1 None None O
. None None O

Cancer None None O
stem None None O
cells None None O
( None None O
CSC None None O
) None None O
are None None O
predicted None None O
to None None O
be None None O
critical None None O
drivers None None O
of None None O
tumor None None O
progression None None O
due None None O
to None None O
their None None O
self None None O
- None None O
renewal None None O
capacity None None O
and None None O
limitless None None O
proliferative None None O
potential None None O
. None None O

An None None O
emerging None None O
area None None O
of None None O
research None None O
suggests None None O
that None None O
CSC None None O
may None None O
also None None O
support None None O
tumor None None O
progression None None O
by None None O
promoting None None O
tumor None None O
angiogenesis None None O
. None None O

To None None O
investigate None None O
how None None O
CSC None None O
contribute None None O
to None None O
tumor None None O
vascular None None O
development None None O
, None None O
we None None O
used None None O
an None None O
approach None None O
comparing None None O
tumor None None O
xenografts None None O
of None None O
the None None O
C6 None None I-Cell-line-name
glioma None None O
cell None None O
line None None O
containing None None O
either None None O
a None None O
low None None O
or None None O
a None None O
high None None O
fraction None None O
of None None O
CSC None None O
. None None O

Compared None None O
with None None O
CSC None None O
- None None O
low None None O
tumors None None O
, None None O
CSC None None O
- None None O
high None None O
tumors None None O
exhibited None None O
increased None None O
microvessel None None O
density None None O
and None None O
blood None None O
perfusion None None O
and None None O
induced None None O
increased None None O
mobilization None None O
and None None O
tumor None None O
recruitment None None O
of None None O
bone None None O
marrow None None O
- None None O
derived None None O
endothelial None None O
progenitor None None O
cells None None O
( None None O
EPC None None O
) None None O
. None None O

CSC None None O
- None None O
high None None O
C6 None None I-Cell-line-name
cell None None O
cultures None None O
also None None O
induced None None O
higher None None O
levels None None O
of None None O
endothelial None None O
cell None None O
proliferation None None O
and None None O
tubule None None O
organization None None O
in None None O
vitro None None O
compared None None O
with None None O
CSC None None O
- None None O
low None None O
cultures None None O
. None None O

CSC None None O
- None None O
high None None O
cultures None None O
and None None O
tumors None None O
expressed None None O
increased None None O
levels None None O
of None None O
the None None O
proangiogenic None None O
factors None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
and None None O
stromal None None O
- None None O
derived None None O
factor None None O
1 None None O
, None None O
and None None O
when None None O
signaling None None O
by None None O
either None None O
factor None None O
was None None O
blocked None None O
, None None O
all None None O
aspects None None O
of None None O
angiogenesis None None O
observed None None O
in None None O
CSC None None O
- None None O
high None None O
cultures None None O
and None None O
tumors None None O
, None None O
including None None O
microvessel None None O
density None None O
, None None O
perfusion None None O
, None None O
EPC None None O
mobilization None None O
/ None None O
recruitment None None O
, None None O
and None None O
stimulation None None O
of None None O
endothelial None None O
cell None None O
activity None None O
, None None O
were None None O
reduced None None O
to None None O
levels None None O
comparable None None O
with None None O
those None None O
observed None None O
in None None O
CSC None None O
- None None O
low None None O
cultures None None O
/ None None O
tumors None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
CSC None None O
contribute None None O
to None None O
tumor None None O
angiogenesis None None O
by None None O
promoting None None O
both None None O
local None None O
endothelial None None O
cell None None O
activity None None O
and None None O
systemic None None O
angiogenic None None O
processes None None O
involving None None O
bone None None O
marrow None None O
- None None O
derived None None O
EPC None None O
in None None O
a None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
dependent None None O
and None None O
stromal None None O
- None None O
derived None None O
factor None None O
1 None None O
- None None O
dependent None None O
manner None None O
. None None O

Aglycon None None O
of None None O
rhizochalin None None O
from None None O
the None None O
Rhizochalina None None O
incrustata None None O
induces None None O
apoptosis None None O
via None None O
activation None None O
of None None O
AMP None None O
- None None O
activated None None O
protein None None O
kinase None None O
in None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
colon None None O
cancer None None O
cells None None O
. None None O

Rhizochalin None None O
is None None O
a None None O
two None None O
- None None O
headed None None O
sphingolipid None None O
- None None O
like None None O
compound None None O
isolated None None O
from None None O
the None None O
sponge None None O
Rhizochalina None None O
incrustata None None O
. None None O

It None None O
has None None O
been None None O
reported None None O
that None None O
rhizocalin None None O
and None None O
its None None O
derivates None None O
have None None O
a None None O
chemopreventive None None O
and None None O
chemotherapeutic None None O
effect None None O
. None None O

However None None O
, None None O
the None None O
molecular None None O
mechanism None None O
of None None O
these None None O
effects None None O
is None None O
not None None O
understood None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
that None None O
aglycon None None O
of None None O
rhizochalin None None O
( None None O
AglRhz None None O
) None None O
from None None O
the None None O
Rhizochalina None None O
incrustata None None O
induces None None O
AMP None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
AMPK None None O
) None None O
phosphorylation None None O
, None None O
and None None O
thereby None None O
inhibits None None O
mammalian None None O
target None None O
of None None O
rapamycin None None O
( None None O
mTOR None None O
) None None O
- None None O
p70S6 None None O
kinase None None O
- None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
( None None O
ERK None None O
) None None O
signaling None None O
and None None O
activator None None O
protein None None O
1 None None O
( None None O
AP None None O
- None None O
1 None None O
) None None O
activity None None O
via None None O
phosphorylation None None O
of None None O
Raptor None None O
in None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
cells None None O
. None None O

In None None O
addition None None O
, None None O
AglRhz None None O
induced None None O
activation None None O
of None None O
caspase None None O
- None None O
3 None None O
and None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
( None None O
PARP None None O
) None None O
, None None O
and None None O
DNA None None O
fragmentation None None O
in None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
cells None None O
, None None O
leads None None O
to None None O
induction None None O
of None None O
apoptosis None None O
as None None O
well None None O
as None None O
suppression None None O
of None None O
tumorigenicity None None O
of None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
cells None None O
. None None O

Notably None None O
, None None O
AglRhz None None O
inhibits None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
( None None O
IGF None None O
) None None O
- None None O
1 None None O
- None None O
induced None None O
AP None None O
- None None O
1 None None O
activity None None O
and None None O
cell None None O
transformation None None O
in None None O
JB6 None None I-Cell-line-name
Cl41 None None I-Cell-line-name
cells None None O
. None None O

Overall None None O
, None None O
our None None O
findings None None O
identify None None O
AMPK None None O
as None None O
an None None O
important None None O
target None None O
protein None None O
for None None O
mediating None None O
the None None O
anti None None O
- None None O
tumor None None O
properties None None O
of None None O
AglRhz None None O
in None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
colon None None O
cancer None None O
cells None None O
and None None O
have None None O
important None None O
implication None None O
for None None O
sponges None None O
, None None O
the None None O
most None None O
important None None O
marine None None O
source None None O
, None None O
in None None O
colon None None O
cancer None None O
. None None O

Anti None None O
- None None O
metastasis None None O
effects None None O
of None None O
gallic None None O
acid None None O
on None None O
gastric None None O
cancer None None O
cells None None O
involves None None O
inhibition None None O
of None None O
NF None None O
- None None O
kappaB None None O
activity None None O
and None None O
downregulation None None O
of None None O
PI3K None None O
/ None None O
AKT None None O
/ None None O
small None None O
GTPase None None O
signals None None O
. None None O

Polyphenols None None O
are None None O
natural None None O
antioxidants None None O
that None None O
are None None O
thought None None O
to None None O
contribute None None O
to None None O
prevention None None O
of None None O
cardiovascular None None O
disease None None O
and None None O
malignancy None None O
. None None O

Although None None O
many None None O
studies None None O
have None None O
been None None O
carried None None O
out None None O
to None None O
investigate None None O
the None None O
chemopreventive None None O
role None None O
of None None O
flavonoids None None O
, None None O
less None None O
attention None None O
has None None O
been None None O
focused None None O
on None None O
phenolic None None O
acids None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
aim None None O
was None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
phenolic None None O
acids None None O
found None None O
abundantly None None O
in None None O
vegetables None None O
, None None O
i None None O
. None None O
e None None O
. None None O
gallic None None O
acid None None O
( None None O
GA None None O
) None None O
, None None O
caffeic None None O
acid None None O
( None None O
CA None None O
) None None O
and None None O
protocatechuic None None O
acid None None O
( None None O
PCA None None O
) None None O
, None None O
on None None O
the None None O
inhibition None None O
of None None O
gastric None None O
adenocarcinoma None None O
( None None O
AGS None None O
) None None O
cell None None O
metastasis None None O
. None None O

The None None O
results None None O
showed None None O
0 None None O
. None None O
01 None None O
mM None None O
GA None None O
induced None None O
the None None O
same None None O
level None None O
of None None O
cell None None O
toxicity None None O
as None None O
4 None None O
. None None O
0mM None None O
PCA None None O
. None None O

Using None None O
wound None None O
- None None O
healing None None O
assay None None O
and None None O
Boyden None None O
chamber None None O
assay None None O
, None None O
GA None None O
had None None O
potent None None O
inhibitory None None O
effects None None O
on None None O
AGS None None O
cell None None O
migration None None O
. None None O

The None None O
expression None None O
of None None O
MMP None None O
- None None O
2 None None O
/ None None O
9 None None O
of None None O
AGS None None O
cells None None O
was None None O
inhibited None None O
by None None O
2 None None O
. None None O
0 None None O
microM None None O
of None None O
GA None None O
. None None O

It None None O
is None None O
possible None None O
that None None O
the None None O
suppressive None None O
effect None None O
of None None O
GA None None O
on None None O
MMP None None O
- None None O
2 None None O
/ None None O
9 None None O
might None None O
involve None None O
the None None O
inhibition None None O
of None None O
NF None None O
- None None O
kappaB None None O
activity None None O
. None None O

Multiple None None O
proteins None None O
involved None None O
in None None O
metastasis None None O
and None None O
the None None O
cytoskeletal None None O
reorganization None None O
signal None None O
pathway None None O
, None None O
including None None O
Ras None None O
, None None O
Cdc42 None None O
, None None O
Rac1 None None O
, None None O
RhoA None None O
, None None O
RhoB None None O
, None None O
PI3K None None O
and None None O
p38MAPK None None O
, None None O
were None None O
also None None O
inhibited None None O
by None None O
GA None None O
. None None O

Furthermore None None O
, None None O
immunoreactivity None None O
assay None None O
of None None O
cytoskeletal None None O
F None None O
- None None O
actin None None O
demonstrated None None O
a None None O
significant None None O
inhibitory None None O
effect None None O
of None None O
GA None None O
treatment None None O
. None None O

In None None O
conclusion None None O
, None None O
GA None None O
may None None O
have None None O
the None None O
potential None None O
to None None O
be None None O
an None None O
effective None None O
agent None None O
for None None O
prevention None None O
and None None O
treatment None None O
of None None O
gastric None None O
cancer None None O
metastasis None None O
. None None O

5 None None O
. None None O

Conclusion None None O

RLs None None O
are None None O
new None None O
actors None None O
in None None O
animal None None O
and None None O
plant None None O
defense None None O
and None None O
their None None O
low None None O
toxicity None None O
and None None O
biodegradability None None O
make None None O
them None None O
promising None None O
molecules None None O
to None None O
be None None O
used None None O
against None None O
pathogens None None O
. None None O

In None None O
this None None O
respect None None O
, None None O
there None None O
are None None O
some None None O
clues None None O
now None None O
available None None O
for None None O
the None None O
success None None O
of None None O
RL None None O
applications None None O
in None None O
greenhouses None None O
to None None O
fight None None O
phytopathogens None None O
. None None O

A None None O
better None None O
understanding None None O
of None None O
RL None None O
mode None None O
of None None O
action None None O
, None None O
especially None None O
their None None O
perception None None O
and None None O
the None None O
signaling None None O
pathways None None O
activated None None O
, None None O
will None None O
be None None O
very None None O
important None None O
to None None O
potentiate None None O
their None None O
beneficial None None O
effects None None O
in None None O
plants None None O
. None None O

RLs None None O
have None None O
a None None O
dual None None O
mode None None O
of None None O
action None None O
: None None O
they None None O
are None None O
antimicrobial None None O
and None None O
also None None O
stimulate None None O
plant None None O
defense None None O
responses None None O
. None None O

This None None O
dual None None O
property None None O
is None None O
probably None None O
very None None O
important None None O
for None None O
the None None O
efficiency None None O
of None None O
new None None O
biopesticides None None O
. None None O

In None None O
animals None None O
, None None O
the None None O
use None None O
of None None O
RLs None None O
is None None O
also None None O
at None None O
an None None O
advanced None None O
stage None None O
. None None O

RLs None None O
are None None O
successfully None None O
used None None O
as None None O
antimicrobial None None O
agents None None O
, None None O
especially None None O
for None None O
skin None None O
disease None None O
treatment None None O
. None None O

Deep None None O
insight None None O
into None None O
the None None O
physiochemical None None O
effects None None O
of None None O
RLs None None O
and None None O
their None None O
biological None None O
importance None None O
would None None O
reveal None None O
new None None O
dimensions None None O
in None None O
the None None O
fields None None O
of None None O
research None None O
like None None O
agriculture None None O
and None None O
medicine None None O
, None None O
precisely None None O
in None None O
plant None None O
defense None None O
, None None O
disease None None O
control None None O
and None None O
pathogenesis None None O
. None None O

An None None O
understanding None None O
of None None O
bacterial None None O
genera None None O
producing None None O
RLs None None O
that None None O
are None None O
not None None O
yet None None O
well None None O
studied None None O
would None None O
provide None None O
light None None O
on None None O
these None None O
fascinating None None O
aspects None None O
. None None O

Western None None O
blots None None O
showing None None O
C None None O
/ None None O
EBPalpha None None O
( None None O
top None None O
) None None O
, None None O
adiponectin None None O
( None None O
middle None None O
) None None O
, None None O
and None None O
GAPDH None None O
( None None O
bottom None None O
) None None O
protein None None O
bands None None O
in None None O
confluent None None O
GO None None O
orbital None None O
fibroblast None None O
cultures None None O
exposed None None O
throughout None None O
10 None None O
days None None O
in None None O
culture None None O
to None None O
the None None O
indicated None None O
treatments None None O
. None None O

Lane None None O
1 None None O
) None None O
no None None O
treatment None None O
; None None O
2 None None O
) None None O
LY294002 None None O
( None None O
10 None None O
muM None None O
) None None O
; None None O
3 None None O
) None None O
M22 None None O
( None None O
10 None None O
ng None None O
/ None None O
ml None None O
) None None O
; None None O
4 None None O
) None None O
M22 None None O
plus None None O
LY294002 None None O
. None None O

Glucose None None O
catabolism None None O
in None None O
cancer None None O
cells None None O
: None None O
identification None None O
and None None O
characterization None None O
of None None O
a None None O
marked None None O
activation None None O
response None None O
of None None O
the None None O
type None None O
II None None O
hexokinase None None O
gene None None O
to None None O
hypoxic None None O
conditions None None O
. None None O

One None None O
of None None O
the None None O
most None None O
common None None O
signatures None None O
of None None O
highly None None O
malignant None None O
tumors None None O
is None None O
their None None O
capacity None None O
to None None O
metabolize None None O
more None None O
glucose None None O
to None None O
lactic None None O
acid None None O
than None None O
their None None O
tissues None None O
of None None O
origin None None O
. None None O

Hepatomas None None O
exhibiting None None O
this None None O
phenotype None None O
are None None O
dependent None None O
on None None O
the None None O
high None None O
expression None None O
of None None O
type None None O
II None None O
hexokinase None None O
, None None O
which None None O
supplies None None O
such None None O
tumors None None O
with None None O
abundant None None O
amounts None None O
of None None O
glucose None None O
6 None None O
- None None O
phosphate None None O
, None None O
a None None O
significant None None O
carbon None None O
and None None O
energy None None O
source None None O
especially None None O
under None None O
hypoxic None None O
conditions None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
the None None O
distal None None O
region None None O
of None None O
the None None O
hepatoma None None O
type None None O
II None None O
hexokinase None None O
promoter None None O
displays None None O
consensus None None O
motifs None None O
for None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
( None None O
HIF None None O
- None None O
1 None None O
) None None O
that None None O
overlap None None O
E None None O
- None None O
box None None O
sequences None None O
known None None O
to None None O
be None None O
related None None O
in None None O
other None None O
gene None None O
promoters None None O
to None None O
glucose None None O
response None None O
. None None O

Moreover None None O
, None None O
we None None O
show None None O
that None None O
subjecting None None O
transfected None None O
hepatoma None None O
cells None None O
to None None O
hypoxic None None O
conditions None None O
activates None None O
the None None O
type None None O
II None None O
hexokinase None None O
promoter None None O
almost None None O
3 None None O
- None None O
fold None None O
, None None O
a None None O
value None None O
that None None O
approaches None None O
7 None None O
- None None O
fold None None O
in None None O
the None None O
presence None None O
of None None O
glucose None None O
. None None O

Consistent None None O
with None None O
these None None O
findings None None O
is None None O
the None None O
induction None None O
under None None O
hypoxic None None O
conditions None None O
of None None O
the None None O
HIF None None O
- None None O
1 None None O
protein None None O
. None None O

Reporter None None O
gene None None O
analyses None None O
with None None O
a None None O
series None None O
of None None O
nested None None O
deletion None None O
mutants None None O
of None None O
the None None O
hepatoma None None O
type None None O
II None None O
hexokinase None None O
promoter None None O
show None None O
that None None O
a None None O
significant None None O
fraction None None O
of None None O
the None None O
total None None O
activation None None O
observed None None O
under None None O
hypoxic None None O
conditions None None O
localizes None None O
to None None O
the None None O
distal None None O
region None None O
where None None O
the None None O
overlapping None None O
HIF None None O
- None None O
1 None None O
/ None None O
E None None O
- None None O
box None None O
sequences None None O
are None None O
located None None O
. None None O

Finally None None O
, None None O
DNase None None O
I None None O
footprint None None O
analysis None None O
with None None O
a None None O
segment None None O
of None None O
the None None O
promoter None None O
containing None None O
these None None O
elements None None O
reveals None None O
the None None O
binding None None O
of None None O
several None None O
nuclear None None O
proteins None None O
. None None O

In None None O
summary None None O
, None None O
these None None O
novel None None O
studies None None O
identify None None O
and None None O
characterize None None O
a None None O
marked None None O
glucose None None O
- None None O
modulated None None O
activation None None O
response None None O
of None None O
the None None O
type None None O
II None None O
hexokinase None None O
gene None None O
to None None O
hypoxic None None O
conditions None None O
within None None O
highly None None O
glycolytic None None O
hepatoma None None O
cells None None O
, None None O
a None None O
property None None O
that None None O
may None None O
help None None O
assure None None O
that None None O
such None None O
cells None None O
exhibit None None O
a None None O
growth None None O
and None None O
survival None None O
advantage None None O
over None None O
their None None O
parental None None O
cells None None O
of None None O
origin None None O
. None None O

Geometric None None O
correlations None None O
and None None O
breakdown None None O
of None None O
mesoscopic None None O
universality None None O
in None None O
spin None None O
transport None None O
. None None O

We None None O
construct None None O
a None None O
unified None None O
semiclassical None None O
theory None None O
of None None O
charge None None O
and None None O
spin None None O
transport None None O
in None None O
chaotic None None O
ballistic None None O
and None None O
disordered None None O
diffusive None None O
mesoscopic None None O
systems None None O
with None None O
spin None None O
- None None O
orbit None None O
interaction None None O
. None None O

Neglecting None None O
dynamic None None O
effects None None O
of None None O
spin None None O
- None None O
orbit None None O
interaction None None O
, None None O
we None None O
reproduce None None O
the None None O
random None None O
matrix None None O
theory None None O
results None None O
that None None O
the None None O
spin None None O
conductance None None O
fluctuates None None O
universally None None O
around None None O
zero None None O
average None None O
. None None O

Incorporating None None O
these None None O
effects None None O
into None None O
the None None O
theory None None O
, None None O
we None None O
show None None O
that None None O
geometric None None O
correlations None None O
generate None None O
finite None None O
average None None O
spin None None O
conductances None None O
, None None O
but None None O
that None None O
they None None O
do None None O
not None None O
affect None None O
the None None O
charge None None O
conductance None None O
to None None O
leading None None O
order None None O
. None None O

The None None O
theory None None O
, None None O
which None None O
is None None O
confirmed None None O
by None None O
numerical None None O
transport None None O
calculations None None O
, None None O
allows None None O
us None None O
to None None O
investigate None None O
the None None O
entire None None O
range None None O
from None None O
the None None O
weak None None O
to None None O
the None None O
previously None None O
unexplored None None O
strong None None O
spin None None O
- None None O
orbit None None O
regime None None O
, None None O
where None None O
the None None O
spin None None O
rotation None None O
time None None O
is None None O
shorter None None O
than None None O
the None None O
momentum None None O
relaxation None None O
time None None O
. None None O

Angiogenesis None None O
inhibitors None None O
: None None O
current None None O
strategies None None O
and None None O
future None None O
prospects None None O
. None None O

Angiogenesis None None O
has None None O
become None None O
an None None O
attractive None None O
target None None O
for None None O
drug None None O
therapy None None O
because None None O
of None None O
its None None O
key None None O
role None None O
in None None O
tumor None None O
growth None None O
. None None O

An None None O
extensive None None O
array None None O
of None None O
compounds None None O
is None None O
currently None None O
in None None O
preclinical None None O
development None None O
, None None O
with None None O
many None None O
now None None O
entering None None O
the None None O
clinic None None O
and None None O
/ None None O
or None None O
achieving None None O
approval None None O
from None None O
the None None O
US None None O
Food None None O
and None None O
Drug None None O
Administration None None O
. None None O

Several None None O
regulatory None None O
and None None O
signaling None None O
molecules None None O
governing None None O
angiogenesis None None O
are None None O
of None None O
interest None None O
, None None O
including None None O
growth None None O
factors None None O
( None None O
eg None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
, None None O
fibroblast None None O
growth None None O
factor None None O
, None None O
and None None O
epidermal None None O
growth None None O
factor None None O
) None None O
, None None O
receptor None None O
tyrosine None None O
kinases None None O
, None None O
and None None O
transcription None None O
factors None None O
such None None O
as None None O
hypoxia None None O
inducible None None O
factor None None O
, None None O
as None None O
well None None O
as None None O
molecules None None O
involved None None O
in None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
and None None O
phosphoinositide None None O
3 None None O
- None None O
kinase None None O
( None None O
PI3K None None O
) None None O
signaling None None O
. None None O

Pharmacologic None None O
agents None None O
have None None O
been None None O
identified None None O
that None None O
target None None O
these None None O
pathways None None O
, None None O
yet None None O
for None None O
some None None O
agents None None O
( None None O
notably None None O
thalidomide None None O
) None None O
, None None O
an None None O
understanding None None O
of None None O
the None None O
specific None None O
mechanisms None None O
of None None O
antitumor None None O
action None None O
has None None O
proved None None O
elusive None None O
. None None O

The None None O
following None None O
review None None O
describes None None O
key None None O
molecular None None O
mechanisms None None O
and None None O
novel None None O
therapies None None O
that None None O
are None None O
on None None O
the None None O
horizon None None O
for None None O
antiangiogenic None None O
tumor None None O
therapy None None O
. None None O

Effects None None O
of None None O
growth None None O
temperature None None O
, None None O
47 None None O
- None None O
megadalton None None O
plasmid None None O
, None None O
and None None O
calcium None None O
deficiency None None O
on None None O
the None None O
outer None None O
membrane None None O
protein None None O
porin None None O
and None None O
lipopolysaccharide None None O
composition None None O
of None None O
Yersinia None None O
pestis None None O
EV76 None None O
. None None O

The None None O
expression None None O
of None None O
several None None O
virulence None None O
determinants None None O
of None None O
Yersinia None None O
pestis None None O
is None None O
known None None O
to None None O
be None None O
dependent None None O
on None None O
the None None O
in None None O
vitro None None O
growth None None O
temperature None None O
. None None O

One None None O
of None None O
these None None O
, None None O
calcium None None O
dependence None None O
, None None O
is None None O
associated None None O
with None None O
the None None O
presence None None O
of None None O
a None None O
47 None None O
- None None O
megadalton None None O
plasmid None None O
. None None O

We None None O
have None None O
examined None None O
the None None O
effects None None O
of None None O
incubation None None O
temperature None None O
, None None O
calcium None None O
in None None O
the None None O
growth None None O
medium None None O
, None None O
the None None O
presence None None O
of None None O
the None None O
47 None None O
- None None O
megadalton None None O
plasmid None None O
on None None O
the None None O
outer None None O
membrane None None O
protein None None O
, None None O
and None None O
the None None O
lipopolysaccharide None None O
composition None None O
of None None O
Y None None O
. None None O
pestis None None O
EV76 None None O
. None None O

When None None O
cells None None O
were None None O
grown None None O
at None None O
37 None None O
degrees None None O
C None None O
as None None O
opposed None None O
to None None O
26 None None O
degrees None None O
C None None O
, None None O
a None None O
change None None O
in None None O
lipopolysaccharide None None O
composition None None O
and None None O
a None None O
decrease None None O
in None None O
the None None O
amount None None O
of None None O
an None None O
outer None None O
membrane None None O
protein None None O
( None None O
protein None None O
E None None O
) None None O
were None None O
observed None None O
. None None O

The None None O
lipopolysaccharide None None O
obtained None None O
from None None O
cells None None O
incubated None None O
at None None O
37 None None O
degrees None None O
C None None O
had None None O
a None None O
lower None None O
proportion None None O
of None None O
2 None None O
keto None None O
- None None O
3 None None O
- None None O
deoxyoctanate None None O
, None None O
a None None O
lower None None O
phosphate None None O
to None None O
2 None None O
- None None O
keto None None O
- None None O
3 None None O
- None None O
deoxyoctanate None None O
ratio None None O
, None None O
and None None O
an None None O
increased None None O
gel None None O
mobility None None O
upon None None O
sodium None None O
dodecyl None None O
sulfate None None O
- None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
when None None O
compared None None O
with None None O
lipopolysaccharide None None O
obtained None None O
from None None O
cells None None O
grown None None O
at None None O
26 None None O
degrees None None O
C None None O
. None None O

Because None None O
of None None O
its None None O
growth None None O
temperature None None O
- None None O
related None None O
abundance None None O
, None None O
we None None O
investigated None None O
the None None O
nature None None O
of None None O
protein None None O
E None None O
. None None O

This None None O
protein None None O
had None None O
physical None None O
properties None None O
similar None None O
to None None O
those None None O
of None None O
other None None O
enterobacterial None None O
porins None None O
, None None O
including None None O
apparent None None O
formation None None O
of None None O
an None None O
oligomer None None O
on None None O
sodium None None O
dodecyl None None O
sulfate None None O
- None None O
polyacrylamide None None O
gels None None O
when None None O
solubilized None None O
at None None O
low None None O
temperature None None O
, None None O
acidic None None O
isoelectric None None O
point None None O
, None None O
and None None O
strong None None O
noncovalent None None O
association None None O
with None None O
the None None O
peptidoglycan None None O
. None None O

Protein None None O
E None None O
was None None O
purified None None O
and None None O
shown None None O
to None None O
form None None O
an None None O
aqueous None None O
channel None None O
in None None O
planar None None O
lipid None None O
membranes None None O
with None None O
a None None O
conductance None None O
of None None O
1 None None O
. None None O
1 None None O
nS None None O
in None None O
1 None None O
M None None O
KCl None None O
. None None O

In None None O
addition None None O
to None None O
growth None None O
temperature None None O
- None None O
related None None O
alterations None None O
in None None O
the None None O
lipopolysaccharide None None O
and None None O
porin None None O
components None None O
of None None O
the None None O
outer None None O
membrane None None O
, None None O
the None None O
amount None None O
of None None O
three None None O
spots None None O
in None None O
two None None O
- None None O
dimensional None None O
polyacrylamide None None O
gels None None O
was None None O
shown None None O
to None None O
be None None O
related None None O
to None None O
the None None O
temperature None None O
or None None O
the None None O
presence None None O
of None None O
calcium None None O
during None None O
growth None None O
. None None O

One None None O
of None None O
these None None O
spots None None O
was None None O
shown None None O
to None None O
contain None None O
residual None None O
unmodified None None O
portions None None O
of None None O
two None None O
major None None O
heat None None O
- None None O
modifiable None None O
proteins None None O
which None None O
failed None None O
to None None O
shift None None O
to None None O
their None None O
heat None None O
- None None O
modified None None O
positions None None O
on None None O
gels None None O
, None None O
despite None None O
solubilization None None O
at None None O
100 None None O
degrees None None O
C None None O
for None None O
10 None None O
min None None O
before None None O
electrophoresis None None O
. None None O

The None None O
other None None O
two None None O
spots None None O
were None None O
the None None O
heat None None O
- None None O
modified None None O
and None None O
unmodified None None O
forms None None O
of None None O
another None None O
outer None None O
membrane None None O
protein None None O
( None None O
J None None O
) None None O
which None None O
did None None O
not None None O
appear None None O
in None None O
the None None O
isoelectric None None O
focusing None None O
gel None None O
of None None O
cells None None O
grown None None O
at None None O
37 None None O
degrees None None O
C None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
the None None O
appearance None None O
of None None O
these None None O
spots None None O
in None None O
two None None O
- None None O
dimensional None None O
analyses None None O
is None None O
related None None O
to None None O
the None None O
lipopolysaccharide None None O
composition None None O
of None None O
the None None O
cells None None O
from None None O
which None None O
the None None O
outer None None O
membrane None None O
is None None O
derived None None O
and None None O
reflects None None O
lipopolysaccharide None None O
- None None O
protein None None O
interactions None None O
or None None O
calcium None None O
- None None O
protein None None O
interactions None None O
. None None O

Mean None None O
differences None None O
of None None O
scores None None O
with None None O
baseline None None O
of None None O
the None None O
22 None None O
patients None None O
who None None O
competed None None O
all None None O
QLQ None None O
- None None O
C30 None None O
questionnaires None None O
- None None O
symptoms None None O
scores None None O
. None None O

Suppressed None None O
transformation None None O
and None None O
induced None None O
differentiation None None O
of None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
- None None O
overexpressing None None O
breast None None O
cancer None None O
cells None None O
by None None O
emodin None None O
. None None O

The None None O
amplification None None O
and None None O
overexpression None None O
of None None O
the None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
proto None None O
- None None O
oncogene None None O
, None None O
which None None O
encodes None None O
the None None O
tyrosine None None O
kinase None None O
receptor None None O
p185neu None None O
, None None O
have None None O
been None None O
observed None None O
frequently None None O
in None None O
tumors None None O
from None None O
human None None O
breast None None O
cancer None None O
patients None None O
and None None O
are None None O
correlated None None O
with None None O
poor None None O
prognosis None None O
. None None O

To None None O
explore None None O
the None None O
potential None None O
of None None O
chemotherapy None None O
directed None None O
at None None O
the None None O
tyrosine None None O
kinase None None O
of None None O
p185neu None None O
, None None O
we None None O
have None None O
found None None O
that None None O
emodin None None O
( None None O
3 None None O
- None None O
methyl None None O
- None None O
1 None None O
, None None O
6 None None O
, None None O
8 None None O
- None None O
trihydroxyanthraquinone None None O
) None None O
, None None O
a None None O
tyrosine None None O
kinase None None O
inhibitor None None O
, None None O
suppresses None None O
autophosphorylation None None O
and None None O
transphosphorylation None None O
activities None None O
of None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
tyrosine None None O
kinase None None O
, None None O
resulting None None O
in None None O
tyrosine None None O
hypophosphorylation None None O
of None None O
p185neu None None O
in None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
- None None O
overexpressing None None O
breast None None O
cancer None None O
cells None None O
. None None O

Emodin None None O
, None None O
at None None O
a None None O
40 None None O
- None None O
microM None None O
concentration None None O
, None None O
which None None O
repressed None None O
tyrosine None None O
kinase None None O
of None None O
p185neu None None O
, None None O
efficiently None None O
inhibited None None O
both None None O
anchorage None None O
- None None O
dependent None None O
and None None O
anchorage None None O
- None None O
independent None None O
growth None None O
of None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
- None None O
overexpressing None None O
breast None None O
cancer None None O
cells None None O
. None None O

However None None O
, None None O
the None None O
inhibition None None O
was None None O
much None None O
less None None O
effective None None O
for None None O
those None None O
cells None None O
expressing None None O
basal None None O
levels None None O
of None None O
p185neu None None O
under None None O
the None None O
same None None O
conditions None None O
. None None O

Emodin None None O
also None None O
induced None None O
differentiation None None O
of None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
- None None O
overexpressing None None O
breast None None O
cancer None None O
cells None None O
by None None O
exhibiting None None O
a None None O
morphological None None O
maturation None None O
property None None O
of None None O
large None None O
lacy None None O
nuclei None None O
surrounded None None O
by None None O
sizable None None O
flat None None O
cytoplasm None None O
and None None O
by None None O
showing None None O
a None None O
measurable None None O
production None None O
of None None O
large None None O
lipid None None O
droplets None None O
, None None O
which None None O
is None None O
a None None O
marker None None O
of None None O
mature None None O
breast None None O
cells None None O
. None None O

Therefore None None O
, None None O
our None None O
results None None O
indicate None None O
that None None O
emodin None None O
inhibits None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
tyrosine None None O
kinase None None O
activity None None O
and None None O
preferentially None None O
suppresses None None O
growth None None O
and None None O
induces None None O
differentiation None None O
of None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
- None None O
overexpressing None None O
cancer None None O
cells None None O
. None None O

These None None O
results None None O
may None None O
have None None O
chemotherapeutic None None O
implications None None O
for None None O
using None None O
emodin None None O
to None None O
target None None O
HER None None O
- None None O
2 None None O
/ None None O
neu None None O
- None None O
overexpressing None None O
cancer None None O
cells None None O
. None None O

Acknowledgements None None O

We None None O
thank None None O
Dr None None O
. None None O
Neva None None O
Meyer None None O
for None None O
confocal None None O
imaging None None O
and None None O
generation None None O
of None None O
Z None None O
- None None O
stack None None O
projection None None O
, None None O
and None None O
the None None O
following None None O
members None None O
of None None O
the None None O
Seaver None None O
lab None None O
for None None O
their None None O
continued None None O
support None None O
of None None O
this None None O
project None None O
: None None O
Dr None None O
. None None O
Neva None None O
Meyer None None O
, None None O
Dr None None O
. None None O
Aldine None None O
Amiel None None O
, None None O
and None None O
Tyler None None O
Smith None None O
. None None O

This None None O
work None None O
was None None O
supported None None O
by None None O
the None None O
National None None O
Science None None O
Foundation None None O
( None None O
REU None None O
Supplement None None O
of None None O
10B05 None None O
- None None O
44869 None None O
to None None O
E None None O
. None None O
C None None O
. None None O
S None None O
. None None O
) None None O
. None None O

Dopamine None None O
regulates None None O
phosphorylation None None O
of None None O
VEGF None None O
receptor None None O
2 None None O
by None None O
engaging None None O
Src None None O
- None None O
homology None None O
- None None O
2 None None O
- None None O
domain None None O
- None None O
containing None None O
protein None None O
tyrosine None None O
phosphatase None None O
2 None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
- None None O
induced None None O
receptor None None O
phosphorylation None None O
is None None O
the None None O
crucial None None O
step None None O
for None None O
initiating None None O
downstream None None O
signaling None None O
pathways None None O
that None None O
lead None None O
to None None O
angiogenesis None None O
or None None O
related None None O
pathophysiological None None O
outcomes None None O
. None None O

Our None None O
previous None None O
studies None None O
have None None O
shown None None O
that None None O
the None None O
neurotransmitter None None O
dopamine None None O
could None None O
inhibit None None O
VEGF None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
VEGF None None O
receptor None None O
2 None None O
( None None O
VEGFR None None O
- None None O
2 None None O
) None None O
, None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
migration None None O
, None None O
microvascular None None O
permeability None None O
, None None O
and None None O
thus None None O
, None None O
angiogenesis None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
address None None O
the None None O
mechanism None None O
by None None O
which None None O
VEGFR None None O
- None None O
2 None None O
phosphorylation None None O
is None None O
regulated None None O
by None None O
dopamine None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
that None None O
D2 None None O
dopamine None None O
receptor None None O
( None None O
D2DR None None O
) None None O
colocalizes None None O
with None None O
VEGFR None None O
- None None O
2 None None O
at None None O
the None None O
cell None None O
surface None None O
. None None O

Dopamine None None O
pretreatment None None O
increases None None O
the None None O
translocation None None O
and None None O
colocalization None None O
of None None O
Src None None O
- None None O
homology None None O
- None None O
2 None None O
- None None O
domain None None O
- None None O
containing None None O
protein None None O
tyrosine None None O
phosphatase None None O
( None None O
SHP None None O
- None None O
2 None None O
) None None O
with None None O
D2DR None None O
at None None O
the None None O
cell None None O
surface None None O
. None None O

Dopamine None None O
administration None None O
leads None None O
to None None O
increased None None O
VEGF None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
SHP None None O
- None None O
2 None None O
and None None O
this None None O
increased None None O
phosphorylation None None O
parallels None None O
the None None O
increased None None O
phosphatase None None O
activity None None O
of None None O
SHP None None O
- None None O
2 None None O
. None None O

Active None None O
SHP None None O
- None None O
2 None None O
then None None O
dephosphorylates None None O
VEGFR None None O
- None None O
2 None None O
at None None O
Y951 None None O
, None None O
Y996 None None O
and None None O
Y1059 None None O
, None None O
but None None O
not None None O
Y1175 None None O
. None None O

We None None O
also None None O
observe None None O
that None None O
SHP None None O
- None None O
2 None None O
knockdown None None O
impairs None None O
the None None O
dopamine None None O
- None None O
regulated None None O
inhibition None None O
of None None O
VEGF None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
VEGFR None None O
- None None O
2 None None O
and None None O
, None None O
subsequently None None O
, None None O
Src None None O
phosphorylation None None O
and None None O
migration None None O
. None None O

Our None None O
data None None O
establish None None O
a None None O
novel None None O
role None None O
for None None O
SHP None None O
- None None O
2 None None O
phosphatase None None O
in None None O
the None None O
dopamine None None O
- None None O
mediated None None O
regulation None None O
of None None O
VEGFR None None O
- None None O
2 None None O
phosphorylation None None O
. None None O

Antimicrobial None None O
prophylaxis None None O
in None None O
vaginal None None O
gynecologic None None O
surgery None None O
: None None O
a None None O
prospective None None O
randomized None None O
study None None O
comparing None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
with None None O
cefazolin None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
prospective None None O
, None None O
randomized None None O
study None None O
was None None O
to None None O
compare None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
with None None O
cefazolin None None O
as None None O
ultra None None O
- None None O
short None None O
term None None O
prophylaxis None None O
in None None O
vaginal None None O
gynecologic None None O
surgery None None O
. None None O

It None None O
was None None O
conducted None None O
at None None O
the None None O
Department None None O
of None None O
Obstetrics None None O
and None None O
Gynecology None None O
, None None O
University None None O
of None None O
Bari None None O
. None None O

Patients None None O
were None None O
randomly None None O
allocated None None O
to None None O
receive None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
( None None O
2 None None O
. None None O
2 None None O
g None None O
) None None O
[ None None O
Group None None O
A None None O
] None None O
or None None O
cefazolin None None O
( None None O
2 None None O
g None None O
) None None O
[ None None O
Group None None O
B None None O
] None None O
as None None O
a None None O
single None None O
dose None None O
30 None None O
minutes None None O
before None None O
surgery None None O
. None None O

Each None None O
patient None None O
was None None O
assessed None None O
daily None None O
until None None O
discharge None None O
to None None O
evidence None None O
febrile None None O
status None None O
and None None O
the None None O
presence None None O
of None None O
infections None None O
at None None O
the None None O
operative None None O
site None None O
, None None O
urinary None None O
tract None None O
and None None O
respiratory None None O
tract None None O
. None None O

In None None O
the None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
( None None O
Group None None O
A None None O
) None None O
and None None O
cefazolin None None O
( None None O
Group None None O
B None None O
) None None O
groups None None O
, None None O
overall None None O
88 None None O
and None None O
90 None None O
patients None None O
, None None O
respectively None None O
, None None O
were None None O
evaluable None None O
for None None O
prophylactic None None O
efficacy None None O
at None None O
hospital None None O
discharge None None O
. None None O

Infectious None None O
complications None None O
were None None O
infrequent None None O
in None None O
both None None O
arms None None O
, None None O
with None None O
febrile None None O
morbidity None None O
occurring None None O
in None None O
4 None None O
( None None O
4 None None O
. None None O
5 None None O
% None None O
) None None O
and None None O
16 None None O
( None None O
8 None None O
. None None O
9 None None O
% None None O
) None None O
patients None None O
respectively None None O
in None None O
the None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
and None None O
cefazolin None None O
groups None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
016 None None O
) None None O
. None None O

Urinary None None O
tract None None O
infections None None O
were None None O
higher None None O
but None None O
not None None O
significantly None None O
in None None O
the None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
group None None O
( None None O
6 None None O
. None None O
8 None None O
% None None O
versus None None O
4 None None O
. None None O
4 None None O
% None None O
) None None O
, None None O
whereas None None O
asymptomatic None None O
bacteriuria None None O
was None None O
detected None None O
in None None O
2 None None O
. None None O
2 None None O
% None None O
of None None O
the None None O
patients None None O
in None None O
both None None O
groups None None O
. None None O

There None None O
was None None O
no None None O
respiratory None None O
tract None None O
infection None None O
or None None O
septic None None O
death None None O
in None None O
either None None O
group None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
ultra None None O
- None None O
short None None O
term None None O
prophylaxis None None O
with None None O
both None None O
amoxicillin None None O
- None None O
clavulanic None None O
acid None None O
and None None O
cefazolin None None O
is None None O
safe None None O
and None None O
effective None None O
in None None O
elective None None O
vaginal None None O
gynecologic None None O
surgery None None O
. None None O

Molecular None None O
requirements None None O
for None None O
epithelial None None O
- None None O
mesenchymal None None O
transition None None O
during None None O
tumor None None O
progression None None O
. None None O

Epithelial None None O
- None None O
mesenchymal None None O
transitions None None O
( None None O
EMTs None None O
) None None O
occur None None O
as None None O
key None None O
steps None None O
during None None O
embryonic None None O
morphogenesis None None O
, None None O
and None None O
are None None O
now None None O
implicated None None O
in None None O
the None None O
progression None None O
of None None O
primary None None O
tumors None None O
towards None None O
metastases None None O
. None None O

Recent None None O
advances None None O
have None None O
fostered None None O
a None None O
more None None O
detailed None None O
understanding None None O
of None None O
molecular None None O
mechanisms None None O
and None None O
networks None None O
governing None None O
EMT None None O
in None None O
tumor None None O
progression None None O
. None None O

Besides None None O
TGFbeta None None O
and None None O
RTK None None O
/ None None O
Ras None None O
signaling None None O
, None None O
autocrine None None O
factors None None O
and None None O
Wnt None None O
- None None O
, None None O
Notch None None O
- None None O
, None None O
Hedgehog None None O
- None None O
and None None O
NF None None O
- None None O
kappaB None None O
- None None O
dependent None None O
pathways None None O
were None None O
found None None O
to None None O
contribute None None O
to None None O
EMT None None O
. None None O

Repression None None O
of None None O
E None None O
- None None O
cadherin None None O
by None None O
transcriptional None None O
regulators None None O
such None None O
as None None O
Snail None None O
or None None O
Twist None None O
emerges None None O
as None None O
one None None O
critical None None O
step None None O
driving None None O
EMT None None O
, None None O
and None None O
this None None O
stage None None O
is None None O
currently None None O
being None None O
molecularly None None O
linked None None O
with None None O
many None None O
of None None O
the None None O
new None None O
players None None O
. None None O

Increasing None None O
evidence None None O
suggests None None O
that None None O
EMT None None O
plays None None O
a None None O
specific None None O
role None None O
in None None O
the None None O
migration None None O
of None None O
cells None None O
from None None O
a None None O
primary None None O
tumor None None O
into None None O
the None None O
circulation None None O
and None None O
may None None O
provide None None O
a None None O
rationale None None O
for None None O
developing None None O
more None None O
effective None None O
cancer None None O
therapies None None O
. None None O

Treatment None None O
of None None O
transplanted None None O
CT26 None None I-Cell-line-name
tumour None None O
with None None O
dendritic None None O
cell None None O
vaccine None None O
in None None O
combination None None O
with None None O
blockade None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
2 None None O
and None None O
CTLA None None O
- None None O
4 None None O
. None None O

We None None O
investigated None None O
the None None O
anti None None O
CT26 None None I-Cell-line-name
tumour None None O
effect None None O
of None None O
dendritic None None O
cell None None O
based None None O
vaccination None None O
with None None O
the None None O
MuLV None None O
gp70 None None O
envelope None None O
protein None None O
- None None O
derived None None O
peptides None None O
AH1 None None O
and None None O
p320 None None O
- None None O
333 None None O
. None None O

Vaccination None None O
lead None None O
to None None O
generation None None O
of None None O
AH1 None None O
specific None None O
cytotoxic None None O
lymphocytes None None O
( None None O
CTL None None O
) None None O
and None None O
some None None O
decrease None None O
in None None O
tumour None None O
growth None None O
of None None O
simultaneously None None O
inoculated None None O
CT26 None None I-Cell-line-name
cells None None O
. None None O

After None None O
combination None None O
with None None O
an None None O
antibody None None O
against None None O
VEGF None None O
receptor None None O
2 None None O
( None None O
DC101 None None O
) None None O
, None None O
a None None O
significant None None O
increase None None O
in None None O
survival None None O
of None None O
the None None O
tumour None None O
cell None None O
recipients None None O
was None None O
observed None None O
. None None O

Also None None O
, None None O
monotherapy None None O
with None None O
an None None O
antibody None None O
against None None O
CTLA None None O
- None None O
4 None None O
( None None O
9H10 None None O
) None None O
, None None O
led None None O
to None None O
approximately None None O
100 None None O
% None None O
survival None None O
of None None O
tumour None None O
cell None None O
recipients None None O
. None None O

However None None O
, None None O
effective None None O
treatment None None O
of None None O
mice None None O
with None None O
already None None O
established None None O
tumours None None O
was None None O
only None None O
obtained None None O
after None None O
combination None None O
of None None O
vaccination None None O
, None None O
DC101 None None O
and None None O
9H10 None None O
treatment None None O
in None None O
which None None O
setting None None O
80 None None O
% None None O
of None None O
the None None O
mice None None O
rejected None None O
their None None O
tumours None None O
. None None O

Determination None None O
of None None O
As None None O
metabolites None None O

We None None O
assessed None None O
As None None O
metabolism None None O
using None None O
the None None O
percentages None None O
of None None O
iAs None None O
, None None O
MMA None None O
, None None O
and None None O
DMA None None O
in None None O
urine None None O
, None None O
as None None O
well None None O
as None None O
two None None O
methylation None None O
indexes None None O
[ None None O
i None None O
. None None O
e None None O
. None None O
, None None O
primary None None O
methylation None None O
index None None O
( None None O
PMI None None O
) None None O
, None None O
defined None None O
as None None O
the None None O
ratio None None O
between None None O
MMA None None O
and None None O
iAs None None O
, None None O
and None None O
secondary None None O
methylation None None O
index None None O
( None None O
SMI None None O
) None None O
, None None O
defined None None O
as None None O
the None None O
ratio None None O
between None None O
DMA None None O
and None None O
MMA None None O
. None None O

We None None O
used None None O
total None None O
urinary None None O
As None None O
[ None None O
U None None O
- None None O
As None None O
; None None O
the None None O
sum None None O
of None None O
As None None O
metabolites None None O
( None None O
iAs None None O
+ None None O
MMA None None O
+ None None O
DMA None None O
) None None O
in None None O
urine None None O
] None None O
as None None O
the None None O
measure None None O
of None None O
iAs None None O
exposure None None O
. None None O

Concentrations None None O
of None None O
As None None O
metabolites None None O
in None None O
urine None None O
were None None O
measured None None O
with None None O
an None None O
Agilent None None O
1100 None None O
HPLC None None O
system None None O
( None None O
Agilent None None O
Technologies None None O
, None None O
Waldbronn None None O
, None None O
Germany None None O
) None None O
, None None O
coupled None None O
with None None O
hydride None None O
generation None None O
( None None O
HG None None O
) None None O
inductively None None O
coupled None None O
plasma None None O
mass None None O
spectrometry None None O
( None None O
ICPMS None None O
) None None O
( None None O
Agilent None None O
7500ce None None O
series None None O
; None None O
Agilent None None O
Technologies None None O
, None None O
Japan None None O
) None None O
. None None O

The None None O
method None None O
measures None None O
metabolites None None O
of None None O
iAs None None O
[ None None O
iAs None None O
( None None O
III None None O
) None None O
, None None O
iAs None None O
( None None O
V None None O
) None None O
, None None O
MMA None None O
, None None O
and None None O
DMA None None O
] None None O
, None None O
but None None O
not None None O
organic None None O
As None None O
species None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
arsenobetaine None None O
, None None O
arsenocholine None None O
) None None O
originating None None O
from None None O
the None None O
diet None None O
, None None O
because None None O
those None None O
arsenicals None None O
do None None O
not None None O
form None None O
volatile None None O
arsines None None O
( None None O
hydride None None O
generation None None O
) None None O
like None None O
iAs None None O
and None None O
its None None O
metabolites None None O
do None None O
. None None O

The None None O
method None None O
was None None O
described None None O
in None None O
detail None None O
by None None O
Lindberg None None O
et None None O
al None None O
. None None O

( None None O
2006 None None O
) None None O
. None None O

Determination None None O
limits None None O
were None None O
0 None None O
. None None O
1 None None O
mug None None O
/ None None O
L None None O
for None None O
arsenite None None O
[ None None O
As None None O
( None None O
III None None O
) None None O
] None None O
and None None O
MMA None None O
and None None O
0 None None O
. None None O
2 None None O
mug None None O
/ None None O
L None None O
for None None O
DMA None None O
and None None O
arsenate None None O
[ None None O
As None None O
( None None O
V None None O
) None None O
] None None O
. None None O

We None None O
adjusted None None O
As None None O
concentrations None None O
for None None O
variations None None O
in None None O
dilution None None O
by None None O
specific None None O
gravity None None O
( None None O
to None None O
the None None O
mean None None O
value None None O
of None None O
1 None None O
. None None O
012 None None O
g None None O
/ None None O
mL None None O
) None None O
; None None O
U None None O
- None None O
Cre None None O
, None None O
which None None O
is None None O
commonly None None O
used None None O
for None None O
dilution None None O
adjustment None None O
, None None O
was None None O
influenced None None O
more None None O
by None None O
age None None O
and None None O
nutrition None None O
than None None O
was None None O
specific None None O
gravity None None O
, None None O
and None None O
U None None O
- None None O
Cre None None O
was None None O
also None None O
associated None None O
with None None O
urinary None None O
As None None O
( None None O
Nermell None None O
et None None O
al None None O
. None None O
2007 None None O
) None None O
. None None O

For None None O
quality None None O
control None None O
purposes None None O
, None None O
we None None O
analyzed None None O
the None None O
reference None None O
material None None O
( None None O
CRM None None O
No None None O
. None None O
18 None None O
; None None O
National None None O
Institute None None O
for None None O
Environmental None None O
Studies None None O
, None None O
Ibaraki None None O
, None None O
Japan None None O
) None None O
with None None O
a None None O
certified None None O
DMA None None O
concentration None None O
of None None O
36 None None O
+ None None O
/ None None O
- None None O
9 None None O
mug None None O
/ None None O
L None None O
together None None O
with None None O
the None None O
collected None None O
urine None None O
samples None None O
. None None O

The None None O
concentration None None O
of None None O
DMA None None O
was None None O
41 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
4 None None O
mug None None O
/ None None O
L None None O
( None None O
mean None None O
+ None None O
/ None None O
- None None O
SD None None O
; None None O
n None None O
= None None O
18 None None O
) None None O
. None None O

Urine None None O
samples None None O
were None None O
also None None O
analyzed None None O
for None None O
As None None O
metabolites None None O
by None None O
atomic None None O
fluorescence None None O
spectrometry None None O
( None None O
AFS None None O
) None None O
and None None O
for None None O
the None None O
sum None None O
of None None O
As None None O
metabolites None None O
by None None O
atomic None None O
absorption None None O
spectrometry None None O
( None None O
AAS None None O
) None None O
, None None O
as None None O
reported None None O
by None None O
Lindberg None None O
et None None O
al None None O
. None None O

( None None O
2007a None None O
) None None O
. None None O

The None None O
results None None O
of None None O
ICPMS None None O
and None None O
AFS None None O
showed None None O
good None None O
agreement None None O
for None None O
all None None O
metabolites None None O
; None None O
for None None O
iAs None None O
[ None None O
As None None O
( None None O
III None None O
) None None O
+ None None O
As None None O
( None None O
V None None O
) None None O
] None None O
, None None O
MMA None None O
, None None O
and None None O
DMA None None O
, None None O
R2 None None O
= None None O
0 None None O
. None None O
91 None None O
, None None O
0 None None O
. None None O
91 None None O
, None None O
and None None O
0 None None O
. None None O
97 None None O
, None None O
respectively None None O
( None None O
n None None O
= None None O
221 None None O
) None None O
. None None O

Further None None O
, None None O
we None None O
obtained None None O
good None None O
agreement None None O
for None None O
the None None O
sum None None O
of None None O
As None None O
metabolites None None O
between None None O
the None None O
three None None O
different None None O
methods None None O
( None None O
for None None O
ICPMS None None O
vs None None O
. None None O
AFS None None O
, None None O
R2 None None O
= None None O
0 None None O
. None None O
97 None None O
; None None O
for None None O
ICPMS None None O
vs None None O
. None None O
AAS None None O
, None None O
R2 None None O
= None None O
0 None None O
. None None O
96 None None O
( None None O
n None None O
= None None O
221 None None O
) None None O
. None None O

Decrease None None O
in None None O
c None None O
- None None O
Myc None None O
activity None None O
enhances None None O
cancer None None O
cell None None O
sensitivity None None O
to None None O
vinblastine None None O
. None None O

The None None O
c None None O
- None None O
myc None None O
oncogene None None O
encodes None None O
for None None O
a None None O
transcriptional None None O
factor None None O
involved None None O
in None None O
many None None O
cellular None None O
processes None None O
such None None O
as None None O
proliferation None None O
, None None O
differentiation None None O
and None None O
apoptosis None None O
. None None O

According None None O
to None None O
these None None O
different None None O
functions None None O
, None None O
the None None O
role None None O
of None None O
c None None O
- None None O
Myc None None O
protein None None O
in None None O
cellular None None O
sensitivity None None O
to None None O
anti None None O
- None None O
cancer None None O
drugs None None O
is None None O
controversial None None O
. None None O

We None None O
defined None None O
the None None O
role None None O
of None None O
c None None O
- None None O
Myc None None O
in None None O
cancer None None O
cell None None O
sensitivity None None O
to None None O
vinblastine None None O
( None None O
VLB None None O
) None None O
using None None O
human None None O
colon None None O
cancer None None O
cells None None O
: None None O
LoVo None None I-Cell-line-name
wild None None O
- None None O
type None None O
or None None O
transfected None None O
with None None O
a None None O
plasmid None None O
containing None None O
the None None O
human None None O
c None None O
- None None O
myc None None O
gene None None O
in None None O
antisense None None O
orientation None None O
( None None O
LoVo None None I-Cell-line-name
- None None O
mycANS None None O
) None None O
. None None O

Analysis None None O
of None None O
VLB None None O
cytotoxicity None None O
demonstrated None None O
a None None O
3 None None O
- None None O
fold None None O
increase None None O
in None None O
VLB None None O
sensitivity None None O
in None None O
LoVo None None I-Cell-line-name
- None None O
mycANS None None O
cells None None O
. None None O

Comparison None None O
between None None O
cells None None O
revealed None None O
different None None O
apoptosis None None O
kinetics None None O
: None None O
accumulation None None O
of None None O
cells None None O
in None None O
sub None None O
- None None O
G1 None None O
phase None None O
and None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
cleavage None None O
occurred None None O
earlier None None O
in None None O
LoVo None None I-Cell-line-name
- None None O
mycANS None None O
. None None O

Then None None O
, None None O
we None None O
demonstrated None None O
a None None O
mitochondrial None None O
membrane None None O
potential None None O
disruption None None O
followed None None O
by None None O
cytochrome None None O
c None None O
release None None O
that None None O
indicates None None O
the None None O
involvement None None O
of None None O
mitochondria None None O
in None None O
this None None O
apoptotic None None O
signaling None None O
pathway None None O
. None None O

This None None O
earlier None None O
apoptosis None None O
was None None O
accompanied None None O
by None None O
a None None O
Bcl None None O
- None None O
2 None None O
decrease None None O
and None None O
a None None O
p53 None None O
increase None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
decrease None None O
in None None O
c None None O
- None None O
Myc None None O
expression None None O
enhanced None None O
the None None O
VLB None None O
sensitivity None None O
, None None O
triggering None None O
earlier None None O
apoptosis None None O
through None None O
induction None None O
of None None O
the None None O
intrinsic None None O
pathway None None O
. None None O

Thus None None O
, None None O
c None None O
- None None O
myc None None O
induction None None O
is None None O
a None None O
resistance None None O
factor None None O
and None None O
our None None O
findings None None O
suggest None None O
that None None O
tumors None None O
carrying None None O
low None None O
levels None None O
of None None O
c None None O
- None None O
Myc None None O
protein None None O
could None None O
be None None O
more None None O
responsive None None O
to None None O
vinca None None O
alkaloids None None O
treatment None None O
. None None O

Moreover None None O
, None None O
the None None O
downregulation None None O
of None None O
c None None O
- None None O
myc None None O
oncogene None None O
by None None O
an None None O
antisense None None O
strategy None None O
might None None O
represent None None O
a None None O
useful None None O
goal None None O
for None None O
improving None None O
the None None O
efficacy None None O
of None None O
this None None O
anti None None O
- None None O
neoplastic None None O
drug None None O
family None None O
. None None O

Loss None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
in None None O
gastric None None O
carcinoma None None O
. None None O

BACKGROUND None None O
: None None O
CDC4 None None O
/ None None O
FBXW7 None None O
, None None O
encoding None None O
a None None O
ubiquitin None None O
ligase None None O
, None None O
maps None None O
to None None O
4q32 None None O
and None None O
has None None O
been None None O
implicated None None O
as None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
and None None O
therapeutic None None O
target None None O
in None None O
many None None O
tumor None None O
types None None O
. None None O

Mutations None None O
in None None O
colonic None None O
adenomas None None O
, None None O
and None None O
the None None O
frequent None None O
losses None None O
on None None O
4q None None O
described None None O
in None None O
gastric None None O
cancer None None O
prompt None None O
speculation None None O
about None None O
the None None O
role None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
in None None O
gastric None None O
carcinogenesis None None O
. None None O

METHODS None None O
: None None O
We None None O
assessed None None O
the None None O
role None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
in None None O
gastric None None O
cancer None None O
, None None O
through None None O
loss None None O
of None None O
heterozygosity None None O
( None None O
LOH None None O
) None None O
and None None O
multiplex None None O
ligation None None O
- None None O
dependent None None O
probe None None O
amplification None None O
( None None O
MLPA None None O
) None None O
on None None O
47 None None O
flow None None O
- None None O
sorted None None O
gastric None None O
carcinomas None None O
including None None O
early None None O
- None None O
onset None None O
gastric None None O
cancers None None O
( None None O
EOGC None None O
) None None O
and None None O
xenografted None None O
conventional None None O
gastric None None O
carcinomas None None O
. None None O

Ploidy None None O
analysis None None O
was None None O
carried None None O
out None None O
on None None O
39 None None O
EOGCs None None O
and None None O
immunohistochemistry None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
and None None O
its None None O
substrates None None O
c None None O
- None None O
myc None None O
, None None O
c None None O
- None None O
jun None None O
, None None O
Notch None None O
and None None O
cyclin None None O
E None None O
was None None O
performed None None O
on None None O
204 None None O
gastric None None O
carcinomas None None O
using None None O
tissue None None O
microarrays None None O
( None None O
TMAs None None O
) None None O
. None None O

Sequence None None O
analysis None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
was None None O
carried None None O
out None None O
on None None O
gastric None None O
carcinoma None None O
cell None None O
lines None None O
and None None O
xenografts None None O
. None None O

RESULTS None None O
: None None O
Loss None None O
of None None O
heterozygosity None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
occurred None None O
in None None O
32 None None O
% None None O
of None None O
EOGCs None None O
, None None O
and None None O
correlated None None O
with None None O
loss None None O
of None None O
expression None None O
in None None O
26 None None O
% None None O
. None None O

Loss None None O
of None None O
expression None None O
was None None O
frequent None None O
in None None O
both None None O
EOGC None None O
and None None O
conventional None None O
gastric None None O
cancers None None O
. None None O

No None None O
CDC4 None None O
/ None None O
FBXW7 None None O
mutations None None O
were None None O
found None None O
and None None O
loss None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
did None None O
not None None O
correlate None None O
with None None O
ploidy None None O
status None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
between None None O
loss None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
expression None None O
and None None O
upregulation None None O
of None None O
c None None O
- None None O
myc None None O
. None None O

CONCLUSION None None O
: None None O
Loss None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
appears None None O
to None None O
play None None O
a None None O
role None None O
in None None O
both None None O
EOGC None None O
and None None O
conventional None None O
gastric None None O
carcinogenesis None None O
, None None O
and None None O
c None None O
- None None O
myc None None O
overexpression None None O
is None None O
likely None None O
to None None O
be None None O
an None None O
important None None O
oncogenic None None O
consequence None None O
of None None O
CDC4 None None O
/ None None O
FBXW7 None None O
loss None None O
. None None O

Assessment None None O
instruments None None O

The None None O
SCID None None O
- None None O
I None None O
/ None None O
P None None O
was None None O
administered None None O
by None None O
psychiatrists None None O
trained None None O
and None None O
certified None None O
in None None O
the None None O
use None None O
of None None O
all None None O
instruments None None O
in None None O
this None None O
study None None O
. None None O

The None None O
ICG None None O
is None None O
a None None O
self None None O
- None None O
report None None O
instrument None None O
that None None O
can None None O
be None None O
used None None O
to None None O
identify None None O
CG None None O
when None None O
the None None O
total None None O
score None None O
is None None O
> None None O
25 None None O
, None None O
that None None O
demonstrated None None O
high None None O
internal None None O
consistency None None O
( None None O
Cronbach None None O
' None None O
s None None O
alpha None None O
= None None O
0 None None O
. None None O
94 None None O
) None None O
, None None O
and None None O
convergent None None O
and None None O
criterion None None O
validity None None O
[ None None O
27 None None O
] None None O
. None None O

The None None O
ICG None None O
total None None O
score None None O
also None None O
showed None None O
a None None O
fairly None None O
high None None O
association None None O
with None None O
the None None O
Beck None None O
Depression None None O
Inventory None None O
( None None O
BDI None None O
) None None O
[ None None O
32 None None O
] None None O
total None None O
score None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
67 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
the None None O
Texas None None O
Revised None None O
Inventory None None O
of None None O
Grief None None O
( None None O
TRIG None None O
) None None O
[ None None O
33 None None O
] None None O
score None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
87 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
and None None O
the None None O
Grief None None O
Measurement None None O
Scale None None O
( None None O
GMS None None O
) None None O
[ None None O
34 None None O
] None None O
score None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
70 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

The None None O
ASA None None O
- None None O
27 None None O
is None None O
a None None O
self None None O
- None None O
report None None O
measure None None O
developed None None O
to None None O
rate None None O
separation None None O
anxiety None None O
symptoms None None O
in None None O
adult None None O
life None None O
( None None O
from None None O
18 None None O
years None None O
of None None O
age None None O
) None None O
. None None O

Principal None None O
components None None O
analysis None None O
revealed None None O
a None None O
coherent None None O
construct None None O
of None None O
adult None None O
separation None None O
anxiety None None O
with None None O
high None None O
internal None None O
consistency None None O
( None None O
Cronbach None None O
' None None O
s None None O
alpha None None O
= None None O
0 None None O
. None None O
95 None None O
) None None O
and None None O
sound None None O
test None None O
- None None O
retest None None O
reliability None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
86 None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Further None None O
, None None O
a None None O
receiver None None O
operation None None O
characteristic None None O
( None None O
ROC None None O
) None None O
analysis None None O
against None None O
the None None O
semistructured None None O
interview None None O
yielded None None O
a None None O
high None None O
area None None O
under None None O
the None None O
curve None None O
( None None O
AUC None None O
) None None O
index None None O
of None None O
0 None None O
. None None O
9 None None O
, None None O
suggesting None None O
that None None O
the None None O
questionnaire None None O
is None None O
an None None O
adequate None None O
alternative None None O
measure None None O
of None None O
adult None None O
separation None None O
anxiety None None O
[ None None O
29 None None O
] None None O
. None None O

The None None O
WSAS None None O
is None None O
a None None O
self None None O
- None None O
report None None O
scale None None O
of None None O
functional None None O
impairment None None O
that None None O
includes None None O
five None None O
questions None None O
rating None None O
interference None None O
of None None O
psychiatric None None O
symptoms None None O
in None None O
work None None O
, None None O
home None None O
management None None O
, None None O
social None None O
or None None O
private None None O
leisure None None O
activities None None O
, None None O
and None None O
ability None None O
to None None O
form None None O
and None None O
maintain None None O
close None None O
relationships None None O
with None None O
others None None O
. None None O

Each None None O
question None None O
is None None O
rated None None O
on None None O
a None None O
0 None None O
to None None O
8 None None O
scale None None O
with None None O
0 None None O
indicating None None O
no None None O
impairment None None O
at None None O
all None None O
and None None O
8 None None O
indicating None None O
very None None O
severe None None O
impairment None None O
. None None O

The None None O
Cronbach None None O
' None None O
s None None O
alpha None None O
measure None None O
of None None O
internal None None O
scale None None O
consistency None None O
ranged None None O
from None None O
0 None None O
. None None O
70 None None O
to None None O
0 None None O
. None None O
94 None None O
, None None O
the None None O
test None None O
- None None O
retest None None O
correlation None None O
was None None O
0 None None O
. None None O
73 None None O
, None None O
and None None O
the None None O
WSAS None None O
interactive None None O
voice None None O
response None None O
administrations None None O
gave None None O
correlations None None O
of None None O
0 None None O
. None None O
81 None None O
and None None O
0 None None O
. None None O
86 None None O
with None None O
clinician None None O
interviews None None O
[ None None O
30 None None O
] None None O
. None None O

Correlations None None O
of None None O
WSAS None None O
with None None O
severity None None O
of None None O
depression None None O
and None None O
obsessive None None O
- None None O
compulsive None None O
disorder None None O
symptoms None None O
were None None O
0 None None O
. None None O
76 None None O
and None None O
0 None None O
. None None O
61 None None O
, None None O
respectively None None O
, None None O
and None None O
the None None O
scores None None O
were None None O
sensitive None None O
to None None O
patient None None O
differences None None O
in None None O
disorder None None O
severity None None O
and None None O
treatment None None O
- None None O
related None None O
change None None O
[ None None O
30 None None O
] None None O
. None None O

The None None O
MOODS None None O
- None None O
SR None None O
is None None O
an None None O
instrument None None O
developed None None O
and None None O
validated None None O
to None None O
assess None None O
lifetime None None O
mood None None O
spectrum None None O
symptoms None None O
[ None None O
35 None None O
] None None O
, None None O
including None None O
manic None None O
and None None O
depressive None None O
features None None O
, None None O
rhythmicity None None O
and None None O
vegetative None None O
functions None None O
. None None O

The None None O
manic None None O
and None None O
depressive None None O
components None None O
are None None O
subtyped None None O
into None None O
mood None None O
, None None O
energy None None O
and None None O
cognition None None O
domains None None O
, None None O
focusing None None O
on None None O
manic None None O
or None None O
depressive None None O
symptoms None None O
, None None O
respectively None None O
. None None O

The None None O
rhythmicity None None O
and None None O
vegetative None None O
functions None None O
domain None None O
include None None O
changes None None O
in None None O
energy None None O
, None None O
physical None None O
wellbeing None None O
, None None O
mental None None O
and None None O
physical None None O
efficiency None None O
, None None O
related None None O
to None None O
the None None O
weather None None O
and None None O
season None None O
, None None O
and None None O
changes None None O
in None None O
appetite None None O
, None None O
sleep None None O
and None None O
sexual None None O
activities None None O
. None None O

The None None O
sum None None O
of None None O
the None None O
scores None None O
on None None O
the None None O
3 None None O
manic None None O
domains None None O
( None None O
mood None None O
, None None O
energy None None O
, None None O
cognition None None O
) None None O
constitutes None None O
the None None O
' None None O
manic None None O
component None None O
' None None O
( None None O
62 None None O
items None None O
) None None O
and None None O
that None None O
of None None O
the None None O
3 None None O
depressive None None O
domains None None O
the None None O
' None None O
depressive None None O
component None None O
' None None O
( None None O
63 None None O
items None None O
) None None O
. None None O

The None None O
rhythmicity None None O
and None None O
vegetative None None O
functions None None O
domain None None O
includes None None O
29 None None O
items None None O
. None None O

The None None O
instrument None None O
can None None O
be None None O
downloaded None None O
from None None O
http None None O
: None None O
/ None None O
/ None None O
www None None O
. None None O
spectrum None None O
- None None O
project None None O
. None None O
org None None O
. None None O

[ None None O
Epidemiology None None O
of None None O
fractures None None O
of None None O
the None None O
proximal None None O
femur None None O
] None None O
. None None O

Fractures None None O
of None None O
the None None O
upper None None O
end None None O
of None None O
the None None O
femur None None O
constitute None None O
a None None O
major None None O
public None None O
health None None O
problem None None O
which None None O
, None None O
for None None O
demographic None None O
reasons None None O
, None None O
will None None O
become None None O
worse None None O
during None None O
the None None O
next None None O
decades None None O
. None None O

The None None O
clinical None None O
determination None None O
of None None O
femoral None None O
neck None None O
fractures None None O
is None None O
imperfectly None None O
known None None O
. None None O

Two None None O
factors None None O
seem None None O
to None None O
be None None O
determinant None None O
: None None O
bone None None O
fragility None None O
and None None O
fall None None O
, None None O
but None None O
these None None O
factors None None O
are None None O
frequent None None O
in None None O
the None None O
elderly None None O
and None None O
other None None O
factors None None O
seem None None O
to None None O
intervene None None O
, None None O
notably None None O
the None None O
modality None None O
of None None O
the None None O
impact None None O
and None None O
the None None O
protection None None O
reflexes None None O
during None None O
the None None O
fall None None O
. None None O

The None None O
epidemiology None None O
of None None O
proximal None None O
femur None None O
fractures None None O
therefore None None O
cannot None None O
be None None O
restricted None None O
to None None O
the None None O
diminution None None O
of None None O
bone None None O
mass None None O
. None None O

Beside None None O
age None None O
and None None O
female None None O
sex None None O
, None None O
the None None O
confirmed None None O
risk None None O
factors None None O
for None None O
these None None O
fractures None None O
are None None O
: None None O
ethnic None None O
origin None None O
, None None O
absence None None O
of None None O
replacement None None O
hormonal None None O
therapy None None O
in None None O
menopausal None None O
women None None O
, None None O
slight None None O
build None None O
and None None O
absorption None None O
of None None O
certain None None O
psychotropic None None O
drugs None None O
. None None O

To None None O
be None None O
efficient None None O
, None None O
preventive None None O
measures None None O
must None None O
rest None None O
on None None O
a None None O
better None None O
knowledge None None O
of None None O
the None None O
determinant None None O
factors None None O
. None None O

Epidemiological None None O
research None None O
should None None O
develop None None O
rationally None None O
and None None O
aim None None O
at None None O
identifying None None O
more None None O
accurate None None O
risk None None O
factors None None O
, None None O
taking None None O
into None None O
account None None O
the None None O
mechanisms None None O
responsible None None O
for None None O
proximal None None O
femur None None O
fractures None None O
: None None O
fall None None O
, None None O
lack None None O
of None None O
cushioning None None O
and None None O
protection None None O
during None None O
the None None O
fall None None O
, None None O
and None None O
bone None None O
fragility None None O
. None None O

UFT None None O
and None None O
its None None O
metabolites None None O
inhibit None None O
the None None O
angiogenesis None None O
induced None None O
by None None O
murine None None O
renal None None O
cell None None O
carcinoma None None O
, None None O
as None None O
determined None None O
by None None O
a None None O
dorsal None None O
air None None O
sac None None O
assay None None O
in None None O
mice None None O
. None None O

UFT None None O
, None None O
an None None O
anticancer None None O
agent None None O
that None None O
is None None O
composed None None O
of None None O
tegafur None None O
( None None O
FT None None O
) None None O
and None None O
uracil None None O
at None None O
a None None O
molar None None O
ratio None None O
of None None O
1 None None O
: None None O
4 None None O
, None None O
is None None O
widely None None O
used None None O
in None None O
clinical None None O
practice None None O
in None None O
Japan None None O
to None None O
treat None None O
cancer None None O
patients None None O
requiring None None O
a None None O
long None None O
- None None O
term None None O
chemotherapy None None O
, None None O
and None None O
it None None O
is None None O
associated None None O
with None None O
few None None O
side None None O
effects None None O
, None None O
if None None O
any None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
evaluated None None O
the None None O
inhibitory None None O
effect None None O
of None None O
UFT None None O
against None None O
RENCA None None I-Cell-line-name
cell None None O
- None None O
induced None None O
angiogenesis None None O
by None None O
a None None O
dorsal None None O
air None None O
sac None None O
assay None None O
. None None O

Marked None None O
angiogenesis None None O
is None None O
induced None None O
by None None O
implantation None None O
of None None O
a None None O
chamber None None O
containing None None O
RENCA None None I-Cell-line-name
cells None None O
into None None O
mice None None O
. None None O

In None None O
this None None O
model None None O
, None None O
UFT None None O
showed None None O
a None None O
strong None None O
angiogenesis None None O
- None None O
inhibitory None None O
effect None None O
, None None O
whereas None None O
5 None None O
- None None O
fluorouracil None None O
( None None O
5 None None O
- None None O
FU None None O
) None None O
and None None O
doxifluridine None None O
were None None O
less None None O
effective None None O
. None None O

Additional None None O
experiments None None O
revealed None None O
FT None None O
to None None O
be None None O
effective None None O
component None None O
of None None O
UFT None None O
; None None O
uracil None None O
remained None None O
ineffective None None O
in None None O
the None None O
inhibition None None O
of None None O
angiogenesis None None O
. None None O

Moreover None None O
, None None O
we None None O
have None None O
found None None O
that None None O
gamma None None O
- None None O
hydroxybutyric None None O
acid None None O
and None None O
gamma None None O
- None None O
butyrolactone None None O
, None None O
the None None O
metabolites None None O
of None None O
FT None None O
, None None O
possess None None O
a None None O
potent None None O
angiogenesis None None O
inhibitory None None O
effect None None O
that None None O
is None None O
amplified None None O
when None None O
the None None O
compounds None None O
are None None O
administered None None O
by None None O
a None None O
continuous None None O
infusion None None O
. None None O

This None None O
may None None O
reflect None None O
a None None O
transition None None O
in None None O
blood None None O
concentration None None O
of None None O
each None None O
metabolite None None O
resulting None None O
from None None O
the None None O
administration None None O
of None None O
UFT None None O
. None None O

Similar None None O
results None None O
were None None O
also None None O
obtained None None O
with None None O
respect None None O
to None None O
5 None None O
- None None O
FU None None O
. None None O

It None None O
was None None O
suggested None None O
that None None O
UFT None None O
has None None O
a None None O
stronger None None O
angiogenesis None None O
- None None O
inhibitory None None O
effect None None O
than None None O
did None None O
other None None O
fluorinated None None O
pyrimidines None None O
, None None O
partly None None O
due None None O
to None None O
its None None O
pharmacokinetic None None O
properties None None O
characterized None None O
by None None O
maintaining None None O
of None None O
higher None None O
and None None O
long None None O
- None None O
lasting None None O
blood None None O
levels None None O
of None None O
5 None None O
- None None O
FU None None O
and None None O
partly None None O
due None None O
the None None O
inhibitory None None O
effects None None O
derived None None O
from None None O
gamma None None O
- None None O
hydroxybutyric None None O
acid None None O
and None None O
gamma None None O
- None None O
butyrolactone None None O
, None None O
UFT None None O
- None None O
specific None None O
metabolites None None O
. None None O

Targeting None None O
glucose None None O
consumption None None O
and None None O
autophagy None None O
in None None O
myeloma None None O
with None None O
the None None O
novel None None O
nucleoside None None O
analogue None None O
8 None None O
- None None O
aminoadenosine None None O
. None None O

Multiple None None O
myeloma None None O
, None None O
an None None O
incurable None None O
plasma None None O
cell None None O
malignancy None None O
, None None O
is None None O
characterized None None O
by None None O
altered None None O
cellular None None O
metabolism None None O
and None None O
resistance None None O
to None None O
apoptosis None None O
. None None O

Recent None None O
connections None None O
between None None O
glucose None None O
metabolism None None O
and None None O
resistance None None O
to None None O
apoptosis None None O
provide None None O
a None None O
compelling None None O
rationale None None O
for None None O
targeting None None O
metabolic None None O
changes None None O
in None None O
cancer None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
examined None None O
the None None O
ability None None O
of None None O
the None None O
purine None None O
analogue None None O
8 None None O
- None None O
aminoadenosine None None O
to None None O
acutely None None O
reduce None None O
glucose None None O
consumption None None O
by None None O
regulating None None O
localization None None O
and None None O
expression None None O
of None None O
key None None O
glucose None None O
transporters None None O
. None None O

Myeloma None None O
cells None None O
counteracted None None O
the None None O
metabolic None None O
stress None None O
by None None O
activating None None O
autophagy None None O
. None None O

Co None None O
- None None O
treatment None None O
with None None O
inhibitors None None O
of None None O
autophagy None None O
results None None O
in None None O
marked None None O
enhancement None None O
of None None O
cell None None O
death None None O
. None None O

Glucose None None O
consumption None None O
by None None O
drug None None O
- None None O
resistant None None O
myeloma None None O
cells None None O
was None None O
unaffected None None O
by None None O
8 None None O
- None None O
aminoadenosine None None O
, None None O
and None None O
accordingly None None O
, None None O
no None None O
activation None None O
of None None O
autophagy None None O
was None None O
observed None None O
. None None O

However None None O
, None None O
these None None O
cells None None O
can None None O
be None None O
sensitized None None O
to None None O
8 None None O
- None None O
aminoadenosine None None O
under None None O
glucose None None O
- None None O
limiting None None O
conditions None None O
. None None O

The None None O
prosurvival None None O
autophagic None None O
response None None O
of None None O
myeloma None None O
to None None O
nutrient None None O
deprivation None None O
or None None O
to None None O
nucleoside None None O
analogue None None O
treatment None None O
has None None O
not None None O
been None None O
described None None O
previously None None O
. None None O

This None None O
study None None O
establishes None None O
the None None O
potential None None O
of None None O
metabolic None None O
targeting None None O
as None None O
a None None O
broader None None O
means None None O
to None None O
kill None None O
and None None O
sensitize None None O
myeloma None None O
and None None O
identifies None None O
a None None O
compound None None O
that None None O
can None None O
achieve None None O
this None None O
goal None None O
. None None O

Click None None O
here None None O
for None None O
file None None O

Authors None None O
' None None O
contributions None None O

OK None None O
and None None O
MG None None O
analyzed None None O
and None None O
interpreted None None O
the None None O
patient None None O
data None None O
regarding None None O
his None None O
hospitalization None None O
. None None O

SP None None O
and None None O
PK None None O
performed None None O
the None None O
coronary None None O
angiography None None O
, None None O
and None None O
were None None O
the None None O
major None None O
contributors None None O
in None None O
writing None None O
the None None O
manuscript None None O
. None None O

All None None O
authors None None O
read None None O
and None None O
approved None None O
the None None O
final None None O
manuscript None None O
. None None O

Model None None O
of None None O
how None None O
estrogen None None O
induces None None O
DNA None None O
damage None None O
. None None O

Estrogen None None O
enters None None O
the None None O
cell None None O
and None None O
is None None O
bound None None O
by None None O
the None None O
ER None None O
. None None O

The None None O
dimeric None None O
ER None None O
- None None O
estrogen None None O
complex None None O
enters None None O
the None None O
nucleus None None O
and None None O
induces None None O
AID None None O
expression None None O
. None None O

This None None O
leads None None O
to None None O
an None None O
increase None None O
in None None O
mutations None None O
and None None O
translocations None None O
, None None O
and None None O
potentially None None O
cancer None None O

Osteonectin None None O
transcript None None O
and None None O
metastatic None None O
behavior None None O
in None None O
v None None O
- None None O
Ki None None O
- None None O
ras None None O
transformed None None O
fibroblasts None None O
. None None O

Osteonectin None None O
is None None O
one None None O
of None None O
the None None O
major None None O
non None None O
- None None O
collagenous None None O
proteins None None O
of None None O
bone None None O
. None None O

However None None O
, None None O
its None None O
transcript None None O
has None None O
been None None O
found None None O
in None None O
many None None O
soft None None O
, None None O
extracellular None None O
matrix None None O
- None None O
producing None None O
tissues None None O
; None None O
an None None O
osteonectin None None O
- None None O
related None None O
protein None None O
was None None O
detected None None O
in None None O
tumor None None O
basement None None O
membrane None None O
. None None O

We None None O
have None None O
investigated None None O
the None None O
expression None None O
of None None O
osteonectin None None O
gene None None O
in None None O
fresh None None O
BALB None None I-Cell-line-name
/ None None I-Cell-line-name
c None None I-Cell-line-name
fibroblasts None None O
transformed None None O
by None None O
v None None O
- None None O
Ki None None O
- None None O
ras None None O
. None None O

Transformed None None O
cells None None O
exhibited None None O
lower None None O
levels None None O
of None None O
RNA None None O
as None None O
compared None None O
with None None O
normal None None O
fibroblasts None None O
. None None O

The None None O
transformed None None O
cells None None O
were None None O
cloned None None O
after None None O
in None None O
vivo None None O
tumorigenic None None O
assay None None O
, None None O
and None None O
4 None None O
clones None None O
were None None O
analyzed None None O
for None None O
osteonectin None None O
expression None None O
by None None O
Northern None None O
blots None None O
. None None O

Two None None O
of None None O
them None None O
were None None O
selected None None O
for None None O
high None None O
or None None O
low None None O
osteonectin None None O
expression None None O
and None None O
tested None None O
in None None O
vivo None None O
in None None O
spontaneous None None O
and None None O
artificial None None O
metastasis None None O
assays None None O
. None None O

High None None O
osteonectin None None O
expression None None O
was None None O
correlated None None O
with None None O
high None None O
lung None None O
colonization None None O
. None None O

When None None O
10 None None O
( None None O
5 None None O
) None None O
cells None None O
were None None O
injected None None O
i None None O
. None None O
v None None O
. None None O
, None None O
median None None O
colony None None O
value None None O
was None None O
55 None None O
and None None O
20 None None O
in None None O
higher None None O
expressor None None O
vs None None O
. None None O
lower None None O
expressor None None O
respectively None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
005 None None O
) None None O
. None None O

Spontaneous None None O
metastasis None None O
indicates None None O
a None None O
possible None None O
reverse None None O
correlation None None O
. None None O

Our None None O
data None None O
align None None O
osteonectin None None O
with None None O
other None None O
matrix None None O
- None None O
components None None O
and None None O
adhesion None None O
molecules None None O
in None None O
affecting None None O
potential None None O
metastatic None None O
spreading None None O
of None None O
transformed None None O
cells None None O
. None None O

Glycolysis None None O
and None None O
glutaminolysis None None O
in None None O
perifused None None O
Ehrlich None None O
ascites None None O
tumour None None O
cells None None O
. None None O

A None None O
perifusion None None O
system None None O
was None None O
designed None None O
in None None O
order None None O
to None None O
study None None O
glucose None None O
and None None O
glutamine None None O
metabolism None None O
by None None O
freshly None None O
harvested None None O
Ehrlich None None O
ascites None None O
tumour None None O
cells None None O
in None None O
steady None None O
state None None O
conditions None None O
. None None O

Cells None None O
were None None O
perifused None None O
in None None O
the None None O
presence None None O
of None None O
5 None None O
mM None None O
glucose None None O
, None None O
0 None None O
. None None O
5 None None O
mM None None O
glutamine None None O
or None None O
5 None None O
mM None None O
glucose None None O
and None None O
0 None None O
. None None O
5 None None O
mM None None O
glutamine None None O
. None None O

The None None O
results None None O
in None None O
steady None None O
state None None O
reveal None None O
that None None O
both None None O
substrates None None O
glucose None None O
and None None O
glutamine None None O
are None None O
continuously None None O
wasted None None O
by None None O
tumour None None O
cells None None O
, None None O
excreting None None O
two None None O
moles None None O
of None None O
lactate None None O
per None None O
mol None None O
of None None O
glucose None None O
and None None O
one None None O
mol None None O
of None None O
glutamate None None O
and None None O
ammonia None None O
per None None O
mol None None O
of None None O
glutamine None None O
consumed None None O
into None None O
the None None O
medium None None O
. None None O

Glutamine None None O
consumption None None O
in None None O
the None None O
presence None None O
of None None O
glucose None None O
was None None O
higher None None O
than None None O
with None None O
glutamine None None O
alone None None O
. None None O

The None None O
effect None None O
of None None O
PCL None None O
elevation None None O

Our None None O
hypothesis None None O
that None None O
the None None O
dynamics None None O
of None None O
the None None O
flexion None None O
gap None None O
depend None None O
on None None O
the None None O
orientation None None O
of None None O
the None None O
PCL None None O
was None None O
confirmed None None O
. None None O

Distraction None None O
of None None O
the None None O
knee None None O
with None None O
a None None O
low None None O
PCL None None O
elevation None None O
angle None None O
( None None O
i None None O
. None None O
e None None O
. None None O
a None None O
flat None None O
PCL None None O
) None None O
resulted None None O
in None None O
greater None None O
increase None None O
in None None O
gap None None O
height None None O
than None None O
distraction None None O
of None None O
a None None O
knee None None O
with None None O
a None None O
steep None None O
PCL None None O
. None None O

This None None O
result None None O
was None None O
to None None O
be None None O
expected None None O
; None None O
when None None O
the None None O
gap None None O
between None None O
the None None O
tibia None None O
and None None O
femur None None O
was None None O
increased None None O
, None None O
the None None O
increase None None O
in None None O
PCL None None O
tension None None O
resulted None None O
in None None O
the None None O
tibia None None O
pivoting None None O
around None None O
the None None O
femoral None None O
insertion None None O
of None None O
the None None O
PCL None None O
. None None O

Thus None None O
, None None O
the None None O
greatest None None O
increase None None O
in None None O
gap None None O
height None None O
will None None O
occur None None O
when None None O
the None None O
PCL None None O
is None None O
flat None None O
. None None O

Taking None None O
this None None O
finding None None O
into None None O
consideration None None O
, None None O
the None None O
surgeon None None O
should None None O
be None None O
aware None None O
of None None O
the None None O
strong None None O
effect None None O
of None None O
PCL None None O
elevation None None O
on None None O
the None None O
relationship None None O
between None None O
gap None None O
height None None O
increase None None O
and None None O
tibial None None O
translation None None O
. None None O

A None None O
flat None None O
PCL None None O
will None None O
lead None None O
to None None O
a None None O
mean None None O
anterior None None O
tibial None None O
translation None None O
of None None O
1 None None O
. None None O
7 None None O
mm None None O
when None None O
the None None O
gap None None O
is None None O
distracted None None O
1 None None O
mm None None O
. None None O

A None None O
knee None None O
with None None O
a None None O
steep None None O
PCL None None O
will None None O
even None None O
translate None None O
2 None None O
. None None O
3 None None O
mm None None O
on None None O
average None None O
with None None O
1 None None O
mm None None O
of None None O
gap None None O
distraction None None O
. None None O

If None None O
the None None O
PCL None None O
were None None O
the None None O
only None None O
structure None None O
that None None O
was None None O
tensioned None None O
with None None O
distraction None None O
of None None O
the None None O
flexion None None O
gap None None O
, None None O
then None None O
at None None O
100 None None O
N None None O
it None None O
would None None O
be None None O
oriented None None O
vertically None None O
. None None O

This None None O
is None None O
not None None O
the None None O
case None None O
, None None O
and None None O
therefore None None O
other None None O
structures None None O
such None None O
as None None O
the None None O
collateral None None O
ligaments None None O
must None None O
have None None O
restrained None None O
the None None O
translation None None O
. None None O

From None None O
an None None O
anatomical None None O
point None None O
of None None O
view None None O
, None None O
the None None O
collateral None None O
structures None None O
are None None O
the None None O
only None None O
structures None None O
that None None O
could None None O
have None None O
had None None O
a None None O
restraining None None O
function None None O
on None None O
vertical None None O
movements None None O
. None None O

For None None O
obvious None None O
reasons None None O
, None None O
in None None O
this None None O
in None None O
vivo None None O
study None None O
we None None O
could None None O
not None None O
test None None O
what None None O
would None None O
have None None O
happened None None O
to None None O
the None None O
orientation None None O
of None None O
the None None O
PCL None None O
when None None O
the None None O
collateral None None O
structures None None O
were None None O
resected None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
PCL None None O
elevation None None O
angle None None O
at None None O
100 None None O
N None None O
influenced None None O
the None None O
increase None None O
in None None O
PCL None None O
elevation None None O
angle None None O
between None None O
100 None None O
N None None O
and None None O
200 None None O
N None None O
( None None O
DeltaPCLe None None O
) None None O
. None None O

This None None O
seems None None O
logical None None O
: None None O
a None None O
flat None None O
PCL None None O
can None None O
be None None O
recruited None None O
more None None O
easily None None O
whereas None None O
knees None None O
with None None O
a None None O
steep None None O
PCL None None O
might None None O
already None None O
be None None O
tensioned None None O
at None None O
100 None None O
N None None O
so None None O
that None None O
a None None O
further None None O
increase None None O
in None None O
PCL None None O
elevation None None O
angle None None O
would None None O
be None None O
hard None None O
to None None O
achieve None None O
. None None O

However None None O
, None None O
steep None None O
PCLs None None O
are None None O
not None None O
necessarily None None O
recruited None None O
more None None O
than None None O
flat None None O
PCLs None None O
. None None O

Furthermore None None O
, None None O
the None None O
situation None None O
during None None O
implantation None None O
of None None O
a None None O
TKR None None O
is None None O
quite None None O
unnatural None None O
: None None O
we None None O
investigated None None O
the None None O
PCL None None O
elevation None None O
after None None O
the None None O
tibia None None O
was None None O
cut None None O
. None None O

Retinal None None O
microangiopathies None None O
overlying None None O
pigment None None O
epithelial None None O
detachment None None O
in None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
. None None O

PURPOSE None None O
: None None O
To None None O
evaluate None None O
alterations None None O
in None None O
the None None O
retinal None None O
vasculature None None O
overlying None None O
pigment None None O
epithelial None None O
detachments None None O
( None None O
PED None None O
) None None O
in None None O
exudative None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
( None None O
ARMD None None O
) None None O
using None None O
indocyanine None None O
green None None O
and None None O
fluorescein None None O
angiography None None O
. None None O

METHODS None None O
: None None O
Forty None None O
- None None O
one None None O
patients None None O
( None None O
41 None None O
eyes None None O
) None None O
with None None O
a None None O
clinical None None O
diagnosis None None O
of None None O
exudative None None O
ARMD None None O
with None None O
PED None None O
underwent None None O
simultaneous None None O
fluorescein None None O
and None None O
indocyanine None None O
green None None O
angiography None None O
, None None O
also None None O
under None None O
high None None O
( None None O
10 None None O
degrees None None O
) None None O
magnification None None O
. None None O

Vascular None None O
abnormalities None None O
in None None O
the None None O
retina None None O
were None None O
compared None None O
between None None O
patients None None O
with None None O
vascularized None None O
( None None O
n None None O
= None None O
34 None None O
, None None O
group None None O
1 None None O
) None None O
and None None O
nonvascularized None None O
( None None O
n None None O
= None None O
7 None None O
, None None O
group None None O
2 None None O
) None None O
PED None None O
on None None O
indocyanine None None O
green None None O
angiography None None O
and None None O
correlated None None O
with None None O
the None None O
size None None O
of None None O
the None None O
PED None None O
and None None O
the None None O
presence None None O
of None None O
serous None None O
retinal None None O
detachment None None O
. None None O

RESULTS None None O
: None None O
In None None O
all None None O
, None None O
67 None None O
vascular None None O
abnormalities None None O
were None None O
found None None O
by None None O
indocyanine None None O
green None None O
angiography None None O
and None None O
only None None O
22 None None O
by None None O
fluorescein None None O
angiography None None O
; None None O
this None None O
finding None None O
was None None O
statistically None None O
significant None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

The None None O
finding None None O
of None None O
retinal None None O
vasculopathy None None O
( None None O
32 None None O
patients None None O
in None None O
group None None O
1 None None O
and None None O
two None None O
patients None None O
in None None O
group None None O
2 None None O
) None None O
was None None O
directly None None O
correlated None None O
with None None O
the None None O
presence None None O
of None None O
choroidal None None O
neovascularizations None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
002 None None O
) None None O
. None None O

There None None O
was None None O
also None None O
a None None O
direct None None O
correlation None None O
between None None O
the None None O
presence None None O
of None None O
choroidal None None O
neovascularization None None O
and None None O
size None None O
of None None O
the None None O
PED None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
. None None O

The None None O
number None None O
of None None O
retinal None None O
vascular None None O
findings None None O
was None None O
not None None O
significantly None None O
correlated None None O
with None None O
serous None None O
elevation None None O
of None None O
the None None O
retina None None O
. None None O

CONCLUSIONS None None O
: None None O
Retinal None None O
vasculopathies None None O
may None None O
be None None O
observed None None O
in None None O
eyes None None O
with None None O
PED None None O
and None None O
are None None O
detectable None None O
by None None O
indocyanine None None O
green None None O
and None None O
fluorescein None None O
angiography None None O
. None None O

Comment None None O
on None None O
" None None O
Why None None O
reduced None None O
- None None O
form None None O
regression None None O
models None None O
of None None O
health None None O
effects None None O
versus None None O
exposures None None O
should None None O
not None None O
replace None None O
QRA None None O
: None None O
livestock None None O
production None None O
and None None O
infant None None O
mortality None None O
as None None O
an None None O
example None None O
, None None O
" None None O
by None None O
Louis None None O
Anthony None None O
( None None O
Tony None None O
) None None O
Cox None None O
, None None O
Jr None None O
. None None O
, None None O
Risk None None O
Analysis None None O
2009 None None O
, None None O
Vol None None O
. None None O

29 None None O
, None None O
No None None O
. None None O
12 None None O
. None None O

While None None O
a None None O
recent None None O
paper None None O
by None None O
Cox None None O
in None None O
this None None O
journal None None O
uses None None O
as None None O
its None None O
motivating None None O
factor None None O
the None None O
benefits None None O
of None None O
quantitative None None O
risk None None O
assessment None None O
, None None O
its None None O
content None None O
is None None O
entirely None None O
devoted None None O
to None None O
critiquing None None O
Sneeringer None None O
' None None O
s None None O
article None None O
in None None O
the None None O
American None None O
Journal None None O
of None None O
Agricultural None None O
Economics None None O
. None None O

Cox None None O
' None None O
s None None O
two None None O
main None None O
critiques None None O
of None None O
Sneeringer None None O
are None None O
fundamentally None None O
flawed None None O
and None None O
misrepresent None None O
the None None O
original None None O
article None None O
. None None O

Cox None None O
posits None None O
that None None O
Sneeringer None None O
did None None O
A None None O
and None None O
B None None O
, None None O
and None None O
then None None O
argues None None O
why None None O
A None None O
and None None O
B None None O
are None None O
incorrect None None O
. None None O

However None None O
, None None O
Sneeringer None None O
in None None O
fact None None O
did None None O
C None None O
and None None O
D None None O
; None None O
thus None None O
critiques None None O
of None None O
A None None O
and None None O
B None None O
are None None O
not None None O
applicable None None O
to None None O
Sneeringer None None O
' None None O
s None None O
analysis None None O
. None None O

Fas None None O
- None None O
Fas None None O
ligand None None O
signaling None None O
pathway None None O
mediates None None O
an None None O
interleukin None None O
- None None O
12 None None O
- None None O
induced None None O
rejection None None O
of None None O
a None None O
murine None None O
prostate None None O
tumor None None O
system None None O
. None None O

BACKGROUND None None O
: None None O
Recent None None O
data None None O
suggest None None O
that None None O
anti None None O
- None None O
tumor None None O
activities None None O
of None None O
interleukin None None O
- None None O
12 None None O
( None None O
IL None None O
- None None O
12 None None O
) None None O
involve None None O
the None None O
induction None None O
of None None O
apoptosis None None O
. None None O

Fas None None O
( None None O
APO None None O
- None None O
1 None None O
/ None None O
CD95 None None O
) None None O
is None None O
a None None O
type None None O
I None None O
membrane None None O
protein None None O
that None None O
is None None O
capable None None O
of None None O
initiating None None O
an None None O
apoptosis None None O
signaling None None O
pathway None None O
when None None O
bound None None O
to None None O
its None None O
ligand None None O
( None None O
FasL None None O
) None None O
. None None O

We None None O
undertook None None O
this None None O
study None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
Fas None None O
- None None O
FasL None None O
- None None O
mediated None None O
apoptosis None None O
plays None None O
a None None O
role None None O
in None None O
IL None None O
- None None O
12 None None O
- None None O
induced None None O
tumor None None O
regression None None O
. None None O

METHODS None None O
: None None O
An None None O
mIL None None O
- None None O
12 None None O
expression None None O
vector None None O
driven None None O
by None None O
cytomegalovirus None None O
promoter None None O
was None None O
used None None O
to None None O
express None None O
murine None None O
IL None None O
- None None O
12 None None O
cDNA None None O
in None None O
the None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
murine None None O
prostate None None O
carcinoma None None O
cell None None O
line None None O
. None None O

Control None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
cells None None O
and None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
cells None None O
stably None None O
transfected None None O
with None None O
IL None None O
- None None O
12 None None O
gene None None O
( None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
- None None O
IL12 None None O
) None None O
were None None O
inoculated None None O
subcutaneously None None O
in None None O
4 None None O
- None None O
to None None O
6 None None O
- None None O
week None None O
- None None O
old None None O
male None None O
C57BL None None O
/ None None O
J6 None None O
mice None None O
. None None O

Tumor None None O
size None None O
was None None O
measured None None O
every None None O
3 None None O
days None None O
. None None O

Western None None O
blot None None O
and None None O
immunohistochemical None None O
assays None None O
were None None O
used None None O
to None None O
evaluate None None O
Fas None None O
and None None O
FasL None None O
protein None None O
expression None None O
. None None O

In None None O
situ None None O
fluorescent None None O
end None None O
labeling None None O
was None None O
used None None O
to None None O
label None None O
apoptotic None None O
cells None None O
. None None O

RESULTS None None O
: None None O
IL None None O
- None None O
12 None None O
- None None O
expressing None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
prostate None None O
carcinoma None None O
cells None None O
transplanted None None O
into None None O
C57BL None None O
/ None None O
J6 None None O
mice None None O
grew None None O
more None None O
slowly None None O
than None None O
control None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
cells None None O
and None None O
vector None None O
control None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
- None None O
Luc None None O
cells None None O
. None None O

The None None O
average None None O
survival None None O
time None None O
of None None O
the None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
- None None O
IL12 None None O
mice None None O
was None None O
longer None None O
than None None O
53 None None O
days None None O
, None None O
whereas None None O
the None None O
mean None None O
survival None None O
for None None O
mice None None O
transplanted None None O
with None None O
control None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
cells None None O
was None None O
only None None O
16 None None O
days None None O
. None None O

Apoptotic None None O
cells None None O
were None None O
more None None O
numerous None None O
in None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
- None None O
IL12 None None O
tumors None None O
: None None O
10 None None O
. None None O
3 None None O
% None None O
vs None None O
. None None O
1 None None O
. None None O
5 None None O
% None None O
in None None O
control None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Fas None None O
and None None O
FasL None None O
proteins None None O
were None None O
increased None None O
approximately None None O
twofold None None O
in None None O
the None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
- None None O
IL12 None None O
tumors None None O
compared None None O
with None None O
the None None O
RM None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
control None None O
tumors None None O
as None None O
determined None None O
by None None O
Western None None O
blot None None O
and None None O
immunohistochemical None None O
analyses None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
Fas None None O
- None None O
FasL None None O
- None None O
mediated None None O
apoptosis None None O
pathway None None O
may None None O
contribute None None O
to None None O
the None None O
IL None None O
- None None O
12 None None O
- None None O
induced None None O
rejection None None O
of None None O
prostate None None O
carcinoma None None O
. None None O

Results None None O
: None None O

In None None O
the None None O
total None None O
population None None O
( None None O
N None None O
= None None O
95 None None O
) None None O
, None None O
median None None O
OS None None O
was None None O
significantly None None O
longer None None O
in None None O
patients None None O
with None None O
baseline None None O
CA None None O
19 None None O
- None None O
9 None None O
values None None O
at None None O
or None None O
below None None O
the None None O
median None None O
than None None O
in None None O
those None None O
with None None O
values None None O
above None None O
it None None O
( None None O
12 None None O
. None None O
2 None None O
months None None O
[ None None O
95 None None O
% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
, None None O
8 None None O
. None None O
6 None None O
- None None O
16 None None O
. None None O
6 None None O
% None None O
] None None O
vs None None O
5 None None O
. None None O
0 None None O
months None None O
[ None None O
95 None None O
% None None O
CI None None O
, None None O
3 None None O
. None None O
9 None None O
- None None O
5 None None O
. None None O
7 None None O
% None None O
] None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

This None None O
also None None O
reached None None O
significance None None O
in None None O
the None None O
Gem None None O
+ None None O
A None None O
arm None None O
( None None O
median None None O
OS None None O
, None None O
12 None None O
. None None O
5 None None O
months None None O
[ None None O
95 None None O
% None None O
CI None None O
, None None O
8 None None O
. None None O
6 None None O
- None None O
16 None None O
. None None O
6 None None O
% None None O
] None None O
vs None None O
4 None None O
. None None O
9 None None O
months None None O
[ None None O
95 None None O
% None None O
CI None None O
, None None O
3 None None O
. None None O
6 None None O
- None None O
5 None None O
. None None O
6 None None O
% None None O
] None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

Patients None None O
with None None O
any None None O
dBP None None O
> None None O
90 None None O
mmHg None None O
had None None O
significantly None None O
longer None None O
OS None None O
than None None O
those None None O
who None None O
did None None O
not None None O
. None None O

However None None O
, None None O
there None None O
was None None O
no None None O
predictive None None O
significance None None O
of None None O
CA None None O
19 None None O
- None None O
9 None None O
. None None O

Nf None None O
and None None O
GA None None O
- None None O
1 None None O
DNA None None O
polymerases None None O
couple None None O
polymerization None None O
to None None O
strand None None O
displacement None None O
processively None None O

The None None O
results None None O
presented None None O
in None None O
this None None O
paper None None O
clearly None None O
indicate None None O
that None None O
Nf None None O
and None None O
GA None None O
- None None O
1 None None O
DNA None None O
polymerases None None O
can None None O
account None None O
for None None O
their None None O
genome None None O
replication None None O
without None None O
the None None O
assistance None None O
of None None O
unwinding None None O
and None None O
processivity None None O
factors None None O
, None None O
in None None O
contrast None None O
to None None O
most None None O
replicative None None O
DNA None None O
polymerases None None O
which None None O
require None None O
their None None O
physical None None O
association None None O
to None None O
processivity None None O
factors None None O
and None None O
DNA None None O
unwinding None None O
proteins None None O
( None None O
1 None None O
, None None O
70 None None O
) None None O
. None None O

Strand None None O
displacement None None O
capacity None None O
has None None O
also None None O
been None None O
shown None None O
for None None O
other None None O
protein None None O
- None None O
primed None None O
DNA None None O
polymerases None None O
as None None O
those None None O
of None None O
bacteriophages None None O
phi29 None None O
( None None O
10 None None O
) None None O
, None None O
Cp None None O
- None None O
1 None None O
( None None O
71 None None O
) None None O
and None None O
PRD1 None None O
( None None O
72 None None O
, None None O
73 None None O
) None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
adenovirus None None O
DNA None None O
polymerase None None O
, None None O
although None None O
processive None None O
, None None O
cannot None None O
couple None None O
polymerization None None O
to None None O
strand None None O
displacement None None O
, None None O
requiring None None O
the None None O
DNA None None O
unwinding None None O
activity None None O
of None None O
the None None O
adenovirus None None O
DBP None None O
to None None O
perform None None O
strand None None O
displacement None None O
( None None O
74 None None O
, None None O
75 None None O
) None None O
. None None O

Whereas None None O
it None None O
was None None O
possible None None O
to None None O
obtain None None O
GA None None O
- None None O
1 None None O
DNA None None O
replication None None O
by None None O
using None None O
exclusively None None O
the None None O
GA None None O
- None None O
1 None None O
TP None None O
and None None O
DNA None None O
polymerase None None O
, None None O
Nf None None O
DNA None None O
polymerase None None O
, None None O
although None None O
provided None None O
with None None O
competent None None O
strand None None O
displacement None None O
and None None O
processivity None None O
features None None O
, None None O
required None None O
the None None O
presence None None O
of None None O
Nf None None O
DBP None None O
for None None O
an None None O
effective None None O
in None None O
vitro None None O
replication None None O
of None None O
Nf None None O
TP None None O
- None None O
DNA None None O
. None None O

Results None None O
presented None None O
here None None O
show None None O
that None None O
Nf None None O
DBP None None O
strongly None None O
stimulates None None O
the None None O
formation None None O
of None None O
the None None O
TP None None O
- None None O
dAMP None None O
initiation None None O
complex None None O
by None None O
decreasing None None O
the None None O
Km None None O
for None None O
dATP None None O
and None None O
facilitates None None O
the None None O
transition None None O
from None None O
initiation None None O
to None None O
elongation None None O
, None None O
as None None O
it None None O
occurs None None O
in None None O
phi29 None None O
( None None O
76 None None O
) None None O
. None None O

These None None O
results None None O
point None None O
to None None O
either None None O
a None None O
specific None None O
and None None O
direct None None O
contact None None O
between None None O
DBP None None O
and None None O
DNA None None O
polymerase None None O
that None None O
promotes None None O
conformational None None O
changes None None O
at None None O
the None None O
polymerization None None O
active None None O
site None None O
or None None O
to None None O
an None None O
effect None None O
of None None O
DBP None None O
in None None O
conferring None None O
the None None O
optimal None None O
template None None O
structure None None O
to None None O
direct None None O
initiating None None O
nucleotide None None O
insertion None None O
. None None O

A None None O
similar None None O
role None None O
has None None O
been None None O
proposed None None O
for None None O
adenovirus None None O
DBP None None O
, None None O
a None None O
DNA None None O
unwinding None None O
protein None None O
( None None O
77 None None O
) None None O
. None None O

As None None O
in None None O
the None None O
case None None O
of None None O
phi29 None None O
and None None O
Nf None None O
DBP None None O
, None None O
this None None O
protein None None O
stimulates None None O
the None None O
rate None None O
of None None O
initiation None None O
also None None O
by None None O
decreasing None None O
the None None O
Km None None O
for None None O
the None None O
initiating None None O
nucleotide None None O
( None None O
74 None None O
) None None O
. None None O

The None None O
fact None None O
that None None O
an None None O
adenovirus None None O
DBP None None O
mutant None None O
defective None None O
in None None O
unwinding None None O
can None None O
still None None O
stimulate None None O
initiation None None O
precludes None None O
the None None O
unwinding None None O
role None None O
as None None O
the None None O
one None None O
responsible None None O
for None None O
such None None O
an None None O
activation None None O
( None None O
77 None None O
, None None O
78 None None O
) None None O
. None None O

In None None O
this None None O
case None None O
, None None O
contacts None None O
between None None O
DBP None None O
and None None O
pTP None None O
/ None None O
DNA None None O
polymerase None None O
complex None None O
have None None O
been None None O
reported None None O
( None None O
77 None None O
) None None O
. None None O

The None None O
effect None None O
of None None O
Nf None None O
DBP None None O
in None None O
promoting None None O
elongation None None O
of None None O
the None None O
initiation None None O
products None None O
could None None O
be None None O
due None None O
to None None O
a None None O
decrease None None O
of None None O
the None None O
Km None None O
also None None O
for None None O
the None None O
incorporation None None O
of None None O
the None None O
dNMPs None None O
during None None O
the None None O
transition None None O
stage None None O
from None None O
initiation None None O
to None None O
elongation None None O
, None None O
to None None O
a None None O
different None None O
type None None O
of None None O
contact None None O
with None None O
the None None O
DNA None None O
polymerase None None O
that None None O
helps None None O
transition None None O
to None None O
elongation None None O
, None None O
or None None O
both None None O
. None None O

The None None O
similarity None None O
in None None O
replication None None O
rates None None O
when None None O
comparing None None O
M13 None None O
DNA None None O
replication None None O
, None None O
performed None None O
in None None O
the None None O
absence None None O
of None None O
DBP None None O
( None None O
2400 None None O
nt None None O
/ None None O
min None None O
) None None O
, None None O
with None None O
Nf None None O
TP None None O
- None None O
DNA None None O
replication None None O
in None None O
the None None O
presence None None O
of None None O
DBP None None O
( None None O
2260 None None O
nt None None O
/ None None O
min None None O
) None None O
, None None O
suggests None None O
that None None O
the None None O
DBP None None O
stimulatory None None O
role None None O
is None None O
restricted None None O
to None None O
the None None O
first None None O
phases None None O
of None None O
Nf None None O
TP None None O
- None None O
DNA None None O
replication None None O
. None None O

Artemisinin None None O
inhibits None None O
tumor None None O
lymphangiogenesis None None O
by None None O
suppression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
C None None O
. None None O

We None None O
have None None O
previously None None O
reported None None O
that None None O
dihydroartemisinin None None O
is None None O
found None None O
to None None O
have None None O
a None None O
potent None None O
ability None None O
in None None O
influencing None None O
lymphatic None None O
endothelial None None O
cell None None O
migration None None O
and None None O
tube None None O
formation None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
effect None None O
of None None O
artemisinin None None O
on None None O
tumor None None O
growth None None O
, None None O
lymphangiogenesis None None O
, None None O
metastasis None None O
and None None O
survival None None O
in None None O
mouse None None O
Lewis None None O
lung None None O
carcinoma None None O
( None None O
LLC None None O
) None None O
models None None O
. None None O

We None None O
found None None O
that None None O
orally None None O
administered None None O
artemisinin None None O
inhibited None None O
lymph None None O
node None None O
and None None O
lung None None O
metastasis None None O
and None None O
prolonged None None O
survival None None O
without None None O
retarding None None O
tumor None None O
growth None None O
. None None O

Consistent None None O
with None None O
the None None O
decrease None None O
in None None O
lymph None None O
node None None O
metastasis None None O
, None None O
tumor None None O
lymphangiogenesis None None O
and None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
C None None O
( None None O
VEGF None None O
- None None O
C None None O
) None None O
was None None O
significantly None None O
decreased None None O
in None None O
artemisinin None None O
- None None O
treated None None O
mice None None O
, None None O
as None None O
compared None None O
to None None O
control None None O
mice None None O
. None None O

Furthermore None None O
, None None O
IL None None O
- None None O
1beta None None O
- None None O
induced None None O
p38 None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
activation None None O
and None None O
upregulation None None O
of None None O
VEGF None None O
- None None O
C None None O
mRNA None None O
and None None O
protein None None O
in None None O
LLC None None O
cells None None O
was None None O
also None None O
suppressed None None O
by None None O
artemisinin None None O
or None None O
by None None O
the None None O
p38 None None O
MAPK None None O
inhibitor None None O
SB None None O
- None None O
203580 None None O
, None None O
suggesting None None O
that None None O
p38 None None O
MAPK None None O
could None None O
serve None None O
as None None O
a None None O
mediator None None O
of None None O
proinflammatory None None O
cytokine None None O
- None None O
induced None None O
VEGF None None O
- None None O
C None None O
expression None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
artemisinin None None O
may None None O
be None None O
useful None None O
for None None O
the None None O
prevention None None O
of None None O
lymph None None O
node None None O
metastasis None None O
by None None O
downregulating None None O
VEGF None None O
- None None O
C None None O
and None None O
reducing None None O
tumor None None O
lymphangiogenesis None None O
. None None O

[ None None O
Intraepithelial None None O
neoplasm None None O
of None None O
the None None O
uterine None None O
cervix None None O
and None None O
angiogenesis None None O
: None None O
morphologic None None O
study None None O
] None None O

Thirty None None O
uterine None None O
cervix None None O
specimens None None O
sampled None None O
following None None O
conization None None O
or None None O
total None None O
hysterectomy None None O
were None None O
studied None None O
using None None O
histology None None O
, None None O
histoenzymology None None O
( None None O
vessel None None O
phosphatase None None O
alkaline None None O
activity None None O
) None None O
, None None O
and None None O
immunohistochemistry None None O
( None None O
demonstration None None O
of None None O
laminin None None O
and None None O
type None None O
IV None None O
collagen None None O
in None None O
epithelium None None O
and None None O
vessel None None O
basement None None O
membranes None None O
) None None O
. None None O

Pathologic None None O
conditions None None O
included None None O
dystrophia None None O
, None None O
moderate None None O
dysplasia None None O
, None None O
severe None None O
dysplasia None None O
, None None O
and None None O
intraepithelial None None O
carcinoma None None O
. None None O

Results None None O
were None None O
compared None None O
to None None O
findings None None O
in None None O
a None None O
control None None O
group None None O
. None None O

We None None O
found None None O
that None None O
the None None O
severity None None O
of None None O
vascular None None O
abnormalities None None O
correlated None None O
positively None None O
with None None O
the None None O
severity None None O
of None None O
histologic None None O
epithelial None None O
lesions None None O
; None None O
this None None O
finding None None O
is None None O
consistent None None O
with None None O
colposcopic None None O
results None None O
. None None O

Anarchic None None O
angiogenesis None None O
with None None O
large None None O
, None None O
moniliform None None O
, None None O
tortuous None None O
vessels None None O
was None None O
seen None None O
in None None O
severe None None O
dysplasias None None O
and None None O
carcinomas None None O
. None None O

The None None O
vascular None None O
anomalies None None O
seem None None O
to None None O
precede None None O
the None None O
development None None O
of None None O
histologic None None O
lesions None None O
in None None O
some None None O
instances None None O
. None None O

Histogenesis None None O
of None None O
the None None O
abnormal None None O
vessels None None O
may None None O
involve None None O
production None None O
of None None O
an None None O
angiogenic None None O
factor None None O
by None None O
the None None O
cancerized None None O
epithelia None None O
. None None O

Apoptosis None None O
induced None None O
by None None O
1 None None O
' None None O
- None None O
acetoxychavicol None None O
acetate None None O
in None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
is None None O
associated None None O
with None None O
modulation None None O
of None None O
polyamine None None O
metabolism None None O
and None None O
caspase None None O
- None None O
3 None None O
activation None None O
. None None O

The None None O
efficacy None None O
of None None O
the None None O
antitumor None None O
activity None None O
of None None O
1 None None O
' None None O
- None None O
acetoxychavicol None None O
acetate None None O
( None None O
ACA None None O
) None None O
, None None O
reported None None O
to None None O
be None None O
a None None O
suppressor None None O
of None None O
chemically None None O
induced None None O
carcinogenesis None None O
, None None O
was None None O
evaluated None None O
in None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
. None None O

ACA None None O
treatment None None O
resulted None None O
in None None O
changes None None O
in None None O
morphology None None O
and None None O
a None None O
dose None None O
- None None O
dependent None None O
suppression None None O
of None None O
cell None None O
viability None None O
. None None O

Apoptosis None None O
, None None O
characterized None None O
by None None O
nuclear None None O
condensation None None O
, None None O
membrane None None O
blebbing None None O
, None None O
cell None None O
shrinkage None None O
and None None O
a None None O
significant None None O
induction None None O
of None None O
caspase None None O
- None None O
3 None None O
- None None O
like None None O
protease None None O
activity None None O
at None None O
8 None None O
h None None O
in None None O
a None None O
time None None O
- None None O
course None None O
study None None O
were None None O
observed None None O
. None None O

Formation None None O
of None None O
apoptotic None None O
bodies None None O
was None None O
preceded None None O
by None None O
lowering None None O
of None None O
intracellular None None O
polyamines None None O
, None None O
particularly None None O
putrescine None None O
, None None O
and None None O
both None None O
dose None None O
- None None O
and None None O
time None None O
- None None O
dependent None None O
inhibitory None None O
and None None O
activation None None O
effect None None O
by None None O
ACA None None O
on None None O
ornithine None None O
decarboxylase None None O
( None None O
ODC None None O
) None None O
and None None O
spermidine None None O
/ None None O
spermine None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
acetyltransferase None None O
( None None O
SSAT None None O
) None None O
, None None O
respectively None None O
. None None O

Administration None None O
of None None O
exogenous None None O
polyamines None None O
prevented None None O
ACA None None O
- None None O
induced None None O
apoptosis None None O
represented None None O
by None None O
a None None O
reduction None None O
in None None O
the None None O
number None None O
of None None O
apoptotic None None O
bodies None None O
and None None O
also None None O
caused None None O
reduction None None O
in None None O
the None None O
induced None None O
caspase None None O
- None None O
3 None None O
- None None O
like None None O
protease None None O
activity None None O
at None None O
8 None None O
h None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
the None None O
anticarcinogenic None None O
effects None None O
of None None O
ACA None None O
might None None O
be None None O
partly None None O
due None None O
to None None O
perturbation None None O
of None None O
the None None O
polyamine None None O
metabolic None None O
pathway None None O
and None None O
triggering None None O
of None None O
caspase None None O
- None None O
3 None None O
- None None O
like None None O
activity None None O
, None None O
which None None O
result None None O
in None None O
apoptosis None None O
. None None O

The None None O
learning None None O
curve None None O
: None None O
the None None O
advantages None None O
and None None O
disadvantages None None O
in None None O
the None None O
use None None O
of None None O
focus None None O
groups None None O
as None None O
a None None O
method None None O
of None None O
data None None O
collection None None O
. None None O

Focus None None O
groups None None O
are None None O
not None None O
simply None None O
a None None O
discussion None None O
between None None O
people None None O
, None None O
but None None O
are None None O
focused None None O
interviews None None O
exploring None None O
interactions None None O
between None None O
participants None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
Ian None None O
Mansell None None O
, None None O
Glynis None None O
Bennett None None O
, None None O
Ruth None None O
Northway None None O
, None None O
Donna None None O
Mead None None O
and None None O
Laurie None None O
Moseley None None O
explore None None O
the None None O
complexities None None O
and None None O
practicalities None None O
of None None O
using None None O
focus None None O
groups None None O
in None None O
research None None O
, None None O
with None None O
reference None None O
to None None O
a None None O
study None None O
of None None O
palliative None None O
care None None O
services None None O
. None None O

[ None None O
The None None O
erbB None None O
gene None None O
family None None O
: None None O
significance None None O
for None None O
tumor None None O
development None None O
, None None O
prognosis None None O
and None None O
new None None O
therapeutic None None O
modalities None None O
] None None O
. None None O

RNA None None O
and None None O
DNA None None O
viruses None None O
can None None O
be None None O
transforming None None O
and None None O
tumourigenic None None O
agents None None O
. None None O

The None None O
transformation None None O
is None None O
a None None O
consequence None None O
of None None O
the None None O
ability None None O
of None None O
viruses None None O
to None None O
integrate None None O
into None None O
the None None O
host None None O
cell None None O
' None None O
s None None O
DNA None None O
and None None O
to None None O
produce None None O
transforming None None O
proteins None None O
. None None O

These None None O
proteins None None O
are None None O
mainly None None O
produced None None O
by None None O
specific None None O
integral None None O
parts None None O
of None None O
the None None O
viral None None O
genome None None O
, None None O
the None None O
oncogenes None None O
. None None O

Comparison None None O
between None None O
RNA None None O
/ None None O
DNA None None O
sequence None None O
of None None O
viral None None O
oncogenes None None O
and None None O
normal None None O
human None None O
genome None None O
of None None O
non None None O
- None None O
transformed None None O
cells None None O
revealed None None O
high None None O
sequence None None O
similarities None None O
in None None O
specific None None O
genomic None None O
areas None None O
, None None O
which None None O
were None None O
named None None O
cellular None None O
proto None None O
- None None O
oncogens None None O
. None None O

They None None O
are None None O
important None None O
components None None O
of None None O
the None None O
growth None None O
regulatory None None O
pathways None None O
in None None O
normal None None O
cells None None O
. None None O

The None None O
accumulation None None O
of None None O
genetic None None O
alterations None None O
of None None O
some None None O
proto None None O
- None None O
oncogens None None O
, None None O
like None None O
the None None O
erbB None None O
- None None O
family None None O
, None None O
may None None O
be None None O
part None None O
of None None O
the None None O
mechanism None None O
, None None O
by None None O
which None None O
malignant None None O
cells None None O
can None None O
acquire None None O
a None None O
selective None None O
growth None None O
advantage None None O
. None None O

The None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGF None None O
- None None O
R None None O
, None None O
c None None O
- None None O
erbB1 None None O
) None None O
, None None O
Her None None O
- None None O
2 None None O
/ None None O
neu None None O
( None None O
c None None O
- None None O
erbB2 None None O
) None None O
, None None O
and None None O
c None None O
- None None O
erbB3 None None O
are None None O
members None None O
of None None O
the None None O
erbB None None O
- None None O
family None None O
. None None O

The None None O
detection None None O
of None None O
increased None None O
abundance None None O
of None None O
EGF None None O
- None None O
R None None O
or None None O
Her None None O
- None None O
2 None None O
/ None None O
neu None None O
proteins None None O
in None None O
human None None O
tumours None None O
can None None O
provide None None O
additional None None O
information None None O
on None None O
the None None O
disease None None O
- None None O
free None None O
survival None None O
and None None O
overall None None O
survival None None O
for None None O
patients None None O
with None None O
breast None None O
, None None O
ovarian None None O
, None None O
endometrial None None O
or None None O
cervical None None O
cancer None None O
. None None O

Molecular None None O
and None None O
cell None None O
- None None O
physiological None None O
analyses None None O
have None None O
improved None None O
the None None O
understanding None None O
of None None O
tumour None None O
biology None None O
and None None O
provide None None O
the None None O
opportunity None None O
for None None O
new None None O
therapeutic None None O
approaches None None O
. None None O

Monoclonal None None O
antibody None None O
targeted None None O
therapy None None O
directed None None O
against None None O
EGF None None O
- None None O
R None None O
or None None O
Her None None O
- None None O
2 None None O
/ None None O
neu None None O
, None None O
the None None O
use None None O
of None None O
anti None None O
- None None O
sense None None O
oligonucleotides None None O
and None None O
oligodeoxynucleotides None None O
, None None O
and None None O
the None None O
application None None O
of None None O
tyrosine None None O
kinase None None O
and None None O
protein None None O
C None None O
- None None O
kinase None None O
inhibitors None None O
are None None O
currently None None O
being None None O
investigated None None O
. None None O

Postoperative None None O
progression None None O
of None None O
pulmonary None None O
metastasis None None O
in None None O
osteosarcoma None None O
. None None O

Early None None O
relapse None None O
with None None O
distant None None O
metastasis None None O
often None None O
is None None O
observed None None O
in None None O
patients None None O
with None None O
cancer None None O
after None None O
resection None None O
of None None O
the None None O
primary None None O
tumor None None O
. None None O

It None None O
is None None O
considered None None O
that None None O
resection None None O
of None None O
the None None O
primary None None O
tumor None None O
induces None None O
activation None None O
of None None O
systemic None None O
angiogenesis None None O
and None None O
enhances None None O
progression None None O
of None None O
remote None None O
metastasis None None O
. None None O

The None None O
authors None None O
show None None O
that None None O
resection None None O
of None None O
the None None O
primary None None O
osteosarcoma None None O
tumor None None O
enhances None None O
progression None None O
of None None O
pulmonary None None O
metastasis None None O
in None None O
animal None None O
osteosarcoma None None O
models None None O
. None None O

Matrigel None None O
plug None None O
neovascularization None None O
assay None None O
revealed None None O
that None None O
systemic None None O
angiogenic None None O
activity None None O
was None None O
elevated None None O
after None None O
primary None None O
tumor None None O
removal None None O
( None None O
tumor None None O
intact None None O
group None None O
, None None O
1 None None O
. None None O
61 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
21 None None O
g None None O
/ None None O
dL None None O
; None None O
tumor None None O
removed None None O
group None None O
, None None O
4 None None O
. None None O
92 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
35 None None O
g None None O
/ None None O
dL None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
serum None None O
concentration None None O
of None None O
the None None O
angiogenesis None None O
inhibitor None None O
, None None O
endostatin None None O
, None None O
decreased None None O
significantly None None O
after None None O
primary None None O
tumor None None O
removal None None O
. None None O

Treatment None None O
with None None O
the None None O
antiangiogenic None None O
reagent None None O
TNP None None O
- None None O
470 None None O
suppressed None None O
postoperative None None O
progression None None O
of None None O
pulmonary None None O
metastasis None None O
. None None O

These None None O
results None None O
indicate None None O
the None None O
possibility None None O
that None None O
activation None None O
of None None O
angiogenic None None O
activity None None O
after None None O
resection None None O
of None None O
osteosarcoma None None O
tumors None None O
enhances None None O
progression None None O
of None None O
pulmonary None None O
metastasis None None O
. None None O

The None None O
current None None O
data None None O
also None None O
suggest None None O
that None None O
administration None None O
of None None O
antiangiogenic None None O
reagents None None O
can None None O
prevent None None O
progression None None O
of None None O
pulmonary None None O
metastasis None None O
in None None O
osteosarcoma None None O
postoperatively None None O
. None None O

Rational None None O
synthesis None None O
of None None O
multicyclic None None O
bis None None O
[ None None O
2 None None O
] None None O
catenanes None None O
. None None O

Bis None None O
- None None O
loop None None O
tetraurea None None O
calix None None O
[ None None O
4 None None O
] None None O
arene None None O
6 None None O
has None None O
been None None O
prepared None None O
by None None O
acylation None None O
of None None O
the None None O
wide None None O
- None None O
rim None None O
calix None None O
[ None None O
4 None None O
] None None O
arene None None O
tetraamine None None O
1 None None O
with None None O
the None None O
activated None None O
bis None None O
( None None O
urethane None None O
) None None O
8 None None O
under None None O
dilution None None O
conditions None None O
. None None O

Similarly None None O
the None None O
bis None None O
( None None O
Boc None None O
- None None O
protected None None O
) None None O
tetraamine None None O
2 None None O
is None None O
converted None None O
into None None O
the None None O
mono None None O
- None None O
loop None None O
derivative None None O
3 None None O
which None None O
after None None O
deprotection None None O
and None None O
acylation None None O
gives None None O
the None None O
bisalkenyl None None O
derivative None None O
5 None None O
. None None O

In None None O
apolar None None O
solvents None None O
this None None O
tetraurea None None O
calix None None O
[ None None O
4 None None O
] None None O
arene None None O
5 None None O
forms None None O
regioselectively None None O
a None None O
single None None O
hydrogen None None O
- None None O
bonded None None O
homodimer None None O
, None None O
from None None O
which None None O
the None None O
bis None None O
[ None None O
2 None None O
] None None O
catenane None None O
10a None None O
is None None O
formed None None O
in None None O
49 None None O
% None None O
by None None O
a None None O
metathesis None None O
reaction None None O
followed None None O
by None None O
hydrogenation None None O
. None None O

Bis None None O
- None None O
loop None None O
derivative None None O
6 None None O
forms None None O
no None None O
homodimers None None O
for None None O
steric None None O
reasons None None O
, None None O
but None None O
a None None O
stoichiometric None None O
mixture None None O
with None None O
the None None O
open None None O
- None None O
chain None None O
tetraalkenyl None None O
derivative None None O
7a None None O
contains None None O
exclusively None None O
the None None O
heterodimer None None O
. None None O

Metathesis None None O
and None None O
subsequent None None O
hydrogenation None None O
now None None O
yields None None O
65 None None O
% None None O
of None None O
the None None O
pure None None O
bis None None O
[ None None O
2 None None O
] None None O
catenane None None O
10a None None O
which None None O
could None None O
not None None O
be None None O
isolated None None O
from None None O
the None None O
complex None None O
reaction None None O
mixture None None O
obtained None None O
from None None O
the None None O
homodimer None None O
7a None None O
. None None O
7a None None O
. None None O

The None None O
chirality None None O
of None None O
10a None None O
( None None O
D None None O
( None None O
2 None None O
) None None O
symmetry None None O
) None None O
has None None O
been None None O
verified None None O
by None None O
optical None None O
resolution None None O
using None None O
HPLC None None O
on None None O
a None None O
chiral None None O
stationary None None O
phase None None O
. None None O

An None None O
evaluation None None O
of None None O
low None None O
molecular None None O
weight None None O
heparin None None O
and None None O
hyperbaric None None O
oxygen None None O
treatment None None O
in None None O
the None None O
prevention None None O
of None None O
intra None None O
- None None O
abdominal None None O
adhesions None None O
and None None O
wound None None O
healing None None O
. None None O

BACKGROUND None None O
: None None O
Abdominal None None O
surgery None None O
can None None O
lead None None O
to None None O
intra None None O
- None None O
abdominal None None O
adhesions None None O
with None None O
significant None None O
morbidity None None O
and None None O
mortality None None O
. None None O

To None None O
prevent None None O
adhesions None None O
, None None O
an None None O
experimental None None O
study None None O
was None None O
planned None None O
to None None O
designate None None O
the None None O
effects None None O
of None None O
low None None O
molecular None None O
weight None None O
( None None O
LMW None None O
) None None O
heparins None None O
and None None O
hyperbaric None None O
oxygen None None O
( None None O
HBO None None O
) None None O
therapy None None O
both None None O
on None None O
the None None O
formation None None O
of None None O
adhesions None None O
and None None O
wound None None O
healing None None O
. None None O

METHODS None None O
: None None O
Thirty None None O
- None None O
eight None None O
Wistar None None O
albino None None O
rats None None O
underwent None None O
laparotomy None None O
to None None O
cause None None O
intra None None O
- None None O
abdominal None None O
adhesions None None O
by None None O
mechanical None None O
abrasion None None O
of None None O
the None None O
cecum None None O
and None None O
ethanol None None O
application None None O
. None None O

The None None O
rats None None O
were None None O
divided None None O
into None None O
4 None None O
groups None None O
. None None O

In None None O
the None None O
control None None O
group None None O
( None None O
group None None O
1 None None O
) None None O
no None None O
further None None O
management None None O
was None None O
undertaken None None O
. None None O

Group None None O
2 None None O
was None None O
treated None None O
by None None O
Enoxaparine None None O
Na None None O
, None None O
group None None O
3 None None O
received None None O
HBO None None O
therapy None None O
, None None O
and None None O
group None None O
4 None None O
was None None O
given None None O
both None None O
enoxaparine None None O
Na None None O
and None None O
HBO None None O
treatment None None O
. None None O

RESULTS None None O
: None None O
There None None O
was None None O
a None None O
statistically None None O
significant None None O
difference None None O
between None None O
the None None O
control None None O
and None None O
enoxaparine None None O
Na None None O
groups None None O
regarding None None O
adhesions None None O
. None None O

Statistically None None O
significant None None O
differences None None O
were None None O
observed None None O
between None None O
groups None None O
1 None None O
and None None O
4 None None O
and None None O
between None None O
groups None None O
1 None None O
and None None O
3 None None O
regarding None None O
the None None O
hydroxyproline None None O
content None None O
of None None O
the None None O
abdominal None None O
wounds None None O
. None None O

In None None O
the None None O
pathologic None None O
analysis None None O
of None None O
the None None O
abdominal None None O
wounds None None O
, None None O
there None None O
was None None O
no None None O
statistically None None O
significant None None O
difference None None O
between None None O
any None None O
of None None O
the None None O
groups None None O
, None None O
including None None O
the None None O
control None None O
group None None O
, None None O
regarding None None O
inflammation None None O
. None None O

Statistically None None O
significant None None O
differences None None O
were None None O
observed None None O
regarding None None O
angiogenesis None None O
between None None O
the None None O
control None None O
group None None O
and None None O
groups None None O
3 None None O
and None None O
4 None None O
. None None O

There None None O
was None None O
also None None O
a None None O
statistically None None O
significant None None O
difference None None O
regarding None None O
fibrosis None None O
between None None O
groups None None O
1 None None O
and None None O
4 None None O
. None None O

CONCLUSIONS None None O
: None None O
Enoxaparine None None O
Na None None O
decreased None None O
intra None None O
- None None O
abdominal None None O
adhesions None None O
, None None O
and None None O
HBO None None O
therapy None None O
had None None O
no None None O
beneficial None None O
effect None None O
on None None O
adhesions None None O
. None None O

Enoxaparine None None O
Na None None O
had None None O
no None None O
harmful None None O
effects None None O
on None None O
wound None None O
healing None None O
, None None O
and None None O
HBO None None O
therapy None None O
increased None None O
the None None O
process None None O
of None None O
wound None None O
healing None None O
. None None O

[ None None O
A None None O
decline None None O
in None None O
the None None O
French None None O
demographic None None O
situation None None O
in None None O
the None None O
context None None O
of None None O
a None None O
Europe None None O
also None None O
in None None O
demographic None None O
decline None None O
] None None O
. None None O

The None None O
author None None O
analyzes None None O
the None None O
decline None None O
in None None O
French None None O
fertility None None O
which None None O
has None None O
occurred None None O
over None None O
the None None O
past None None O
two None None O
years None None O
using None None O
data None None O
from None None O
official None None O
sources None None O
. None None O

Some None None O
comparisons None None O
are None None O
made None None O
with None None O
fertility None None O
trends None None O
in None None O
other None None O
European None None O
countries None None O
. None None O

CA None None O
IX None None O
and None None O
response None None O
to None None O
PMRT None None O

Kaplan None None O
- None None O
Meier None None O
probability None None O
plots None None O
of None None O
OS None None O
after None None O
PMRT None None O
among None None O
CA None None O
IX None None O
positive None None O
and None None O
CA None None O
IX None None O
negative None None O
patients None None O
revealed None None O
improved None None O
survival None None O
after None None O
PMRT None None O
in None None O
both None None O
subgroups None None O
of None None O
patients None None O
( None None O
Figure None None O
2 None None O
) None None O
. None None O

Fifteen None None O
- None None O
year None None O
OS None None O
probabilities None None O
were None None O
improved None None O
by None None O
7 None None O
% None None O
and None None O
9 None None O
% None None O
after None None O
PMRT None None O
for None None O
the None None O
subgroups None None O
of None None O
CA None None O
IX None None O
positive None None O
and None None O
CA None None O
IX None None O
negative None None O
patients None None O
, None None O
respectively None None O
. None None O

The None None O
HR None None O
of None None O
overall None None O
mortality None None O
after None None O
PMRT None None O
was None None O
0 None None O
. None None O
87 None None O
( None None O
95 None None O
% None None O
CI None None O
0 None None O
. None None O
60 None None O
to None None O
1 None None O
. None None O
27 None None O
) None None O
for None None O
the None None O
small None None O
subgroup None None O
of None None O
151 None None O
CA None None O
IX None None O
positive None None O
patients None None O
and None None O
0 None None O
. None None O
82 None None O
( None None O
95 None None O
% None None O
CI None None O
0 None None O
. None None O
69 None None O
to None None O
0 None None O
. None None O
97 None None O
) None None O
for None None O
the None None O
large None None O
subgroup None None O
of None None O
813 None None O
CA None None O
IX None None O
negative None None O
patients None None O
. None None O

HRs None None O
and None None O
95 None None O
% None None O
CIs None None O
after None None O
PMRT None None O
did None None O
not None None O
differ None None O
significantly None None O
between None None O
CA None None O
IX None None O
positive None None O
and None None O
CA None None O
IX None None O
negative None None O
patients None None O
for None None O
OS None None O
, None None O
DSS None None O
, None None O
DM None None O
, None None O
or None None O
LRR None None O
( None None O
Table None None O
4 None None O
) None None O
. None None O

In None None O
multivariate None None O
analysis None None O
by None None O
Cox None None O
regression None None O
, None None O
no None None O
significant None None O
interaction None None O
was None None O
found None None O
between None None O
CA None None O
IX None None O
and None None O
randomization None None O
status None None O
for None None O
any None None O
of None None O
the None None O
four None None O
end None None O
- None None O
points None None O
. None None O

Similar None None O
tendencies None None O
were None None O
observed None None O
when None None O
the None None O
women None None O
were None None O
separated None None O
into None None O
premenopausal None None O
and None None O
postmenopausal None None O
women None None O
, None None O
and None None O
into None None O
women None None O
with None None O
one None None O
to None None O
three None None O
positive None None O
nodes None None O
and None None O
those None None O
with None None O
more None None O
than None None O
three None None O
positive None None O
nodes None None O
. None None O

Table None None O
4 None None O

Hazard None None O
ratios None None O

CA None None O
IX None None O
positive None None O
( None None O
n None None O
= None None O
151 None None O
) None None O
CA None None O
IX None None O
negative None None O
( None None O
n None None O
= None None O
794 None None O
) None None O

Overall None None O
mortality None None O
0 None None O
. None None O
87 None None O
( None None O
0 None None O
. None None O
60 None None O
- None None O
1 None None O
. None None O
27 None None O
) None None O
0 None None O
. None None O
82 None None O
( None None O
0 None None O
. None None O
69 None None O
- None None O
0 None None O
. None None O
97 None None O
) None None O

Disease None None O
- None None O
specific None None O
mortality None None O
0 None None O
. None None O
83 None None O
( None None O
0 None None O
. None None O
55 None None O
- None None O
1 None None O
. None None O
27 None None O
) None None O
0 None None O
. None None O
76 None None O
( None None O
0 None None O
. None None O
63 None None O
- None None O
0 None None O
. None None O
93 None None O
) None None O

Distant None None O
metastases None None O
0 None None O
. None None O
83 None None O
( None None O
0 None None O
. None None O
54 None None O
- None None O
1 None None O
. None None O
25 None None O
) None None O
0 None None O
. None None O
76 None None O
( None None O
0 None None O
. None None O
63 None None O
- None None O
0 None None O
. None None O
91 None None O
) None None O

Locoregional None None O
recurrence None None O
0 None None O
. None None O
23 None None O
( None None O
0 None None O
. None None O
08 None None O
- None None O
0 None None O
. None None O
61 None None O
) None None O
0 None None O
. None None O
16 None None O
( None None O
0 None None O
. None None O
09 None None O
- None None O
0 None None O
. None None O
28 None None O
) None None O

Presented None None O
are None None O
hazard None None O
ratios None None O
( None None O
95 None None O
% None None O
confidence None None O
intervals None None O
) None None O
of None None O
overall None None O
mortality None None O
, None None O
disease None None O
- None None O
specific None None O
mortality None None O
, None None O
distant None None O
metastases None None O
and None None O
loco None None O
- None None O
regional None None O
recurrence None None O
probabilities None None O
after None None O
postmastectomy None None O
radiotherapy None None O
in None None O
carbonic None None O
anhydrase None None O
( None None O
CA None None O
) None None O
IX None None O
positive None None O
and None None O
in None None O
CA None None O
IX None None O
negative None None O
high None None O
- None None O
risk None None O
breast None None O
cancer None None O
patients None None O
. None None O

Figure None None O
2 None None O

Overall None None O
survival None None O
in None None O
high None None O
- None None O
risk None None O
breast None None O
cancer None None O
patients None None O
. None None O

Shown None None O
are None None O
Kaplan None None O
- None None O
Meier None None O
probability None None O
plots None None O
of None None O
overall None None O
survival None None O
in None None O
high None None O
- None None O
risk None None O
breast None None O
cancer None None O
patients None None O
as None None O
a None None O
function None None O
of None None O
randomization None None O
to None None O
postmastectomy None None O
radiotherapy None None O
( None None O
RT None None O
) None None O
within None None O
the None None O
subgroups None None O
of None None O
carbonic None None O
anhydrase None None O
( None None O
CA None None O
) None None O
IX None None O
negative None None O
and None None O
CA None None O
IX None None O
positive None None O
patients None None O
. None None O

The None None O
values None None O
given None None O
in None None O
parentheses None None O
after None None O
hazard None None O
ratios None None O
( None None O
HRs None None O
) None None O
are None None O
the None None O
95 None None O
% None None O
confidence None None O
intervals None None O
. None None O

Changing None None O
the None None O
cutpoints None None O
to None None O
at None None O
least None None O
one None None O
tumour None None O
cell None None O
, None None O
or None None O
> None None O
= None None O
20 None None O
% None None O
or None None O
> None None O
= None None O
30 None None O
% None None O
invasive None None O
tumour None None O
staining None None O
did None None O
not None None O
improve None None O
the None None O
predictive None None O
value None None O
of None None O
positive None None O
CA None None O
IX None None O
staining None None O
( None None O
data None None O
not None None O
presented None None O
) None None O
. None None O

Influences None None O
on None None O
the None None O
pharmacokinetics None None O
of None None O
oxycodone None None O
: None None O
a None None O
multicentre None None O
cross None None O
- None None O
sectional None None O
study None None O
in None None O
439 None None O
adult None None O
cancer None None O
patients None None O
. None None O

OBJECTIVE None None O
: None None O

Oxycodone None None O
is None None O
widely None None O
used None None O
for None None O
the None None O
treatment None None O
of None None O
cancer None None O
pain None None O
, None None O
but None None O
little None None O
is None None O
known None None O
of None None O
its None None O
pharmacokinetics None None O
in None None O
cancer None None O
pain None None O
patients None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
explore None None O
the None None O
relationships None None O
between None None O
ordinary None None O
patient None None O
characteristics None None O
and None None O
serum None None O
concentrations None None O
of None None O
oxycodone None None O
and None None O
the None None O
ratios None None O
noroxycodone None None O
or None None O
oxymorphone None None O
/ None None O
oxycodone None None O
in None None O
cancer None None O
patients None None O
. None None O

METHODS None None O
: None None O

Four None None O
hundred None None O
and None None O
thirty None None O
- None None O
nine None None O
patients None None O
using None None O
oral None None O
oxycodone None None O
for None None O
cancer None None O
pain None None O
were None None O
included None None O
. None None O

The None None O
patients None None O
' None None O
characteristics None None O
( None None O
sex None None O
, None None O
age None None O
, None None O
body None None O
mass None None O
index None None O
[ None None O
BMI None None O
] None None O
, None None O
Karnofsky None None O
performance None None O
status None None O
, None None O
" None None O
time None None O
since None None O
starting None None O
opioids None None O
" None None O
, None None O
" None None O
oxycodone None None O
total None None O
daily None None O
dose None None O
" None None O
, None None O
" None None O
time None None O
from None None O
last None None O
oxycodone None None O
dose None None O
" None None O
, None None O
use None None O
of None None O
CYP3A4 None None O
inducer None None O
/ None None O
inhibitor None None O
, None None O
" None None O
use None None O
of None None O
systemic None None O
steroids None None O
" None None O
, None None O
" None None O
number None None O
of None None O
medications None None O
taken None None O
in None None O
the None None O
last None None O
24 None None O
h None None O
" None None O
, None None O
glomerular None None O
filtration None None O
rate None None O
( None None O
GFR None None O
) None None O
and None None O
albumin None None O
serum None None O
concentrations None None O
) None None O
influence None None O
on None None O
oxycodone None None O
serum None None O
concentrations None None O
or None None O
metabolite None None O
/ None None O
oxycodone None None O
ratios None None O
were None None O
explored None None O
by None None O
multiple None None O
regression None None O
analyses None None O
. None None O

RESULTS None None O
: None None O

Sex None None O
, None None O
CYP3A4 None None O
inducers None None O
/ None None O
inhibitors None None O
, None None O
total None None O
daily None None O
dose None None O
, None None O
and None None O
" None None O
time None None O
from None None O
last None None O
oxycodone None None O
dose None None O
" None None O
predicted None None O
oxycodone None None O
concentrations None None O
. None None O

CYP3A4 None None O
inducers None None O
, None None O
total None None O
daily None None O
dose None None O
, None None O
and None None O
" None None O
number None None O
of None None O
medications None None O
taken None None O
in None None O
the None None O
last None None O
24 None None O
h None None O
" None None O
predicted None None O
the None None O
oxymorphone None None O
/ None None O
oxycodone None None O
ratio None None O
. None None O

Total None None O
daily None None O
dose None None O
, None None O
" None None O
time None None O
from None None O
last None None O
dose None None O
to None None O
blood None None O
sample None None O
" None None O
, None None O
albumin None None O
, None None O
sex None None O
, None None O
CYP3A4 None None O
inducers None None O
/ None None O
inhibitors None None O
, None None O
steroids None None O
, None None O
BMI None None O
and None None O
GFR None None O
predicted None None O
the None None O
noroxycodone None None O
/ None None O
oxycodone None None O
ratio None None O
. None None O

CONCLUSION None None O
: None None O

Women None None O
had None None O
lower None None O
oxycodone None None O
serum None None O
concentrations None None O
than None None O
men None None O
. None None O

CYP3A4 None None O
inducers None None O
/ None None O
inhibitors None None O
should None None O
be None None O
used None None O
with None None O
caution None None O
as None None O
these None None O
are None None O
predicted None None O
to None None O
have None None O
a None None O
significant None None O
impact None None O
on None None O
oxycodone None None O
pharmacokinetics None None O
. None None O

Other None None O
characteristics None None O
explained None None O
only None None O
minor None None O
parts None None O
of None None O
the None None O
variability None None O
of None None O
the None None O
outcomes None None O
. None None O

Authors None None O
' None None O
contributions None None O

CM None None O
, None None O
JRH None None O
, None None O
HJP None None O
, None None O
and None None O
JH None None O
carried None None O
animal None None O
studies None None O
. None None O

CM None None O
performed None None O
the None None O
statistical None None O
analysis None None O
. None None O

JLK None None O
conceived None None O
of None None O
the None None O
study None None O
, None None O
participated None None O
in None None O
its None None O
design None None O
and None None O
coordination None None O
, None None O
and None None O
drafted None None O
and None None O
edited None None O
the None None O
manuscript None None O
. None None O

All None None O
authors None None O
read None None O
and None None O
approved None None O
the None None O
final None None O
manuscript None None O
. None None O

Ca2 None None O
+ None None O
Dependence None None O
of None None O
Slob57 None None O
Modulation None None O
of None None O
the None None O
Voltage None None O
Dependence None None O
of None None O
Activation None None O
of None None O
dSlo None None O

Ca2 None None O
+ None None O
plays None None O
a None None O
fundamental None None O
role None None O
in None None O
regulating None None O
the None None O
dSlo None None O
response None None O
to None None O
membrane None None O
depolarization None None O
. None None O

One None None O
of None None O
the None None O
three None None O
known None None O
Ca2 None None O
+ None None O
binding None None O
sites None None O
( None None O
Xia None None O
et None None O
al None None O
. None None O
, None None O
2002 None None O
; None None O
Bao None None O
et None None O
al None None O
. None None O
, None None O
2002 None None O
; None None O
Zeng None None O
et None None O
al None None O
. None None O
, None None O
2005b None None O
) None None O
, None None O
known None None O
as None None O
the None None O
calcium None None O
bowl None None O
( None None O
Schreiber None None O
and None None O
Salkoff None None O
, None None O
1997 None None O
) None None O
, None None O
contributes None None O
to None None O
the None None O
high None None O
- None None O
affinity None None O
Ca2 None None O
+ None None O
sensitivity None None O
of None None O
the None None O
channel None None O
( None None O
Schreiber None None O
and None None O
Salkoff None None O
, None None O
1997 None None O
; None None O
Schreiber None None O
et None None O
al None None O
. None None O
, None None O
1999 None None O
; None None O
Braun None None O
and None None O
Sy None None O
, None None O
2001 None None O
; None None O
Bao None None O
et None None O
al None None O
. None None O
, None None O
2002 None None O
; None None O
Niu None None O
and None None O
Magleby None None O
, None None O
2002 None None O
; None None O
Xia None None O
et None None O
al None None O
. None None O
, None None O
2002 None None O
; None None O
Bao None None O
et None None O
al None None O
. None None O
, None None O
2004 None None O
; None None O
Zeng None None O
et None None O
al None None O
. None None O
, None None O
2005b None None O
) None None O
. None None O

We None None O
used None None O
a None None O
mutated None None O
dSlo None None O
channel None None O
with None None O
substitution None None O
of None None O
Asp966 None None O
- None None O
Asp970 None None O
by None None O
Asn966 None None O
- None None O
Asn970 None None O
within None None O
its None None O
calcium None None O
bowl None None O
, None None O
which None None O
greatly None None O
reduces None None O
the None None O
channel None None O
' None None O
s None None O
calcium None None O
sensitivity None None O
( None None O
Bian None None O
et None None O
al None None O
. None None O
, None None O
2001 None None O
) None None O
, None None O
to None None O
determine None None O
whether None None O
Ca2 None None O
+ None None O
participates None None O
in None None O
Slob57 None None O
modulation None None O
of None None O
dSlo None None O
. None None O

This None None O
mutated None None O
channel None None O
, None None O
dSloD5N5 None None O
, None None O
still None None O
binds None None O
to None None O
full None None O
- None None O
length None None O
and None None O
truncated None None O
Slobs None None O
( None None O
Fig None None O
. None None O
1 None None O
B None None O
, None None O
lanes None None O
4 None None O
- None None O
6 None None O
) None None O
. None None O

During None None O
a None None O
350 None None O
- None None O
ms None None O
test None None O
pulse None None O
( None None O
Fig None None O
. None None O
7 None None O
E None None O
) None None O
, None None O
Slob57 None None O
causes None None O
dSloD5N5 None None O
inactivation None None O
( None None O
Fig None None O
. None None O
7 None None O
B None None O
) None None O
, None None O
consistent None None O
with None None O
our None None O
previous None None O
finding None None O
that None None O
the None None O
inactivation None None O
caused None None O
by None None O
Slob57 None None O
is None None O
Ca2 None None O
+ None None O
independent None None O
( None None O
Zeng None None O
et None None O
al None None O
. None None O
, None None O
2005a None None O
) None None O
. None None O

After None None O
deletion None None O
of None None O
the None None O
amino None None O
- None None O
terminal None None O
residues None None O
2 None None O
- None None O
6 None None O
of None None O
Slob57 None None O
, None None O
the None None O
inactivation None None O
of None None O
dSloD5N5 None None O
is None None O
eliminated None None O
( None None O
Fig None None O
. None None O
7 None None O
C None None O
) None None O
, None None O
and None None O
further None None O
truncation None None O
of None None O
Slob57 None None O
to None None O
Arg16 None None O
also None None O
eliminates None None O
the None None O
inactivation None None O
( None None O
Fig None None O
. None None O
7 None None O
D None None O
) None None O
, None None O
just None None O
as None None O
observed None None O
with None None O
wild None None O
- None None O
type None None O
dSlo None None O
( None None O
Fig None None O
. None None O
2 None None O
, None None O
C None None O
and None None O
D None None O
) None None O
. None None O

Figure None None O
7 None None O
. None None O

Slob57 None None O
causes None None O
inactivation None None O
of None None O
dSloD5N5 None None O
. None None O

Same None None O
as None None O
Fig None None O
. None None O

2 None None O
, None None O
except None None O
that None None O
the None None O
mutated None None O
channel None None O
dSloD5N5 None None O
was None None O
used None None O
instead None None O
of None None O
wild None None O
- None None O
type None None O
dSlo None None O
. None None O

( None None O
A None None O
) None None O
dSloD5N5 None None O
alone None None O
, None None O
( None None O
B None None O
) None None O
dSloD5N5 None None O
together None None O
with None None O
Slob57 None None O
, None None O
( None None O
C None None O
) None None O
dSloD5N5 None None O
together None None O
with None None O
Slob57DeltaN5 None None O
, None None O
( None None O
D None None O
) None None O
dSloD5N5 None None O
together None None O
with None None O
Slob57DeltaN15 None None O
, None None O
( None None O
E None None O
) None None O
pulse None None O
protocol None None O
. None None O

We None None O
next None None O
used None None O
a None None O
100 None None O
- None None O
ms None None O
test None None O
pulse None None O
( None None O
during None None O
which None None O
no None None O
inactivation None None O
occurs None None O
) None None O
to None None O
measure None None O
the None None O
voltage None None O
dependence None None O
of None None O
activation None None O
of None None O
dSloD5N5 None None O
in None None O
the None None O
presence None None O
of None None O
110 None None O
muM None None O
free None None O
Ca2 None None O
+ None None O
, None None O
as None None O
only None None O
at None None O
high None None O
concentrations None None O
of None None O
free None None O
Ca2 None None O
+ None None O
can None None O
tail None None O
current None None O
saturation None None O
be None None O
achieved None None O
with None None O
the None None O
mutant None None O
channel None None O
( None None O
Fig None None O
. None None O
8 None None O
) None None O
. None None O

As None None O
shown None None O
in None None O
Fig None None O
. None None O

8 None None O
, None None O
Slob57 None None O
does None None O
not None None O
rightward None None O
shift None None O
the None None O
conductance None None O
- None None O
voltage None None O
relationship None None O
of None None O
dSloD5N5 None None O
. None None O

Because None None O
dSloD5N5 None None O
can None None O
still None None O
respond None None O
to None None O
an None None O
increment None None O
of None None O
free None None O
Ca2 None None O
+ None None O
at None None O
high None None O
concentration None None O
( None None O
Bian None None O
et None None O
al None None O
. None None O
, None None O
2001 None None O
) None None O
, None None O
we None None O
then None None O
increased None None O
the None None O
concentration None None O
of None None O
free None None O
Ca2 None None O
+ None None O
to None None O
300 None None O
muM None None O
. None None O

As None None O
shown None None O
in None None O
Fig None None O
. None None O

8 None None O
, None None O
the None None O
conductance None None O
- None None O
voltage None None O
relationship None None O
of None None O
dSloD5N5 None None O
shifts None None O
to None None O
less None None O
depolarized None None O
voltages None None O
when None None O
the None None O
concentration None None O
of None None O
free None None O
Ca2 None None O
+ None None O
is None None O
increased None None O
from None None O
110 None None O
to None None O
300 None None O
muM None None O
, None None O
but None None O
again None None O
the None None O
V1 None None O
/ None None O
2 None None O
is None None O
not None None O
modulated None None O
by None None O
Slob57 None None O
. None None O

Figure None None O
8 None None O
. None None O

Conductance None None O
- None None O
voltage None None O
relationships None None O
for None None O
dSloD5N5 None None O
. None None O

Same None None O
protocol None None O
as None None O
Fig None None O
. None None O

6 None None O
, None None O
except None None O
that None None O
the None None O
mutated None None O
channel None None O
dSloD5N5 None None O
was None None O
used None None O
in None None O
the None None O
presence None None O
( None None O
circles None None O
) None None O
or None None O
absence None None O
( None None O
squares None None O
) None None O
of None None O
Slob57 None None O
, None None O
and None None O
the None None O
concentration None None O
of None None O
free None None O
Ca2 None None O
+ None None O
was None None O
either None None O
110 None None O
muM None None O
( None None O
filled None None O
symbols None None O
) None None O
or None None O
300 None None O
muM None None O
( None None O
open None None O
symbols None None O
) None None O
. None None O

We None None O
next None None O
measured None None O
the None None O
voltage None None O
dependence None None O
of None None O
activation None None O
of None None O
wild None None O
- None None O
type None None O
dSlo None None O
, None None O
in None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
Slob57 None None O
, None None O
at None None O
free None None O
Ca2 None None O
+ None None O
concentrations None None O
ranging None None O
from None None O
20 None None O
to None None O
300 None None O
muM None None O
. None None O

As None None O
shown None None O
in None None O
Fig None None O
. None None O

9 None None O
A None None O
( None None O
and None None O
by None None O
many None None O
previous None None O
investigators None None O
) None None O
, None None O
in None None O
the None None O
absence None None O
of None None O
Slob57 None None O
, None None O
the None None O
voltage None None O
- None None O
conductance None None O
relationship None None O
of None None O
dSlo None None O
shifts None None O
to None None O
less None None O
depolarized None None O
voltages None None O
as None None O
the None None O
free None None O
Ca2 None None O
+ None None O
concentration None None O
is None None O
increased None None O
in None None O
this None None O
range None None O
. None None O

The None None O
V1 None None O
/ None None O
2 None None O
decreases None None O
from None None O
85 None None O
to None None O
- None None O
22 None None O
mV None None O
, None None O
a None None O
change None None O
of None None O
107 None None O
mV None None O
, None None O
when None None O
the None None O
concentration None None O
of None None O
free None None O
Ca2 None None O
+ None None O
is None None O
increased None None O
from None None O
20 None None O
to None None O
300 None None O
muM None None O
. None None O

In None None O
contrast None None O
, None None O
when None None O
dSlo None None O
is None None O
coexpressed None None O
with None None O
Slob57 None None O
, None None O
this None None O
increment None None O
of None None O
free None None O
Ca2 None None O
+ None None O
concentration None None O
shifts None None O
the None None O
V1 None None O
/ None None O
2 None None O
to None None O
a None None O
much None None O
lesser None None O
extent None None O
( None None O
Fig None None O
. None None O
9 None None O
B None None O
and None None O
Fig None None O
. None None O
10 None None O
A None None O
) None None O
. None None O

Note None None O
also None None O
that None None O
the None None O
effect None None O
of None None O
Slob57 None None O
on None None O
the None None O
V1 None None O
/ None None O
2 None None O
is None None O
more None None O
apparent None None O
at None None O
higher None None O
free None None O
Ca2 None None O
+ None None O
concentrations None None O
( None None O
Fig None None O
. None None O
10 None None O
A None None O
) None None O
. None None O

To None None O
illustrate None None O
this None None O
better None None O
, None None O
we None None O
plotted None None O
the None None O
V1 None None O
/ None None O
2 None None O
change None None O
evoked None None O
by None None O
Slob57 None None O
( None None O
DeltaV1 None None O
/ None None O
2 None None O
) None None O
as None None O
a None None O
function None None O
of None None O
the None None O
free None None O
Ca2 None None O
+ None None O
concentration None None O
( None None O
Fig None None O
. None None O
10 None None O
B None None O
) None None O
to None None O
demonstrate None None O
that None None O
the None None O
magnitude None None O
of None None O
the None None O
modulatory None None O
shift None None O
in None None O
V1 None None O
/ None None O
2 None None O
evoked None None O
by None None O
Slob57 None None O
itself None None O
is None None O
calcium None None O
dependent None None O
. None None O

Figure None None O
9 None None O
. None None O

Effect None None O
of None None O
calcium None None O
on None None O
dSlo None None O
voltage None None O
dependence None None O
of None None O
activation None None O
in None None O
the None None O
absence None None O
or None None O
presence None None O
of None None O
Slob57 None None O
. None None O

Same None None O
as None None O
Fig None None O
. None None O

6 None None O
, None None O
except None None O
that None None O
the None None O
measurements None None O
of None None O
dSlo None None O
expressed None None O
alone None None O
( None None O
A None None O
) None None O
or None None O
together None None O
with None None O
Slob57 None None O
( None None O
B None None O
) None None O
were None None O
performed None None O
in None None O
the None None O
presence None None O
of None None O
different None None O
concentrations None None O
of None None O
free None None O
Ca2 None None O
+ None None O
: None None O
20 None None O
muM None None O
( None None O
diamonds None None O
) None None O
, None None O
40 None None O
muM None None O
( None None O
inverted None None O
triangles None None O
) None None O
, None None O
80 None None O
muM None None O
( None None O
triangles None None O
) None None O
, None None O
110 None None O
muM None None O
( None None O
squares None None O
) None None O
, None None O
and None None O
300 None None O
muM None None O
( None None O
circles None None O
) None None O
. None None O

Figure None None O
10 None None O
. None None O

Interaction None None O
between None None O
Slob57 None None O
and None None O
calcium None None O
. None None O

The None None O
V1 None None O
/ None None O
2 None None O
( None None O
A None None O
) None None O
of None None O
the None None O
conductance None None O
- None None O
voltage None None O
relationship None None O
for None None O
dSlo None None O
expressed None None O
alone None None O
( None None O
O None None O
) None None O
or None None O
together None None O
with None None O
Slob57 None None O
( None None O
* None None O
) None None O
, None None O
taken None None O
from None None O
Fig None None O
. None None O

9 None None O
, None None O
and None None O
the None None O
difference None None O
in None None O
V1 None None O
/ None None O
2 None None O
( None None O
DeltaV1 None None O
/ None None O
2 None None O
) None None O
evoked None None O
by None None O
Slob57 None None O
( None None O
B None None O
) None None O
are None None O
plotted None None O
as None None O
a None None O
function None None O
of None None O
the None None O
concentration None None O
of None None O
free None None O
Ca2 None None O
+ None None O
. None None O

Childhood None None O
conscientiousness None None O
and None None O
longevity None None O
: None None O
health None None O
behaviors None None O
and None None O
cause None None O
of None None O
death None None O
. None None O

Previous None None O
research None None O
showed None None O
that None None O
conscientiousness None None O
( None None O
social None None O
dependability None None O
) None None O
in None None O
childhood None None O
predicted None None O
longevity None None O
in None None O
an None None O
archival None None O
prospective None None O
cohort None None O
study None None O
of None None O
bright None None O
children None None O
first None None O
studied None None O
by None None O
Terman None None O
in None None O
the None None O
1920s None None O
( None None O
H None None O
. None None O
S None None O
. None None O
Friedman None None O
et None None O
al None None O
. None None O
, None None O
1993 None None O
) None None O
. None None O

Possible None None O
behavioral None None O
mechanisms None None O
for None None O
this None None O
robust None None O
association None None O
are None None O
now None None O
examined None None O
by None None O
gathering None None O
cause None None O
of None None O
death None None O
information None None O
and None None O
by None None O
considering None None O
the None None O
possible None None O
mediating None None O
influences None None O
of None None O
drinking None None O
alcohol None None O
, None None O
smoking None None O
, None None O
and None None O
overeating None None O
. None None O

Survival None None O
analyses None None O
( None None O
N None None O
= None None O
1 None None O
, None None O
215 None None O
) None None O
suggest None None O
that None None O
the None None O
protective None None O
effect None None O
of None None O
conscientiousness None None O
is None None O
not None None O
primarily None None O
due None None O
to None None O
accident None None O
avoidance None None O
and None None O
cannot None None O
be None None O
mostly None None O
explained None None O
by None None O
abstinence None None O
from None None O
unhealthy None None O
substance None None O
intake None None O
. None None O

Conscientiousness None None O
may None None O
have None None O
more None None O
wide None None O
- None None O
ranging None None O
effects None None O
on None None O
health None None O
- None None O
relevant None None O
activities None None O
. None None O

Nitric None None O
oxide None None O
synthase None None O
inhibition None None O
results None None O
in None None O
synergistic None None O
anti None None O
- None None O
tumour None None O
activity None None O
with None None O
melphalan None None O
and None None O
tumour None None O
necrosis None None O
factor None None O
alpha None None O
- None None O
based None None O
isolated None None O
limb None None O
perfusions None None O
. None None O

Nitric None None O
oxide None None O
( None None O
NO None None O
) None None O
is None None O
an None None O
important None None O
molecule None None O
in None None O
regulating None None O
tumour None None O
blood None None O
flow None None O
and None None O
stimulating None None O
tumour None None O
angiogenesis None None O
. None None O

Inhibition None None O
of None None O
NO None None O
synthase None None O
by None None O
L None None O
- None None O
NAME None None O
might None None O
induce None None O
an None None O
anti None None O
- None None O
tumour None None O
effect None None O
by None None O
limiting None None O
nutrients None None O
and None None O
oxygen None None O
to None None O
reach None None O
tumour None None O
tissue None None O
or None None O
affecting None None O
vascular None None O
growth None None O
. None None O

The None None O
anti None None O
- None None O
tumour None None O
effect None None O
of None None O
L None None O
- None None O
NAME None None O
after None None O
systemic None None O
administration None None O
was None None O
studied None None O
in None None O
a None None O
renal None None O
subcapsular None None O
CC531 None None I-Cell-line-name
adenocarcinoma None None O
model None None O
in None None O
rats None None O
. None None O

Moreover None None O
, None None O
regional None None O
administration None None O
of None None O
L None None O
- None None O
NAME None None O
, None None O
in None None O
combination None None O
with None None O
TNF None None O
and None None O
melphalan None None O
, None None O
was None None O
studied None None O
in None None O
an None None O
isolated None None O
limb None None O
perfusion None None O
( None None O
ILP None None O
) None None O
model None None O
using None None O
BN175 None None O
soft None None O
- None None O
tissue None None O
sarcomas None None O
. None None O

Systemic None None O
treatment None None O
with None None O
L None None O
- None None O
NAME None None O
inhibited None None O
growth None None O
of None None O
adenocarcinoma None None O
significantly None None O
but None None O
was None None O
accompanied None None O
by None None O
impaired None None O
renal None None O
function None None O
. None None O

In None None O
ILP None None O
, None None O
reduced None None O
tumour None None O
growth None None O
was None None O
observed None None O
when None None O
L None None O
- None None O
NAME None None O
was None None O
used None None O
alone None None O
. None None O

In None None O
combination None None O
with None None O
TNF None None O
or None None O
melphalan None None O
, None None O
L None None O
- None None O
NAME None None O
increased None None O
response None None O
rates None None O
significantly None None O
compared None None O
to None None O
perfusions None None O
without None None O
L None None O
- None None O
NAME None None O
( None None O
0 None None O
- None None O
64 None None O
% None None O
and None None O
0 None None O
- None None O
63 None None O
% None None O
respectively None None O
) None None O
. None None O

An None None O
additional None None O
anti None None O
- None None O
tumour None None O
effect None None O
was None None O
demonstrated None None O
when None None O
L None None O
- None None O
NAME None None O
was None None O
added None None O
to None None O
the None None O
synergistic None None O
combination None None O
of None None O
melphalan None None O
and None None O
TNF None None O
( None None O
responses None None O
increased None None O
from None None O
70 None None O
to None None O
100 None None O
% None None O
) None None O
. None None O

Inhibition None None O
of None None O
NO None None O
synthase None None O
reduces None None O
tumour None None O
growth None None O
both None None O
after None None O
systemic None None O
and None None O
regional None None O
( None None O
ILP None None O
) None None O
treatment None None O
. None None O

A None None O
synergistic None None O
anti None None O
- None None O
tumour None None O
effect None None O
of None None O
L None None O
- None None O
NAME None None O
is None None O
observed None None O
in None None O
combination None None O
with None None O
melphalan None None O
and None None O
/ None None O
or None None O
TNF None None O
using None None O
ILP None None O
. None None O

These None None O
results None None O
indicate None None O
a None None O
possible None None O
role None None O
of None None O
L None None O
- None None O
NAME None None O
for None None O
the None None O
treatment None None O
of None None O
solid None None O
tumours None None O
in None None O
a None None O
systemic None None O
or None None O
regional None None O
setting None None O
. None None O

Ectopic None None O
decorin None None O
expression None None O
up None None O
- None None O
regulates None None O
VEGF None None O
expression None None O
in None None O
mouse None None O
cerebral None None O
endothelial None None O
cells None None O
via None None O
activation None None O
of None None O
the None None O
transcription None None O
factors None None O
Sp1 None None O
, None None O
HIF1alpha None None O
, None None O
and None None O
Stat3 None None O
. None None O

We None None O
demonstrate None None O
that None None O
a None None O
proteoglycan None None O
decorin None None O
( None None O
DCN None None O
) None None O
up None None O
- None None O
regulates None None O
the None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
expression None None O
with None None O
activation None None O
of None None O
VEGF None None O
regulating None None O
transcription None None O
factors None None O
Sp1 None None O
, None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
1alpha None None O
( None None O
HIF1alpha None None O
) None None O
, None None O
and None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
3 None None O
( None None O
Stat3 None None O
) None None O
via None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGFR None None O
) None None O
, None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
1 None None O
/ None None O
2 None None O
( None None O
ERK1 None None O
/ None None O
2 None None O
) None None O
, None None O
and None None O
protein None None O
kinase None None O
B None None O
( None None O
AKT None None O
) None None O
pathways None None O
in None None O
DCN None None O
transfected None None O
mouse None None O
cerebral None None O
endothelial None None O
( None None O
MCE None None O
) None None O
cells None None O
. None None O

Treatment None None O
with None None O
pharmacological None None O
inhibitors None None O
and None None O
small None None O
interfering None None O
RNAs None None O
reveal None None O
that None None O
induction None None O
and None None O
activation None None O
of None None O
Sp1 None None O
, None None O
HIF1alpha None None O
, None None O
and None None O
Stat3 None None O
facilitate None None O
their None None O
nuclear None None O
localization None None O
and None None O
binding None None O
to None None O
their None None O
specific None None O
motifs None None O
of None None O
the None None O
VEGF None None O
promoter None None O
and None None O
induce None None O
VEGF None None O
expression None None O
via None None O
two None None O
independent None None O
pathways None None O
, None None O
DCN None None O
/ None None O
EGFR None None O
/ None None O
phosphoinositide None None O
- None None O
3 None None O
kinase None None O
/ None None O
AKT None None O
and None None O
DCN None None O
/ None None O
EGFR None None O
/ None None O
ERK1 None None O
/ None None O
2 None None O
, None None O
respectively None None O
, None None O
in None None O
DCN None None O
synthesizing None None O
MCE None None O
cells None None O
. None None O

The None None O
cell None None O
type None None O
specific None None O
glycosylation None None O
protects None None O
Sp1 None None O
and None None O
HIF1alpha None None O
from None None O
proteosome None None O
degradation None None O
and None None O
plays None None O
an None None O
important None None O
and None None O
novel None None O
role None None O
in None None O
the None None O
regulation None None O
of None None O
VEGF None None O
in None None O
DCN None None O
transfected None None O
MCE None None O
cells None None O
. None None O

Induction None None O
of None None O
gelatinases None None O
( None None O
matrix None None O
metalloproteinase None None O
2 None None O
and None None O
9 None None O
) None None O
, None None O
the None None O
serine None None O
protease None None O
tissue None None O
plasminogen None None O
activator None None O
and None None O
plasmin None None O
by None None O
DCN None None O
transfection None None O
in None None O
MCE None None O
cells None None O
leads None None O
to None None O
extracellular None None O
proteolysis None None O
and None None O
to None None O
release None None O
of None None O
matrix None None O
- None None O
bound None None O
VEGF None None O
and None None O
activation None None O
of None None O
angiogenesis None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
that None None O
two None None O
independent None None O
downstream None None O
signal None None O
pathways None None O
, None None O
DCN None None O
/ None None O
EGFR None None O
/ None None O
ERK1 None None O
/ None None O
2 None None O
and None None O
DCN None None O
/ None None O
EGFR None None O
/ None None O
phosphoinositide None None O
- None None O
3 None None O
kinase None None O
/ None None O
AKT None None O
, None None O
mediate None None O
up None None O
- None None O
regulation None None O
and None None O
activation None None O
of None None O
transcription None None O
factors None None O
of None None O
VEGF None None O
such None None O
as None None O
HIF1alpha None None O
, None None O
Stat3 None None O
, None None O
and None None O
Sp1 None None O
and None None O
increase None None O
VEGF None None O
transcription None None O
and None None O
angiogenesis None None O
in None None O
MCE None None O
cells None None O
. None None O

Identification None None O
of None None O
NAB1 None None O
, None None O
a None None O
repressor None None O
of None None O
NGFI None None O
- None None O
A None None O
- None None O
and None None O
Krox20 None None O
- None None O
mediated None None O
transcription None None O
. None None O

NGFI None None O
- None None O
A None None O
( None None O
also None None O
called None None O
Egr1 None None O
, None None O
Zif268 None None O
, None None O
or None None O
Krox24 None None O
) None None O
and None None O
the None None O
closely None None O
related None None O
proteins None None O
Krox20 None None O
, None None O
NGFI None None O
- None None O
C None None O
, None None O
and None None O
Egr3 None None O
are None None O
zinc None None O
- None None O
finger None None O
transcription None None O
factors None None O
encoded None None O
by None None O
immediate None None O
- None None O
early None None O
genes None None O
which None None O
are None None O
induced None None O
by None None O
a None None O
wide None None O
variety None None O
of None None O
extracellular None None O
stimuli None None O
. None None O

NGFI None None O
- None None O
A None None O
has None None O
been None None O
implicated None None O
in None None O
cell None None O
proliferation None None O
, None None O
macrophage None None O
differentiation None None O
, None None O
synaptic None None O
activation None None O
, None None O
and None None O
long None None O
- None None O
term None None O
potentiation None None O
, None None O
whereas None None O
Krox20 None None O
is None None O
critical None None O
for None None O
proper None None O
hindbrain None None O
segmentation None None O
and None None O
peripheral None None O
nerve None None O
myelination None None O
. None None O

In None None O
previous None None O
work None None O
, None None O
a None None O
structure None None O
/ None None O
function None None O
analysis None None O
of None None O
NGFI None None O
- None None O
A None None O
revealed None None O
a None None O
34 None None O
- None None O
aa None None O
inhibitory None None O
domain None None O
that None None O
was None None O
hypothesized None None O
to None None O
be None None O
the None None O
target None None O
of None None O
a None None O
cellular None None O
factor None None O
that None None O
represses None None O
NGFI None None O
- None None O
A None None O
transcriptional None None O
activity None None O
. None None O

Using None None O
the None None O
yeast None None O
two None None O
- None None O
hybrid None None O
system None None O
, None None O
we None None O
have None None O
isolated None None O
a None None O
cDNA None None O
clone None None O
which None None O
encodes None None O
a None None O
protein None None O
that None None O
interacts None None O
with None None O
this None None O
inhibitory None None O
domain None None O
and None None O
inhibits None None O
the None None O
ability None None O
of None None O
NGFI None None O
- None None O
A None None O
to None None O
activate None None O
transcription None None O
. None None O

This None None O
NGFI None None O
- None None O
A None None O
- None None O
binding None None O
protein None None O
, None None O
NAB1 None None O
, None None O
is None None O
a None None O
570 None None O
- None None O
aa None None O
nuclear None None O
protein None None O
that None None O
bears None None O
no None None O
obvious None None O
sequence None None O
homology None None O
to None None O
known None None O
proteins None None O
. None None O

NAB1 None None O
also None None O
represses None None O
Krox20 None None O
activity None None O
, None None O
but None None O
it None None O
does None None O
not None None O
influence None None O
Egr3 None None O
or None None O
NGFI None None O
- None None O
G None None O
, None None O
thus None None O
providing None None O
a None None O
mechanism None None O
for None None O
the None None O
differential None None O
regulation None None O
of None None O
this None None O
family None None O
of None None O
immediate None None O
- None None O
early None None O
transcription None None O
factors None None O
. None None O

Introduction None None O

Tea None None O
( None None O
Camellia None None O
sinensis None None O
L None None O
. None None O
) None None O
is None None O
one None None O
of None None O
the None None O
most None None O
widely None None O
consumed None None O
beverages None None O
in None None O
the None None O
world None None O
. None None O

( None None O
- None None O
) None None O
- None None O
Epigallocatechin None None O
- None None O
3 None None O
- None None O
O None None O
- None None O
gallate None None O
( None None O
EGCG None None O
) None None O
, None None O
which None None O
is None None O
the None None O
major None None O
green None None O
tea None None O
catechin None None O
present None None O
in None None O
the None None O
leaves None None O
, None None O
is None None O
believed None None O
to None None O
the None None O
compound None None O
most None None O
responsible None None O
for None None O
the None None O
health None None O
benefits None None O
attributed None None O
to None None O
tea None None O
. None None O

EGCG None None O
was None None O
reported None None O
to None None O
have None None O
antioxidative None None O
[ None None O
1 None None O
] None None O
, None None O
[ None None O
2 None None O
] None None O
, None None O
antimutagenic None None O
[ None None O
3 None None O
] None None O
, None None O
anti None None O
- None None O
inflammatory None None O
[ None None O
4 None None O
] None None O
, None None O
and None None O
anticarcinogenic None None O
activities None None O
[ None None O
5 None None O
] None None O
. None None O

Although None None O
the None None O
EGCG None None O
concentrations None None O
required None None O
to None None O
elicit None None O
the None None O
anticancer None None O
activity None None O
have None None O
been None None O
shown None None O
to None None O
be None None O
more None None O
than None None O
1 None None O
microM None None O
, None None O
the None None O
blood None None O
level None None O
of None None O
EGCG None None O
after None None O
consuming None None O
the None None O
equivalent None None O
of None None O
2 None None O
- None None O
3 None None O
cups None None O
of None None O
green None None O
tea None None O
was None None O
0 None None O
. None None O
1 None None O
- None None O
0 None None O
. None None O
6 None None O
microM None None O
and None None O
for None None O
an None None O
equivalent None None O
of None None O
7 None None O
- None None O
9 None None O
cups None None O
was None None O
still None None O
lower None None O
than None None O
1 None None O
microM None None O
[ None None O
6 None None O
] None None O
, None None O
[ None None O
7 None None O
] None None O
. None None O

In None None O
a None None O
cohort None None O
study None None O
, None None O
daily None None O
consumption None None O
of None None O
ten None None O
cups None None O
of None None O
green None None O
tea None None O
was None None O
required None None O
for None None O
the None None O
cancer None None O
preventive None None O
effect None None O
[ None None O
8 None None O
] None None O
. None None O

Moreover None None O
, None None O
adverse None None O
effects None None O
of None None O
green None None O
tea None None O
, None None O
mainly None None O
hepatitis None None O
, None None O
by None None O
consumption None None O
of None None O
high None None O
doses None None O
of None None O
green None None O
tea None None O
have None None O
been None None O
reported None None O
[ None None O
9 None None O
] None None O
. None None O

Therefore None None O
, None None O
it None None O
is None None O
important None None O
to None None O
enhance None None O
the None None O
pharmacologic None None O
effect None None O
of None None O
EGCG None None O
to None None O
obtain None None O
the None None O
health None None O
benefit None None O
in None None O
reasonable None None O
concentration None None O
in None None O
daily None None O
life None None O
. None None O

We None None O
have None None O
reported None None O
that None None O
the None None O
cell None None O
- None None O
surface None None O
binding None None O
of None None O
EGCG None None O
and None None O
its None None O
derivatives None None O
is None None O
involved None None O
in None None O
their None None O
biological None None O
activities None None O
[ None None O
10 None None O
] None None O
- None None O
[ None None O
15 None None O
] None None O
. None None O

We None None O
have None None O
identified None None O
the None None O
67 None None O
- None None O
kDa None None O
laminin None None O
receptor None None O
( None None O
67LR None None O
) None None O
as None None O
a None None O
cell None None O
surface None None O
receptor None None O
for None None O
EGCG None None O
that None None O
mediates None None O
the None None O
anticancer None None O
activity None None O
of None None O
EGCG None None O
[ None None O
16 None None O
] None None O
. None None O

67LR None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
overexpressed None None O
on None None O
the None None O
cell None None O
surface None None O
of None None O
various None None O
tumor None None O
cells None None O
[ None None O
17 None None O
] None None O
. None None O

It None None O
was None None O
postulated None None O
that None None O
67LR None None O
plays None None O
a None None O
significant None None O
role None None O
in None None O
the None None O
tumor None None O
progression None None O
and None None O
speculated None None O
that None None O
studies None None O
conducted None None O
to None None O
define None None O
the None None O
function None None O
of None None O
67LR None None O
could None None O
provide None None O
a None None O
new None None O
approach None None O
to None None O
cancer None None O
prevention None None O
. None None O

Indeed None None O
, None None O
expression None None O
of None None O
67 None None O
LR None None O
confers None None O
EGCG None None O
responsiveness None None O
to None None O
tumor None None O
cells None None O
in None None O
vivo None None O
[ None None O
18 None None O
] None None O
. None None O

Vitamin None None O
A None None O
, None None O
also None None O
known None None O
as None None O
retinol None None O
, None None O
participates None None O
in None None O
physiological None None O
activities None None O
related None None O
to None None O
the None None O
immune None None O
system None None O
, None None O
maintenance None None O
of None None O
epithelial None None O
and None None O
mucosa None None O
tissues None None O
, None None O
growth None None O
, None None O
reproduction None None O
, None None O
and None None O
bone None None O
development None None O
. None None O

It None None O
comes None None O
from None None O
animal None None O
sources None None O
, None None O
such None None O
as None None O
eggs None None O
, None None O
meat None None O
, None None O
milk None None O
, None None O
cheese None None O
, None None O
cream None None O
, None None O
liver None None O
, None None O
kidney None None O
, None None O
cod None None O
and None None O
halibut None None O
fish None None O
oil None None O
. None None O

In None None O
vitro None None O
and None None O
in None None O
animal None None O
models None None O
, None None O
it None None O
has None None O
been None None O
demonstrated None None O
that None None O
vitamin None None O
A None None O
is None None O
involved None None O
in None None O
the None None O
regulation None None O
and None None O
promotion None None O
of None None O
growth None None O
and None None O
differentiation None None O
of None None O
many None None O
cells None None O
[ None None O
19 None None O
] None None O
. None None O

The None None O
visual None None O
function None None O
of None None O
vitamin None None O
A None None O
depends None None O
on None None O
its None None O
natural None None O
and None None O
synthetic None None O
derivatives None None O
, None None O
retinoids None None O
[ None None O
20 None None O
] None None O
. None None O

All None None O
- None None O
trans None None O
- None None O
retinoic None None O
acid None None O
( None None O
ATRA None None O
) None None O
, None None O
the None None O
active None None O
derivative None None O
of None None O
vitamin None None O
A None None O
, None None O
has None None O
been None None O
well None None O
documented None None O
as None None O
a None None O
growth None None O
and None None O
differentiation None None O
factor None None O
in None None O
many None None O
tissues None None O
and None None O
cells None None O
, None None O
and None None O
proved None None O
to None None O
be None None O
an None None O
effective None None O
treatment None None O
to None None O
many None None O
diseases None None O
including None None O
cancers None None O
[ None None O
21 None None O
] None None O
, None None O
[ None None O
22 None None O
] None None O
. None None O

Retinoids None None O
exert None None O
their None None O
physiological None None O
activities None None O
through None None O
retinoid None None O
receptor None None O
nuclear None None O
proteins None None O
that None None O
belong None None O
to None None O
the None None O
superfamily None None O
of None None O
steroid None None O
/ None None O
thyroid None None O
hormone None None O
receptors None None O
, None None O
of None None O
which None None O
there None None O
are None None O
two None None O
classes None None O
, None None O
retinoic None None O
acid None None O
receptors None None O
( None None O
RARs None None O
) None None O
and None None O
the None None O
retinoic None None O
- None None O
X None None O
receptors None None O
( None None O
RXRs None None O
) None None O
, None None O
each None None O
of None None O
which None None O
has None None O
three None None O
subtypes None None O
, None None O
alpha None None O
, None None O
beta None None O
, None None O
and None None O
gamma None None O
[ None None O
23 None None O
] None None O
, None None O
[ None None O
24 None None O
] None None O
. None None O

The None None O
natural None None O
ligands None None O
for None None O
the None None O
RARs None None O
are None None O
ATRA None None O
and None None O
its None None O
stereoisomers None None O
9 None None O
- None None O
cis None None O
- None None O
RA None None O
and None None O
13 None None O
- None None O
cis None None O
- None None O
RA None None O
, None None O
whereas None None O
RXRs None None O
are None None O
activated None None O
by None None O
9 None None O
- None None O
cis None None O
- None None O
RA None None O
only None None O
. None None O

ATRA None None O
acts None None O
through None None O
RAR None None O
to None None O
transcriptionally None None O
activate None None O
target None None O
genes None None O
, None None O
such None None O
as None None O
cytochrome None None O
P450 None None O
and None None O
CRABI None None O
[ None None O
24 None None O
] None None O
. None None O

This None None O
study None None O
was None None O
designed None None O
to None None O
identify None None O
a None None O
food None None O
component None None O
that None None O
could None None O
be None None O
effectively None None O
used None None O
in None None O
combination None None O
with None None O
EGCG None None O
and None None O
to None None O
investigate None None O
the None None O
mechanism None None O
of None None O
action None None O
of None None O
this None None O
combination None None O
. None None O

By None None O
using None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
systems None None O
involving None None O
a None None O
highly None None O
metastatic None None O
mouse None None O
B16 None None I-Cell-line-name
melanoma None None O
cell None None O
line None None O
[ None None O
25 None None O
] None None O
, None None O
we None None O
found None None O
that None None O
ATRA None None O
enhances None None O
the None None O
antitumor None None O
activity None None O
of None None O
EGCG None None O
by None None O
upregulating None None O
the None None O
67 None None O
LR None None O
expression None None O
through None None O
RAR None None O
. None None O

Effects None None O
of None None O
rule None None O
- None None O
breakers None None O
on None None O
intermediary None None O
- None None O
based None None O
networks None None O
. None None O

Individuals None None O
using None None O
rule None None O
- None None O
breaking None None O
strategy None None O
primarily None None O
affected None None O
( None None O
A None None O
) None None O
their None None O
own None None O
social None None O
position None None O
( None None O
H None None O
( None None O
2 None None O
) None None O
= None None O
213 None None O
. None None O
18 None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
, None None O
but None None O
also None None O
made None None O
an None None O
impact None None O
on None None O
the None None O
other None None O
aspects None None O
of None None O
the None None O
social None None O
system None None O
, None None O
affecting None None O
( None None O
B None None O
) None None O
the None None O
social None None O
position None None O
of None None O
others None None O
( None None O
H None None O
( None None O
2 None None O
) None None O
= None None O
6 None None O
. None None O
79 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
034 None None O
) None None O
and None None O
( None None O
C None None O
) None None O
group None None O
organization None None O
( None None O
H None None O
( None None O
2 None None O
) None None O
= None None O
125 None None O
. None None O
3 None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
as None None O
their None None O
frequency None None O
in None None O
a None None O
population None None O
increased None None O
. None None O

The None None O
boxes None None O
show None None O
medians None None O
, None None O
quartiles None None O
, None None O
minima None None O
and None None O
maxima None None O
. None None O

Results None None O
significantly None None O
different None None O
from None None O
a None None O
relevant None None O
uniform None None O
network None None O
with None None O
no None None O
rule None None O
- None None O
breaking None None O
behavior None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
in None None O
Dunn None None O
' None None O
s None None O
multiple None None O
comparison None None O
test None None O
for None None O
comparing None None O
each None None O
group None None O
with None None O
control None None O
) None None O
are None None O
designated None None O
with None None O
* None None O
. None None O

Structural None None O
evolution None None O
in None None O
cationic None None O
micelles None None O
upon None None O
incorporation None None O
of None None O
a None None O
polar None None O
organic None None O
dopant None None O
. None None O

Micelles None None O
of None None O
cetyltrimethylammonium None None O
bromide None None O
( None None O
CTAB None None O
) None None O
, None None O
when None None O
doped None None O
with None None O
increasing None None O
levels None None O
of None None O
4 None None O
- None None O
ethylphenol None None O
, None None O
show None None O
microstructural None None O
transitions None None O
from None None O
spherical None None O
micelles None None O
to None None O
elongated None None O
wormlike None None O
micelles None None O
, None None O
disks None None O
, None None O
and None None O
subsequently None None O
to None None O
globular None None O
and None None O
then None None O
to None None O
tubular None None O
vesicles None None O
. None None O

Wormlike None None O
micelles None None O
are None None O
observed None None O
at None None O
a None None O
dopant None None O
- None None O
to None None O
- None None O
CTAB None None O
molar None None O
ratio None None O
of None None O
1 None None O
: None None O
3 None None O
. None None O

At None None O
higher None None O
dopant None None O
ratios None None O
( None None O
1 None None O
: None None O
1 None None O
) None None O
, None None O
globular None None O
vesicles None None O
are None None O
observed None None O
which None None O
transition None None O
to None None O
tubular None None O
vesicles None None O
when None None O
the None None O
dopant None None O
becomes None None O
the None None O
predominant None None O
species None None O
at None None O
a None None O
ratio None None O
of None None O
3 None None O
: None None O
1 None None O
. None None O

These None None O
transitions None None O
are None None O
reflected None None O
in None None O
small None None O
- None None O
angle None None O
neutron None None O
scattering None None O
analysis None None O
and None None O
, None None O
interestingly None None O
, None None O
can None None O
be None None O
directly None None O
observed None None O
through None None O
cryo None None O
- None None O
transmission None None O
electron None None O
microscopy None None O
. None None O

The None None O
para None None O
- None None O
substituted None None O
phenol None None O
is None None O
interfacially None None O
active None None O
and None None O
modulates None None O
interfacial None None O
curvature None None O
of None None O
the None None O
micelles None None O
. None None O

The None None O
observations None None O
of None None O
microstructure None None O
modifications None None O
have None None O
relevance None None O
to None None O
the None None O
synthesis None None O
of None None O
mesoporous None None O
materials None None O
using None None O
CTAB None None O
as None None O
the None None O
template None None O
. None None O

The None None O
tyrosine None None O
kinase None None O
inhibitor None None O
cediranib None None O
blocks None None O
ligand None None O
- None None O
induced None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
- None None O
3 None None O
activity None None O
and None None O
lymphangiogenesis None None O
. None None O

Solid None None O
tumors None None O
express None None O
a None None O
range None None O
of None None O
factors None None O
required None None O
to None None O
sustain None None O
their None None O
growth None None O
and None None O
promote None None O
their None None O
dissemination None None O
. None None O

Among None None O
these None None O
are None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
A None None O
( None None O
VEGF None None O
- None None O
A None None O
) None None O
, None None O
the None None O
key None None O
angiogenic None None O
stimulant None None O
, None None O
and None None O
VEGF None None O
- None None O
C None None O
, None None O
a None None O
primary None None O
mediator None None O
of None None O
lymphangiogenesis None None O
. None None O

Small None None O
molecule None None O
tyrosine None None O
kinase None None O
inhibitors None None O
offer None None O
the None None O
potential None None O
to None None O
inhibit None None O
more None None O
than None None O
one None None O
kinase None None O
and None None O
impede None None O
tumor None None O
growth None None O
by None None O
multiple None None O
mechanisms None None O
. None None O

However None None O
, None None O
their None None O
potency None None O
toward None None O
individual None None O
targets None None O
can None None O
vary None None O
. None None O

Cediranib None None O
( None None O
RECENTIN None None O
; None None O
AZD2171 None None O
) None None O
is None None O
an None None O
inhibitor None None O
of None None O
VEGF None None O
signaling None None O
that None None O
has None None O
been None None O
shown None None O
in None None O
experimental None None O
models None None O
to None None O
prevent None None O
VEGF None None O
- None None O
A None None O
- None None O
induced None None O
angiogenesis None None O
and None None O
primary None None O
tumor None None O
growth None None O
, None None O
yet None None O
the None None O
effects None None O
of None None O
cediranib None None O
on None None O
VEGF None None O
receptor None None O
( None None O
VEGFR None None O
) None None O
- None None O
3 None None O
- None None O
mediated None None O
endothelial None None O
cell None None O
function None None O
and None None O
lymphangiogenesis None None O
are None None O
unknown None None O
. None None O

To None None O
better None None O
understand None None O
the None None O
activity None None O
of None None O
cediranib None None O
against None None O
VEGFR None None O
- None None O
3 None None O
and None None O
its None None O
associated None None O
signaling None None O
events None None O
compared None None O
with None None O
its None None O
activity None None O
against None None O
VEGFR None None O
- None None O
2 None None O
, None None O
we None None O
used None None O
the None None O
receptor None None O
- None None O
specific None None O
ligands None None O
VEGF None None O
- None None O
E None None O
and None None O
VEGF None None O
- None None O
C156S None None O
. None None O

In None None O
human None None O
endothelial None None O
cells None None O
, None None O
cediranib None None O
inhibited None None O
VEGF None None O
- None None O
E None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
VEGFR None None O
- None None O
2 None None O
and None None O
VEGF None None O
- None None O
C156S None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
VEGFR None None O
- None None O
3 None None O
at None None O
concentrations None None O
of None None O
less None None O
than None None O
/ None None O
= None None O
1nmol None None O
/ None None O
L None None O
and None None O
inhibited None None O
activation None None O
of None None O
downstream None None O
signaling None None O
molecules None None O
. None None O

Additionally None None O
, None None O
cediranib None None O
blocked None None O
VEGF None None O
- None None O
C156S None None O
- None None O
induced None None O
and None None O
VEGF None None O
- None None O
E None None O
- None None O
induced None None O
proliferation None None O
, None None O
survival None None O
, None None O
and None None O
migration None None O
of None None O
lymphatic None None O
and None None O
blood None None O
vascular None None O
endothelial None None O
cells None None O
. None None O

In None None O
vivo None None O
, None None O
cediranib None None O
( None None O
6 None None O
mg None None O
/ None None O
kg None None O
/ None None O
d None None O
) None None O
prevented None None O
angiogenesis None None O
and None None O
lymphangiogenesis None None O
induced None None O
by None None O
VEGF None None O
- None None O
E None None O
- None None O
expressing None None O
and None None O
VEGF None None O
- None None O
C156S None None O
- None None O
expressing None None O
adenoviruses None None O
, None None O
respectively None None O
. None None O

Cediranib None None O
( None None O
6 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
) None None O
also None None O
blocked None None O
angiogenesis None None O
and None None O
lymphangiogenesis None None O
induced None None O
by None None O
adenoviruses None None O
expressing None None O
VEGF None None O
- None None O
A None None O
or None None O
VEGF None None O
- None None O
C None None O
and None None O
compromised None None O
the None None O
blood None None O
and None None O
lymphatic None None O
vasculatures None None O
of None None O
VEGF None None O
- None None O
C None None O
- None None O
expressing None None O
tumors None None O
. None None O

Cediranib None None O
may None None O
, None None O
therefore None None O
, None None O
be None None O
an None None O
effective None None O
means None None O
of None None O
preventing None None O
tumor None None O
progression None None O
, None None O
not None None O
only None None O
by None None O
inhibiting None None O
VEGFR None None O
- None None O
2 None None O
activity None None O
and None None O
angiogenesis None None O
, None None O
but None None O
also None None O
by None None O
concomitantly None None O
inhibiting None None O
VEGFR None None O
- None None O
3 None None O
activity None None O
and None None O
lymphangiogenesis None None O
. None None O

Complications None None O
after None None O
plate None None O
fixation None None O
of None None O
phalangeal None None O
fractures None None O
. None None O

PURPOSE None None O
: None None O

To None None O
assess None None O
the None None O
complications None None O
after None None O
plate None None O
fixation None None O
of None None O
phalangeal None None O
fractures None None O
, None None O
their None None O
correlation None None O
with None None O
the None None O
type None None O
of None None O
injury None None O
, None None O
and None None O
the None None O
outcome None None O
. None None O

METHODS None None O
: None None O

We None None O
retrospectively None None O
reviewed None None O
the None None O
clinical None None O
records None None O
and None None O
the None None O
x None None O
- None None O
rays None None O
of None None O
54 None None O
consecutive None None O
patients None None O
with None None O
64 None None O
phalangeal None None O
fractures None None O
treated None None O
by None None O
open None None O
reduction None None O
and None None O
plate None None O
fixation None None O
with None None O
regard None None O
to None None O
fracture None None O
healing None None O
, None None O
plate None None O
loosening None None O
or None None O
failure None None O
, None None O
infection None None O
, None None O
complex None None O
regional None None O
pain None None O
syndrome None None O
, None None O
pain None None O
, None None O
return None None O
to None None O
work None None O
, None None O
and None None O
range None None O
of None None O
motion None None O
. None None O

RESULTS None None O
: None None O

In None None O
31 None None O
out None None O
of None None O
54 None None O
patients None None O
( None None O
57 None None O
% None None O
) None None O
and None None O
33 None None O
out None None O
of None None O
64 None None O
fractures None None O
( None None O
52 None None O
% None None O
) None None O
, None None O
one None None O
or None None O
more None None O
major None None O
complications None None O
occurred None None O
. None None O

Stiffness None None O
( None None O
definition None None O
is None None O
composite None None O
range None None O
of None None O
motion None None O
of None None O
metaphalangeal None None O
, None None O
proximal None None O
interphalangeal None None O
, None None O
and None None O
distal None None O
interphalangeal None None O
joints None None O
added None None O
together None None O
equaling None None O
< None None O
180 None None O
degrees None None O
) None None O
contributed None None O
the None None O
highest None None O
number None None O
( None None O
22 None None O
patients None None O
, None None O
24 None None O
fractures None None O
) None None O
. None None O

The None None O
complication None None O
rates None None O
were None None O
not None None O
different None None O
whether None None O
the None None O
fracture None None O
was None None O
open None None O
or None None O
closed None None O
, None None O
if None None O
it None None O
was None None O
located None None O
in None None O
the None None O
proximal None None O
or None None O
middle None None O
phalanx None None O
, None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
an None None O
associated None None O
soft None None O
tissue None None O
lesion None None O
, None None O
and None None O
the None None O
patient None None O
' None None O
s None None O
occupation None None O
. None None O

CONCLUSIONS None None O
: None None O

In None None O
spite None None O
of None None O
early None None O
mobilization None None O
, None None O
stiffness None None O
is None None O
the None None O
most None None O
frequent None None O
complication None None O
after None None O
open None None O
reduction None None O
and None None O
plate None None O
fixation None None O
of None None O
phalangeal None None O
fractures None None O
. None None O

The None None O
undue None None O
amount None None O
of None None O
scarring None None O
and None None O
adhesion None None O
may None None O
arise None None O
from None None O
the None None O
implant None None O
itself None None O
or None None O
the None None O
difficulty None None O
in None None O
finding None None O
the None None O
perfect None None O
mixture None None O
between None None O
the None None O
minimal None None O
surgical None None O
invasiveness None None O
and None None O
a None None O
sufficient None None O
restoration None None O
of None None O
skeletal None None O
stability None None O
. None None O

Otherwise None None O
, None None O
plate None None O
fixation None None O
of None None O
unstable None None O
and None None O
complex None None O
phalangeal None None O
fractures None None O
proved None None O
efficient None None O
and None None O
reliable None None O
, None None O
although None None O
not None None O
free None None O
of None None O
potential None None O
problems None None O
. None None O

Behavior None None O

Across None None O
all None None O
participants None None O
, None None O
50 None None O
% None None O
+ None None O
/ None None O
- None None O
13 None None O
of None None O
studied None None O
high None None O
- None None O
complexity None None O
scene None None O
were None None O
later None None O
recognized None None O
as None None O
" None None O
old None None O
" None None O
( None None O
hit None None O
rate None None O
) None None O
, None None O
and None None O
52 None None O
% None None O
+ None None O
/ None None O
- None None O
18 None None O
of None None O
studied None None O
low None None O
- None None O
complexity None None O
scenes None None O
were None None O
later None None O
recognized None None O
as None None O
" None None O
old None None O
" None None O
. None None O

For None None O
new None None O
scenes None None O
presented None None O
at None None O
test None None O
( None None O
foils None None O
) None None O
, None None O
22 None None O
% None None O
+ None None O
/ None None O
- None None O
16 None None O
of None None O
high None None O
- None None O
complexity None None O
scenes None None O
were None None O
falsely None None O
categorized None None O
as None None O
" None None O
old None None O
" None None O
( None None O
false None None O
alarm None None O
rate None None O
) None None O
, None None O
and None None O
22 None None O
% None None O
+ None None O
/ None None O
- None None O
14 None None O
of None None O
low None None O
- None None O
complexity None None O
scenes None None O
were None None O
falsely None None O
categorized None None O
as None None O
" None None O
old None None O
" None None O
. None None O

Across None None O
all None None O
participants None None O
, None None O
adjusted None None O
hit None None O
rate None None O
( None None O
hit None None O
rate None None O
- None None O
false None None O
alarm None None O
rate None None O
) None None O
for None None O
high None None O
- None None O
complexity None None O
scenes None None O
( None None O
28 None None O
% None None O
+ None None O
/ None None O
- None None O
13 None None O
) None None O
did None None O
not None None O
differ None None O
from None None O
that None None O
for None None O
low None None O
- None None O
complexity None None O
scenes None None O
( None None O
30 None None O
% None None O
+ None None O
/ None None O
- None None O
14 None None O
) None None O
( None None O
t None None O
( None None O
45 None None O
) None None O
= None None O
1 None None O
. None None O
02 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
31 None None O
) None None O
. None None O

Critically None None O
, None None O
the None None O
adjusted None None O
hit None None O
rate None None O
increased None None O
with None None O
age None None O
for None None O
high None None O
- None None O
complexity None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
40 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
006 None None O
) None None O
, None None O
but None None O
not None None O
for None None O
low None None O
- None None O
complexity None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
11 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
46 None None O
) None None O
scenes None None O
. None None O

Thus None None O
, None None O
overall None None O
participants None None O
had None None O
similar None None O
memory None None O
accuracy None None O
for None None O
high None None O
- None None O
and None None O
low None None O
- None None O
complexity None None O
scenes None None O
, None None O
but None None O
memory None None O
accuracy None None O
improved None None O
with None None O
age None None O
only None None O
for None None O
high None None O
- None None O
complexity None None O
scenes None None O
. None None O

Participants None None O
categorized None None O
as None None O
" None None O
remembered None None O
" None None O
( None None O
RHIT None None O
) None None O
, None None O
28 None None O
% None None O
+ None None O
/ None None O
- None None O
12 None None O
of None None O
the None None O
studied None None O
high None None O
- None None O
complexity None None O
scenes None None O
, None None O
and None None O
29 None None O
% None None O
+ None None O
/ None None O
- None None O
15 None None O
of None None O
the None None O
studied None None O
low None None O
- None None O
complexity None None O
scenes None None O
. None None O

Participants None None O
had None None O
similar None None O
rates None None O
of None None O
falsely None None O
categorizing None None O
as None None O
" None None O
remembered None None O
" None None O
( None None O
RFA None None O
) None None O
high None None O
( None None O
5 None None O
% None None O
+ None None O
/ None None O
- None None O
6 None None O
) None None O
and None None O
low None None O
( None None O
5 None None O
% None None O
+ None None O
/ None None O
- None None O
6 None None O
) None None O
complexity None None O
foils None None O
. None None O

Across None None O
all None None O
participants None None O
, None None O
adjusted None None O
R None None O
rates None None O
( None None O
RHIT None None O
- None None O
RFA None None O
) None None O
for None None O
high None None O
- None None O
complexity None None O
scenes None None O
did None None O
not None None O
differ None None O
from None None O
that None None O
for None None O
low None None O
- None None O
complexity None None O
scenes None None O
( None None O
t None None O
( None None O
45 None None O
) None None O
= None None O
1 None None O
. None None O
41 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
17 None None O
) None None O
. None None O

Adjusted None None O
R None None O
rates None None O
increased None None O
with None None O
age None None O
for None None O
high None None O
- None None O
complexity None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
38 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
009 None None O
) None None O
, None None O
but None None O
not None None O
for None None O
low None None O
- None None O
complexity None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
16 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
30 None None O
) None None O
, None None O
scenes None None O
( None None O
Figures None None O
1C None None O
, None None O
D None None O
) None None O
. None None O

The None None O
difference None None O
between None None O
the None None O
adjusted None None O
R None None O
rates None None O
of None None O
high None None O
- None None O
and None None O
low None None O
- None None O
complexity None None O
scenes None None O
increased None None O
with None None O
age None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
27 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
03 None None O
; None None O
1 None None O
- None None O
tailed None None O
) None None O
, None None O
suggesting None None O
that None None O
the None None O
age None None O
- None None O
related None None O
improvements None None O
in None None O
memory None None O
performance None None O
were None None O
more None None O
robust None None O
for None None O
recollected None None O
high None None O
- None None O
complexity None None O
scenes None None O
. None None O

Thus None None O
, None None O
overall None None O
, None None O
participants None None O
had None None O
similar None None O
memory None None O
accuracy None None O
for None None O
recollected None None O
high None None O
- None None O
and None None O
low None None O
- None None O
complexity None None O
scenes None None O
, None None O
but None None O
accuracy None None O
for None None O
recollected None None O
high None None O
- None None O
complexity None None O
scenes None None O
improved None None O
with None None O
age None None O
, None None O
whereas None None O
accuracy None None O
for None None O
recollected None None O
low None None O
- None None O
complexity None None O
scenes None None O
did None None O
not None None O
change None None O
with None None O
age None None O
. None None O

Participants None None O
categorized None None O
as None None O
" None None O
familiar None None O
" None None O
( None None O
KHIT None None O
) None None O
, None None O
22 None None O
% None None O
+ None None O
/ None None O
- None None O
9 None None O
of None None O
studied None None O
high None None O
- None None O
complexity None None O
scenes None None O
, None None O
and None None O
22 None None O
% None None O
+ None None O
/ None None O
- None None O
10 None None O
of None None O
studied None None O
low None None O
- None None O
complexity None None O
scenes None None O
. None None O

Participants None None O
falsely None None O
categorized None None O
as None None O
" None None O
familiar None None O
" None None O
( None None O
KFA None None O
) None None O
17 None None O
% None None O
+ None None O
/ None None O
- None None O
11 None None O
of None None O
high None None O
- None None O
complexity None None O
, None None O
and None None O
17 None None O
% None None O
+ None None O
/ None None O
- None None O
12 None None O
of None None O
low None None O
- None None O
complexity None None O
foils None None O
. None None O

Across None None O
all None None O
participants None None O
, None None O
adjusted None None O
K None None O
rates None None O
( None None O
KHIT None None O
- None None O
KFA None None O
) None None O
for None None O
high None None O
- None None O
complexity None None O
scenes None None O
did None None O
not None None O
differ None None O
from None None O
that None None O
for None None O
low None None O
- None None O
complexity None None O
scenes None None O
( None None O
t None None O
( None None O
45 None None O
) None None O
= None None O
0 None None O
. None None O
06 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
95 None None O
) None None O
. None None O

Adjusted None None O
K None None O
rates None None O
did None None O
not None None O
change None None O
with None None O
age None None O
for None None O
either None None O
high None None O
- None None O
complexity None None O
or None None O
low None None O
- None None O
complexity None None O
scenes None None O
( None None O
| None None O
r None None O
| None None O
s None None O
< None None O
0 None None O
. None None O
09 None None O
, None None O
ps None None O
> None None O
0 None None O
. None None O
56 None None O
) None None O
( None None O
Figures None None O
1C None None O
, None None O
D None None O
) None None O
. None None O

During None None O
the None None O
encoding None None O
task None None O
, None None O
participants None None O
were None None O
overall None None O
faster None None O
to None None O
respond None None O
to None None O
low None None O
- None None O
complexity None None O
scenes None None O
( None None O
1072 None None O
+ None None O
/ None None O
- None None O
275 None None O
ms None None O
) None None O
than None None O
to None None O
high None None O
- None None O
complexity None None O
scenes None None O
( None None O
1093 None None O
+ None None O
/ None None O
- None None O
287 None None O
ms None None O
) None None O
( None None O
t None None O
( None None O
45 None None O
) None None O
= None None O
2 None None O
. None None O
31 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
. None None O

Response None None O
times None None O
decreased None None O
with None None O
age None None O
for None None O
low None None O
- None None O
( None None O
r None None O
= None None O
- None None O
0 None None O
. None None O
37 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
and None None O
high None None O
- None None O
( None None O
r None None O
= None None O
- None None O
0 None None O
. None None O
33 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
complexity None None O
scenes None None O
. None None O

The None None O
difference None None O
between None None O
the None None O
response None None O
times None None O
for None None O
high None None O
- None None O
and None None O
low None None O
- None None O
complexity None None O
scenes None None O
, None None O
however None None O
, None None O
did None None O
not None None O
change None None O
with None None O
age None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
14 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
35 None None O
) None None O
. None None O

Response None None O
times None None O
decreased None None O
with None None O
age None None O
for None None O
R None None O
, None None O
K None None O
and None None O
F None None O
trial None None O
types None None O
for None None O
both None None O
high None None O
- None None O
and None None O
low None None O
- None None O
complexity None None O
scenes None None O
( None None O
- None None O
0 None None O
. None None O
36 None None O
< None None O
r None None O
< None None O
- None None O
0 None None O
. None None O
30 None None O
, None None O
ps None None O
< None None O
0 None None O
. None None O
04 None None O
) None None O
. None None O

The None None O
difference None None O
between None None O
response None None O
times None None O
for None None O
R None None O
and None None O
F None None O
trial None None O
types None None O
, None None O
however None None O
, None None O
did None None O
not None None O
change None None O
with None None O
age None None O
for None None O
either None None O
high None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
12 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
43 None None O
) None None O
or None None O
low None None O
complexity None None O
scenes None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
08 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
60 None None O
) None None O
. None None O

Deletion None None O
of None None O
guanine None None O
nucleotide None None O
binding None None O
protein None None O
alpha None None O
z None None O
subunit None None O
in None None O
mice None None O
induces None None O
a None None O
gene None None O
dose None None O
dependent None None O
tolerance None None O
to None None O
morphine None None O
. None None O

The None None O
mechanism None None O
underlying None None O
the None None O
development None None O
of None None O
tolerance None None O
to None None O
morphine None None O
is None None O
still None None O
incompletely None None O
understood None None O
. None None O

Morphine None None O
binds None None O
to None None O
opioid None None O
receptors None None O
, None None O
which None None O
in None None O
turn None None O
activates None None O
downstream None None O
second None None O
messenger None None O
cascades None None O
through None None O
heterotrimeric None None O
guanine None None O
nucleotide None None O
binding None None O
proteins None None O
( None None O
G None None O
proteins None None O
) None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
show None None O
that None None O
G None None O
( None None O
z None None O
) None None O
, None None O
a None None O
member None None O
of None None O
the None None O
inhibitory None None O
G None None O
protein None None O
family None None O
, None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
mediating None None O
the None None O
analgesic None None O
and None None O
lethality None None O
effects None None O
of None None O
morphine None None O
after None None O
tolerance None None O
development None None O
. None None O

We None None O
blocked None None O
signaling None None O
through None None O
the None None O
G None None O
( None None O
z None None O
) None None O
second None None O
messenger None None O
cascade None None O
by None None O
genetic None None O
ablation None None O
of None None O
the None None O
alpha None None O
subunit None None O
of None None O
the None None O
G None None O
protein None None O
in None None O
mice None None O
. None None O

The None None O
Galpha None None O
( None None O
z None None O
) None None O
knockout None None O
mouse None None O
develops None None O
significantly None None O
increased None None O
tolerance None None O
to None None O
morphine None None O
, None None O
which None None O
depends None None O
on None None O
Galpha None None O
( None None O
z None None O
) None None O
gene None None O
dosage None None O
. None None O

Further None None O
experiments None None O
demonstrate None None O
that None None O
the None None O
enhanced None None O
morphine None None O
tolerance None None O
is None None O
not None None O
caused None None O
by None None O
pharmacokinetic None None O
and None None O
behavioural None None O
learning None None O
mechanisms None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
G None None O
( None None O
z None None O
) None None O
signaling None None O
pathways None None O
are None None O
involved None None O
in None None O
transducing None None O
the None None O
analgesic None None O
and None None O
lethality None None O
effects None None O
of None None O
morphine None None O
following None None O
chronic None None O
morphine None None O
treatment None None O
. None None O

Overexpression None None O
of None None O
Bax None None O
inhibitor None None O
- None None O
1 None None O
( None None O
BI None None O
- None None O
1 None None O
) None None O
induces None None O
cell None None O
transformation None None O
in None None O
NIH3T3 None None I-Cell-line-name
cells None None O
. None None O

BI None None O
- None None O
1 None None O
( None None O
Bax None None O
inhibitor None None O
- None None O
1 None None O
) None None O
, None None O
an None None O
apoptosis None None O
- None None O
inhibiting None None O
gene None None O
belonging None None O
to None None O
the None None O
Bcl None None O
- None None O
2 None None O
protein None None O
family None None O
, None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
mitochondrial None None O
apoptosis None None O
pathway None None O
to None None O
suppress None None O
Bax None None O
- None None O
induced None None O
apoptosis None None O
. None None O

To None None O
investigate None None O
the None None O
potential None None O
role None None O
of None None O
BI None None O
- None None O
1 None None O
in None None O
promoting None None O
cell None None O
growth None None O
and None None O
tumorigenesis None None O
, None None O
in None None O
the None None O
present None None O
study None None O
we None None O
overexpressed None None O
the None None O
BI None None O
- None None O
1 None None O
gene None None O
in None None O
NIH3T3 None None I-Cell-line-name
cells None None O
using None None O
the None None O
lentivirus None None O
- None None O
mediated None None O
gene None None O
expression None None O
system None None O
. None None O

Our None None O
in None None O
vitro None None O
studies None None O
showed None None O
that None None O
NIH3T3 None None I-Cell-line-name
cells None None O
overexpressing None None O
BI None None O
- None None O
1 None None O
displayed None None O
a None None O
significantly None None O
higher None None O
growth None None O
rate None None O
and None None O
formed None None O
more None None O
and None None O
larger None None O
colonies None None O
than None None O
the None None O
control None None O
cells None None O
. None None O

In None None O
addition None None O
, None None O
our None None O
in None None O
vivo None None O
studies None None O
indicated None None O
that None None O
the None None O
lenti None None O
- None None O
BI None None O
- None None O
1 None None O
- None None O
infected None None O
cells None None O
formed None None O
obvious None None O
tumours None None O
, None None O
while None None O
no None None O
tumours None None O
were None None O
formed None None O
by None None O
the None None O
control None None O
cells None None O
after None None O
subcutaneously None None O
injected None None O
into None None O
nude None None O
mice None None O
. None None O

These None None O
results None None O
strongly None None O
suggested None None O
that None None O
the None None O
BI None None O
- None None O
1 None None O
gene None None O
might None None O
play None None O
a None None O
crucial None None O
role None None O
in None None O
neoplastic None None O
genesis None None O
and None None O
development None None O
. None None O

Sanguinarine None None O
induces None None O
apoptosis None None O
of None None O
human None None O
osteosarcoma None None O
cells None None O
through None None O
the None None O
extrinsic None None O
and None None O
intrinsic None None O
pathways None None O
. None None O

The None None O
quaternary None None O
benzo None None O
[ None None O
c None None O
] None None O
phenanthridine None None O
alkaloid None None O
sanguinarine None None O
inhibits None None O
the None None O
proliferation None None O
of None None O
cancerous None None O
cells None None O
from None None O
different None None O
origins None None O
, None None O
including None None O
lung None None O
, None None O
breast None None O
, None None O
pancreatic None None O
and None None O
colon None None O
, None None O
but None None O
nothing None None O
is None None O
known None None O
of None None O
its None None O
effects None None O
on None None O
osteosarcoma None None O
, None None O
a None None O
primary None None O
malignant None None O
bone None None O
tumour None None O
. None None O

We None None O
have None None O
found None None O
that None None O
sanguinarine None None O
alters None None O
the None None O
morphology None None O
and None None O
reduces None None O
the None None O
viability None None O
of None None O
MG None None I-Cell-line-name
- None None I-Cell-line-name
63 None None I-Cell-line-name
and None None O
SaOS None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
human None None O
osteosarcoma None None O
cell None None O
lines None None O
in None None O
concentration None None O
- None None O
and None None O
time None None O
- None None O
dependent None None O
manner None None O
. None None O

Incubation None None O
with None None O
1 None None O
micromol None None O
/ None None O
L None None O
sanguinarine None None O
for None None O
4 None None O
and None None O
24h None None O
killed None None O
more None None O
efficiently None None O
MG None None I-Cell-line-name
- None None I-Cell-line-name
63 None None I-Cell-line-name
cells None None O
than None None O
SaOS None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
, None None O
while None None O
incubation None None O
with None None O
5 None None O
micromol None None O
/ None None O
L None None O
sanguinarine None None O
killed None None O
almost None None O
100 None None O
% None None O
of None None O
both None None O
cell None None O
populations None None O
within None None O
24h None None O
. None None O

This None None O
treatment None None O
also None None O
changed None None O
the None None O
mitochondrial None None O
membrane None None O
potential None None O
in None None O
both None None O
MG None None I-Cell-line-name
- None None I-Cell-line-name
63 None None I-Cell-line-name
and None None O
SaOS None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
within None None O
1h None None O
, None None O
caused None None O
chromatin None None O
condensation None None O
and None None O
the None None O
formation None None O
of None None O
apoptotic None None O
bodies None None O
. None None O

It None None O
activated None None O
multicaspases None None O
, None None O
and None None O
increased None None O
the None None O
activities None None O
of None None O
caspase None None O
- None None O
8 None None O
and None None O
caspase None None O
- None None O
9 None None O
in None None O
both None None O
MG None None I-Cell-line-name
- None None I-Cell-line-name
63 None None I-Cell-line-name
and None None O
SaOS None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

These None None O
data None None O
highlight None None O
sanguinarine None None O
as None None O
a None None O
novel None None O
potential None None O
agent None None O
for None None O
bone None None O
cancer None None O
therapy None None O
. None None O

Expression None None O
of None None O
DCC None None O
and None None O
netrin None None O
- None None O
1 None None O
in None None O
normal None None O
human None None O
endometrium None None O
and None None O
its None None O
implication None None O
in None None O
endometrial None None O
carcinogenesis None None O
. None None O

OBJECTIVE None None O
: None None O
Although None None O
DCC None None O
has None None O
been None None O
considered None None O
as None None O
a None None O
candidate None None O
tumor None None O
suppressor None None O
, None None O
the None None O
roles None None O
it None None O
plays None None O
in None None O
the None None O
uterine None None O
endometrium None None O
and None None O
in None None O
the None None O
carcinogenic None None O
process None None O
remains None None O
unclear None None O
. None None O

To None None O
define None None O
these None None O
roles None None O
more None None O
clearly None None O
, None None O
we None None O
examined None None O
the None None O
expression None None O
of None None O
DCC None None O
and None None O
its None None O
ligand None None O
, None None O
netrin None None O
- None None O
1 None None O
, None None O
in None None O
the None None O
normal None None O
endometrium None None O
and None None O
in None None O
endometrial None None O
cancer None None O
. None None O

METHODS None None O
: None None O
The None None O
expression None None O
of None None O
DCC None None O
and None None O
netrin None None O
- None None O
1 None None O
in None None O
normal None None O
endometrial None None O
glands None None O
and None None O
in None None O
cancer None None O
cell None None O
lines None None O
was None None O
examined None None O
by None None O
RT None None O
- None None O
PCR None None O
and None None O
immunohistochemistry None None O
. None None O

The None None O
effects None None O
of None None O
exogenous None None O
DCC None None O
and None None O
netrin None None O
- None None O
1 None None O
expression None None O
were None None O
observed None None O
together None None O
with None None O
the None None O
respective None None O
expression None None O
vector None None O
transfection None None O
. None None O

RESULTS None None O
: None None O
Endometrial None None O
glands None None O
in None None O
the None None O
proliferative None None O
and None None O
early None None O
secretory None None O
phase None None O
expressed None None O
both None None O
DCC None None O
and None None O
netrin None None O
- None None O
1 None None O
, None None O
but None None O
glands None None O
in None None O
the None None O
late None None O
- None None O
secretory None None O
phase None None O
tended None None O
to None None O
silence None None O
DCC None None O
expression None None O
. None None O

In None None O
addition None None O
, None None O
all None None O
of None None O
the None None O
endometrial None None O
cancer None None O
cell None None O
lines None None O
lost None None O
normal None None O
DCC None None O
expression None None O
. None None O

Restored None None O
DCC None None O
expression None None O
in None None O
the None None O
cancer None None O
cell None None O
lines None None O
in None None O
the None None O
absence None None O
of None None O
netrin None None O
- None None O
1 None None O
induced None None O
apoptosis None None O
. None None O

However None None O
, None None O
no None None O
changes None None O
were None None O
observed None None O
in None None O
the None None O
presence None None O
of None None O
netrin None None O
- None None O
1 None None O
. None None O

CONCLUSION None None O
: None None O
Our None None O
observations None None O
suggest None None O
that None None O
DCC None None O
/ None None O
netrin None None O
- None None O
1 None None O
signaling None None O
may None None O
commit None None O
cells None None O
to None None O
the None None O
transition None None O
of None None O
endometrial None None O
gland None None O
architecture None None O
or None None O
function None None O
from None None O
a None None O
proliferating None None O
to None None O
a None None O
secretory None None O
phase None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
silencing None None O
of None None O
DCC None None O
expression None None O
may None None O
contribute None None O
to None None O
the None None O
escape None None O
of None None O
endometrial None None O
cancer None None O
cells None None O
from None None O
a None None O
DCC None None O
- None None O
regulated None None O
apoptotic None None O
program None None O
, None None O
thereby None None O
promoting None None O
malignant None None O
phenotypes None None O
. None None O

[ None None O
Diagnostic None None O
value None None O
of None None O
DNA None None O
, None None O
RNA None None O
and None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
examination None None O
in None None O
malignant None None O
pleural None None O
effusions None None O
by None None O
flow None None O
cytometry None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
study None None O
the None None O
diagnostic None None O
value None None O
of None None O
DNA None None O
, None None O
RNA None None O
and None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
( None None O
PCNA None None O
) None None O
examination None None O
in None None O
malignant None None O
effusion None None O
by None None O
multiparametric None None O
flow None None O
cytometry None None O
, None None O
and None None O
therefore None None O
to None None O
provide None None O
proof None None O
for None None O
clinical None None O
application None None O
. None None O

METHODS None None O
: None None O

Forty None None O
seven None None O
patients None None O
with None None O
pleural None None O
effusions None None O
in None None O
our None None O
hospital None None O
from None None O
August None None O
2003 None None O
to None None O
February None None O
2004 None None O
were None None O
divided None None O
into None None O
two None None O
groups None None O
: None None O
19 None None O
suffering None None O
from None None O
benign None None O
pleural None None O
effusions None None O
and None None O
28 None None O
from None None O
malignant None None O
effusions None None O
confirmed None None O
by None None O
pathologic None None O
examination None None O
. None None O

The None None O
cells None None O
for None None O
diagnosis None None O
were None None O
divided None None O
into None None O
four None None O
groups None None O
stained None None O
by None None O
PI None None O
( None None O
Propidium None None O
- None None O
iodide None None O
) None None O
, None None O
PY None None O
( None None O
Pyronin None None O
) None None O
, None None O
PCNA None None O
- None None O
FITC None None O
and None None O
PCNA None None O
- None None O
mouse None None O
- None None O
alpha None None O
- None None O
2a None None O
. None None O

The None None O
specimens None None O
were None None O
analyzed None None O
by None None O
a None None O
flow None None O
cytometer None None O
( None None O
FacS None None O
Caliber None None O
, None None O
Becton None None O
Dickinson None None O
) None None O
. None None O

The None None O
sensitivity None None O
and None None O
the None None O
specificity None None O
of None None O
each None None O
examination None None O
and None None O
combined None None O
examination None None O
were None None O
calculated None None O
by None None O
statistic None None O
software None None O
SPSS None None O
13 None None O
. None None O
0 None None O
. None None O

RESULTS None None O
: None None O

( None None O
1 None None O
) None None O
The None None O
expression None None O
of None None O
DI None None O
, None None O
RI None None O
, None None O
and None None O
PI None None O
in None None O
benign None None O
pleural None None O
effusion None None O
was None None O
1 None None O
. None None O
03 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
06 None None O
, None None O
10 None None O
. None None O
03 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
54 None None O
, None None O
and None None O
( None None O
4 None None O
. None None O
86 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
72 None None O
) None None O
% None None O
, None None O
respectively None None O
, None None O
and None None O
those None None O
in None None O
malignant None None O
ones None None O
was None None O
1 None None O
. None None O
26 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
17 None None O
, None None O
11 None None O
. None None O
65 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
45 None None O
, None None O
and None None O
( None None O
11 None None O
. None None O
97 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
50 None None O
) None None O
% None None O
, None None O
respectively None None O
, None None O
the None None O
difference None None O
being None None O
statistically None None O
significant None None O
. None None O

The None None O
cutoff None None O
value None None O
of None None O
DI None None O
, None None O
RI None None O
and None None O
PI None None O
was None None O
1 None None O
. None None O
10 None None O
% None None O
, None None O
10 None None O
. None None O
75 None None O
% None None O
and None None O
4 None None O
. None None O
56 None None O
% None None O
, None None O
and None None O
the None None O
sensitivity None None O
of None None O
DI None None O
examination None None O
was None None O
89 None None O
. None None O
3 None None O
% None None O
, None None O
78 None None O
. None None O
6 None None O
% None None O
, None None O
75 None None O
. None None O
0 None None O
% None None O
, None None O
and None None O
the None None O
specificity None None O
was None None O
89 None None O
. None None O
5 None None O
% None None O
, None None O
98 None None O
. None None O
5 None None O
% None None O
, None None O
84 None None O
. None None O
2 None None O
% None None O
, None None O
respectively None None O
. None None O

( None None O
2 None None O
) None None O
In None None O
6 None None O
cases None None O
suffering None None O
from None None O
malignant None None O
pleural None None O
effusions None None O
, None None O
RI None None O
was None None O
positive None None O
but None None O
DI None None O
was None None O
negative None None O
, None None O
indicating None None O
that None None O
DI None None O
combined None None O
with None None O
RI None None O
examination None None O
was None None O
better None None O
than None None O
DI None None O
examination None None O
alone None None O
. None None O

( None None O
3 None None O
) None None O
In None None O
5 None None O
cases None None O
suffering None None O
from None None O
malignant None None O
pleural None None O
effusions None None O
confirmed None None O
by None None O
tissue None None O
examination None None O
, None None O
the None None O
cytology None None O
was None None O
negative None None O
, None None O
but None None O
the None None O
result None None O
of None None O
DI None None O
and None None O
RI None None O
was None None O
abnormal None None O
, None None O
indicating None None O
that None None O
flow None None O
cytometry None None O
was None None O
complementary None None O
to None None O
pathologic None None O
examination None None O
. None None O

( None None O
4 None None O
) None None O
The None None O
sensitivity None None O
of None None O
DI None None O
+ None None O
RI None None O
, None None O
DI None None O
+ None None O
PI None None O
, None None O
RI None None O
+ None None O
PI None None O
and None None O
DI None None O
+ None None O
RI None None O
+ None None O
PI None None O
combined None None O
examination None None O
was None None O
98 None None O
. None None O
2 None None O
% None None O
, None None O
89 None None O
. None None O
3 None None O
% None None O
, None None O
89 None None O
. None None O
3 None None O
% None None O
, None None O
92 None None O
. None None O
9 None None O
% None None O
; None None O
the None None O
specificity None None O
was None None O
84 None None O
. None None O
2 None None O
% None None O
, None None O
89 None None O
. None None O
5 None None O
% None None O
, None None O
84 None None O
. None None O
2 None None O
% None None O
, None None O
94 None None O
. None None O
2 None None O
% None None O
respectively None None O
. None None O

The None None O
results None None O
demonstrated None None O
that None None O
DI None None O
+ None None O
RI None None O
+ None None O
PI None None O
combined None None O
examination None None O
was None None O
the None None O
best None None O
, None None O
which None None O
showed None None O
the None None O
least None None O
false None None O
negative None None O
and None None O
false None None O
positive None None O
results None None O
. None None O

The None None O
sensitivity None None O
of None None O
DI None None O
+ None None O
RI None None O
combined None None O
examination None None O
was None None O
98 None None O
. None None O
2 None None O
% None None O
, None None O
but None None O
the None None O
specificity None None O
was None None O
84 None None O
. None None O
2 None None O
% None None O
, None None O
the None None O
false None None O
positive None None O
rate None None O
being None None O
higher None None O
than None None O
DI None None O
+ None None O
RI None None O
+ None None O
PI None None O
combined None None O
examination None None O
. None None O

In None None O
none None None O
of None None O
the None None O
benign None None O
pleural None None O
effusions None None O
was None None O
the None None O
DI None None O
+ None None O
RI None None O
+ None None O
PI None None O
higher None None O
than None None O
the None None O
cutoff None None O
value None None O
, None None O
suggesting None None O
that None None O
combined None None O
examination None None O
can None None O
exclude None None O
benign None None O
pleural None None O
effusions None None O
. None None O

CONCLUSIONS None None O
: None None O

DNA None None O
, None None O
RNA None None O
and None None O
PCNA None None O
examinations None None O
by None None O
flow None None O
cytometry None None O
are None None O
of None None O
value None None O
in None None O
the None None O
diagnosis None None O
of None None O
malignant None None O
effusion None None O
, None None O
especially None None O
for None None O
cases None None O
which None None O
can None None O
not None None O
be None None O
diagnosed None None O
by None None O
cytological None None O
examination None None O
. None None O

DI None None O
+ None None O
RI None None O
+ None None O
PI None None O
combined None None O
examination None None O
showed None None O
better None None O
results None None O
with None None O
the None None O
lowest None None O
false None None O
negative None None O
and None None O
false None None O
positive None None O
rates None None O
. None None O

Down None None O
- None None O
regulation None None O
of None None O
collagen None None O
XII None None O
in None None O
transformed None None O
mesenchymal None None O
cells None None O
. None None O

Collagen None None O
XII None None O
is None None O
a None None O
complex None None O
multidomain None None O
protein None None O
associated None None O
with None None O
the None None O
surface None None O
of None None O
interstitial None None O
collagen None None O
fibrils None None O
. None None O

This None None O
protein None None O
is None None O
produced None None O
in None None O
large None None O
amounts None None O
by None None O
fibroblasts None None O
cultivated None None O
in None None O
vitro None None O
. None None O

However None None O
, None None O
it None None O
is None None O
completely None None O
absent None None O
from None None O
cells None None O
transformed None None O
by None None O
the None None O
oncogene None None O
v None None O
- None None O
myc None None O
or None None O
v None None O
- None None O
src None None O
and None None O
from None None O
cells None None O
derived None None O
from None None O
a None None O
methylcholanthrene None None O
- None None O
induced None None O
fibrosarcoma None None O
. None None O

Since None None O
all None None O
these None None O
cells None None O
lack None None O
any None None O
mRNA None None O
for None None O
collagen None None O
, None None O
XII None None O
, None None O
it None None O
seems None None O
likely None None O
that None None O
the None None O
synthesis None None O
is None None O
blocked None None O
at None None O
the None None O
transcriptional None None O
level None None O
. None None O

Experiments None None O
with None None O
a None None O
temperature None None O
- None None O
sensitive None None O
mutant None None O
of None None O
Rous None None O
sarcoma None None O
virus None None O
demonstrated None None O
that None None O
a None None O
single None None O
oncogene None None O
product None None O
is None None O
sufficient None None O
to None None O
inhibit None None O
the None None O
synthesis None None O
. None None O

A None None O
reduction None None O
in None None O
the None None O
expression None None O
of None None O
collagen None None O
XII None None O
might None None O
have None None O
profound None None O
effects None None O
on None None O
the None None O
stability None None O
of None None O
the None None O
extracellular None None O
matrix None None O
of None None O
transformed None None O
cells None None O
. None None O

Effects None None O
of None None O
buffer None None O
properties None None O
on None None O
cyclodextrin None None O
glucanotransferase None None O
reactions None None O
and None None O
cyclodextrin None None O
production None None O
from None None O
raw None None O
sago None None O
( None None O
Cycas None None O
revoluta None None O
) None None O
starch None None O
. None None O

Results None None O
from None None O
the None None O
present None None O
study None None O
have None None O
shown None None O
that None None O
the None None O
ionic None None O
species None None O
of None None O
buffers None None O
, None None O
pH None None O
values None None O
and None None O
reaction None None O
temperature None None O
can None None O
affect None None O
the None None O
enzyme None None O
unit None None O
activities None None O
and None None O
product None None O
specificity None None O
of None None O
Toruzyme None None O
( None None O
Novo None None O
Nordisk None None O
A None None O
/ None None O
S None None O
Bagsvaerd None None O
, None None O
Denmark None None O
) None None O
CGTase None None O
( None None O
cyclodextrin None None O
glucanotransferase None None O
) None None O
. None None O

Applying None None O
a None None O
similar None None O
reaction None None O
environment None None O
( None None O
acetate None None O
buffer None None O
, None None O
pH None None O
6 None None O
. None None O
0 None None O
; None None O
temperature None None O
, None None O
60 None None O
degrees None None O
C None None O
) None None O
, None None O
the None None O
CGTase None None O
was None None O
found None None O
to None None O
be None None O
capable None None O
of None None O
producing None None O
pre None None O
dominantly None None O
beta None None O
- None None O
cyclodextrin None None O
from None None O
either None None O
raw None None O
or None None O
gelatinized None None O
sago None None O
( None None O
Cycas None None O
revoluta None None O
) None None O
starch None None O
. None None O

Changing None None O
the None None O
buffer None None O
from None None O
acetate None None O
to None None O
phosphate None None O
reduced None None O
the None None O
yield None None O
of None None O
beta None None O
- None None O
cyclodextrin None None O
from None None O
2 None None O
. None None O
48 None None O
to None None O
1 None None O
. None None O
42 None None O
mg None None O
/ None None O
ml None None O
and None None O
also None None O
affected None None O
the None None O
product None None O
specificity None None O
, None None O
where None None O
production None None O
of None None O
both None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
cyclodextrins None None O
were None None O
more None None O
pronounced None None O
. None None O

The None None O
decrease None None O
in None None O
the None None O
production None None O
of None None O
cyclodextrins None None O
in None None O
phosphate None None O
buffer None None O
was None None O
significant None None O
at None None O
both None None O
pH None None O
6 None None O
. None None O
0 None None O
and None None O
7 None None O
. None None O
0 None None O
. None None O

However None None O
, None None O
changing None None O
the None None O
buffer None None O
to None None O
Tris None None O
/ None None O
HCl None None O
( None None O
pH None None O
7 None None O
. None None O
0 None None O
) None None O
showed None None O
a None None O
significant None None O
increase None None O
in None None O
beta None None O
- None None O
cyclodextrin None None O
production None None O
. None None O

Increasing None None O
the None None O
ionic None None O
strength None None O
of None None O
sodium None None O
acetate None None O
and None None O
Tris None None O
/ None None O
HCl None None O
buffers None None O
at None None O
pH None None O
6 None None O
. None None O
0 None None O
and None None O
7 None None O
. None None O
0 None None O
to None None O
equivalent None None O
ionic None None O
strength None None O
of None None O
phosphate None None O
buffers None None O
showed None None O
no None None O
significant None None O
effects None None O
on None None O
cyclodextrin None None O
production None None O
. None None O

Higher None None O
yield None None O
of None None O
cyclodextrins None None O
at None None O
pH None None O
7 None None O
. None None O
0 None None O
when None None O
Tris None None O
/ None None O
HCl None None O
was None None O
used None None O
might None None O
be None None O
due None None O
to None None O
the None None O
binding None None O
of None None O
chloride None None O
ions None None O
at None None O
the None None O
calcium None None O
- None None O
binding None None O
sites None None O
of None None O
the None None O
CGTase None None O
, None None O
resulting None None O
in None None O
the None None O
shift None None O
of None None O
the None None O
optimum None None O
pH None None O
close None None O
to None None O
physiological None None O
environment None None O
, None None O
leading None None O
to None None O
an None None O
increase None None O
in None None O
the None None O
activities None None O
and None None O
specificity None None O
. None None O

Objectives None None O

Evaluate None None O
relationships None None O
between None None O
MRI None None O
and None None O
clinical None None O
/ None None O
laboratory None None O
/ None None O
radiographic None None O
findings None None O
in None None O
rheumatoid None None O
arthritis None None O
( None None O
RA None None O
) None None O
. None None O

Methods None None O

High None None O
- None None O
mobility None None O
group None None O
A2 None None O
protein None None O
modulates None None O
hTERT None None O
transcription None None O
to None None O
promote None None O
tumorigenesis None None O
. None None O

The None None O
high None None O
- None None O
mobility None None O
group None None O
A2 None None O
gene None None O
( None None O
HMGA2 None None O
) None None O
is None None O
one None None O
of None None O
the None None O
most None None O
frequently None None O
amplified None None O
genes None None O
in None None O
human None None O
cancers None None O
. None None O

However None None O
, None None O
functions None None O
of None None O
HMGA2 None None O
in None None O
tumorigenesis None None O
are None None O
not None None O
fully None None O
understood None None O
due None None O
to None None O
limited None None O
knowledge None None O
of None None O
its None None O
targets None None O
in None None O
tumor None None O
cells None None O
. None None O

Our None None O
study None None O
reveals None None O
a None None O
novel None None O
link None None O
between None None O
HMGA2 None None O
and None None O
the None None O
regulation None None O
of None None O
human None None O
telomerase None None O
reverse None None O
transcriptase None None O
( None None O
hTERT None None O
) None None O
, None None O
the None None O
catalytic None None O
subunit None None O
of None None O
telomerase None None O
, None None O
which None None O
offers None None O
critical None None O
insight None None O
into None None O
how None None O
HMGA2 None None O
contributes None None O
to None None O
tumorigenesis None None O
. None None O

The None None O
expression None None O
of None None O
HMGA2 None None O
modulates None None O
the None None O
expression None None O
of None None O
hTERT None None O
, None None O
resulting None None O
in None None O
cells None None O
with None None O
enhanced None None O
telomerase None None O
activities None None O
and None None O
increased None None O
telomere None None O
length None None O
. None None O

Treatment None None O
with None None O
suberoylanilide None None O
hydroxamide None None O
( None None O
SAHA None None O
) None None O
, None None O
a None None O
histone None None O
deacetylase None None O
( None None O
HDAC None None O
) None None O
inhibitor None None O
, None None O
causes None None O
dose None None O
- None None O
dependent None None O
hTERT None None O
reporter None None O
activation None None O
, None None O
mimicking None None O
HMGA2 None None O
overexpression None None O
. None None O

By None None O
interacting None None O
with None None O
Sp1 None None O
, None None O
HMGA2 None None O
interferes None None O
with None None O
the None None O
recruitment None None O
of None None O
HDAC2 None None O
to None None O
the None None O
hTERT None None O
proximal None None O
promoter None None O
, None None O
enhancing None None O
localized None None O
histone None None O
H3 None None O
- None None O
K9 None None O
acetylation None None O
and None None O
thereby None None O
stimulating None None O
hTERT None None O
expression None None O
and None None O
telomerase None None O
activity None None O
. None None O

Moreover None None O
, None None O
HMGA2 None None O
knockdown None None O
by None None O
short None None O
hairpin None None O
HMGA2 None None O
in None None O
HepG2 None None I-Cell-line-name
cells None None O
leads None None O
to None None O
progressive None None O
telomere None None O
shortening None None O
and None None O
a None None O
concurrent None None O
decrease None None O
of None None O
steady None None O
- None None O
state None None O
hTERT None None O
mRNA None None O
levels None None O
, None None O
attenuating None None O
their None None O
ability None None O
to None None O
form None None O
colonies None None O
in None None O
soft None None O
agar None None O
. None None O

Importantly None None O
, None None O
HMGA2 None None O
partially None None O
replaces None None O
the None None O
function None None O
of None None O
hTERT None None O
during None None O
the None None O
tumorigenic None None O
transformation None None O
of None None O
normal None None O
human None None O
fibroblasts None None O
. None None O

These None None O
findings None None O
are None None O
potentially None None O
clinically None None O
relevant None None O
, None None O
because None None O
HMGA2 None None O
expression None None O
is None None O
reported None None O
to None None O
be None None O
upregulated None None O
in None None O
a None None O
number None None O
of None None O
human None None O
cancers None None O
as None None O
telomere None None O
maintenance None None O
is None None O
essential None None O
for None None O
tumorigenesis None None O
. None None O

Schizophrenia None None O
: None None O
a None None O
common None None O
disease None None O
caused None None O
by None None O
multiple None None O
rare None None O
alleles None None O
. None None O

Schizophrenia None None O
is None None O
widely None None O
held None None O
to None None O
stem None None O
from None None O
the None None O
combined None None O
effects None None O
of None None O
multiple None None O
common None None O
polymorphisms None None O
, None None O
each None None O
with None None O
a None None O
small None None O
impact None None O
on None None O
disease None None O
risk None None O
. None None O

We None None O
suggest None None O
an None None O
alternative None None O
view None None O
: None None O
that None None O
schizophrenia None None O
is None None O
highly None None O
heterogeneous None None O
genetically None None O
and None None O
that None None O
many None None O
predisposing None None O
mutations None None O
are None None O
highly None None O
penetrant None None O
and None None O
individually None None O
rare None None O
, None None O
even None None O
specific None None O
to None None O
single None None O
cases None None O
or None None O
families None None O
. None None O

This None None O
" None None O
common None None O
disease None None O
- None None O
- None None O
rare None None O
alleles None None O
" None None O
hypothesis None None O
is None None O
supported None None O
by None None O
recent None None O
findings None None O
in None None O
human None None O
genomics None None O
and None None O
by None None O
allelic None None O
and None None O
locus None None O
heterogeneity None None O
for None None O
other None None O
complex None None O
traits None None O
. None None O

We None None O
review None None O
the None None O
implications None None O
of None None O
this None None O
model None None O
for None None O
gene None None O
discovery None None O
research None None O
in None None O
schizophrenia None None O
. None None O

Novel None None O
mechanism None None O
for None None O
the None None O
impairment None None O
of None None O
cell None None O
proliferation None None O
in None None O
HIV None None O
- None None O
1 None None O
infection None None O
. None None O

The None None O
synthesis None None O
of None None O
ribonucleotides None None O
is None None O
essential None None O
to None None O
cell None None O
proliferation None None O
. None None O

Defects None None O
in None None O
the None None O
relevant None None O
metabolic None None O
pathways None None O
have None None O
been None None O
demonstrated None None O
in None None O
stimulated None None O
T None None O
cells None None O
from None None O
AIDS None None O
patients None None O
and None None O
are None None O
associated None None O
with None None O
lymphocyte None None O
necrotic None None O
death None None O
. None None O

Here None None O
, None None O
Margarita None None O
Bofill None None O
and None None O
colleagues None None O
discuss None None O
the None None O
possibility None None O
that None None O
an None None O
impaired None None O
ribonucleotide None None O
metabolism None None O
might None None O
be None None O
common None None O
to None None O
all None None O
rapidly None None O
dividing None None O
cells None None O
and None None O
thus None None O
contribute None None O
to None None O
other None None O
recognized None None O
symptoms None None O
of None None O
HIV None None O
- None None O
1 None None O
infection None None O
. None None O

Angiogenesis None None O
: None None O
initiation None None O
and None None O
control None None O
. None None O

From None None O
in None None O
vivo None None O
experiments None None O
using None None O
new None None O
methods None None O
such None None O
as None None O
the None None O
rabbit None None O
cornea None None O
, None None O
it None None O
is None None O
now None None O
becoming None None O
clear None None O
that None None O
the None None O
growth None None O
of None None O
a None None O
capillary None None O
involves None None O
an None None O
ordered None None O
sequence None None O
of None None O
events None None O
that None None O
includes None None O
lysis None None O
of None None O
the None None O
basement None None O
membrane None None O
of None None O
a None None O
parent None None O
venule None None O
, None None O
directional None None O
migration None None O
of None None O
capillary None None O
endothelial None None O
cells None None O
toward None None O
the None None O
angiogenic None None O
stimulus None None O
, None None O
lumen None None O
formation None None O
, None None O
development None None O
of None None O
branches None None O
, None None O
and None None O
anastomosis None None O
of None None O
the None None O
tip None None O
of None None O
one None None O
tube None None O
with None None O
another None None O
to None None O
form None None O
a None None O
loop None None O
. None None O

It None None O
is None None O
also None None O
clear None None O
that None None O
diffusible None None O
angiogenic None None O
stimuli None None O
can None None O
be None None O
released None None O
not None None O
only None None O
from None None O
most None None O
solid None None O
tumors None None O
, None None O
but None None O
also None None O
from None None O
at None None O
least None None O
three None None O
non None None O
- None None O
neoplastic None None O
cells None None O
. None None O

These None None O
include None None O
activated None None O
macrophages None None O
, None None O
sensitized None None O
lymphocytes None None O
, None None O
and None None O
adipocytes None None O
. None None O

Other None None O
normal None None O
tissues None None O
can None None O
also None None O
stimulate None None O
angiogenesis None None O
, None None O
but None None O
the None None O
type None None O
of None None O
cell None None O
giving None None O
rise None None O
to None None O
the None None O
angiogenic None None O
stimulus None None O
is None None O
unknown None None O
, None None O
and None None O
the None None O
period None None O
of None None O
angiogenic None None O
stimulation None None O
is None None O
brief None None O
. None None O

With None None O
the None None O
recent None None O
ability None None O
to None None O
clone None None O
capillary None None O
endothelial None None O
cells None None O
and None None O
to None None O
carry None None O
them None None O
in None None O
long None None O
- None None O
term None None O
culture None None O
, None None O
it None None O
has None None O
been None None O
possible None None O
to None None O
further None None O
delineate None None O
the None None O
mechanism None None O
of None None O
capillary None None O
growth None None O
. None None O

In None None O
vitro None None O
studies None None O
have None None O
shown None None O
that None None O
the None None O
mast None None O
cell None None O
seems None None O
to None None O
behave None None O
as None None O
a None None O
helper None None O
cell None None O
for None None O
capillary None None O
endothelial None None O
cells None None O
, None None O
in None None O
some None None O
way None None O
speeding None None O
up None None O
their None None O
rate None None O
of None None O
directional None None O
migration None None O
. None None O

At None None O
this None None O
writing None None O
, None None O
heparin None None O
appears None None O
to None None O
be None None O
the None None O
principal None None O
mast None None O
cell None None O
factor None None O
responsible None None O
for None None O
this None None O
effect None None O
on None None O
capillary None None O
endothelial None None O
cells None None O
. None None O

One None None O
theoretical None None O
possibility None None O
is None None O
that None None O
mast None None O
cells None None O
may None None O
prepare None None O
the None None O
matrix None None O
, None None O
perhaps None None O
by None None O
slow None None O
release None None O
of None None O
heparin None None O
, None None O
so None None O
that None None O
capillary None None O
sprouts None None O
can None None O
more None None O
easily None None O
move None None O
through None None O
it None None O
toward None None O
their None None O
angiogenic None None O
target None None O
. None None O

While None None O
the None None O
study None None O
of None None O
angiogenesis None None O
as None None O
a None None O
phenomenon None None O
is None None O
still None None O
in None None O
an None None O
early None None O
phase None None O
, None None O
it None None O
has None None O
become None None O
possible None None O
, None None O
by None None O
using None None O
a None None O
combination None None O
of None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
techniques None None O
, None None O
to None None O
more None None O
thoroughly None None O
understand None None O
the None None O
initiation None None O
and None None O
control None None O
of None None O
capillary None None O
growth None None O
. None None O

H None None O
- None None O
ras None None O
mutations None None O
in None None O
human None None O
pituitary None None O
carcinoma None None O
metastases None None O
. None None O

Molecular None None O
mechanisms None None O
of None None O
pituitary None None O
tumorigenesis None None O
were None None O
studied None None O
using None None O
Polymerase None None O
chain None None O
reaction None None O
- None None O
single None None O
stranded None None O
conformational None None O
polymorphism None None O
with None None O
DNA None None O
sequencing None None O
to None None O
identify None None O
potential None None O
mutations None None O
in None None O
the None None O
ras None None O
protooncogenes None None O
and None None O
the None None O
tumor None None O
suppressor None None O
gene None None O
p53 None None O
in None None O
invasive None None O
pituitary None None O
adenomas None None O
and None None O
carcinomas None None O
. None None O

Sequencing None None O
of None None O
exons None None O
5 None None O
through None None O
8 None None O
of None None O
the None None O
p53 None None O
gene None None O
revealed None None O
no None None O
mutations None None O
, None None O
nor None None O
were None None O
mutations None None O
detected None None O
in None None O
the None None O
N None None O
- None None O
or None None O
K None None O
- None None O
ras None None O
protooncogenes None None O
in None None O
four None None O
of None None O
the None None O
carcinomas None None O
and None None O
their None None O
respective None None O
metastatic None None O
deposits None None O
. None None O

Point None None O
mutations None None O
of None None O
H None None O
- None None O
ras None None O
however None None O
, None None O
were None None O
identified None None O
in None None O
three None None O
distant None None O
metastatic None None O
pituitary None None O
tumor None None O
secondaries None None O
, None None O
but None None O
not None None O
in None None O
their None None O
respective None None O
primary None None O
pituitary None None O
carcinomas None None O
, None None O
or None None O
in None None O
six None None O
invasive None None O
adenomas None None O
. None None O

Two None None O
of None None O
the None None O
mutations None None O
included None None O
a None None O
G None None O
to None None O
C None None O
substitution None None O
at None None O
codon None None O
12 None None O
, None None O
and None None O
a None None O
G None None O
to None None O
A None None O
substitution None None O
at None None O
codon None None O
18 None None O
, None None O
resulting None None O
in None None O
a None None O
glycine None None O
to None None O
arginine None None O
, None None O
and None None O
an None None O
alanine None None O
to None None O
threonine None None O
change None None O
at None None O
these None None O
amino None None O
acids None None O
, None None O
respectively None None O
. None None O

A None None O
third None None O
mutation None None O
involved None None O
a None None O
single None None O
base None None O
pair None None O
( None None O
adenine None None O
) None None O
deletion None None O
in None None O
codon None None O
3 None None O
of None None O
H None None O
- None None O
ras None None O
which None None O
causes None None O
a None None O
frame None None O
shift None None O
, None None O
resulting None None O
in None None O
a None None O
termination None None O
signal None None O
at None None O
codon None None O
19 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
point None None O
mutations None None O
in None None O
p53 None None O
and None None O
ras None None O
are None None O
not None None O
associated None None O
with None None O
pituitary None None O
tumorigenesis None None O
, None None O
however None None O
, None None O
point None None O
mutations None None O
of None None O
the None None O
H None None O
- None None O
ras None None O
gene None None O
may None None O
be None None O
important None None O
in None None O
the None None O
formation None None O
and None None O
or None None O
growth None None O
of None None O
pituitary None None O
metastases None None O
. None None O

This None None O
observed None None O
genomic None None O
instability None None O
will None None O
be None None O
of None None O
value None None O
in None None O
predicting None None O
the None None O
potential None None O
metastatic None None O
behavior None None O
of None None O
these None None O
aggressive None None O
pituitary None None O
tumors None None O
. None None O

Neoplastic None None O
progression None None O
of None None O
human None None O
colorectal None None O
cancer None None O
is None None O
associated None None O
with None None O
overexpression None None O
of None None O
the None None O
stromelysin None None O
- None None O
3 None None O
and None None O
BM None None O
- None None O
40 None None O
/ None None O
SPARC None None O
genes None None O
. None None O

The None None O
interaction None None O
of None None O
neoplastic None None O
cells None None O
with None None O
the None None O
extracellular None None O
matrix None None O
is None None O
a None None O
critical None None O
event None None O
for None None O
the None None O
initiation None None O
of None None O
cancer None None O
invasion None None O
and None None O
metastasis None None O
. None None O

This None None O
study None None O
was None None O
designed None None O
to None None O
evaluate None None O
the None None O
potential None None O
implication None None O
of None None O
stromelysin None None O
- None None O
3 None None O
( None None O
ST3 None None O
) None None O
, None None O
a None None O
newly None None O
identified None None O
member None None O
of None None O
the None None O
matrix None None O
- None None O
degrading None None O
metalloproteinase None None O
family None None O
, None None O
and None None O
of None None O
BM None None O
- None None O
40 None None O
/ None None O
SPARC None None O
, None None O
a None None O
glycoprotein None None O
associated None None O
with None None O
the None None O
extracellular None None O
matrix None None O
, None None O
during None None O
the None None O
progression None None O
of None None O
human None None O
colorectal None None O
cancers None None O
. None None O

We None None O
analyzed None None O
the None None O
relative None None O
abundance None None O
of None None O
ST3 None None O
and None None O
BM None None O
- None None O
40 None None O
/ None None O
SPARC None None O
transcripts None None O
by None None O
Northern None None O
blot None None O
, None None O
and None None O
their None None O
distribution None None O
by None None O
in None None O
situ None None O
hybridization None None O
, None None O
in None None O
normal None None O
mucosa None None O
, None None O
benign None None O
adenomas None None O
, None None O
and None None O
primary None None O
colorectal None None O
adenocarcinomas None None O
and None None O
their None None O
liver None None O
metastases None None O
. None None O

The None None O
ST3 None None O
and None None O
BM None None O
- None None O
40 None None O
/ None None O
SPARC None None O
transcripts None None O
were None None O
overexpressed None None O
in None None O
primary None None O
colorectal None None O
cancers None None O
and None None O
their None None O
liver None None O
metastases None None O
compared None None O
to None None O
non None None O
- None None O
neoplastic None None O
mucosa None None O
. None None O

These None None O
transcripts None None O
were None None O
localized None None O
in None None O
stromal None None O
fibroblasts None None O
adjacent None None O
to None None O
the None None O
neoplastic None None O
foci None None O
. None None O

Overexpression None None O
of None None O
ST3 None None O
correlated None None O
with None None O
the None None O
progression None None O
of None None O
human None None O
colorectal None None O
tumors None None O
toward None None O
local None None O
invasion None None O
and None None O
liver None None O
metastasis None None O
. None None O

Induction None None O
of None None O
these None None O
genes None None O
also None None O
occurred None None O
in None None O
diverticulitis None None O
and None None O
digestive None None O
neoplasms None None O
such None None O
as None None O
gastric None None O
and None None O
esophageal None None O
carcinomas None None O
. None None O

Differential None None O
expression None None O
of None None O
drug None None O
- None None O
induced None None O
drug None None O
targets None None O

Integrating None None O
4849 None None O
CMap None None O
arrays None None O
with None None O
40 None None O
, None None O
656 None None O
drug None None O
target None None O
relations None None O
from None None O
STITCH None None O
resulted None None O
in None None O
a None None O
set None None O
of None None O
1 None None O
, None None O
290 None None O
drug None None O
- None None O
target None None O
relations None None O
for None None O
which None None O
a None None O
genome None None O
- None None O
wide None None O
cellular None None O
response None None O
is None None O
available None None O
. None None O

We None None O
found None None O
that None None O
thirteen None None O
out None None O
of None None O
167 None None O
distinct None None O
drug None None O
targets None None O
in None None O
this None None O
set None None O
( None None O
8 None None O
% None None O
; None None O
86 None None O
drug None None O
target None None O
relations None None O
) None None O
are None None O
subjected None None O
to None None O
significant None None O
differential None None O
expression None None O
upon None None O
drug None None O
treatment None None O
( None None O
Figure None None O
3 None None O
) None None O
by None None O
comparing None None O
the None None O
drug None None O
- None None O
induced None None O
expression None None O
changes None None O
of None None O
the None None O
drug None None O
target None None O
against None None O
all None None O
other None None O
treatments None None O
present None None O
in None None O
CMap None None O
( None None O
see None None O
methods None None O
) None None O
. None None O

We None None O
found None None O
supporting None None O
evidence None None O
in None None O
the None None O
literature None None O
for None None O
seven None None O
out None None O
of None None O
thirteen None None O
( None None O
q None None O
- None None O
value None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
significant None None O
differential None None O
regulations None None O
of None None O
drug None None O
targets None None O
shown None None O
in None None O
Figure None None O
3 None None O
, None None O
confirming None None O
the None None O
rationale None None O
and None None O
predictive None None O
power None None O
of None None O
our None None O
systematic None None O
approach None None O
. None None O

For None None O
the None None O
remaining None None O
six None None O
targets None None O
we None None O
can None None O
predict None None O
a None None O
hitherto None None O
unknown None None O
drug None None O
- None None O
induced None None O
differential None None O
regulation None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pcbi None None O
. None None O
1000925 None None O
. None None O
g003 None None O
Figure None None O
3 None None O

Drug None None O
- None None O
induced None None O
differentially None None O
regulated None None O
drug None None O
targets None None O
. None None O

Anova None None O
is None None O
used None None O
to None None O
assess None None O
the None None O
significance None None O
of None None O
the None None O
differential None None O
expression None None O
of None None O
drug None None O
- None None O
induced None None O
drug None None O
targets None None O
against None None O
the None None O
mRNA None None O
changes None None O
of None None O
the None None O
same None None O
gene None None O
in None None O
the None None O
population None None O
of None None O
heterogeneous None None O
drug None None O
treatments None None O
from None None O
CMap None None O
. None None O

The None None O
genes None None O
are None None O
mainly None None O
ordered None None O
based None None O
on None None O
their None None O
q None None O
- None None O
values None None O
as None None O
provided None None O
in None None O
Table None None O
S1 None None O
. None None O

In None None O
the None None O
scatter None None O
plots None None O
, None None O
inhibitors None None O
/ None None O
activators None None O
are None None O
labeled None None O
in None None O
red None None O
/ None None O
green None None O
respectively None None O
and None None O
grey None None O
represents None None O
all None None O
other None None O
treatments None None O
present None None O
in None None O
CMap None None O
. None None O

The None None O
identified None None O
, None None O
differentially None None O
regulated None None O
drug None None O
targets None None O
are None None O
enriched None None O
in None None O
G None None O
- None None O
protein None None O
coupled None None O
receptors None None O
( None None O
GPCRs None None O
) None None O
( None None O
Figure None None O
S4 None None O
) None None O
, None None O
in None None O
agreement None None O
with None None O
previous None None O
reports None None O
that None None O
members None None O
of None None O
the None None O
GPCR None None O
family None None O
are None None O
generally None None O
regulated None None O
by None None O
several None None O
mechanisms None None O
including None None O
receptor None None O
desensitization None None O
, None None O
endocytosis None None O
at None None O
the None None O
protein None None O
level None None O
and None None O
regulation None None O
of None None O
the None None O
cellular None None O
receptor None None O
content None None O
[ None None O
18 None None O
] None None O
, None None O
[ None None O
19 None None O
] None None O
. None None O

In None None O
the None None O
three None None O
cancer None None O
cell None None O
lines None None O
used None None O
, None None O
we None None O
observe None None O
agonist None None O
- None None O
induced None None O
down None None O
- None None O
regulation None None O
of None None O
GPCR None None O
mRNAs None None O
for None None O
beta None None O
- None None O
2 None None O
adrenergic None None O
receptor None None O
( None None O
ADRB2 None None O
) None None O
, None None O
prostaglandin None None O
E2 None None O
receptor None None O
subtype None None O
EP2 None None O
and None None O
prostaglandin None None O
E4 None None O
receptor None None O
subtype None None O
EP4 None None O
( None None O
Figure None None O
3 None None O
, None None O
Genes None None O
3 None None O
, None None O
4 None None O
, None None O
12 None None O
) None None O
, None None O
which None None O
were None None O
previously None None O
reported None None O
in None None O
DDT1 None None I-Cell-line-name
MF None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
smooth None None O
muscle None None O
cells None None O
( None None O
ADRB2 None None O
) None None O
and None None O
293 None None I-Cell-line-name
- None None I-Cell-line-name
EBNA None None I-Cell-line-name
human None None O
embryonic None None O
kidney None None O
cells None None O
( None None O
prostaglandin None None O
E2 None None O
/ None None O
E4 None None O
receptor None None O
subtypes None None O
EP2 None None O
/ None None O
EP4 None None O
) None None O
[ None None O
20 None None O
] None None O
, None None O
[ None None O
21 None None O
] None None O
. None None O

This None None O
indicates None None O
that None None O
drugs None None O
can None None O
induce None None O
similar None None O
feedback None None O
loops None None O
in None None O
a None None O
wide None None O
variety None None O
of None None O
cell None None O
types None None O
. None None O

However None None O
, None None O
we None None O
cannot None None O
rule None None O
out None None O
that None None O
cross None None O
- None None O
regulation None None O
among None None O
signaling None None O
pathways None None O
may None None O
be None None O
responsible None None O
for None None O
the None None O
regulation None None O
of None None O
GPCR None None O
mRNAs None None O
as None None O
it None None O
has None None O
been None None O
described None None O
before None None O
[ None None O
22 None None O
] None None O
. None None O

For None None O
example None None O
, None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
a None None O
beta None None O
adrenergic None None O
mRNA None None O
- None None O
binding None None O
protein None None O
, None None O
ELAV None None O
- None None O
like None None O
protein None None O
1 None None O
( None None O
ELAVL1 None None O
) None None O
can None None O
be None None O
induced None None O
by None None O
ADRB2 None None O
agonist None None O
or None None O
elevated None None O
levels None None O
of None None O
cyclic None None O
adenosine None None O
monophosphate None None O
( None None O
cAMP None None O
) None None O
[ None None O
22 None None O
] None None O
, None None O
[ None None O
23 None None O
] None None O
and None None O
destabilizes None None O
ADRB2 None None O
mRNA None None O
. None None O

The None None O
ELAVL1 None None O
protein None None O
binds None None O
to None None O
GPCR None None O
mRNAs None None O
and None None O
recognizes None None O
a None None O
cognate None None O
sequence None None O
located None None O
at None None O
the None None O
3 None None O
' None None O
- None None O
UTR None None O
of None None O
ADRB2 None None O
, None None O
proteinase None None O
- None None O
activated None None O
receptor None None O
and None None O
M2 None None O
, None None O
M3 None None O
muscarinic None None O
acetylcholine None None O
receptor None None O
mRNAs None None O
[ None None O
24 None None O
] None None O
, None None O
[ None None O
25 None None O
] None None O
. None None O

Therefore None None O
cAMP None None O
provides None None O
cross None None O
- None None O
talk None None O
among None None O
GPCR None None O
regulatory None None O
networks None None O
. None None O

However None None O
, None None O
it None None O
is None None O
shown None None O
that None None O
intracellular None None O
cAMP None None O
accumulation None None O
is None None O
not None None O
the None None O
only None None O
factor None None O
contributing None None O
to None None O
the None None O
reduction None None O
of None None O
ADRB2 None None O
mRNA None None O
levels None None O
[ None None O
20 None None O
] None None O
. None None O

Moreover None None O
, None None O
we None None O
find None None O
that None None O
GPCR None None O
- None None O
targeting None None O
drugs None None O
regulate None None O
the None None O
transcription None None O
of None None O
their None None O
specific None None O
targets None None O
( None None O
Figure None None O
S5 None None O
) None None O
. None None O

We None None O
conclude None None O
that None None O
in None None O
addition None None O
to None None O
the None None O
cross None None O
- None None O
regulation None None O
of None None O
G None None O
- None None O
protein None None O
signaling None None O
pathways None None O
drug None None O
target None None O
- None None O
specific None None O
feedback None None O
loops None None O
are None None O
also None None O
responsible None None O
for None None O
the None None O
regulation None None O
of None None O
drug None None O
target None None O
mRNAs None None O
. None None O

In None None O
addition None None O
to None None O
cross None None O
- None None O
regulation None None O
of None None O
multiple None None O
drugs None None O
through None None O
the None None O
same None None O
signaling None None O
pathways None None O
, None None O
promiscuous None None O
drugs None None O
targeting None None O
multiple None None O
proteins None None O
may None None O
cause None None O
complex None None O
regulatory None None O
networks None None O
. None None O

In None None O
order None None O
to None None O
explore None None O
the None None O
cross None None O
- None None O
regulation None None O
of None None O
drug None None O
targets None None O
induced None None O
by None None O
a None None O
promiscuous None None O
drug None None O
, None None O
we None None O
searched None None O
and None None O
found None None O
that None None O
259 None None O
out None None O
of None None O
466 None None O
total None None O
drugs None None O
are None None O
multi None None O
- None None O
target None None O
drugs None None O
and None None O
4 None None O
of None None O
these None None O
drugs None None O
act None None O
on None None O
multiple None None O
differentially None None O
regulated None None O
drug None None O
targets None None O
upon None None O
drug None None O
treatment None None O
. None None O

For None None O
example None None O
, None None O
Podophyllotoxin None None O
used None None O
in None None O
various None None O
chemotherapies None None O
is None None O
known None None O
to None None O
target None None O
both None None O
tubulin None None O
beta None None O
2C None None O
and None None O
DNA None None O
topoisomerase None None O
2 None None O
- None None O
alpha None None O
. None None O

The None None O
tubulin None None O
beta None None O
2C None None O
and None None O
DNA None None O
topoisomerase None None O
2 None None O
- None None O
alpha None None O
mRNAs None None O
are None None O
both None None O
down None None O
- None None O
regulated None None O
upon None None O
drug None None O
treatment None None O
in None None O
three None None O
cell None None O
lines None None O
( None None O
Figure None None O
3 None None O
, None None O
Genes None None O
8 None None O
, None None O
13 None None O
) None None O
. None None O

Tubulin None None O
beta None None O
2C None None O
inhibitors None None O
induce None None O
microtubule None None O
depolymerization None None O
that None None O
leads None None O
to None None O
the None None O
specific None None O
down None None O
- None None O
regulation None None O
of None None O
tubulin None None O
beta None None O
2C None None O
mRNAs None None O
preventing None None O
the None None O
translational None None O
synthesis None None O
and None None O
thus None None O
the None None O
further None None O
accumulation None None O
of None None O
abundant None None O
tubulin None None O
monomers None None O
[ None None O
26 None None O
] None None O
. None None O

Moreover None None O
, None None O
we None None O
found None None O
that None None O
DNA None None O
topoisomerase None None O
2 None None O
- None None O
alpha None None O
mRNAs None None O
are None None O
not None None O
down None None O
- None None O
regulated None None O
upon None None O
treatment None None O
of None None O
other None None O
tubulin None None O
inhibitors None None O
( None None O
Figure None None O
S5 None None O
) None None O
. None None O

Therefore None None O
, None None O
we None None O
conclude None None O
that None None O
feedback None None O
loops None None O
of None None O
tubulin None None O
beta None None O
2C None None O
and None None O
DNA None None O
topoisomerase None None O
2 None None O
- None None O
alpha None None O
are None None O
not None None O
cross None None O
- None None O
regulated None None O
. None None O

Two None None O
other None None O
examples None None O
of None None O
multi None None O
- None None O
target None None O
drugs None None O
are None None O
vorinostat None None O
used None None O
for None None O
the None None O
treatment None None O
of None None O
cutaneous None None O
T None None O
cell None None O
lymphoma None None O
and None None O
trichostatin None None O
A None None O
that None None O
serves None None O
as None None O
an None None O
antifungal None None O
antibiotic None None O
. None None O

Vorinostat None None O
and None None O
trichostatin None None O
A None None O
are None None O
considered None None O
to None None O
be None None O
nonspecific None None O
histone None None O
deacetylase None None O
inhibitors None None O
. None None O

These None None O
drugs None None O
lead None None O
to None None O
the None None O
up None None O
- None None O
regulation None None O
of None None O
histone None None O
deacetylase None None O
3 None None O
( None None O
HDAC3 None None O
) None None O
and None None O
down None None O
- None None O
regulation None None O
of None None O
histone None None O
deacetylase None None O
7 None None O
( None None O
HDAC7 None None O
) None None O
( None None O
Figure None None O
3 None None O
, None None O
Genes None None O
1 None None O
, None None O
5 None None O
) None None O
. None None O

In None None O
this None None O
case None None O
it None None O
is None None O
unclear None None O
whether None None O
there None None O
is None None O
cross None None O
- None None O
regulation None None O
, None None O
although None None O
HDAC7 None None O
siRNA None None O
experiments None None O
failed None None O
to None None O
induce None None O
the None None O
up None None O
- None None O
regulation None None O
of None None O
HDAC3 None None O
mRNAs None None O
[ None None O
27 None None O
] None None O
, None None O
a None None O
result None None O
that None None O
is None None O
disfavoring None None O
the None None O
cross None None O
- None None O
regulation None None O
. None None O

While None None O
the None None O
above None None O
cases None None O
only None None O
confirm None None O
literature None None O
reports None None O
in None None O
other None None O
cell None None O
lines None None O
or None None O
tissues None None O
, None None O
we None None O
also None None O
identified None None O
new None None O
cases None None O
of None None O
drug None None O
- None None O
induced None None O
expression None None O
regulation None None O
of None None O
drug None None O
targets None None O
. None None O

The None None O
significant None None O
novel None None O
findings None None O
are None None O
the None None O
inhibitor None None O
- None None O
induced None None O
down None None O
- None None O
regulation None None O
of None None O
calmodulin None None O
1 None None O
, None None O
DNA None None O
topoisomerase None None O
2 None None O
- None None O
alpha None None O
and None None O
up None None O
- None None O
regulation None None O
of None None O
endoplasmin None None O
, None None O
lanosterol None None O
14 None None O
- None None O
alpha None None O
demethylase None None O
and None None O
cAMP None None O
- None None O
specific None None O
phosphodiesterase None None O
4D None None O
( None None O
Figure None None O
3 None None O
, None None O
Genes None None O
9 None None O
, None None O
8 None None O
, None None O
2 None None O
, None None O
7 None None O
, None None O
10 None None O
) None None O
. None None O

Lanosterol None None O
14 None None O
- None None O
alpha None None O
demethylase None None O
is None None O
actually None None O
an None None O
off None None O
- None None O
target None None O
of None None O
antifungal None None O
drugs None None O
that None None O
bind None None O
the None None O
mammalian None None O
version None None O
with None None O
lower None None O
affinity None None O
than None None O
the None None O
fungal None None O
lanosterol None None O
14 None None O
- None None O
alpha None None O
demethylase None None O
. None None O

Probably None None O
, None None O
the None None O
up None None O
- None None O
regulation None None O
of None None O
the None None O
mammalian None None O
lanosterol None None O
14 None None O
- None None O
alpha None None O
demethylase None None O
compensates None None O
for None None O
the None None O
undesired None None O
inhibition None None O
and None None O
modulates None None O
the None None O
adverse None None O
effects None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
we None None O
observed None None O
a None None O
feedback None None O
loop None None O
that None None O
accelerates None None O
the None None O
down None None O
regulation None None O
of None None O
calmodulin None None O
1 None None O
mRNA None None O
induced None None O
by None None O
calmodulin None None O
inhibitors None None O
. None None O

Calmodulin None None O
targeting None None O
drugs None None O
can None None O
provide None None O
a None None O
rapid None None O
and None None O
effective None None O
therapeutic None None O
effect None None O
, None None O
while None None O
at None None O
the None None O
same None None O
time None None O
small None None O
variations None None O
of None None O
drug None None O
concentrations None None O
can None None O
increase None None O
adverse None None O
effects None None O
. None None O

Therefore None None O
, None None O
it None None O
would None None O
be None None O
interesting None None O
to None None O
study None None O
further None None O
the None None O
functional None None O
effects None None O
upon None None O
target None None O
inhibition None None O
of None None O
lanosterol None None O
14 None None O
- None None O
alpha None None O
demethylase None None O
, None None O
endoplasmin None None O
and None None O
calmodulin None None O
1 None None O
to None None O
elucidate None None O
the None None O
roles None None O
of None None O
feedback None None O
loops None None O
in None None O
drug None None O
mode None None O
of None None O
action None None O
and None None O
adverse None None O
effects None None O
. None None O

Drug None None O
- None None O
induced None None O
target None None O
regulation None None O
might None None O
be None None O
implicated None None O
in None None O
tolerance None None O
development None None O
and None None O
thus None None O
identifying None None O
potential None None O
target None None O
regulation None None O
should None None O
be None None O
an None None O
integral None None O
part None None O
of None None O
drug None None O
discovery None None O
to None None O
prevent None None O
failures None None O
in None None O
later None None O
stages None None O
of None None O
clinical None None O
trials None None O
. None None O

For None None O
example None None O
, None None O
we None None O
have None None O
observed None None O
the None None O
inhibitor None None O
- None None O
induced None None O
up None None O
- None None O
regulation None None O
of None None O
ADRB2 None None O
and None None O
thymidylate None None O
synthetase None None O
( None None O
TYMS None None O
) None None O
( None None O
Figure None None O
3 None None O
, None None O
Genes None None O
3 None None O
, None None O
11 None None O
) None None O
[ None None O
28 None None O
] None None O
. None None O

TYMS None None O
is None None O
an None None O
essential None None O
enzyme None None O
for None None O
DNA None None O
replication None None O
/ None None O
repair None None O
and None None O
an None None O
important None None O
drug None None O
target None None O
in None None O
cancerous None None O
cells None None O
. None None O

Indeed None None O
, None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
inhibitor None None O
- None None O
induced None None O
TYMS None None O
over None None O
- None None O
expression None None O
obstructs None None O
the None None O
clinical None None O
efficiency None None O
by None None O
inducing None None O
tumor None None O
drug None None O
resistance None None O
[ None None O
29 None None O
] None None O
. None None O

In None None O
addition None None O
to None None O
over None None O
- None None O
expression None None O
, None None O
down None None O
- None None O
regulation None None O
of None None O
drug None None O
targets None None O
upon None None O
agonist None None O
treatment None None O
may None None O
also None None O
cause None None O
treatment None None O
tolerance None None O
as None None O
observed None None O
for None None O
ADRB2 None None O
long None None O
- None None O
acting None None O
agonist None None O
treatment None None O
. None None O

ADRB2 None None O
is None None O
a None None O
therapeutic None None O
target None None O
activated None None O
to None None O
treat None None O
the None None O
symptoms None None O
of None None O
asthma None None O
. None None O

We None None O
observe None None O
the None None O
agonist None None O
- None None O
induced None None O
up None None O
- None None O
regulation None None O
of None None O
ADRB2 None None O
and None None O
already None None O
in None None O
2005 None None O
, None None O
the None None O
FDA None None O
warned None None O
patients None None O
that None None O
ADRB2 None None O
might None None O
be None None O
down None None O
- None None O
regulated None None O
( None None O
desensitization None None O
) None None O
and None None O
be None None O
unresponsive None None O
for None None O
asthma None None O
treatment None None O
due None None O
to None None O
long None None O
- None None O
acting None None O
agonist None None O
exposure None None O
[ None None O
20 None None O
] None None O
, None None O
[ None None O
30 None None O
] None None O
. None None O

Thus None None O
, None None O
robustness None None O
in None None O
biological None None O
systems None None O
could None None O
prevent None None O
the None None O
applicability None None O
of None None O
the None None O
long None None O
- None None O
term None None O
treatments None None O
via None None O
positive None None O
/ None None O
negative None None O
feedback None None O
loops None None O
of None None O
the None None O
drug None None O
target None None O
affecting None None O
the None None O
clinical None None O
efficiency None None O
of None None O
drugs None None O
in None None O
trial None None O
and None None O
on None None O
the None None O
market None None O
. None None O

Drug None None O
- None None O
induced None None O
regulation None None O
of None None O
drug None None O
targets None None O
can None None O
thus None None O
be None None O
linked None None O
to None None O
tolerance None None O
development None None O
, None None O
which None None O
restricts None None O
the None None O
efficiency None None O
of None None O
clinical None None O
treatments None None O
where None None O
the None None O
drug None None O
concentration None None O
is None None O
limited None None O
to None None O
avoid None None O
an None None O
excess None None O
of None None O
adverse None None O
drug None None O
reactions None None O
. None None O

Taken None None O
together None None O
, None None O
we None None O
have None None O
identified None None O
drug None None O
- None None O
induced None None O
differential None None O
regulation None None O
of None None O
drug None None O
targets None None O
. None None O

Due None None O
to None None O
the None None O
limited None None O
signal None None O
to None None O
noise None None O
ratio None None O
in None None O
the None None O
data None None O
at None None O
hand None None O
, None None O
the None None O
identified None None O
8 None None O
% None None O
of None None O
all None None O
drug None None O
targets None None O
that None None O
show None None O
feedback None None O
loops None None O
has None None O
to None None O
be None None O
seen None None O
as None None O
a None None O
lower None None O
limit None None O
, None None O
i None None O
. None None O
e None None O
. None None O
target None None O
- None None O
regulation None None O
appears None None O
as None None O
a None None O
wide None None O
- None None O
spread None None O
biological None None O
phenomenon None None O
that None None O
has None None O
to None None O
be None None O
taken None None O
into None None O
account None None O
during None None O
drug None None O
development None None O
. None None O

Safety None None O
of None None O
verteporfin None None O
for None None O
treatment None None O
of None None O
subfoveal None None O
choroidal None None O
neovascular None None O
membranes None None O
associated None None O
with None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
. None None O

Photodynamic None None O
therapy None None O
( None None O
PDT None None O
) None None O
is None None O
a None None O
novel None None O
treatment None None O
entity None None O
that None None O
exploits None None O
the None None O
photophysical None None O
properties None None O
of None None O
various None None O
photosensitive None None O
chemical None None O
entities None None O
which None None O
, None None O
upon None None O
light None None O
activation None None O
, None None O
results None None O
in None None O
targeted None None O
photooxidation None None O
and None None O
subsequent None None O
tissue None None O
destruction None None O
. None None O

The None None O
antiangiogenic None None O
properties None None O
of None None O
PDT None None O
have None None O
been None None O
adapted None None O
for None None O
treatment None None O
of None None O
subfoveal None None O
choroidal None None O
neovascular None None O
membranes None None O
due None None O
to None None O
disease None None O
states None None O
such None None O
as None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
( None None O
AMD None None O
) None None O
. None None O

Historically None None O
, None None O
PDT None None O
has None None O
been None None O
limited None None O
by None None O
a None None O
lack None None O
of None None O
suitable None None O
photosensitive None None O
dyes None None O
. None None O

However None None O
, None None O
agents None None O
such None None O
as None None O
verteporfin None None O
, None None O
a None None O
second None None O
- None None O
generation None None O
benzoporphyrin None None O
derivative None None O
, None None O
appear None None O
to None None O
be None None O
free None None O
from None None O
the None None O
extensive None None O
phototoxicity None None O
that None None O
limited None None O
the None None O
success None None O
of None None O
previous None None O
agents None None O
. None None O

Verteporfin None None O
has None None O
a None None O
high None None O
affinity None None O
for None None O
choroidal None None O
neovascular None None O
membranes None None O
, None None O
typically None None O
found None None O
with None None O
exudative None None O
AMD None None O
, None None O
and None None O
upon None None O
photoactivation None None O
results None None O
in None None O
targeted None None O
microvascular None None O
damage None None O
and None None O
thrombus None None O
formation None None O
with None None O
resultant None None O
vessel None None O
occlusion None None O
. None None O

Scrutiny None None O
of None None O
diagnostic None None O
indicators None None O
for None None O
verteporfin None None O
administration None None O
, None None O
including None None O
critical None None O
angiographic None None O
evaluation None None O
of None None O
lesion None None O
size None None O
and None None O
visual None None O
acuity None None O
, None None O
is None None O
essential None None O
to None None O
treatment None None O
success None None O
. None None O

Large None None O
lesions None None O
with None None O
relatively None None O
good None None O
visual None None O
acuity None None O
( None None O
20 None None O
/ None None O
50 None None O
or None None O
better None None O
) None None O
may None None O
be None None O
at None None O
particular None None O
risk None None O
for None None O
marked None None O
vision None None O
loss None None O
following None None O
verteporfin None None O
administration None None O
. None None O

Lesion None None O
composition None None O
also None None O
appears None None O
to None None O
influence None None O
visual None None O
outcome None None O
with None None O
verteporfin None None O
use None None O
. None None O

The None None O
safety None None O
of None None O
verteporfin None None O
is None None O
directly None None O
dependent None None O
upon None None O
the None None O
appropriate None None O
integration None None O
of None None O
dosage None None O
, None None O
infusion None None O
and None None O
light None None O
activation None None O
required None None O
for None None O
a None None O
suitable None None O
pharmacotherapeutic None None O
outcome None None O
. None None O

When None None O
used None None O
appropriately None None O
, None None O
and None None O
with None None O
adequate None None O
patient None None O
education None None O
regarding None None O
photosensitivity None None O
, None None O
the None None O
risk None None O
- None None O
benefit None None O
of None None O
verteporfin None None O
for None None O
the None None O
medical None None O
treatment None None O
of None None O
neovascular None None O
AMD None None O
is None None O
favourable None None O
. None None O

Molecular None None O
mediators None None O
of None None O
interactions None None O
with None None O
extracellular None None O
matrix None None O
components None None O
in None None O
metastasis None None O
and None None O
angiogenesis None None O
. None None O

Metastasis None None O
and None None O
tumor None None O
angiogenesis None None O
are None None O
invasive None None O
phenomena None None O
and None None O
share None None O
many None None O
common None None O
properties None None O
at None None O
the None None O
physiological None None O
level None None O
and None None O
some None None O
similarities None None O
at None None O
the None None O
molecular None None O
level None None O
. None None O

Each None None O
consists None None O
of None None O
repetitive None None O
cycles None None O
of None None O
interaction None None O
with None None O
adjacent None None O
extracellular None None O
matrix None None O
components None None O
by None None O
mediating None None O
cellular None None O
adhesion None None O
, None None O
matrix None None O
dissolution None None O
, None None O
and None None O
cellular None None O
motility None None O
to None None O
achieve None None O
metastasis None None O
of None None O
cancer None None O
cells None None O
or None None O
neovascularization None None O
of None None O
tumors None None O
. None None O

Molecular None None O
factors None None O
which None None O
implement None None O
this None None O
triad None None O
of None None O
events None None O
are None None O
reviewed None None O
, None None O
as None None O
are None None O
several None None O
signal None None O
transduction None None O
components None None O
which None None O
may None None O
regulate None None O
them None None O
. None None O

Some None None O
potentially None None O
promising None None O
prognostic None None O
, None None O
diagnostic None None O
, None None O
and None None O
therapeutic None None O
modalities None None O
for None None O
tumor None None O
angiogenesis None None O
and None None O
metastatic None None O
disease None None O
are None None O
also None None O
discussed None None O
. None None O

Cognitive None None O
function None None O
and None None O
number None None O
of None None O
teeth None None O
in None None O
a None None O
community None None O
- None None O
dwelling None None O
elderly None None O
population None None O
without None None O
dementia None None O
. None None O

Although None None O
the None None O
number None None O
of None None O
sound None None O
or None None O
decayed None None O
teeth None None O
has None None O
been None None O
reported None None O
to None None O
be None None O
associated None None O
with None None O
cognitive None None O
function None None O
in None None O
elderly None None O
populations None None O
with None None O
dementia None None O
, None None O
little None None O
is None None O
known None None O
about None None O
this None None O
association None None O
in None None O
elderly None None O
populations None None O
without None None O
dementia None None O
. None None O

We None None O
evaluated None None O
this None None O
relationship None None O
, None None O
with None None O
adjustment None None O
for None None O
confounding None None O
factors None None O
, None None O
in None None O
Japanese None None O
populations None None O
of None None O
60 None None O
- None None O
year None None O
- None None O
old None None O
( None None O
n None None O
= None None O
270 None None O
; None None O
120 None None O
males None None O
and None None O
150 None None O
females None None O
) None None O
and None None O
65 None None O
- None None O
year None None O
- None None O
old None None O
( None None O
n None None O
= None None O
123 None None O
; None None O
57 None None O
males None None O
and None None O
66 None None O
females None None O
) None None O
individuals None None O
residing None None O
in None None O
Fukuoka None None O
Prefecture None None O
of None None O
Japan None None O
. None None O

Dental None None O
examinations None None O
were None None O
performed None None O
in None None O
all None None O
subjects None None O
, None None O
along None None O
with None None O
the None None O
Mini None None O
- None None O
mental None None O
state None None O
examination None None O
( None None O
MMSE None None O
) None None O
for None None O
assessing None None O
cognitive None None O
function None None O
. None None O

Among None None O
the None None O
total None None O
of None None O
393 None None O
subjects None None O
, None None O
the None None O
mean None None O
MMSE None None O
score None None O
was None None O
27 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
, None None O
and None None O
391 None None O
subjects None None O
scored None None O
24 None None O
or None None O
higher None None O
. None None O

The None None O
mean None None O
numbers None None O
of None None O
sound None None O
and None None O
decayed None None O
teeth None None O
were None None O
12 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
6 None None O
. None None O
3 None None O
and None None O
0 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
2 None None O
, None None O
respectively None None O
. None None O

Associations None None O
were None None O
found None None O
between None None O
the None None O
numbers None None O
of None None O
sound None None O
and None None O
decayed None None O
teeth None None O
and None None O
MMSE None None O
in None None O
total None None O
subjects None None O
and None None O
males None None O
, None None O
but None None O
not None None O
in None None O
females None None O
, None None O
by None None O
multiple None None O
regression None None O
analysis None None O
adjusted None None O
for None None O
gender None None O
, None None O
age None None O
, None None O
level None None O
of None None O
education None None O
, None None O
marital None None O
status None None O
, None None O
smoking None None O
, None None O
alcohol None None O
drinking None None O
, None None O
working None None O
status None None O
, None None O
systolic None None O
blood None None O
pressure None None O
and None None O
blood None None O
glucose None None O
. None None O

An None None O
association None None O
was None None O
also None None O
found None None O
between None None O
MMSE None None O
and None None O
the None None O
number None None O
of None None O
sound None None O
teeth None None O
in None None O
a None None O
logistic None None O
regression None None O
analysis None None O
. None None O

In None None O
conclusion None None O
, None None O
associations None None O
were None None O
found None None O
between None None O
normal None None O
- None None O
range None None O
cognitive None None O
function None None O
and None None O
the None None O
numbers None None O
of None None O
sound None None O
and None None O
decayed None None O
teeth None None O
, None None O
after None None O
adjustment None None O
for None None O
various None None O
confounding None None O
factors None None O
, None None O
in None None O
an None None O
elderly None None O
Japanese None None O
population None None O
. None None O

Stochastic None None O
models None None O

Stochasticity None None O
inevitably None None O
emerges None None O
when None None O
molecular None None O
components None None O
are None None O
present None None O
at None None O
low None None O
cellular None None O
concentrations None None O
( None None O
McAdams None None O
& None None O
Arkin None None O
, None None O
1997 None None O
; None None O
Kierzek None None O
et None None O
al None None O
. None None O
, None None O
2001 None None O
) None None O
. None None O

This None None O
physical None None O
phenomenon None None O
generates None None O
noise None None O
in None None O
synthetic None None O
and None None O
natural None None O
circuits None None O
( None None O
Paulsson None None O
, None None O
2004 None None O
; None None O
Mettetal None None O
et None None O
al None None O
. None None O
, None None O
2006 None None O
) None None O
, None None O
and None None O
its None None O
consequences None None O
over None None O
the None None O
phenotype None None O
are None None O
starting None None O
to None None O
be None None O
explored None None O
( None None O
Suel None None O
et None None O
al None None O
. None None O
, None None O
2006 None None O
) None None O
. None None O

For None None O
example None None O
, None None O
noise None None O
constitutes None None O
the None None O
driving None None O
force None None O
behind None None O
differentiation None None O
in None None O
isogenetic None None O
colonies None None O
( None None O
Colman None None O
- None None O
Lerner None None O
et None None O
al None None O
. None None O
, None None O
2005 None None O
) None None O
. None None O

Biological None None O
and None None O
theoretical None None O
studies None None O
have None None O
aided None None O
to None None O
delineate None None O
the None None O
regulatory None None O
mechanism None None O
by None None O
which None None O
the None None O
cell None None O
handles None None O
noise None None O
efficiently None None O
and None None O
effectively None None O
to None None O
carry None None O
out None None O
its None None O
biological None None O
functions None None O
( None None O
Gardner None None O
& None None O
Collins None None O
, None None O
2000 None None O
; None None O
Orrell None None O
& None None O
Bolouri None None O
, None None O
2004 None None O
; None None O
Raser None None O
& None None O
O None None O
' None None O
Shea None None O
, None None O
2005 None None O
) None None O
. None None O

From None None O
a None None O
theoretical None None O
point None None O
of None None O
view None None O
, None None O
stochastic None None O
models None None O
are None None O
the None None O
most None None O
challenging None None O
but None None O
also None None O
the None None O
most None None O
realistic None None O
ones None None O
: None None O
there None None O
is None None O
a None None O
precise None None O
counting None None O
of None None O
how None None O
, None None O
through None None O
individual None None O
chemical None None O
reactions None None O
, None None O
the None None O
populations None None O
of None None O
every None None O
chemical None None O
species None None O
change None None O
. None None O

The None None O
milestone None None O
to None None O
simulate None None O
stochastic None None O
processes None None O
is None None O
the None None O
Gillespie None None O
algorithm None None O
( None None O
Gillespie None None O
, None None O
1992 None None O
) None None O
. None None O

Because None None O
of None None O
their None None O
analytical None None O
and None None O
computational None None O
complexity None None O
, None None O
the None None O
present None None O
models None None O
do None None O
not None None O
surpass None None O
a None None O
handful None None O
of None None O
chemical None None O
species None None O
. None None O

Two None None O
immediate None None O
problems None None O
must None None O
be None None O
solved None None O
to None None O
model None None O
systems None None O
with None None O
several None None O
dozens None None O
of None None O
genetic None None O
components None None O
: None None O
the None None O
systematic None None O
determination None None O
of None None O
kinetic None None O
constants None None O
and None None O
the None None O
efficient None None O
computation None None O
of None None O
thousands None None O
of None None O
chemical None None O
stochastic None None O
equations None None O
( None None O
Kuwahara None None O
et None None O
al None None O
. None None O
, None None O
2006 None None O
; None None O
Sanchez None None O
& None None O
Kondev None None O
, None None O
2008 None None O
) None None O
. None None O

[ None None O
Parotid None None O
gland None None O
' None None O
s None None O
tumors None None O
in None None O
children None None O
] None None O
. None None O

The None None O
tumors None None O
of None None O
the None None O
salivary None None O
glands None None O
are None None O
infrequent None None O
in None None O
children None None O
, None None O
and None None O
parotid None None O
gland None None O
is None None O
involved None None O
in None None O
80 None None O
% None None O
of None None O
them None None O
. None None O

When None None O
a None None O
salivary None None O
gland None None O
tumor None None O
is None None O
present None None O
, None None O
the None None O
chance None None O
of None None O
malignancy None None O
is None None O
greater None None O
in None None O
the None None O
child None None O
than None None O
in None None O
the None None O
adult None None O
. None None O

We None None O
reviewed None None O
8 None None O
cases None None O
identified None None O
in None None O
patients None None O
aged None None O
14 None None O
years None None O
and None None O
younger None None O
in None None O
our None None O
hospital None None O
, None None O
analyzing None None O
its None None O
antecedents None None O
, None None O
signs None None O
and None None O
symptoms None None O
, None None O
histological None None O
features None None O
, None None O
diagnosis None None O
, None None O
treatment None None O
and None None O
evolution None None O
. None None O

All None None O
the None None O
patients None None O
displayed None None O
preauricular None None O
painless None None O
, None None O
non None None O
- None None O
inflammatory None None O
and None None O
slow None None O
- None None O
growing None None O
masses None None O
to None None O
an None None O
age None None O
between None None O
10 None None O
months None None O
and None None O
14 None None O
years None None O
. None None O

Four None None O
or None None O
them None None O
were None None O
pleomorphic None None O
adenomas None None O
, None None O
two None None O
haemangiomas None None O
, None None O
one None None O
epidermal None None O
cysts None None O
and None None O
one None None O
myoepithelial None None O
carcinoma None None O
. None None O

We None None O
emphasize None None O
the None None O
exceptional None None O
nature None None O
of None None O
the None None O
carcinoma None None O
for None None O
its None None O
rareness None None O
and None None O
for None None O
the None None O
high None None O
degree None None O
of None None O
malignancy None None O
expressed None None O
. None None O

We None None O
made None None O
a None None O
fine None None O
needle None None O
aspiration None None O
biopsy None None O
in None None O
four None None O
cases None None O
but None None O
they None None O
were None None O
conclusive None None O
only None None O
in None None O
three None None O
. None None O

All None None O
were None None O
treated None None O
by None None O
surgical None None O
resection None None O
of None None O
the None None O
tumour None None O
except None None O
for None None O
the None None O
myoepithelial None None O
carcinoma None None O
and None None O
the None None O
recurrent None None O
pleomorphic None None O
adenoma None None O
that None None O
were None None O
treated None None O
by None None O
total None None O
parotidectomy None None O
. None None O

The None None O
malignant None None O
tumours None None O
of None None O
the None None O
parotid None None O
gland None None O
are None None O
clinically None None O
indistinguishable None None O
of None None O
the None None O
benign None None O
ones None None O
, None None O
thus None None O
when None None O
any None None O
palpable None None O
mass None None O
appears None None O
in None None O
the None None O
zone None None O
of None None O
the None None O
parotid None None O
gland None None O
, None None O
an None None O
accurate None None O
diagnosis None None O
should None None O
be None None O
made None None O
without None None O
delay None None O
. None None O

The None None O
treatment None None O
of None None O
choice None None O
is None None O
the None None O
surgical None None O
excision None None O
with None None O
wide None None O
margins None None O
, None None O
being None None O
other None None O
adjuvant None None O
treatments None None O
less None None O
useful None None O
to None None O
this None None O
age None None O
than None None O
in None None O
the None None O
adult None None O
age None None O
. None None O

Histopathological None None O
development None None O
of None None O
gastric None None O
tumors None None O
induced None None O
by None None O
N None None O
- None None O
methyl None None O
- None None O
N None None O
' None None O
- None None O
nitro None None O
- None None O
N None None O
- None None O
nitrosoguanidine None None O
in None None O
rats None None O
. None None O

The None None O
development None None O
of None None O
carcinoma None None O
was None None O
examined None None O
in None None O
male None None O
Wistar None None O
rats None None O
( None None O
n None None O
= None None O
120 None None O
) None None O
exposed None None O
to None None O
N None None O
- None None O
methyl None None O
- None None O
N None None O
' None None O
- None None O
nitro None None O
- None None O
N None None O
- None None O
nitrosoguanidine None None O
( None None O
MNNG None None O
) None None O
in None None O
the None None O
drinking None None O
water None None O
( None None O
83 None None O
micrograms None None O
/ None None O
ml None None O
) None None O
for None None O
16 None None O
weeks None None O
. None None O

After None None O
MNNG None None O
administration None None O
, None None O
rats None None O
were None None O
investigated None None O
by None None O
endoscopic None None O
observation None None O
, None None O
visualization None None O
of None None O
microvascular None None O
structure None None O
, None None O
and None None O
estimation None None O
of None None O
lectin None None O
binding None None O
sites None None O
. None None O

Changes None None O
of None None O
bile None None O
reflux None None O
to None None O
the None None O
stomach None None O
was None None O
observed None None O
endoscopically None None O
at None None O
24 None None O
weeks None None O
as None None O
well None None O
as None None O
the None None O
development None None O
of None None O
gastric None None O
mucosal None None O
erosions None None O
. None None O

Protruding None None O
and None None O
expansive None None O
ulcerating None None O
carcinomas None None O
developed None None O
at None None O
36 None None O
weeks None None O
and None None O
had None None O
a None None O
microvascular None None O
pattern None None O
similar None None O
to None None O
that None None O
of None None O
human None None O
adenocarcinoma None None O
. None None O

Estimation None None O
of None None O
lectin None None O
binding None None O
site None None O
and None None O
pattern None None O
was None None O
useful None None O
to None None O
evaluate None None O
the None None O
malignant None None O
potential None None O
of None None O
cell None None O
proliferation None None O
. None None O

We None None O
postulate None None O
that None None O
endoscopic None None O
observation None None O
is None None O
valuable None None O
in None None O
investigating None None O
the None None O
development None None O
of None None O
gastric None None O
carcinoma None None O
, None None O
and None None O
microvascular None None O
structure None None O
and None None O
lectin None None O
binding None None O
pattern None None O
may None None O
be None None O
useful None None O
to None None O
demonstrate None None O
the None None O
mechanism None None O
of None None O
growth None None O
of None None O
gastric None None O
carcinoma None None O
. None None O

Protein None None O
kinase None None O
activities None None O
in None None O
immune None None O
complexes None None O
of None None O
simian None None O
virus None None O
40 None None O
large None None O
T None None O
- None None O
antigen None None O
and None None O
transformation None None O
- None None O
associated None None O
cellular None None O
p53 None None O
protein None None O
. None None O

Immune None None O
complex None None O
kinase None None O
assays None None O
in None None O
the None None O
simian None None O
virus None None O
40 None None O
system None None O
were None None O
performed None None O
by None None O
incubation None None O
of None None O
immunoprecipitates None None O
containing None None O
tumor None None O
antigens None None O
with None None O
[ None None O
gamma None None O
- None None O
32P None None O
] None None O
ATP None None O
, None None O
followed None None O
by None None O
analysis None None O
of None None O
any None None O
phosphoacceptor None None O
proteins None None O
. None None O

These None None O
assays None None O
yielded None None O
mainly None None O
the None None O
viral None None O
large None None O
T None None O
- None None O
antigen None None O
and None None O
, None None O
in None None O
particular None None O
, None None O
the None None O
associated None None O
cellular None None O
p53 None None O
as None None O
endogenous None None O
substrates None None O
. None None O

The None None O
nature None None O
of None None O
these None None O
substrates None None O
was None None O
confirmed None None O
by None None O
proteolysis None None O
techniques None None O
. None None O

Under None None O
specific None None O
conditions None None O
, None None O
casein None None O
could None None O
be None None O
used None None O
as None None O
an None None O
exogenous None None O
substrate None None O
as None None O
well None None O
. None None O

The None None O
kinase None None O
reactions None None O
showed None None O
preference None None O
for None None O
ATP None None O
and None None O
MgCl2 None None O
instead None None O
of None None O
GTP None None O
or None None O
MnCl2 None None O
. None None O

Both None None O
phosphoserine None None O
and None None O
phosphothreonine None None O
, None None O
but None None O
in None None O
no None None O
case None None O
phosphotyrosine None None O
, None None O
were None None O
detected None None O
after None None O
an None None O
immune None None O
complex None None O
kinase None None O
reaction None None O
. None None O

Apparently None None O
, None None O
several None None O
in None None O
vivo None None O
phosphorylation None None O
sites None None O
were None None O
recognized None None O
in None None O
vitro None None O
in None None O
both None None O
large None None O
T None None O
- None None O
antigen None None O
and None None O
p53 None None O
, None None O
but None None O
the None None O
presence None None O
of None None O
some None None O
artifactual None None O
sites None None O
could None None O
not None None O
be None None O
completely None None O
excluded None None O
. None None O

Although None None O
contaminating None None O
kinases None None O
were None None O
detectable None None O
in None None O
the None None O
immune None None O
complexes None None O
, None None O
at None None O
least None None O
the None None O
p53 None None O
molecules None None O
were None None O
phosphorylated None None O
in None None O
vitro None None O
in None None O
a None None O
more None None O
specific None None O
way None None O
. None None O

This None None O
followed None None O
from None None O
several None None O
characteristics None None O
of None None O
the None None O
immune None None O
complex None None O
kinase None None O
reactions None None O
and None None O
especially None None O
from None None O
the None None O
strong None None O
inhibition None None O
of None None O
p53 None None O
phosphorylation None None O
by None None O
two None None O
anti None None O
- None None O
large None None O
- None None O
T None None O
monoclonal None None O
antibodies None None O
. None None O

It None None O
was None None O
shown None None O
that None None O
large None None O
T None None O
- None None O
antigen None None O
showed None None O
associated None None O
kinase None None O
activity None None O
, None None O
although None None O
none None None O
of None None O
our None None O
results None None O
could None None O
unambiguously None None O
demonstrate None None O
an None None O
intrinsic None None O
kinase None None O
activity None None O
of None None O
this None None O
protein None None O
. None None O

Finally None None O
, None None O
anti None None O
- None None O
p53 None None O
monoclonal None None O
antibodies None None O
only None None O
slightly None None O
affected None None O
in None None O
vitro None None O
phosphorylation None None O
reactions None None O
, None None O
whereas None None O
a None None O
p53 None None O
molecule None None O
from None None O
a None None O
simian None None O
virus None None O
40 None None O
- None None O
free None None O
, None None O
chemically None None O
transformed None None O
human None None O
cell None None O
line None None O
was None None O
not None None O
phosphorylated None None O
in None None O
vitro None None O
under None None O
any None None O
condition None None O
tested None None O
. None None O

Thus None None O
, None None O
it None None O
is None None O
highly None None O
unlikely None None O
that None None O
the None None O
p53 None None O
molecule None None O
per None None O
se None None O
carries None None O
intrinsic None None O
or None None O
even None None O
associated None None O
kinase None None O
activities None None O
. None None O

Cigarette None None O
smoking None None O
and None None O
alveolar None None O
bone None None O
height None None O
in None None O
subjects None None O
with None None O
a None None O
high None None O
standard None None O
of None None O
oral None None O
hygiene None None O
. None None O

Smokers None None O
and None None O
non None None O
- None None O
smokers None None O
were None None O
compared None None O
with None None O
respect None None O
to None None O
alveolar None None O
bone None None O
height None None O
. None None O

The None None O
study None None O
covered None None O
235 None None O
subjects None None O
aged None None O
21 None None O
- None None O
60 None None O
years None None O
, None None O
72 None None O
of None None O
whom None None O
were None None O
smokers None None O
. None None O

Oral None None O
hygiene None None O
status None None O
and None None O
dental None None O
care None None O
habits None None O
were None None O
above None None O
average None None O
and None None O
of None None O
equal None None O
standard None None O
in None None O
both None None O
groups None None O
( None None O
PlI None None O
= None None O
0 None None O
. None None O
9 None None O
) None None O
. None None O

Alveolar None None O
bone None None O
height None None O
was None None O
assessed None None O
on None None O
radiographs None None O
and None None O
expressed None None O
as None None O
% None None O
of None None O
the None None O
root None None O
length None None O
. None None O

Alveolar None None O
bone None None O
height None None O
was None None O
significantly None None O
reduced None None O
in None None O
smokers None None O
as None None O
compared None None O
to None None O
non None None O
- None None O
smokers None None O
, None None O
the None None O
mean None None O
+ None None O
/ None None O
- None None O
SEM None None O
being None None O
77 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
3 None None O
% None None O
and None None O
82 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
6 None None O
% None None O
, None None O
respectively None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Regression None None O
analysis None None O
suggested None None O
that None None O
periodontal None None O
breakdown None None O
judged None None O
from None None O
loss None None O
of None None O
alveolar None None O
bone None None O
over None None O
time None None O
was None None O
more None None O
accelerated None None O
in None None O
smokers None None O
than None None O
non None None O
- None None O
smokers None None O
. None None O

The None None O
lower None None O
bone None None O
height None None O
in None None O
smokers None None O
remained None None O
when None None O
age None None O
and None None O
oral None None O
hygiene None None O
were None None O
allowed None None O
for None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
smoking None None O
is None None O
a None None O
risk None None O
factor None None O
for None None O
periodontal None None O
health None None O
. None None O

Results None None O

High None None O
density None None O
of None None O
somatostatin None None O
receptors None None O
in None None O
veins None None O
surrounding None None O
human None None O
cancer None None O
tissue None None O
: None None O
role None None O
in None None O
tumor None None O
- None None O
host None None O
interaction None None O
? None None O

Somatostatin None None O
receptors None None O
were None None O
detected None None O
in None None O
peritumoral None None O
veins None None O
of None None O
various None None O
human None None O
cancer None None O
tissue None None O
specimens None None O
. None None O

Vascular None None O
and None None O
neoplastic None None O
tissue None None O
from None None O
14 None None O
colonic None None O
adenocarcinomas None None O
, None None O
13 None None O
carcinoids None None O
, None None O
6 None None O
renal None None O
- None None O
cell None None O
carcinomas None None O
and None None O
7 None None O
malignant None None O
lymphomas None None O
were None None O
analyzed None None O
for None None O
somatostatin None None O
receptors None None O
by None None O
use None None O
of None None O
quantitative None None O
receptor None None O
autoradiography None None O
. None None O

In None None O
colonic None None O
carcinoma None None O
specimens None None O
, None None O
the None None O
peritumoral None None O
vessels None None O
expressed None None O
a None None O
high None None O
density None None O
of None None O
somatostatin None None O
receptors None None O
, None None O
whereas None None O
the None None O
neoplastic None None O
tissue None None O
itself None None O
was None None O
receptor None None O
- None None O
negative None None O
in None None O
many None None O
cases None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
incidence None None O
and None None O
density None None O
of None None O
somatostatin None None O
receptors None None O
in None None O
peritumoral None None O
vessels None None O
was None None O
low None None O
in None None O
well None None O
- None None O
differentiated None None O
gastrointestinal None None O
and None None O
bronchial None None O
carcinoids None None O
, None None O
in None None O
contrast None None O
to None None O
the None None O
high None None O
density None None O
of None None O
such None None O
receptors None None O
in None None O
the None None O
carcinoid None None O
tumor None None O
tissue None None O
. None None O

Autochthonous None None O
vessels None None O
surrounding None None O
other None None O
tumors None None O
such None None O
as None None O
renal None None O
- None None O
cell None None O
carcinomas None None O
or None None O
malignant None None O
lymphomas None None O
also None None O
frequently None None O
expressed None None O
somatostatin None None O
receptors None None O
. None None O

In None None O
all None None O
cases None None O
, None None O
the None None O
somatostatin None None O
receptors None None O
were None None O
localized None None O
in None None O
veins None None O
, None None O
particularly None None O
in None None O
the None None O
smooth None None O
- None None O
muscle None None O
cell None None O
layer None None O
. None None O

They None None O
exhibited None None O
specific None None O
and None None O
high None None O
- None None O
affinity None None O
binding None None O
of None None O
somatostatin None None O
- None None O
14 None None O
, None None O
somatostatin None None O
- None None O
28 None None O
and None None O
octreotide None None O
, None None O
suggesting None None O
a None None O
preferential None None O
expression None None O
of None None O
the None None O
SSTR2 None None O
receptor None None O
subtype None None O
. None None O

Since None None O
the None None O
vessels None None O
of None None O
normal None None O
non None None O
- None None O
neoplastic None None O
human None None O
tissues None None O
, None None O
e None None O
. None None O
g None None O
. None None O
of None None O
intestine None None O
or None None O
lymphatic None None O
organs None None O
, None None O
have None None O
few None None O
somatostatin None None O
receptors None None O
, None None O
the None None O
increased None None O
somatostatin None None O
receptor None None O
expression None None O
in None None O
peritumoral None None O
vessels None None O
observed None None O
in None None O
this None None O
study None None O
may None None O
be None None O
linked None None O
to None None O
the None None O
neoplastic None None O
process None None O
itself None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
somatostatin None None O
and None None O
somatostatin None None O
receptors None None O
may None None O
play None None O
a None None O
regulatory None None O
role None None O
for None None O
hemodynamic None None O
tumor None None O
- None None O
host None None O
interactions None None O
, None None O
possibly None None O
involving None None O
tumor None None O
stroma None None O
generation None None O
, None None O
tumor None None O
environment None None O
, None None O
angiogenesis None None O
and None None O
, None None O
particularly None None O
, None None O
vascular None None O
drainage None None O
of None None O
poorly None None O
differentiated None None O
neoplasms None None O
. None None O

Amplification None None O
of None None O
mineralocorticoid None None O
activity None None O
of None None O
aldosterone None None O
by None None O
18 None None O
- None None O
hydroxy None None O
- None None O
corticosterone None None O
and None None O
18 None None O
- None None O
hydroxy None None O
- None None O
19 None None O
- None None O
nor None None O
- None None O
corticosterone None None O
in None None O
adrenalectomized None None O
rats None None O
. None None O

A None None O
combination None None O
of None None O
aldosterone None None O
( None None O
1 None None O
micrograms None None O
) None None O
with None None O
either None None O
18 None None O
- None None O
OH None None O
- None None O
corticosterone None None O
( None None O
1 None None O
micrograms None None O
) None None O
or None None O
18 None None O
- None None O
OH None None O
- None None O
19 None None O
- None None O
norcorticosterone None None O
( None None O
1 None None O
micrograms None None O
) None None O
injected None None O
to None None O
adrenalectomized None None O
rats None None O
indicated None None O
an None None O
amplification None None O
of None None O
mineralocorticoid None None O
activity None None O
as None None O
expressed None None O
by None None O
Na None None O
/ None None O
K None None O
ratio None None O
in None None O
urine None None O
. None None O

Without None None O
aldosterone None None O
their None None O
mineralocorticoid None None O
potency None None O
was None None O
negligible None None O
. None None O

Combined None None O
aortic None None O
, None None O
mitral None None O
and None None O
tricuspid None None O
surgery None None O
: None None O
results None None O
in None None O
78 None None O
patients None None O
. None None O

Between None None O
1968 None None O
and None None O
1984 None None O
, None None O
78 None None O
patients None None O
( None None O
mean None None O
age None None O
43 None None O
, None None O
range None None O
14 None None O
to None None O
65 None None O
years None None O
) None None O
underwent None None O
combined None None O
aortic None None O
, None None O
mitral None None O
and None None O
tricuspid None None O
surgery None None O
( None None O
22 None None O
triple None None O
valve None None O
replacements None None O
, None None O
56 None None O
aortic None None O
valve None None O
replacements None None O
with None None O
tricuspid None None O
conservative None None O
surgery None None O
and None None O
mitral None None O
valve None None O
replacement None None O
( None None O
N None None O
= None None O
48 None None O
) None None O
, None None O
or None None O
commissuroplasty None None O
( None None O
N None None O
= None None O
8 None None O
) None None O
. None None O

Pre None None O
- None None O
operative None None O
consequences None None O
of None None O
valvular None None O
disease None None O
( None None O
mainly None None O
mixed None None O
valve None None O
disease None None O
) None None O
were None None O
severe None None O
as None None O
assessed None None O
by None None O
functional None None O
class None None O
( None None O
72 None None O
pts None None O
in None None O
III None None O
or None None O
IV None None O
NYHA None None O
) None None O
, None None O
cardiomegaly None None O
( None None O
CTR None None O
: None None O
62 None None O
+ None None O
/ None None O
- None None O
6 None None O
% None None O
) None None O
, None None O
increase None None O
of None None O
mean None None O
pulmonary None None O
arterial None None O
and None None O
wedge None None O
pressures None None O
( None None O
respectively None None O
30 None None O
+ None None O
/ None None O
- None None O
12 None None O
and None None O
19 None None O
+ None None O
/ None None O
- None None O
6 None None O
mmHg None None O
) None None O
decrease None None O
in None None O
cardiac None None O
index None None O
( None None O
2 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
5 None None O
l None None O
min None None O
- None None O
1 None None O
m None None O
- None None O
2 None None O
) None None O
, None None O
LV None None O
dilatation None None O
( None None O
LV None None O
end None None O
diastolic None None O
volume None None O
: None None O
184 None None O
+ None None O
/ None None O
- None None O
86 None None O
ml None None O
m None None O
- None None O
2 None None O
) None None O
and None None O
impairment None None O
of None None O
LV None None O
systolic None None O
function None None O
( None None O
LV None None O
ejection None None O
fraction None None O
: None None O
50 None None O
+ None None O
/ None None O
- None None O
12 None None O
% None None O
) None None O
. None None O

Operative None None O
mortality None None O
rate None None O
was None None O
11 None None O
. None None O
5 None None O
% None None O
. None None O

The None None O
69 None None O
survivors None None O
were None None O
all None None O
followed None None O
up None None O
, None None O
for None None O
a None None O
mean None None O
of None None O
56 None None O
months None None O
( None None O
2 None None O
to None None O
207 None None O
) None None O
. None None O

16 None None O
late None None O
deaths None None O
occurred None None O
. None None O

Actuarial None None O
survival None None O
rate None None O
at None None O
10 None None O
years None None O
was None None O
58 None None O
. None None O
4 None None O
% None None O
, None None O
and None None O
greatly None None O
influenced None None O
by None None O
pre None None O
- None None O
operative None None O
NYHA None None O
class None None O
. None None O

Linearized None None O
rates None None O
of None None O
thromboembolic None None O
events None None O
, None None O
valve None None O
thrombosis None None O
and None None O
haemorrhage None None O
were None None O
respectively None None O
6 None None O
. None None O
4 None None O
, None None O
1 None None O
. None None O
5 None None O
and None None O
1 None None O
. None None O
2 None None O
% None None O
pt None None O
- None None O
1 None None O
yr None None O
- None None O
1 None None O
. None None O

Those None None O
of None None O
infective None None O
endocarditis None None O
, None None O
periprosthetic None None O
leak None None O
, None None O
reoperation None None O
and None None O
valve None None O
failure None None O
were None None O
0 None None O
. None None O
6 None None O
, None None O
3 None None O
. None None O
3 None None O
and None None O
4 None None O
. None None O
9 None None O
% None None O
pt None None O
- None None O
1 None None O
yr None None O
- None None O
1 None None O
respectively None None O
. None None O

At None None O
9 None None O
years None None O
, None None O
42 None None O
% None None O
of None None O
the None None O
patients None None O
were None None O
in None None O
NYHA None None O
class None None O
I None None O
or None None O
II None None O
and None None O
free None None O
from None None O
complications None None O
. None None O

Metastatic None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
x None None O
LTA None None I-Cell-line-name
cell None None O
hybrids None None O
express None None O
72 None None O
kDa None None O
type None None O
IV None None O
collagenase None None O
. None None O

We None None O
previously None None O
reported None None O
that None None O
the None None O
murine None None O
fibroblast None None O
cell None None O
line None None O
LTA None None I-Cell-line-name
is None None O
tumorigenic None None O
but None None O
non None None O
- None None O
metastatic None None O
, None None O
and None None O
is None None O
non None None O
- None None O
responsive None None O
to None None O
a None None O
transfected None None O
H None None O
- None None O
ras None None O
oncogene None None O
. None None O

In None None O
contrast None None O
, None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
are None None O
non None None O
- None None O
tumorigenic None None O
but None None O
are None None O
ras None None O
- None None O
responsive None None O
and None None O
become None None O
metastatic None None O
when None None O
transfected None None O
with None None O
ras None None O
. None None O

Somatic None None O
cell None None O
hybrids None None O
between None None O
LTA None None I-Cell-line-name
and None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
are None None O
tumorigenic None None O
, None None O
metastatic None None O
and None None O
ras None None O
- None None O
responsive None None O
. None None O

Here None None O
we None None O
examined None None O
expression None None O
of None None O
type None None O
IV None None O
collagenases None None O
in None None O
parental None None O
LTA None None I-Cell-line-name
and None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
( None None O
with None None O
and None None O
without None None O
ras None None O
) None None O
and None None O
four None None O
metastatic None None O
LTA None None I-Cell-line-name
x None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
hybrids None None O
( None None O
also None None O
with None None O
and None None O
without None None O
ras None None O
) None None O
. None None O

Parental None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
- None None O
derived None None O
cells None None O
had None None O
both None None O
72 None None O
kDa None None O
and None None O
92 None None O
kDa None None O
gelatinase None None O
activities None None O
, None None O
and None None O
LTA None None I-Cell-line-name
- None None O
derived None None O
cells None None O
had None None O
either None None O
aberrantly None None O
sized None None O
approximately None None O
90 None None O
kDa None None O
activity None None O
alone None None O
or None None O
neither None None O
enzyme None None O
activity None None O
. None None O

All None None O
four None None O
metastatic None None O
hybrids None None O
expressed None None O
60 None None O
- None None O
72 None None O
kDa None None O
gelatinase None None O
activity None None O
, None None O
while None None O
three None None O
of None None O
them None None O
also None None O
had None None O
92 None None O
kDa None None O
activity None None O
and None None O
one None None O
had None None O
only None None O
minimal None None O
92 None None O
kDa None None O
activity None None O
. None None O

Thus None None O
the None None O
metastatic None None O
phenotype None None O
of None None O
the None None O
hybrids None None O
was None None O
associated None None O
with None None O
expression None None O
of None None O
72 None None O
kDa None None O
gelatinase None None O
. None None O

Levels None None O
of None None O
RNA None None O
for None None O
tissue None None O
inhibitors None None O
of None None O
metalloproteinases None None O
( None None O
TIMP None None O
- None None O
1 None None O
, None None O
TIMP None None O
- None None O
2 None None O
) None None O
were None None O
relatively None None O
constant None None O
, None None O
suggesting None None O
independent None None O
regulation None None O
of None None O
type None None O
IV None None O
collagenases None None O
and None None O
their None None O
inhibitors None None O
. None None O

Southern None None O
blotting None None O
and None None O
probing None None O
with None None O
PCR None None O
- None None O
synthesized None None O
cDNA None None O
fragments None None O
of None None O
the None None O
mouse None None O
72 None None O
kDa None None O
type None None O
IV None None O
collagenase None None O
gene None None O
showed None None O
that None None O
this None None O
gene None None O
was None None O
present None None O
in None None O
all None None O
cells None None O
although None None O
the None None O
structure None None O
of None None O
this None None O
gene None None O
in None None O
one None None O
of None None O
the None None O
three None None O
LTA None None I-Cell-line-name
cell None None O
lines None None O
differed None None O
from None None O
that None None O
of None None O
the None None O
other None None O
cells None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
a None None O
key None None O
change None None O
in None None O
the None None O
metastatic None None O
hybrids None None O
, None None O
relative None None O
to None None O
non None None O
- None None O
metastatic None None O
parental None None O
LTA None None I-Cell-line-name
cells None None O
, None None O
is None None O
induction None None O
of None None O
expression None None O
of None None O
72 None None O
kDa None None O
type None None O
IV None None O
collagenase None None O
. None None O

Multi None None O
- None None O
step None None O
neoplastic None None O
transformation None None O
of None None O
normal None None O
human None None O
fibroblasts None None O
by None None O
Co None None O
- None None O
60 None None O
gamma None None O
rays None None O
and None None O
Ha None None O
- None None O
ras None None O
oncogenes None None O
. None None O

As None None O
reported None None O
previously None None O
( None None O
Namba None None O
et None None O
al None None O
. None None O
, None None O
1985 None None O
; None None O
Namba None None O
, None None O
1985 None None O
) None None O
, None None O
normal None None O
human None None O
fibroblasts None None O
were None None O
transformed None None O
into None None O
immortal None None O
cells None None O
with None None O
abnormal None None O
karyotypes None None O
by None None O
Co None None O
- None None O
60 None None O
gamma None None O
- None None O
ray None None O
irradiation None None O
. None None O

These None None O
immortally None None O
transformed None None O
cells None None O
( None None O
KMST None None I-Cell-line-name
- None None I-Cell-line-name
6 None None I-Cell-line-name
) None None O
showed None None O
no None None O
clonability None None O
in None None O
soft None None O
agar None None O
and None None O
were None None O
not None None O
tumorigenic None None O
. None None O

However None None O
, None None O
by None None O
treatment None None O
with None None O
Ha None None O
- None None O
ras None None O
oncogenes None None O
derived None None O
from None None O
a None None O
human None None O
lung None None O
carcinoma None None O
or None None O
Harvey None None O
murine None None O
sarcoma None None O
virus None None O
, None None O
the None None O
KMST None None I-Cell-line-name
- None None I-Cell-line-name
6 None None I-Cell-line-name
cells None None O
acquired None None O
elevated None None O
clonability None None O
in None None O
soft None None O
agar None None O
and None None O
transplantability None None O
in None None O
nude None None O
mice None None O
. None None O

All None None O
the None None O
tumors None None O
produced None None O
grew None None O
progressively None None O
without None None O
showing None None O
regression None None O
and None None O
killed None None O
the None None O
mice None None O
. None None O

The None None O
tumors None None O
were None None O
also None None O
serially None None O
transplantable None None O
into None None O
other None None O
mice None None O
. None None O

The None None O
Ha None None O
- None None O
ras None None O
oncogene None None O
alone None None O
did None None O
not None None O
convert None None O
normal None None O
human None None O
fibroblasts None None O
into None None O
either None None O
immortal None None O
or None None O
tumorigenic None None O
cells None None O
. None None O

Our None None O
current None None O
data None None O
suggest None None O
that None None O
gamma None None O
rays None None O
worked None None O
as None None O
an None None O
initiator None None O
of None None O
carcinogenesis None None O
in None None O
normal None None O
human None None O
cells None None O
, None None O
giving None None O
rise None None O
to None None O
chromosome None None O
aberrations None None O
and None None O
immortality None None O
, None None O
and None None O
the None None O
Ha None None O
- None None O
ras None None O
oncogene None None O
played None None O
a None None O
role None None O
in None None O
the None None O
progression None None O
of None None O
the None None O
immortally None None O
transformed None None O
cell None None O
population None None O
to None None O
a None None O
neoplastic None None O
one None None O
showing None None O
enhanced None None O
colony None None O
formation None None O
in None None O
soft None None O
agar None None O
and None None O
tumorigenicity None None O
in None None O
nude None None O
mice None None O
. None None O

Syndecan None None O
- None None O
1 None None O
expression None None O
in None None O
mammary None None O
epithelial None None O
tumor None None O
cells None None O
is None None O
E None None O
- None None O
cadherin None None O
- None None O
dependent None None O
. None None O

E None None O
- None None O
cadherin None None O
is None None O
a None None O
Ca None None O
( None None O
2 None None O
+ None None O
) None None O
- None None O
dependent None None O
cell None None O
- None None O
cell None None O
adhesion None None O
molecule None None O
, None None O
which None None O
is None None O
mainly None None O
expressed None None O
in None None O
epithelial None None O
cells None None O
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
that None None O
E None None O
- None None O
cadherin None None O
has None None O
an None None O
important None None O
role None None O
as None None O
an None None O
invasion None None O
suppressor None None O
molecule None None O
in None None O
epithelial None None O
tumor None None O
cells None None O
. None None O

Syndecan None None O
- None None O
1 None None O
is None None O
a None None O
cell None None O
surface None None O
proteoglycan None None O
that None None O
has None None O
been None None O
implicated None None O
in None None O
a None None O
number None None O
of None None O
cellular None None O
functions None None O
including None None O
cell None None O
- None None O
cell None None O
adhesion None None O
, None None O
cell None None O
- None None O
matrix None None O
anchorage None None O
and None None O
growth None None O
factor None None O
presentation None None O
for None None O
signalling None None O
receptors None None O
. None None O

Its None None O
suppression None None O
has None None O
also None None O
been None None O
shown None None O
to None None O
be None None O
associated None None O
with None None O
malignant None None O
transformation None None O
of None None O
epithelial None None O
cells None None O
. None None O

In None None O
order None None O
to None None O
better None None O
understand None None O
the None None O
coordinated None None O
regulation None None O
of None None O
cell None None O
- None None O
cell None None O
and None None O
cell None None O
- None None O
matrix None None O
interactions None None O
during None None O
malignant None None O
transformation None None O
, None None O
we None None O
have None None O
studied None None O
the None None O
expression None None O
of None None O
syndecan None None O
- None None O
1 None None O
in None None O
malignant None None O
mammary None None O
tumor None None O
cells None None O
genetically None None O
manipulated None None O
for None None O
E None None O
- None None O
cadherin None None O
expression None None O
. None None O

In None None O
invasive None None O
NM None None I-Cell-line-name
- None None I-Cell-line-name
e None None I-Cell-line-name
- None None O
ras None None O
- None None O
MAC1 None None O
cells None None O
, None None O
where None None O
E None None O
- None None O
cadherin None None O
was None None O
partially None None O
downregulated None None O
by None None O
specific None None O
antisense None None O
RNA None None O
, None None O
syndecan None None O
- None None O
1 None None O
expression None None O
was None None O
suppressed None None O
. None None O

Furthermore None None O
, None None O
transfection None None O
of None None O
E None None O
- None None O
cadherin None None O
cDNA None None O
into None None O
invasive None None O
NM None None I-Cell-line-name
- None None I-Cell-line-name
f None None I-Cell-line-name
- None None O
ras None None O
- None None O
TD None None O
cells None None O
resulted None None O
in None None O
the None None O
upregulation None None O
of None None O
syndecan None None O
- None None O
1 None None O
expression None None O
in None None O
association None None O
with None None O
decreased None None O
invasiveness None None O
. None None O

In None None O
both None None O
cases None None O
, None None O
regulation None None O
of None None O
syndecan None None O
- None None O
1 None None O
occurred None None O
post None None O
- None None O
transcriptionally None None O
, None None O
since None None O
syndecan None None O
- None None O
1 None None O
mRNA None None O
levels None None O
remained None None O
unchanged None None O
. None None O

Instead None None O
, None None O
a None None O
translational None None O
regulation None None O
is None None O
suggested None None O
, None None O
since None None O
syndecan None None O
- None None O
1 None None O
core None None O
protein None None O
synthesis None None O
was None None O
E None None O
- None None O
cadherin None None O
dependent None None O
. None None O

Another None None O
cell None None O
adhesion None None O
protein None None O
, None None O
beta None None O
1 None None O
- None None O
integrin None None O
was None None O
not None None O
affected None None O
by None None O
E None None O
- None None O
cadherin None None O
expression None None O
. None None O

The None None O
data None None O
provide None None O
an None None O
example None None O
of None None O
coordinated None None O
changes None None O
in None None O
the None None O
expression None None O
of None None O
two None None O
cell None None O
adhesion None None O
molecules None None O
, None None O
syndecan None None O
- None None O
1 None None O
and None None O
E None None O
- None None O
cadherin None None O
during None None O
epithelial None None O
cell None None O
transformation None None O
. None None O

1 None None O
, None None O
4 None None O
- None None O
phenylenebis None None O
( None None O
methylene None None O
) None None O
selenocyanate None None O
, None None O
but None None O
not None None O
selenomethionine None None O
, None None O
inhibits None None O
androgen None None O
receptor None None O
and None None O
Akt None None O
signaling None None O
in None None O
human None None O
prostate None None O
cancer None None O
cells None None O
. None None O

The None None O
lack None None O
of None None O
treatment None None O
for None None O
worried None None O
- None None O
well None None O
patients None None O
with None None O
high None None O
- None None O
grade None None O
prostatic None None O
intraepithelial None None O
neoplasia None None O
combined None None O
with None None O
issues None None O
of None None O
recurrence None None O
and None None O
hormone None None O
resistance None None O
in None None O
prostate None None O
cancer None None O
survivors None None O
remains None None O
a None None O
major None None O
public None None O
health None None O
obstacle None None O
. None None O

The None None O
long None None O
latency None None O
of None None O
prostate None None O
cancer None None O
development None None O
provides None None O
an None None O
opportunity None None O
to None None O
intervene None None O
with None None O
agents None None O
of None None O
known None None O
mechanisms None None O
at None None O
various None None O
stages None None O
of None None O
disease None None O
progression None None O
. None None O

A None None O
number None None O
of None None O
signaling None None O
cascades None None O
have None None O
been None None O
shown None None O
to None None O
play None None O
important None None O
roles None None O
in None None O
prostate None None O
cancer None None O
development None None O
and None None O
progression None None O
, None None O
including None None O
the None None O
androgen None None O
receptor None None O
( None None O
AR None None O
) None None O
and None None O
phosphatidylinositol None None O
3 None None O
- None None O
kinase None None O
/ None None O
Akt None None O
signaling None None O
pathways None None O
. None None O

Crosstalk None None O
between None None O
these None None O
two None None O
pathways None None O
is None None O
also None None O
thought None None O
to None None O
contribute None None O
to None None O
progression None None O
and None None O
hormone None None O
- None None O
refractory None None O
prostate None None O
disease None None O
. None None O

Our None None O
initial None None O
investigations None None O
show None None O
that None None O
the None None O
naturally None None O
occurring None None O
organoselenium None None O
compound None None O
selenomethionine None None O
( None None O
SM None None O
) None None O
and None None O
the None None O
synthetic None None O
1 None None O
, None None O
4 None None O
- None None O
phenylenebis None None O
( None None O
methylene None None O
) None None O
selenocyanate None None O
( None None O
p None None O
- None None O
XSC None None O
) None None O
can None None O
inhibit None None O
human None None O
prostate None None O
cancer None None O
cell None None O
viability None None O
; None None O
however None None O
, None None O
in None None O
contrast None None O
to None None O
SM None None O
, None None O
p None None O
- None None O
XSC None None O
is None None O
active None None O
at None None O
physiologically None None O
relevant None None O
doses None None O
. None None O

In None None O
the None None O
current None None O
investigation None None O
, None None O
we None None O
show None None O
that None None O
p None None O
- None None O
XSC None None O
, None None O
but None None O
not None None O
an None None O
equivalent None None O
dose None None O
of None None O
SM None None O
, None None O
alters None None O
molecular None None O
targets None None O
and None None O
induces None None O
apoptosis None None O
in None None O
androgen None None O
- None None O
responsive None None O
LNCaP None None I-Cell-line-name
and None None O
androgen None None O
- None None O
independent None None O
LNCaP None None I-Cell-line-name
C4 None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
human None None O
prostate None None O
cancer None None O
cells None None O
. None None O

p None None O
- None None O
XSC None None O
effectively None None O
inhibits None None O
AR None None O
expression None None O
and None None O
transcriptional None None O
activity None None O
in None None O
both None None O
cell None None O
lines None None O
. None None O

p None None O
- None None O
XSC None None O
also None None O
decreases None None O
Akt None None O
phosphorylation None None O
as None None O
well None None O
as None None O
Akt None None O
- None None O
specific None None O
phosphorylation None None O
of None None O
the None None O
AR None None O
. None None O

Inhibition None None O
of None None O
Akt None None O
, None None O
however None None O
, None None O
does None None O
not None None O
fully None None O
attenuate None None O
p None None O
- None None O
XSC None None O
- None None O
mediated None None O
downregulation None None O
of None None O
AR None None O
activity None None O
, None None O
suggesting None None O
that None None O
inhibition None None O
of None None O
AR None None O
signaling None None O
by None None O
p None None O
- None None O
XSC None None O
does None None O
not None None O
occur None None O
solely None None O
through None None O
alterations None None O
in None None O
the None None O
phosphatidylinositol None None O
3 None None O
- None None O
kinase None None O
/ None None O
Akt None None O
survival None None O
pathway None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
p None None O
- None None O
XSC None None O
inhibits None None O
multiple None None O
signaling None None O
pathways None None O
in None None O
prostate None None O
cancer None None O
, None None O
likely None None O
accounting None None O
for None None O
the None None O
downstream None None O
effects None None O
on None None O
proliferation None None O
and None None O
apoptosis None None O
. None None O

2 None None O
- None None O
Theory None None O

Scanning None None O
holography None None O
is None None O
a None None O
two None None O
- None None O
pupil None None O
interaction None None O
method None None O
[ None None O
8 None None O
] None None O
by None None O
which None None O
incoherent None None O
imaging None None O
with None None O
complex None None O
point None None O
- None None O
spread None None O
- None None O
functions None None O
( None None O
PSF None None O
) None None O
is None None O
possible None None O
. None None O

The None None O
method None None O
has None None O
recently None None O
been None None O
applied None None O
to None None O
the None None O
recording None None O
of None None O
high None None O
resolution None None O
holographic None None O
images None None O
of None None O
incoherent None None O
objects None None O
and None None O
fluorescent None None O
biological None None O
specimens None None O
[ None None O
6 None None O
, None None O
7 None None O
] None None O
. None None O

A None None O
single None None O
- None None O
sideband None None O
in None None O
- None None O
line None None O
Fresnel None None O
hologram None None O
is None None O
obtained None None O
by None None O
a None None O
2D None None O
raster None None O
scan None None O
of None None O
the None None O
object None None O
with None None O
the None None O
superposed None None O
3D None None O
diffraction None None O
distributions None None O
of None None O
two None None O
pupils None None O
, None None O
as None None O
sketched None None O
in None None O
fig None None O
. None None O

1 None None O
. None None O

The None None O
two None None O
pupil None None O
distributions None None O
P None None O
~ None None O
1 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa None None O
@ None None O
3295 None None O
@ None None O
and None None O
P None None O
~ None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa None None O
@ None None O
3297 None None O
@ None None O
from None None O
the None None O
same None None O
source None None O
( None None O
for None None O
example None None O
, None None O
but None None O
not None None O
necessarily None None O
, None None O
a None None O
laser None None O
) None None O
are None None O
combined None None O
by None None O
a None None O
beam None None O
splitter None None O
in None None O
the None None O
pupil None None O
plane None None O
of None None O
the None None O
objective None None O
where None None O
they None None O
interfere None None O
, None None O
forming None None O
a None None O
Fresnel None None O
pattern None None O
with None None O
a None None O
depth None None O
- None None O
dependent None None O
Fresnel None None O
number None None O
. None None O

To None None O
obtain None None O
the None None O
conventional None None O
point None None O
- None None O
spread None None O
function None None O
of None None O
wide None None O
field None None O
imaging None None O
, None None O
P1 None None O
is None None O
chosen None None O
as None None O
a None None O
point None None O
source None None O
, None None O
and None None O
P2 None None O
as None None O
a None None O
spherical None None O
wave None None O
with None None O
appropriate None None O
curvature None None O
. None None O

The None None O
3D None None O
specimen None None O
is None None O
placed None None O
in None None O
the None None O
focal None None O
region None None O
of None None O
the None None O
objective None None O
, None None O
and None None O
scattered None None O
lights None None O
( None None O
transmitted None None O
, None None O
reflected None None O
, None None O
and None None O
fluorescent None None O
) None None O
are None None O
collected None None O
by None None O
non None None O
- None None O
imaging None None O
detectors None None O
. None None O

The None None O
hologram None None O
data None None O
can None None O
be None None O
obtained None None O
by None None O
heterodyne None None O
detection None None O
with None None O
one None None O
of None None O
the None None O
pupils None None O
shifted None None O
in None None O
frequency None None O
( None None O
as None None O
done None None O
in None None O
this None None O
work None None O
) None None O
, None None O
or None None O
by None None O
a None None O
homodyne None None O
method None None O
requiring None None O
the None None O
capture None None O
of None None O
at None None O
least None None O
three None None O
frames None None O
with None None O
different None None O
relative None None O
phases None None O
between None None O
the None None O
two None None O
pupils None None O
[ None None O
9 None None O
] None None O
. None None O

The None None O
amplitude None None O
distribution None None O
of None None O
the None None O
illuminating None None O
beam None None O
, None None O
in None None O
a None None O
transverse None None O
plane None None O
at None None O
an None None O
axial None None O
distance None None O
z None None O
from None None O
the None None O
focal None None O
plane None None O
of None None O
the None None O
objective None None O
, None None O
is None None O
the None None O
Fourier None None O
transform None None O
of None None O
the None None O
combined None None O
pupil None None O
distributions None None O
[ None None O
10 None None O
] None None O
. None None O

Namely None None O
: None None O

Figure None None O
1 None None O

Experimental None None O
set None None O
up None None O
of None None O
a None None O
scanning None None O
holographic None None O
microscope None None O
. None None O

Sketch None None O
of None None O
the None None O
experimental None None O
setup None None O
. None None O

M None None O
' None None O
s None None O
are None None O
mirrors None None O
, None None O
BS None None O
' None None O
s None None O
are None None O
beam None None O
splitters None None O
, None None O
EO None None O
is None None O
an None None O
electro None None O
- None None O
optic None None O
phase None None O
modulator None None O
. None None O

Lens None None O
L1 None None O
( None None O
achromat None None O
doublet None None O
16 None None O
cm None None O
focal None None O
length None None O
) None None O
produces None None O
the None None O
desired None None O
Fresnel None None O
pattern None None O
in None None O
the None None O
focal None None O
plane None None O
of None None O
L2 None None O
( None None O
achromat None None O
doublet None None O
16 None None O
cm None None O
focal None None O
length None None O
) None None O
. None None O

L2 None None O
and None None O
the None None O
objective None None O
form None None O
a None None O
4 None None O
- None None O
f None None O
system None None O
projecting None None O
a None None O
reduced None None O
image None None O
of None None O
the None None O
Fresnel None None O
pattern None None O
onto None None O
the None None O
specimen None None O
. None None O

L3 None None O
( None None O
achromat None None O
doublet None None O
12 None None O
cm None None O
focal None None O
length None None O
) None None O
projects None None O
the None None O
images None None O
of None None O
the None None O
pupils None None O
on None None O
the None None O
pinhole None None O
detector None None O
. None None O

( None None O
Not None None O
shown None None O
are None None O
the None None O
beam None None O
expanders None None O
used None None O
to None None O
illuminate None None O
the None None O
pupils None None O
) None None O
. None None O

S None None O
( None None O
r None None O
- None None O
- None None O
> None None O
, None None O
z None None O
) None None O
= None None O
F None None O
- None None O
1 None None O
{ None None O
[ None None O
P None None O
~ None None O
1 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
+ None None O
P None None O
~ None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
exp None None O
( None None O
- None None O
iOmegat None None O
] None None O
} None None O
, None None O
( None None O
1a None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGtbWucqGGOaakcuWGYbGCgaWcaiabcYcaSiabdQha6jabcMcaPiabg2da9iabdAeagnaaCaaaleqabaGaeyOeI0IaeGymaedaaOWaaiWabeaadaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakiiGacuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgUcaRiqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiGbcwgaLjabcIha4jabcchaWjabcIcaOiabgkHiTiabdMgaPjabfM6axjabdsha0bGaay5waiaaw2faaaGaay5Eaiaaw2haaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGHbqyaiaawIcacaGLPaaaaaa None None O
@ None None O
5D95 None None O
@ None None O

where None None O

P None None O
~ None None O
1 None None O
, None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
= None None O
P None None O
~ None None O
1 None None O
, None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
exp None None O
( None None O
ipilambdazrho2 None None O
) None None O
( None None O
1b None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGH9aqpcuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCcqGGOaakcqWGPbqAcqWFapaCcqWF7oaBcqWG6bGEcqWFbpGCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGIbGyaiaawIcacaGLPaaaaaa None None O
@ None None O
53A8 None None O
@ None None O

are None None O
the None None O
generalized None None O
defocused None None O
pupils None None O
[ None None O
11 None None O
] None None O
. None None O

F None None O
- None None O
1 None None O
stands None None O
for None None O
inverse None None O
Fourier None None O
transform None None O
, None None O
and None None O
Omega None None O
is None None O
the None None O
frequency None None O
shift None None O
of None None O
one None None O
of None None O
the None None O
pupils None None O
. None None O

The None None O
transverse None None O
spatial None None O
frequency None None O
vector None None O
rho None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFbpGCgaWcaaaa None None O
@ None None O
2E85 None None O
@ None None O
= None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
P None None O
/ None None O
lambdaf0 None None O
is None None O
proportional None None O
to None None O
the None None O
real None None O
space None None O
coordinate None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
P None None O
in None None O
the None None O
pupil None None O
plane None None O
[ None None O
10 None None O
] None None O
. None None O
lambda None None O
is None None O
the None None O
wavelength None None O
of None None O
the None None O
illumination None None O
, None None O
and None None O
f0 None None O
is None None O
the None None O
focal None None O
length None None O
of None None O
the None None O
objective None None O
. None None O

The None None O
two None None O
pupils None None O
used None None O
to None None O
obtain None None O
an None None O
in None None O
- None None O
line None None O
Fresnel None None O
hologram None None O
are None None O
, None None O
respectively None None O
, None None O
a None None O
spherical None None O
wave None None O
filling None None O
the None None O
pupil None None O
of None None O
the None None O
objective None None O
, None None O
and None None O
a None None O
point None None O
at None None O
the None None O
center None None O
of None None O
that None None O
pupil None None O
: None None O

P None None O
~ None None O
1 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa None None O
@ None None O
3295 None None O
@ None None O
= None None O
exp None None O
( None None O
ipilambdaz0rho2 None None O
) None None O
circ None None O
( None None O
rho None None O
/ None None O
rhoMAX None None O
) None None O

P None None O
~ None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
= None None O
delta None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
. None None O

( None None O
2 None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpcqWF0oazcqGGOaakcuWFbpGCgaWcaiabcMcaPiabc6caUiaaxMaacaWLjaWaaeWaaeaacqaIYaGmaiaawIcacaGLPaaaaaa None None O
@ None None O
3D5F None None O
@ None None O

circ None None O
( None None O
x None None O
) None None O
is None None O
a None None O
disc None None O
function None None O
of None None O
unit None None O
radius None None O
. None None O

rhoMAX None None O
= None None O
sinalpha None None O
/ None None O
lambda None None O
is None None O
the None None O
cutoff None None O
frequency None None O
of None None O
the None None O
objective None None O
, None None O
where None None O
sinalpha None None O
= None None O
NA None None O
is None None O
its None None O
numerical None None O
aperture None None O
. None None O

The None None O
Fresnel None None O
pattern None None O
projected None None O
on None None O
the None None O
object None None O
is None None O
the None None O
interference None None O
of None None O
the None None O
Fourier None None O
transforms None None O
of None None O
the None None O
two None None O
pupils None None O
, None None O
namely None None O
a None None O
spherical None None O
wave None None O
and None None O
a None None O
plane None None O
wave None None O
in None None O
the None None O
paraxial None None O
approximation None None O
. None None O

The None None O
Fresnel None None O
number None None O
of None None O
this None None O
pattern None None O
is None None O
determined None None O
by None None O
the None None O
free None None O
parameter None None O
z0 None None O
, None None O
which None None O
is None None O
the None None O
distance None None O
from None None O
the None None O
objective None None O
' None None O
s None None O
focal None None O
plane None None O
to None None O
the None None O
point None None O
where None None O
the None None O
spherical None None O
wave None None O
comes None None O
to None None O
a None None O
focus None None O
. None None O

There None None O
are None None O
two None None O
possible None None O
modes None None O
of None None O
operation None None O
, None None O
depending None None O
on None None O
the None None O
detector None None O
geometry None None O
[ None None O
5 None None O
] None None O
. None None O

With None None O
a None None O
spatially None None O
integrating None None O
detector None None O
, None None O
the None None O
resulting None None O
data None None O
is None None O
a None None O
convolution None None O
of None None O
the None None O
object None None O
' None None O
s None None O
intensity None None O
distribution None None O
with None None O
the None None O
desired None None O
complex None None O
PSF None None O
( None None O
namely None None O
, None None O
a None None O
spherical None None O
wave None None O
with None None O
a None None O
radius None None O
of None None O
curvature None None O
z0 None None O
+ None None O
z None None O
, None None O
and None None O
a None None O
radius None None O
a None None O
= None None O
z0sinalpha None None O
, None None O
in None None O
this None None O
case None None O
) None None O
. None None O

This None None O
detection None None O
mode None None O
leads None None O
to None None O
a None None O
hologram None None O
from None None O
which None None O
the None None O
three None None O
- None None O
dimensional None None O
distribution None None O
of None None O
scattering None None O
intensity None None O
, None None O
absorption None None O
, None None O
and None None O
fluorescence None None O
intensity None None O
can None None O
be None None O
reconstructed None None O
. None None O

With None None O
a None None O
point None None O
detector None None O
at None None O
the None None O
center None None O
of None None O
a None None O
conjugate None None O
pupil None None O
plane None None O
, None None O
the None None O
resulting None None O
data None None O
is None None O
a None None O
convolution None None O
of None None O
the None None O
object None None O
' None None O
s None None O
complex None None O
amplitude None None O
distribution None None O
with None None O
the None None O
same None None O
complex None None O
PSF None None O
. None None O

The None None O
reconstruction None None O
of None None O
this None None O
hologram None None O
gives None None O
the None None O
three None None O
- None None O
dimensional None None O
distribution None None O
of None None O
the None None O
specimen None None O
' None None O
s None None O
complex None None O
amplitude None None O
transmittance None None O
. None None O

In None None O
particular None None O
, None None O
assuming None None O
that None None O
multiple None None O
scattering None None O
can None None O
be None None O
ignored None None O
, None None O
the None None O
phase None None O
of None None O
the None None O
reconstruction None None O
is None None O
a None None O
quantitative None None O
measure None None O
of None None O
the None None O
integrated None None O
optical None None O
path None None O
length None None O
through None None O
the None None O
specimen None None O
. None None O

These None None O
two None None O
modes None None O
of None None O
operation None None O
are None None O
similar None None O
to None None O
the None None O
usual None None O
coherent None None O
/ None None O
incoherent None None O
imaging None None O
modes None None O
of None None O
a None None O
conventional None None O
system None None O
, None None O
which None None O
are None None O
obtained None None O
by None None O
using None None O
, None None O
respectively None None O
, None None O
a None None O
point None None O
source None None O
, None None O
or None None O
a None None O
large None None O
spatially None None O
incoherent None None O
source None None O
. None None O

In None None O
scanning None None O
holography None None O
, None None O
the None None O
detector None None O
size None None O
plays None None O
a None None O
similar None None O
role None None O
to None None O
that None None O
of None None O
the None None O
source None None O
size None None O
in None None O
conventional None None O
imaging None None O
. None None O

For None None O
simplicity None None O
, None None O
let None None O
' None None O
s None None O
assume None None O
an None None O
object None None O
with None None O
an None None O
amplitude None None O
transmittance None None O
T None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
. None None O

Note None None O
that None None O
for None None O
an None None O
incoherent None None O
or None None O
fluorescent None None O
object None None O
, None None O
the None None O
phase None None O
of None None O
the None None O
transmitted None None O
field None None O
is None None O
a None None O
random None None O
variable None None O
, None None O
and None None O
only None None O
the None None O
intensity None None O
I None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
= None None O
| None None O
T None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
| None None O
2 None None O
is None None O
measurable None None O
. None None O

For None None O
a None None O
quasi None None O
transparent None None O
object None None O
, None None O
the None None O
phase None None O
is None None O
equal None None O
to None None O
the None None O
integrated None None O
optical None None O
thickness None None O
of None None O
the None None O
object None None O
: None None O
Phi None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
) None None O
= None None O
( None None O
2pi None None O
/ None None O
lambda None None O
) None None O
integraldzn None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
, None None O
where None None O
n None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
is None None O
the None None O
3D None None O
distribution None None O
of None None O
refractive None None O
index None None O
. None None O

The None None O
amplitude None None O
distribution None None O
after None None O
the None None O
object None None O
is None None O
written None None O
as None None O

A None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
t None None O
) None None O
= None None O
integraldzS None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
T None None O
[ None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
- None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
S None None O
( None None O
t None None O
) None None O
, None None O
z None None O
] None None O
, None None O
( None None O
3 None None O
) None None O

where None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
S None None O
( None None O
t None None O
) None None O
is None None O
the None None O
instantaneous None None O
position None None O
of None None O
the None None O
2D None None O
raster None None O
scan None None O
. None None O

The None None O
incoherent None None O
imaging None None O
mode None None O
is None None O
obtained None None O
with None None O
a None None O
spatially None None O
integrating None None O
detector None None O
, None None O
leading None None O
to None None O
a None None O
temporal None None O
signal None None O
proportional None None O
to None None O
the None None O
integrated None None O
intensity None None O
, None None O
integrald2r None None O
| None None O
A None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
t None None O
) None None O
| None None O
2 None None O
, None None O
which None None O
is None None O
stored None None O
in None None O
the None None O
computer None None O
. None None O

The None None O
data None None O
corresponding None None O
to None None O
each None None O
hologram None None O
line None None O
is None None O
cut None None O
from None None O
the None None O
signal None None O
, None None O
and None None O
band None None O
pass None None O
filtered None None O
to None None O
extract None None O
the None None O
term None None O
oscillating None None O
at None None O
Omega None None O
. None None O

The None None O
lines None None O
are None None O
then None None O
rearranged None None O
in None None O
a None None O
2D None None O
format None None O
. None None O

The None None O
resulting None None O
hologram None None O
amplitude None None O
is None None O
found None None O
to None None O
be None None O

HI None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
) None None O
= None None O
integraldzI None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
( None None O
+ None None O
) None None O
[ None None O
p1 None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
p None None O
* None None O
2 None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
] None None O
, None None O
( None None O
4 None None O
) None None O

where None None O
( None None O
+ None None O
) None None O
symbolizes None None O
a None None O
convolution None None O
integral None None O
, None None O
I None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
= None None O
| None None O
T None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
| None None O
2 None None O
, None None O
and None None O
p1 None None O
, None None O
2 None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
are None None O
the None None O
inverse None None O
Fourier None None O
transforms None None O
of None None O
the None None O
defocused None None O
pupil None None O
distributions None None O
( None None O
eq None None O
. None None O
1b None None O
) None None O
. None None O

The None None O
superscript None None O
* None None O
stands None None O
for None None O
complex None None O
conjugate None None O
. None None O

The None None O
hologram None None O
is None None O
thus None None O
the None None O
convolution None None O
of None None O
the None None O
object None None O
intensity None None O
with None None O
a None None O
spherical None None O
wave None None O
, None None O
i None None O
. None None O
e None None O
. None None O
an None None O
in None None O
- None None O
line None None O
single None None O
- None None O
sideband None None O
Gabor None None O
hologram None None O
. None None O

In None None O
Fourier None None O
space None None O
, None None O
the None None O
hologram None None O
can None None O
be None None O
written None None O
as None None O

H None None O
~ None None O
I None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
= None None O
integraldzI None None O
~ None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
[ None None O
P None None O
~ None None O
1 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
( None None O
* None None O
) None None O
P None None O
~ None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
] None None O
, None None O
( None None O
5 None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkdaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgEPielqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPaGaay5waiaaw2faaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI1aqnaiaawIcacaGLPaaaaaa None None O
@ None None O
58FF None None O
@ None None O

where None None O
( None None O
+ None None O
) None None O
symbolizes None None O
a None None O
correlation None None O
integral None None O
. None None O

With None None O
the None None O
pupils None None O
of None None O
eq None None O
. None None O
2 None None O
, None None O
we None None O
find None None O
, None None O
in None None O
the None None O
paraxial None None O
approximation None None O
, None None O

H None None O
~ None None O
I None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
= None None O
integraldzI None None O
~ None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
exp None None O
[ None None O
ipilambda None None O
( None None O
z0 None None O
+ None None O
z None None O
) None None O
rho2 None None O
] None None O
circ None None O
( None None O
rho None None O
/ None None O
rhoMAX None None O
) None None O
, None None O
( None None O
6 None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCdaWadaqaaiabdMgaPjab None None O
= None None O
b8aWjab None None O
= None None O
T7aSjabcIcaOiabdQha6naaBaaaleaacqaIWaamaeqaaOGaey4kaSIaemOEaONaeiykaKIae8xWdi3aaWbaaSqabeaacqaIYaGmaaaakiaawUfacaGLDbaacqWGJbWycqWGPbqAcqWGYbGCcqWGJbWycqGGOaakcqWFbpGCcqGGVaWlcqWFbpGCdaWgaaWcbaGaemyta0KaemyqaeKaemiwaGfabeaakiabcMcaPiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI2aGnaiaawIcacaGLPaaaaaa None None O
@ None None O
67E3 None None O
@ None None O

which None None O
is None None O
the None None O
Fourier None None O
transform None None O
of None None O
the None None O
Fresnel None None O
hologram None None O
of None None O
the None None O
object None None O
' None None O
s None None O
intensity None None O
distribution None None O
. None None O

The None None O
coherent None None O
imaging None None O
mode None None O
is None None O
obtained None None O
by None None O
using None None O
a None None O
pinhole None None O
or None None O
a None None O
point None None O
detector None None O
at None None O
the None None O
center None None O
of None None O
a None None O
conjugate None None O
plane None None O
of None None O
the None None O
pupil None None O
of None None O
the None None O
objective None None O
. None None O

This None None O
leads None None O
to None None O
the None None O
hologram None None O
amplitude None None O

HC None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
) None None O
= None None O
integraldz None None O
[ None None O
T None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
( None None O
+ None None O
) None None O
p1 None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
] None None O
[ None None O
T None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
( None None O
+ None None O
) None None O
p2 None None O
( None None O
r None None O
- None None O
- None None O
> None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa None None O
@ None None O
2E2B None None O
@ None None O
, None None O
z None None O
) None None O
] None None O
* None None O
. None None O

( None None O
7 None None O
) None None O

Where None None O
again None None O
, None None O
( None None O
+ None None O
) None None O
symbolizes None None O
a None None O
convolution None None O
product None None O
, None None O
and None None O
the None None O
superscript None None O
* None None O
stands None None O
for None None O
complex None None O
conjugate None None O
. None None O

In None None O
Fourier None None O
space None None O
, None None O

H None None O
~ None None O
C None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
= None None O
integraldzT None None O
~ None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
P None None O
~ None None O
1 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
( None None O
* None None O
) None None O
T None None O
~ None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
P None None O
~ None None O
2 None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
. None None O

( None None O
8 None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGdbWqaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdsfauzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGHxkcXcuWGubavgaacaiabcIcaOiqb None None O
= None None O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIafmiuaaLbaGaadaWgaaWcbaGaeGOmaidabeaakiabcIcaOiqb None None O
= None None O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiIda4aGaayjkaiaawMcaaaaa None None O
@ None None O
5E5B None None O
@ None None O

With None None O
the None None O
pupils None None O
of None None O
eq None None O
. None None O
2 None None O
, None None O
we None None O
find None None O

H None None O
~ None None O
C None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
) None None O
= None None O
integraldzT None None O
~ None None O
* None None O
( None None O
0 None None O
; None None O
z None None O
) None None O
T None None O
~ None None O
( None None O
rho None None O
- None None O
- None None O
> None None O
; None None O
z None None O
) None None O
exp None None O
[ None None O
ipilambda None None O
( None None O
z0 None None O
+ None None O
z None None O
) None None O
rho2 None None O
] None None O
circ None None O
( None None O
rho None None O
/ None None O
rhoMAX None None O
) None None O
. None None O

( None None O
9 None None O
) None None O
MathType None None O
@ None None O
MTEF None None O
@ None None O
5 None None O
@ None None O
5 None None O
@ None None O
+ None None O
= None None O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY None None O
= None None O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 None None O
= None None O
OqFfea0dXdd9vqai None None O
= None None O
hGuQ8kuc9pgc9s8qqaq None None O
= None None O
dirpe0xb9q8qiLsFr0 None None O
= None None O
vr0 None None O
= None None O
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 None None O
= None None O
f8aYjabc None None O
+ None None O
caViab None None O
= None None O
f8aYnaaBaaaleaacqWGnbqtcqWGbbqqcqWGybawaeqaaOGaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiMda5aGaayjkaiaawMcaaaaa None None O
@ None None O
6F41 None None O
@ None None O

Aside None None O
from None None O
an None None O
inconsequential None None O
complex None None O
constant None None O
( None None O
the None None O
first None None O
term None None O
under None None O
the None None O
integral None None O
) None None O
, None None O
eq None None O
. None None O
9 None None O
is None None O
the None None O
Fourier None None O
transform None None O
of None None O
the None None O
Fresnel None None O
hologram None None O
of None None O
the None None O
object None None O
' None None O
s None None O
complex None None O
amplitude None None O
distribution None None O
. None None O

Thus None None O
, None None O
the None None O
reconstruction None None O
of None None O
the None None O
hologram None None O
recorded None None O
in None None O
the None None O
coherent None None O
mode None None O
carries None None O
a None None O
quantitative None None O
measure None None O
of None None O
the None None O
object None None O
' None None O
s None None O
phase None None O
distribution None None O
. None None O

Hypothesis None None O
: None None O
Induced None None O
angiogenesis None None O
after None None O
surgery None None O
in None None O
premenopausal None None O
node None None O
- None None O
positive None None O
breast None None O
cancer None None O
patients None None O
is None None O
a None None O
major None None O
underlying None None O
reason None None O
why None None O
adjuvant None None O
chemotherapy None None O
works None None O
particularly None None O
well None None O
for None None O
those None None O
patients None None O
. None None O

BACKGROUND None None O
: None None O
We None None O
suggest None None O
that None None O
surgical None None O
extirpation None None O
of None None O
primary None None O
breast None None O
cancer None None O
among None None O
other None None O
effects None None O
accelerates None None O
relapse None None O
for None None O
some None None O
premenopausal None None O
node None None O
- None None O
positive None None O
patients None None O
. None None O

These None None O
accelerated None None O
relapses None None O
occur None None O
within None None O
10 None None O
months None None O
of None None O
surgery None None O
for None None O
untreated None None O
patients None None O
. None None O

The None None O
mechanism None None O
proposed None None O
is None None O
a None None O
stimulation None None O
of None None O
angiogenesis None None O
for None None O
distant None None O
dormant None None O
micrometastases None None O
. None None O

This None None O
has None None O
been None None O
suggested None None O
as None None O
one None None O
of None None O
the None None O
mechanisms None None O
to None None O
explain None None O
the None None O
mammography None None O
paradox None None O
for None None O
women None None O
aged None None O
40 None None O
- None None O
49 None None O
years None None O
. None None O

We None None O
could None None O
imagine None None O
that None None O
it None None O
also None None O
plays None None O
a None None O
role None None O
in None None O
adjuvant None None O
chemotherapy None None O
effectiveness None None O
since None None O
, None None O
perhaps None None O
not None None O
coincidentally None None O
, None None O
this None None O
is None None O
most None None O
beneficial None None O
for None None O
premenopausal None None O
node None None O
- None None O
positive None None O
patients None None O
. None None O

HYPOTHESIS None None O
: None None O
We None None O
speculate None None O
that None None O
there None None O
is None None O
a None None O
burst None None O
of None None O
angiogenesis None None O
of None None O
distant None None O
dormant None None O
micrometastases None None O
after None None O
surgery None None O
in None None O
approximately None None O
20 None None O
% None None O
of None None O
premenopausal None None O
node None None O
- None None O
positive None None O
patients None None O
. None None O

We None None O
also None None O
speculate None None O
that None None O
this None None O
synchronizes None None O
them None None O
into None None O
a None None O
temporal None None O
highly None None O
chemosensitive None None O
state None None O
and None None O
is None None O
the None None O
underlying None None O
reason None None O
why None None O
adjuvant None None O
chemotherapy None None O
works None None O
particularly None None O
well None None O
for None None O
that None None O
patient None None O
category None None O
. None None O

Furthermore None None O
, None None O
this None None O
may None None O
explain None None O
why None None O
cancer None None O
in None None O
younger None None O
patients None None O
is None None O
more None None O
often None None O
' None None O
aggressive None None O
' None None O
. None None O

TESTING None None O
THE None None O
HYPOTHESIS None None O
: None None O
Stimulation None None O
of None None O
dormant None None O
micrometastases None None O
by None None O
primary None None O
tumor None None O
removal None None O
is None None O
known None None O
to None None O
occur None None O
in None None O
animal None None O
models None None O
. None None O

However None None O
, None None O
we None None O
need None None O
to None None O
determine None None O
whether None None O
it None None O
happens None None O
in None None O
breast None None O
cancer None None O
. None None O

Transient None None O
circulating None None O
levels None None O
of None None O
angioactive None None O
molecules None None O
and None None O
serial None None O
high None None O
- None None O
resolution None None O
imaging None None O
studies None None O
of None None O
focal None None O
angiogenesis None None O
might None None O
help None None O
. None None O

IMPLICATIONS None None O
: None None O
Short None None O
- None None O
course None None O
cytotoxic None None O
chemotherapy None None O
after None None O
surgery None None O
has None None O
probably None None O
reached None None O
its None None O
zenith None None O
, None None O
and None None O
other None None O
strategies None None O
, None None O
perhaps None None O
antiangiogenic None None O
methods None None O
, None None O
are None None O
needed None None O
to None None O
successfully None None O
treat None None O
more None None O
patients None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
hypothesis None None O
predicts None None O
that None None O
early None None O
detection None None O
, None None O
which None None O
is None None O
designed None None O
to None None O
find None None O
more None None O
patients None None O
without None None O
involved None None O
lymph None None O
nodes None None O
, None None O
may None None O
not None None O
be None None O
a None None O
synergistic None None O
strategy None None O
with None None O
adjuvant None None O
chemotherapy None None O
, None None O
which None None O
works None None O
best None None O
with None None O
positive None None O
lymph None None O
node None None O
patients None None O
. None None O

Results None None O

Here None None O
we None None O
include None None O
data None None O
obtained None None O
from None None O
active None None O
, None None O
oscillatory None None O
brain None None O
slices None None O
as None None O
well None None O
as None None O
from None None O
recordings None None O
during None None O
cortical None None O
slow None None O
oscillations None None O
in None None O
anesthetized None None O
animals None None O
. None None O

All None None O
recordings None None O
included None None O
in None None O
this None None O
study None None O
were None None O
obtained None None O
from None None O
the None None O
visual None None O
cortex None None O
of None None O
the None None O
ferret None None O
( None None O
in None None O
vitro None None O
) None None O
, None None O
cat None None O
( None None O
in None None O
vivo None None O
) None None O
and None None O
from None None O
barrel None None O
cortex None None O
of None None O
the None None O
rat None None O
( None None O
in None None O
vivo None None O
) None None O
. None None O

Twenty None None O
- None None O
nine None None O
neurons None None O
recorded None None O
from None None O
ferret None None O
cortical None None O
slices None None O
are None None O
included None None O
in None None O
this None None O
study None None O
( None None O
22 None None O
regular None None O
spiking None None O
( None None O
RS None None O
) None None O
; None None O
5 None None O
chattering None None O
( None None O
CH None None O
) None None O
and None None O
2 None None O
intrinsic None None O
bursting None None O
( None None O
IB None None O
) None None O
) None None O
, None None O
27 None None O
neurons None None O
from None None O
cat None None O
visual None None O
cortex None None O
in None None O
vivo None None O
( None None O
14 None None O
RS None None O
; None None O
5 None None O
CH None None O
; None None O
2 None None O
IB None None O
; None None O
3 None None O
fast None None O
spiking None None O
( None None O
FS None None O
) None None O
; None None O
plus None None O
3 None None O
non None None O
classified None None O
) None None O
and None None O
14 None None O
neurons None None O
from None None O
rat None None O
barrel None None O
cortex None None O
in None None O
vivo None None O
( None None O
12 None None O
RS None None O
; None None O
1 None None O
CH None None O
; None None O
1 None None O
IB None None O
) None None O
. None None O

Synaptic None None O
potentials None None O
were None None O
evoked None None O
by None None O
electric None None O
shocks None None O
( None None O
intracortical None None O
or None None O
thalamocortical None None O
connections None None O
) None None O
or None None O
by None None O
means None None O
of None None O
sensory None None O
( None None O
visual None None O
or None None O
whisker None None O
) None None O
stimulation None None O
. None None O

The None None O
main None None O
results None None O
are None None O
: None None O
1 None None O
) None None O
Synaptic None None O
potentials None None O
show None None O
more None None O
paired None None O
pulsed None None O
facilitation None None O
and None None O
synaptic None None O
augmentation None None O
in None None O
active None None O
than None None O
in None None O
silent None None O
cortical None None O
networks None None O
and None None O
2 None None O
) None None O
Synaptic None None O
potentials None None O
occurring None None O
during None None O
up None None O
or None None O
activated None None O
states None None O
of None None O
the None None O
cortex None None O
increased None None O
their None None O
amplitude None None O
with None None O
respect None None O
to None None O
those None None O
occurring None None O
during None None O
down None None O
states None None O
. None None O

VEGF None None O
- None None O
targeted None None O
therapy None None O
: None None O
therapeutic None None O
potential None None O
and None None O
recent None None O
advances None None O
. None None O

After None None O
over None None O
30 None None O
years None None O
of None None O
theorizing None None O
, None None O
the None None O
use None None O
of None None O
angiogenesis None None O
inhibitors None None O
as None None O
anticancer None None O
therapy None None O
has None None O
finally None None O
moved None None O
from None None O
the None None O
realm None None O
of None None O
research None None O
to None None O
reality None None O
. None None O

Normal None None O
adult None None O
vasculature None None O
is None None O
generally None None O
quiescent None None O
in None None O
nature None None O
, None None O
with None None O
endothelial None None O
cells None None O
dividing None None O
approximately None None O
every None None O
10 None None O
years None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
growth None None O
of None None O
tumors None None O
requires None None O
constant None None O
vascular None None O
growth None None O
and None None O
remodeling None None O
in None None O
order None None O
for None None O
solid None None O
tumors None None O
to None None O
grow None None O
beyond None None O
1 None None O
- None None O
2 None None O
mm None None O
( None None O
3 None None O
) None None O
in None None O
size None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
its None None O
receptors None None O
are None None O
key None None O
regulators None None O
of None None O
the None None O
process None None O
of None None O
angiogenesis None None O
, None None O
which None None O
makes None None O
them None None O
attractive None None O
therapeutic None None O
targets None None O
. None None O

A None None O
multitude None None O
of None None O
VEGF None None O
- None None O
targeted None None O
inhibitory None None O
agents None None O
are None None O
currently None None O
being None None O
investigated None None O
for None None O
the None None O
treatment None None O
of None None O
cancer None None O
. None None O

This None None O
review None None O
article None None O
focuses None None O
on None None O
recent None None O
developments None None O
in None None O
the None None O
use None None O
of None None O
angiogenesis None None O
inhibitors None None O
for None None O
the None None O
treatment None None O
of None None O
breast None None O
, None None O
lung None None O
, None None O
and None None O
colorectal None None O
cancers None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
B None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
C None None O
expression None None O
in None None O
renal None None O
cell None None O
carcinomas None None O
: None None O
regulation None None O
by None None O
the None None O
von None None O
Hippel None None O
- None None O
Lindau None None O
gene None None O
and None None O
hypoxia None None O
. None None O

Angiogenesis None None O
is None None O
essential None None O
for None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
. None None O

It None None O
is None None O
regulated None None O
by None None O
numerous None None O
angiogenic None None O
factors None None O
, None None O
one None None O
of None None O
the None None O
most None None O
important None None O
being None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
. None None O

Recently None None O
VEGF None None O
- None None O
B None None O
and None None O
VEGF None None O
- None None O
C None None O
, None None O
two None None O
new None None O
VEGF None None O
family None None O
members None None O
, None None O
have None None O
been None None O
identified None None O
that None None O
bind None None O
to None None O
the None None O
tyrosine None None O
kinase None None O
receptors None None O
flt None None O
- None None O
1 None None O
( None None O
VEGFR1 None None O
) None None O
, None None O
KDR None None O
( None None O
VEGFR2 None None O
) None None O
, None None O
and None None O
flt None None O
- None None O
4 None None O
( None None O
VEGFR3 None None O
) None None O
. None None O

Although None None O
the None None O
importance None None O
of None None O
VEGF None None O
- None None O
A None None O
has None None O
been None None O
shown None None O
in None None O
renal None None O
carcinomas None None O
, None None O
the None None O
contribution None None O
of None None O
these None None O
new None None O
ligands None None O
in None None O
kidney None None O
tumors None None O
is None None O
not None None O
clear None None O
. None None O

We None None O
have None None O
, None None O
therefore None None O
, None None O
measured None None O
the None None O
mRNA None None O
level None None O
of None None O
VEGF None None O
- None None O
B None None O
and None None O
VEGF None None O
- None None O
C None None O
together None None O
with None None O
their None None O
receptors None None O
by None None O
RNase None None O
protection None None O
assay None None O
( None None O
RPA None None O
) None None O
in None None O
26 None None O
normal None None O
kidney None None O
samples None None O
and None None O
45 None None O
renal None None O
cell None None O
cancers None None O
. None None O

We None None O
observed None None O
a None None O
significant None None O
up None None O
- None None O
regulation None None O
of None None O
VEGF None None O
- None None O
B None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
002 None None O
) None None O
but None None O
not None None O
VEGF None None O
- None None O
C None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
3 None None O
) None None O
in None None O
neoplastic None None O
kidney None None O
compared None None O
with None None O
normal None None O
tissues None None O
. None None O

In None None O
addition None None O
, None None O
although None None O
VEGF None None O
receptors None None O
were None None O
higher None None O
in None None O
tumors None None O
than None None O
normal None None O
kidney None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
up None None O
- None None O
regulation None None O
of None None O
only None None O
flt None None O
- None None O
1 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
003 None None O
) None None O
but None None O
not None None O
KDR None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
12 None None O
) None None O
or None None O
flt None None O
- None None O
4 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
09 None None O
) None None O
. None None O

There None None O
was None None O
also None None O
a None None O
significant None None O
correlation None None O
between None None O
VEGF None None O
- None None O
C None None O
and None None O
both None None O
of None None O
its None None O
receptors None None O
flt None None O
- None None O
4 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
006 None None O
) None None O
and None None O
KDR None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
but None None O
no None None O
association None None O
between None None O
VEGF None None O
- None None O
B None None O
and None None O
its None None O
receptor None None O
flt None None O
- None None O
1 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
23 None None O
) None None O
. None None O

A None None O
significant None None O
increase None None O
was None None O
observed None None O
in None None O
flt None None O
- None None O
1 None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
KDR None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
02 None None O
) None None O
, None None O
and None None O
flt None None O
- None None O
4 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
but None None O
not None None O
VEGF None None O
- None None O
B None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
82 None None O
) None None O
or None None O
VEGF None None O
- None None O
C None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
52 None None O
) None None O
expression None None O
in None None O
clear None None O
cell None None O
compared None None O
with None None O
chromophil None None O
( None None O
papillary None None O
) None None O
carcinomas None None O
. None None O

No None None O
significant None None O
association None None O
was None None O
demonstrated None None O
between None None O
VEGF None None O
- None None O
B None None O
, None None O
VEGF None None O
- None None O
C None None O
, None None O
flt None None O
- None None O
1 None None O
, None None O
KDR None None O
, None None O
and None None O
flt None None O
- None None O
4 None None O
with None None O
patient None None O
sex None None O
, None None O
patient None None O
age None None O
, None None O
or None None O
tumor None None O
size None None O
( None None O
P None None O
greater None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
effect None None O
of None None O
von None None O
Hippel None None O
- None None O
Lindau None None O
( None None O
VHL None None O
) None None O
gene None None O
and None None O
hypoxia None None O
on None None O
VEGF None None O
- None None O
B None None O
and None None O
VEGF None None O
- None None O
C None None O
expression None None O
in None None O
the None None O
renal None None O
carcinoma None None O
cell None None O
line None None O
786 None None I-Cell-line-name
- None None I-Cell-line-name
0 None None I-Cell-line-name
transfected None None O
with None None O
wild None None O
- None None O
type None None O
and None None O
mutant None None O
VHL None None O
was None None O
determined None None O
by None None O
growing None None O
cells None None O
under None None O
21 None None O
% None None O
O2 None None O
- None None O
and None None O
0 None None O
. None None O
1 None None O
% None None O
O2 None None O
. None None O

In None None O
wild None None O
- None None O
type None None O
VHL None None O
cells None None O
, None None O
whereas None None O
VEGF None None O
- None None O
A None None O
was None None O
significantly None None O
up None None O
- None None O
regulated None None O
under None None O
hypoxic None None O
compared None None O
with None None O
normoxic None None O
conditions None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
expression None None O
of None None O
VEGF None None O
- None None O
C None None O
was None None O
reduced None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
002 None None O
) None None O
. None None O

Nevertheless None None O
, None None O
the None None O
repression None None O
of None None O
VEGF None None O
- None None O
C None None O
was None None O
lost None None O
in None None O
mutant None None O
VHL None None O
cell None None O
lines None None O
under None None O
hypoxia None None O
. None None O

In None None O
contrast None None O
VEGF None None O
- None None O
B None None O
was None None O
not None None O
regulated None None O
by None None O
VHL None None O
despite None None O
clear None None O
up None None O
- None None O
regulation None None O
in None None O
vivo None None O
. None None O

These None None O
findings None None O
strongly None None O
support None None O
an None None O
enhanced None None O
role None None O
for None None O
this None None O
pathway None None O
in None None O
clear None None O
cell None None O
carcinomas None None O
by None None O
regulating None None O
angiogenesis None None O
and None None O
/ None None O
or None None O
lymphangiogenesis None None O
. None None O

The None None O
study None None O
shows None None O
that None None O
clear None None O
cell None None O
tumors None None O
are None None O
able None None O
to None None O
up None None O
- None None O
regulate None None O
angiogenic None None O
growth None None O
factor None None O
receptors None None O
more None None O
efficiently None None O
than None None O
chromophil None None O
( None None O
papillary None None O
) None None O
, None None O
that None None O
clear None None O
cell None None O
tumors None None O
can None None O
use None None O
pathways None None O
independent None None O
of None None O
VHL None None O
to None None O
regulate None None O
angiogenesis None None O
, None None O
and None None O
that None None O
this None None O
combined None None O
regulation None None O
may None None O
account None None O
for None None O
their None None O
more None None O
aggressive None None O
phenotype None None O
, None None O
which None None O
suggests None None O
that None None O
targeting None None O
VEGFR1 None None O
( None None O
flt None None O
- None None O
l None None O
) None None O
may None None O
be None None O
particularly None None O
effective None None O
in None None O
these None None O
tumor None None O
types None None O
. None None O

Impaired None None O
CK1 None None O
delta None None O
activity None None O
attenuates None None O
SV40 None None O
- None None O
induced None None O
cellular None None O
transformation None None O
in None None O
vitro None None O
and None None O
mouse None None O
mammary None None O
carcinogenesis None None O
in None None O
vivo None None O
. None None O

Simian None None O
virus None None O
40 None None O
( None None O
SV40 None None O
) None None O
is None None O
a None None O
powerful None None O
tool None None O
to None None O
study None None O
cellular None None O
transformation None None O
in None None O
vitro None None O
, None None O
as None None O
well None None O
as None None O
tumor None None O
development None None O
and None None O
progression None None O
in None None O
vivo None None O
. None None O

Various None None O
cellular None None O
kinases None None O
, None None O
among None None O
them None None O
members None None O
of None None O
the None None O
CK1 None None O
family None None O
, None None O
play None None O
an None None O
important None None O
role None None O
in None None O
modulating None None O
the None None O
transforming None None O
activity None None O
of None None O
SV40 None None O
, None None O
including None None O
the None None O
transforming None None O
activity None None O
of None None O
T None None O
- None None O
Ag None None O
, None None O
the None None O
major None None O
transforming None None O
protein None None O
of None None O
SV40 None None O
, None None O
itself None None O
. None None O

Here None None O
we None None O
characterized None None O
the None None O
effects None None O
of None None O
mutant None None O
CK1delta None None O
variants None None O
with None None O
impaired None None O
kinase None None O
activity None None O
on None None O
SV40 None None O
- None None O
induced None None O
cell None None O
transformation None None O
in None None O
vitro None None O
, None None O
and None None O
on None None O
SV40 None None O
- None None O
induced None None O
mammary None None O
carcinogenesis None None O
in None None O
vivo None None O
in None None O
a None None O
transgenic None None O
/ None None O
bi None None O
- None None O
transgenic None None O
mouse None None O
model None None O
. None None O

CK1delta None None O
mutants None None O
exhibited None None O
a None None O
reduced None None O
kinase None None O
activity None None O
compared None None O
to None None O
wtCK1delta None None O
in None None O
in None None O
vitro None None O
kinase None None O
assays None None O
. None None O

Molecular None None O
modeling None None O
studies None None O
suggested None None O
that None None O
mutation None None O
N172D None None O
, None None O
located None None O
within None None O
the None None O
substrate None None O
binding None None O
region None None O
, None None O
is None None O
mainly None None O
responsible None None O
for None None O
impaired None None O
mutCK1delta None None O
activity None None O
. None None O

When None None O
stably None None O
over None None O
- None None O
expressed None None O
in None None O
maximal None None O
transformed None None O
SV None None I-Cell-line-name
- None None I-Cell-line-name
52 None None I-Cell-line-name
cells None None O
, None None O
CK1delta None None O
mutants None None O
induced None None O
reversion None None O
to None None O
a None None O
minimal None None O
transformed None None O
phenotype None None O
by None None O
dominant None None O
- None None O
negative None None O
interference None None O
with None None O
endogenous None None O
wtCK1delta None None O
. None None O

To None None O
characterize None None O
the None None O
effects None None O
of None None O
CK1delta None None O
on None None O
SV40 None None O
- None None O
induced None None O
mammary None None O
carcinogenesis None None O
, None None O
we None None O
generated None None O
transgenic None None O
mice None None O
expressing None None O
mutant None None O
CK1delta None None O
under None None O
the None None O
control None None O
of None None O
the None None O
whey None None O
acidic None None O
protein None None O
( None None O
WAP None None O
) None None O
gene None None O
promoter None None O
, None None O
and None None O
crossed None None O
them None None O
with None None O
SV40 None None O
transgenic None None O
WAP None None O
- None None O
T None None O
- None None O
antigen None None O
( None None O
WAP None None O
- None None O
T None None O
) None None O
mice None None O
. None None O

Both None None O
WAP None None O
- None None O
T None None O
mice None None O
as None None O
well None None O
as None None O
WAP None None O
- None None O
mutCK1delta None None O
/ None None O
WAP None None O
- None None O
T None None O
bi None None O
- None None O
transgenic None None O
mice None None O
developed None None O
breast None None O
cancer None None O
. None None O

However None None O
, None None O
tumor None None O
incidence None None O
was None None O
lower None None O
and None None O
life None None O
span None None O
was None None O
significantly None None O
longer None None O
in None None O
WAP None None O
- None None O
mutCK1delta None None O
/ None None O
WAP None None O
- None None O
T None None O
bi None None O
- None None O
transgenic None None O
animals None None O
. None None O

The None None O
reduced None None O
CK1delta None None O
activity None None O
did None None O
not None None O
affect None None O
early None None O
lesion None None O
formation None None O
during None None O
tumorigenesis None None O
, None None O
suggesting None None O
that None None O
impaired None None O
CK1delta None None O
activity None None O
reduces None None O
the None None O
probability None None O
for None None O
outgrowth None None O
of None None O
in None None O
situ None None O
carcinomas None None O
to None None O
invasive None None O
carcinomas None None O
. None None O

The None None O
different None None O
tumorigenic None None O
potential None None O
of None None O
SV40 None None O
in None None O
WAP None None O
- None None O
T None None O
and None None O
WAP None None O
- None None O
mutCK1delta None None O
/ None None O
WAP None None O
- None None O
T None None O
tumors None None O
was None None O
also None None O
reflected None None O
by None None O
a None None O
significantly None None O
different None None O
expression None None O
of None None O
various None None O
genes None None O
known None None O
to None None O
be None None O
involved None None O
in None None O
tumor None None O
progression None None O
, None None O
specifically None None O
of None None O
those None None O
involved None None O
in None None O
wnt None None O
- None None O
signaling None None O
and None None O
DNA None None O
repair None None O
. None None O

Our None None O
data None None O
show None None O
that None None O
inactivating None None O
mutations None None O
in None None O
CK1delta None None O
impair None None O
SV40 None None O
- None None O
induced None None O
cellular None None O
transformation None None O
in None None O
vitro None None O
and None None O
mouse None None O
mammary None None O
carcinogenesis None None O
in None None O
vivo None None O
. None None O

Prenatal None None O
hypoxia None None O
decreases None None O
lung None None O
extracellular None None O
superoxide None None O
dismutase None None O
expression None None O
and None None O
activity None None O
. None None O

Extracellular None None O
superoxide None None O
dismutase None None O
( None None O
EC None None O
- None None O
SOD None None O
) None None O
, None None O
which None None O
scavenges None None O
extracellular None None O
superoxide None None O
( None None O
O None None O
. None None O
) None None O
, None None O
is None None O
highly None None O
regulated None None O
in None None O
the None None O
developing None None O
lung None None O
. None None O

In None None O
the None None O
prenatal None None O
rabbit None None O
, None None O
EC None None O
- None None O
SOD None None O
is None None O
predominantly None None O
intracellular None None O
and None None O
inactive None None O
, None None O
and None None O
postnatally None None O
, None None O
active None None O
EC None None O
- None None O
SOD None None O
is None None O
secreted None None O
. None None O

We None None O
hypothesized None None O
that None None O
prenatal None None O
hypoxia None None O
would None None O
delay None None O
the None None O
normal None None O
postnatal None None O
secretion None None O
of None None O
active None None O
EC None None O
- None None O
SOD None None O
in None None O
the None None O
lung None None O
. None None O

Pregnant None None O
New None None O
Zealand None None O
White None None O
rabbits None None O
were None None O
exposed None None O
to None None O
hypobaric None None O
hypoxia None None O
( None None O
15 None None O
, None None O
000 None None O
ft None None O
x None None O
36 None None O
h None None O
) None None O
to None None O
alter None None O
fetal None None O
O None None O
( None None O
2 None None O
) None None O
tension None None O
or None None O
were None None O
maintained None None O
in None None O
room None None O
air None None O
. None None O

Lungs None None O
were None None O
harvested None None O
from None None O
preterm None None O
( None None O
28 None None O
days None None O
) None None O
, None None O
term None None O
( None None O
30 None None O
+ None None O
/ None None O
- None None O
1 None None O
day None None O
) None None O
, None None O
and None None O
1 None None O
- None None O
wk None None O
- None None O
old None None O
kits None None O
. None None O

After None None O
prenatal None None O
hypobaric None None O
hypoxia None None O
, None None O
EC None None O
- None None O
SOD None None O
mRNA None None O
expression None None O
was None None O
significantly None None O
decreased None None O
in None None O
lungs None None O
of None None O
full None None O
- None None O
term None None O
kits None None O
, None None O
whereas None None O
EC None None O
- None None O
SOD None None O
protein None None O
decreased None None O
at None None O
all None None O
ages None None O
. None None O

Immunohistochemical None None O
staining None None O
for None None O
EC None None O
- None None O
SOD None None O
showed None None O
that None None O
hypoxia None None O
delayed None None O
secretion None None O
of None None O
the None None O
isoenzyme None None O
in None None O
the None None O
airways None None O
and None None O
pulmonary None None O
vasculature None None O
. None None O

Furthermore None None O
, None None O
pulmonary None None O
EC None None O
- None None O
SOD None None O
enzyme None None O
activity None None O
was None None O
significantly None None O
decreased None None O
in None None O
the None None O
1 None None O
- None None O
wk None None O
- None None O
old None None O
kits None None O
exposed None None O
to None None O
prenatal None None O
hypoxia None None O
. None None O

We None None O
conclude None None O
that None None O
prenatal None None O
hypoxia None None O
downregulates None None O
EC None None O
- None None O
SOD None None O
expression None None O
at None None O
both None None O
the None None O
transcriptional None None O
and None None O
posttranslational None None O
levels None None O
. None None O

Furthermore None None O
, None None O
prenatal None None O
hypoxia None None O
delays None None O
secretion None None O
of None None O
active None None O
EC None None O
- None None O
SOD None None O
enzyme None None O
. None None O

These None None O
findings None None O
have None None O
important None None O
implications None None O
for None None O
the None None O
effects None None O
of None None O
prenatal None None O
asphyxia None None O
on None None O
postnatal None None O
response None None O
to None None O
oxidant None None O
stress None None O
. None None O

Angiopoietin None None O
/ None None O
tie None None O
- None None O
2 None None O
as None None O
mediators None None O
of None None O
angiogenesis None None O
: None None O
a None None O
role None None O
in None None O
congestive None None O
heart None None O
failure None None O
? None None O

Angiogenic None None O
factors None None O
, None None O
in None None O
particular None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
the None None O
angiopoietins None None O
, None None O
Ang None None O
- None None O
1 None None O
and None None O
- None None O
2 None None O
, None None O
have None None O
recently None None O
generated None None O
significant None None O
interest None None O
, None None O
especially None None O
in None None O
oncology None None O
. None None O

The None None O
process None None O
of None None O
angiogenesis None None O
is None None O
also None None O
thought None None O
to None None O
occur None None O
in None None O
response None None O
to None None O
ischaemic None None O
conditions None None O
, None None O
which None None O
lie None None O
at None None O
the None None O
core None None O
of None None O
cardiovascular None None O
disease None None O
states None None O
such None None O
as None None O
coronary None None O
artery None None O
disease None None O
and None None O
congestive None None O
heart None None O
failure None None O
. None None O

However None None O
, None None O
current None None O
data None None O
do None None O
not None None O
conclusively None None O
show None None O
evidence None None O
of None None O
angiogenesis None None O
per None None O
se None None O
in None None O
these None None O
conditions None None O
, None None O
despite None None O
( None None O
for None None O
example None None O
) None None O
the None None O
presence None None O
of None None O
high None None O
levels None None O
of None None O
VEGF None None O
and None None O
Ang None None O
- None None O
2 None None O
. None None O

High None None O
levels None None O
of None None O
these None None O
angiogenic None None O
factors None None O
in None None O
heart None None O
disease None None O
also None None O
have None None O
not None None O
translated None None O
into None None O
clinically None None O
significant None None O
new None None O
vessel None None O
formation None None O
, None None O
as None None O
in None None O
accelerated None None O
cancer None None O
growth None None O
or None None O
proliferative None None O
retinopathy None None O
. None None O

Indeed None None O
, None None O
we None None O
would None None O
hypothesize None None O
that None None O
these None None O
angiogenic None None O
markers None None O
- None None O
- None None O
especially None None O
the None None O
angiopoietins None None O
- None None O
- None None O
do None None O
not None None O
necessarily None None O
translate None None O
into None None O
new None None O
vessel None None O
formation None None O
in None None O
congestive None None O
heart None None O
failure None None O
( None None O
CHF None None O
) None None O
, None None O
but None None O
may None None O
well None None O
reflect None None O
disturbances None None O
of None None O
endothelial None None O
integrity None None O
in None None O
CHF None None O
. None None O

Bevacizumab None None O
and None None O
irinotecan None None O
therapy None None O
in None None O
glioblastoma None None O
multiforme None None O
: None None O
a None None O
series None None O
of None None O
13 None None O
cases None None O
. None None O

OBJECT None None O
: None None O
Endothelial None None O
proliferation None None O
has None None O
been None None O
recognized None None O
as None None O
a None None O
marker None None O
of None None O
high None None O
- None None O
grade None None O
or None None O
aggressive None None O
glioma None None O
. None None O

Bevacizumab None None O
is None None O
a None None O
humanized None None O
immunoglobulin None None O
G1 None None O
monoclonal None None O
antibody None None O
to None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
that None None O
has None None O
been None None O
shown None None O
to None None O
have None None O
activity None None O
in None None O
malignant None None O
gliomas None None O
when None None O
combined None None O
with None None O
irinotecan None None O
. None None O

The None None O
authors None None O
report None None O
on None None O
a None None O
case None None O
series None None O
of None None O
13 None None O
patients None None O
with None None O
recurrent None None O
heavily None None O
pretreated None None O
malignant None None O
glioma None None O
that None None O
was None None O
treated None None O
with None None O
the None None O
combination None None O
of None None O
bevacizumab None None O
and None None O
irinotecan None None O
. None None O

METHODS None None O
: None None O
Standard None None O
therapy None None O
with None None O
primary None None O
resection None None O
followed None None O
by None None O
adjuvant None None O
chemotherapy None None O
and None None O
radiation None None O
had None None O
failed None None O
in None None O
all None None O
patients None None O
. None None O

The None None O
median None None O
number None None O
of None None O
therapies None None O
applied None None O
, None None O
including None None O
initial None None O
surgery None None O
, None None O
was None None O
5 None None O
( None None O
range None None O
3 None None O
- None None O
7 None None O
therapies None None O
) None None O
. None None O

Nine None None O
patients None None O
were None None O
started None None O
on None None O
bevacizumab None None O
at None None O
a None None O
dose None None O
of None None O
5 None None O
mg None None O
/ None None O
m2 None None O
every None None O
2 None None O
weeks None None O
. None None O

Four None None O
patients None None O
received None None O
bevacizumab None None O
at None None O
a None None O
dose None None O
of None None O
10 None None O
mg None None O
/ None None O
m2 None None O
; None None O
irinotecan None None O
was None None O
given None None O
at None None O
a None None O
dose None None O
of None None O
125 None None O
mg None None O
/ None None O
m2 None None O
every None None O
week None None O
for None None O
3 None None O
weeks None None O
. None None O

RESULTS None None O
: None None O
Of None None O
the None None O
13 None None O
treated None None O
patients None None O
, None None O
10 None None O
( None None O
77 None None O
% None None O
) None None O
had None None O
a None None O
radiologically None None O
demonstrated None None O
partial None None O
response None None O
and None None O
3 None None O
( None None O
23 None None O
% None None O
) None None O
had None None O
stable None None O
disease None None O
. None None O

Six None None O
patients None None O
( None None O
46 None None O
% None None O
) None None O
had None None O
a None None O
clinical None None O
response None None O
. None None O

The None None O
median None None O
time None None O
to None None O
disease None None O
progression None None O
while None None O
on None None O
treatment None None O
was None None O
24 None None O
weeks None None O
. None None O

The None None O
median None None O
overall None None O
survival None None O
was None None O
27 None None O
weeks None None O
. None None O

The None None O
disease None None O
progressed None None O
in None None O
8 None None O
patients None None O
, None None O
despite None None O
an None None O
initial None None O
response None None O
. None None O

Five None None O
patients None None O
are None None O
still None None O
responding None None O
to None None O
therapy None None O
. None None O

Six None None O
of None None O
the None None O
8 None None O
patients None None O
whose None None O
disease None None O
progressed None None O
have None None O
died None None O
. None None O

Bevacizumab None None O
was None None O
discontinued None None O
in None None O
2 None None O
patients None None O
because None None O
of None None O
nonfatal None None O
intracranial None None O
bleeding None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
combination None None O
of None None O
bevacizumab None None O
and None None O
irinotecan None None O
is None None O
safe None None O
and None None O
has None None O
excellent None None O
activity None None O
even None None O
in None None O
this None None O
relapsed None None O
, None None O
heavily None None O
pretreated None None O
population None None O
of None None O
patients None None O
with None None O
high None None O
- None None O
grade None None O
malignant None None O
glioma None None O
, None None O
most None None O
of None None O
whom None None O
would None None O
not None None O
be None None O
candidates None None O
for None None O
clinical None None O
trials None None O
. None None O

FAS None None O
- None None O
1377 None None O
G None None O
/ None None O
A None None O
polymorphism None None O
and None None O
the None None O
risk None None O
of None None O
lymph None None O
node None None O
metastasis None None O
in None None O
cervical None None O
cancer None None O
. None None O

Single None None O
- None None O
nucleotide None None O
polymorphisms None None O
of None None O
the None None O
FAS None None O
- None None O
1377G None None O
/ None None O
A None None O
, None None O
FAS None None O
- None None O
670A None None O
/ None None O
G None None O
, None None O
and None None O
FASL None None O
- None None O
844T None None O
/ None None O
C None None O
genes None None O
may None None O
alter None None O
transcriptional None None O
activity None None O
of None None O
these None None O
genes None None O
. None None O

Recent None None O
evidence None None O
suggests None None O
an None None O
association None None O
of None None O
these None None O
polymorphisms None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
cervical None None O
cancer None None O
, None None O
so None None O
we None None O
explored None None O
this None None O
relationship None None O
. None None O

Genotypes None None O
of None None O
155 None None O
patients None None O
with None None O
cervical None None O
cancer None None O
and None None O
160 None None O
healthy None None O
control None None O
subjects None None O
were None None O
determined None None O
using None None O
polymerase None None O
chain None None O
reaction None None O
- None None O
based None None O
restriction None None O
fragment None None O
length None None O
polymorphism None None O
( None None O
PCR None None O
- None None O
RFLP None None O
) None None O
. None None O

Associations None None O
with None None O
cancer None None O
risk None None O
were None None O
estimated None None O
using None None O
two None None O
- None None O
sided None None O
logistic None None O
regression None None O
. None None O

We None None O
observed None None O
a None None O
significantly None None O
increased None None O
risk None None O
of None None O
lymph None None O
node None None O
metastasis None None O
associated None None O
with None None O
the None None O
FAS None None O
- None None O
1377 None None O
GA None None O
or None None O
AA None None O
polymorphism None None O
[ None None O
odds None None O
ratio None None O
( None None O
OR None None O
) None None O
= None None O
4 None None O
. None None O
16 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
= None None O
1 None None O
. None None O
10 None None O
to None None O
15 None None O
. None None O
74 None None O
; None None O
P None None O
= None None O
0 None None O
. None None O
036 None None O
] None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
FAS None None O
- None None O
670AG None None O
or None None O
GG None None O
genotype None None O
showed None None O
an None None O
increased None None O
incidence None None O
of None None O
node None None O
metastasis None None O
, None None O
but None None O
these None None O
findings None None O
were None None O
not None None O
statistically None None O
significant None None O
( None None O
OR None None O
= None None O
3 None None O
. None None O
67 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
0 None None O
. None None O
96 None None O
- None None O
14 None None O
. None None O
00 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
059 None None O
) None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
association None None O
between None None O
an None None O
increased None None O
risk None None O
of None None O
cervical None None O
cancer None None O
and None None O
polymorphisms None None O
of None None O
the None None O
death None None O
pathway None None O
genes None None O
FAS None None O
and None None O
FASL None None O
. None None O

None None None O
of None None O
the None None O
polymorphisms None None O
were None None O
associated None None O
with None None O
risk None None O
of None None O
advanced None None O
stage None None O
or None None O
histologic None None O
subtype None None O
of None None O
cervical None None O
cancer None None O
. None None O

In None None O
conclusion None None O
, None None O
FAS None None O
- None None O
1377 None None O
G None None O
- None None O
- None None O
> None None O
A None None O
polymorphism None None O
may None None O
be None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
lymph None None O
node None None O
metastasis None None O
in None None O
Korean None None O
cervical None None O
cancer None None O
patients None None O
. None None O

Role None None O
of None None O
the None None O
interferon None None O
- None None O
inducible None None O
IFI16 None None O
gene None None O
in None None O
the None None O
induction None None O
of None None O
ICAM None None O
- None None O
1 None None O
by None None O
TNF None None O
- None None O
alpha None None O
. None None O

The None None O
Interferon None None O
- None None O
inducible None None O
gene None None O
IFI16 None None O
, None None O
a None None O
member None None O
of None None O
the None None O
HIN200 None None O
family None None O
, None None O
is None None O
activated None None O
by None None O
oxidative None None O
stress None None O
and None None O
cell None None O
density None None O
, None None O
in None None O
addition None None O
to None None O
Interferons None None O
, None None O
and None None O
it None None O
is None None O
implicated None None O
in None None O
the None None O
regulation None None O
of None None O
endothelial None None O
cell None None O
proliferation None None O
and None None O
vessel None None O
formation None None O
in None None O
vitro None None O
. None None O

We None None O
have None None O
previously None None O
shown None None O
that None None O
IFI16 None None O
is None None O
required None None O
for None None O
proinflammatory None None O
gene None None O
stimulation None None O
by None None O
IFN None None O
- None None O
gamma None None O
through None None O
the None None O
NF None None O
- None None O
kappaB None None O
complex None None O
. None None O

To None None O
examine None None O
whether None None O
IFI16 None None O
induction None None O
might None None O
be None None O
extended None None O
to None None O
other None None O
proinflammatory None None O
cytokines None None O
such None None O
as None None O
tumor None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
- None None O
alpha None None O
, None None O
we None None O
used None None O
the None None O
strategy None None O
of None None O
the None None O
RNA None None O
interference None None O
to None None O
knock None None O
down None None O
IFI16 None None O
expression None None O
, None None O
and None None O
analyze None None O
the None None O
capability None None O
of None None O
TNF None None O
- None None O
alpha None None O
to None None O
stimulate None None O
intercellular None None O
adhesion None None O
molecule None None O
- None None O
1 None None O
( None None O
ICAM None None O
- None None O
1 None None O
or None None O
CD54 None None O
) None None O
expression None None O
in None None O
the None None O
absence None None O
of None None O
functional None None O
IFI16 None None O
. None None O

Our None None O
studies None None O
demonstrate None None O
that None None O
IFI16 None None O
mediates None None O
ICAM None None O
- None None O
1 None None O
stimulation None None O
by None None O
TNF None None O
- None None O
alpha None None O
through None None O
the None None O
NF None None O
- None None O
kappaB None None O
pathway None None O
, None None O
thus None None O
reinforcing None None O
the None None O
role None None O
of None None O
the None None O
IFI16 None None O
molecule None None O
in None None O
the None None O
inflammation None None O
process None None O
. None None O

Killing None None O
tumor None None O
cells None None O
through None None O
their None None O
surface None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
microglobulin None None O
or None None O
major None None O
histocompatibility None None O
complex None None O
class None None O
I None None O
molecules None None O
. None None O

Targeted None None O
antibody None None O
- None None O
based None None O
therapy None None O
has None None O
been None None O
used None None O
successfully None None O
to None None O
treat None None O
cancers None None O
. None None O

Recent None None O
studies None None O
have None None O
demonstrated None None O
that None None O
tumor None None O
cells None None O
treated None None O
with None None O
antibodies None None O
specific None None O
for None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
microglobulin None None O
( None None O
beta None None O
( None None O
2 None None O
) None None O
M None None O
) None None O
or None None O
major None None O
histocompatibility None None O
complex None None O
( None None O
MHC None None O
) None None O
class None None O
I None None O
molecules None None O
undergo None None O
apoptosis None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
( None None O
mouse None None O
models None None O
) None None O
. None None O

Antibodies None None O
against None None O
beta None None O
( None None O
2 None None O
) None None O
M None None O
or None None O
MHC None None O
class None None O
I None None O
induce None None O
tumor None None O
cell None None O
apoptosis None None O
by None None O
1 None None O
) None None O
recruiting None None O
MHC None None O
class None None O
I None None O
molecules None None O
to None None O
lipid None None O
rafts None None O
and None None O
activating None None O
LYN None None O
kinase None None O
and None None O
the None None O
signal None None O
- None None O
transducing None None O
enzyme None None O
phospholipase None None O
C None None O
- None None O
gamma2 None None O
- None None O
dependent None None O
c None None O
- None None O
Jun None None O
N None None O
- None None O
terminal None None O
kinase None None O
signaling None None O
pathway None None O
and None None O
2 None None O
) None None O
expelling None None O
interleukin None None O
6 None None O
and None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
1 None None O
receptors None None O
out None None O
of None None O
lipid None None O
rafts None None O
and None None O
inhibiting None None O
the None None O
growth None None O
and None None O
survival None None O
factor None None O
- None None O
induced None None O
activation None None O
of None None O
the None None O
phosphatidylinositol None None O
3 None None O
- None None O
kinase None None O
/ None None O
Akt None None O
and None None O
extracellular None None O
signal None None O
- None None O
related None None O
kinase None None O
pathways None None O
. None None O

Consequently None None O
, None None O
mitochondrial None None O
integrity None None O
is None None O
compromised None None O
, None None O
and None None O
the None None O
caspase None None O
- None None O
9 None None O
- None None O
dependent None None O
cascade None None O
is None None O
activated None None O
in None None O
treated None None O
tumor None None O
cells None None O
. None None O

However None None O
, None None O
although None None O
beta None None O
( None None O
2 None None O
) None None O
M None None O
and None None O
MHC None None O
class None None O
I None None O
are None None O
expressed None None O
on None None O
normal None None O
hematopoietic None None O
cells None None O
, None None O
which None None O
is None None O
a None None O
potential None None O
safety None None O
concern None None O
, None None O
the None None O
monoclonal None None O
antibodies None None O
were None None O
selective None None O
to None None O
tumor None None O
cells None None O
and None None O
did None None O
not None None O
damage None None O
normal None None O
cells None None O
in None None O
vitro None None O
or None None O
in None None O
human None None O
- None None O
like None None O
mouse None None O
models None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
targeting None None O
beta None None O
( None None O
2 None None O
) None None O
M None None O
or None None O
MHC None None O
class None None O
I None None O
by None None O
using None None O
antibodies None None O
or None None O
other None None O
agents None None O
offers None None O
a None None O
potential None None O
therapeutic None None O
approach None None O
for None None O
beta None None O
( None None O
2 None None O
) None None O
M None None O
/ None None O
MHC None None O
class None None O
I None None O
- None None O
expressing None None O
malignancies None None O
. None None O

Cancer None None O
2010 None None O
. None None O

( None None O
c None None O
) None None O
2010 None None O
American None None O
Cancer None None O
Society None None O
. None None O

Preparation None None O
and None None O
physicochemical None None O
and None None O
immunological None None O
characterization None None O
of None None O
polysaccharide None None O
- None None O
outer None None O
membrane None None O
protein None None O
complexes None None O
of None None O
Neisseria None None O
meningitidis None None O
. None None O

A None None O
crude None None O
complex None None O
containing None None O
group None None O
C None None O
polysaccharide None None O
, None None O
outer None None O
membrane None None O
proteins None None O
, None None O
and None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
was None None O
isolated None None O
from None None O
the None None O
cell None None O
- None None O
free None None O
culture None None O
liquid None None O
of None None O
Neisseria None None O
meningitidis None None O
serogroup None None O
C None None O
, None None O
serotype None None O
2a None None O
. None None O

Group None None O
C None None O
polysaccharide None None O
and None None O
LPS None None O
were None None O
removed None None O
from None None O
this None None O
complex None None O
, None None O
resulting None None O
in None None O
an None None O
outer None None O
membrane None None O
complex None None O
and None None O
a None None O
purified None None O
complex None None O
, None None O
respectively None None O
. None None O

Analysis None None O
by None None O
electron None None O
microscopy None None O
showed None None O
the None None O
outer None None O
membrane None None O
origin None None O
of None None O
the None None O
crude None None O
complex None None O
and None None O
the None None O
outer None None O
membrane None None O
complex None None O
, None None O
whereas None None O
such None None O
a None None O
structure None None O
was None None O
absent None None O
in None None O
the None None O
purified None None O
complex None None O
. None None O

Sodium None None O
dodecyl None None O
sulfate None None O
- None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
patterns None None O
of None None O
the None None O
three None None O
complexes None None O
were None None O
identical None None O
. None None O

Pyrolysis None None O
- None None O
mass None None O
spectrometry None None O
data None None O
correlated None None O
well None None O
with None None O
those None None O
obtained None None O
by None None O
the None None O
biochemical None None O
assays None None O
and None None O
suggested None None O
a None None O
low None None O
LPS None None O
content None None O
in None None O
the None None O
purified None None O
complex None None O
and None None O
a None None O
low None None O
polysaccharide None None O
content None None O
in None None O
the None None O
outer None None O
membrane None None O
complex None None O
. None None O

The None None O
purified None None O
complex None None O
was None None O
shown None None O
to None None O
be None None O
nonpyrogenic None None O
and None None O
could None None O
be None None O
prepared None None O
with None None O
the None None O
same None None O
yield None None O
as None None O
that None None O
of None None O
purified None None O
polysaccharide None None O
. None None O

The None None O
immunogenic None None O
activities None None O
of None None O
the None None O
complexes None None O
were None None O
studied None None O
in None None O
mice None None O
. None None O

The None None O
antibodies None None O
were None None O
measured None None O
by None None O
the None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
; None None O
and None None O
the None None O
bactericidal None None O
antibody None None O
assay None None O
. None None O

All None None O
complexes None None O
induced None None O
immunoglobulin None None O
G None None O
antibodies None None O
to None None O
group None None O
C None None O
polysaccharide None None O
as None None O
well None None O
as None None O
to None None O
the None None O
serotype None None O
antigen None None O
, None None O
although None None O
the None None O
removal None None O
of None None O
polysaccharide None None O
and None None O
LPS None None O
resulted None None O
in None None O
a None None O
reduction None None O
of None None O
the None None O
immunogenic None None O
activities None None O
of None None O
outer None None O
membrane None None O
complex None None O
and None None O
purified None None O
complex None None O
, None None O
respectively None None O
. None None O

A None None O
second None None O
dose None None O
of None None O
all None None O
complexes None None O
produced None None O
a None None O
clear None None O
booster None None O
effect None None O
of None None O
both None None O
antibody None None O
responses None None O
. None None O

The None None O
antibodies None None O
were None None O
bactericidal None None O
. None None O

Adaptive None None O
landscapes None None O
and None None O
emergent None None O
phenotypes None None O
: None None O
why None None O
do None None O
cancers None None O
have None None O
high None None O
glycolysis None None O
? None None O

Investigating None None O
the None None O
causes None None O
of None None O
increased None None O
aerobic None None O
glycolysis None None O
in None None O
tumors None None O
( None None O
Warburg None None O
Effect None None O
) None None O
has None None O
gone None None O
in None None O
and None None O
out None None O
of None None O
fashion None None O
many None None O
times None None O
since None None O
it None None O
was None None O
first None None O
described None None O
almost None None O
a None None O
century None None O
ago None None O
. None None O

The None None O
field None None O
is None None O
currently None None O
in None None O
ascendance None None O
due None None O
to None None O
two None None O
factors None None O
. None None O

Over None None O
a None None O
million None None O
FDG None None O
- None None O
PET None None O
studies None None O
have None None O
unequivocally None None O
identified None None O
increased None None O
glucose None None O
uptake None None O
as None None O
a None None O
hallmark None None O
of None None O
metastatic None None O
cancer None None O
in None None O
humans None None O
. None None O

These None None O
observations None None O
, None None O
combined None None O
with None None O
new None None O
molecular None None O
insights None None O
with None None O
HIF None None O
- None None O
1alpha None None O
and None None O
c None None O
- None None O
myc None None O
, None None O
have None None O
rekindled None None O
an None None O
interest None None O
in None None O
this None None O
important None None O
phenotype None None O
. None None O

A None None O
preponderance None None O
of None None O
work None None O
has None None O
been None None O
focused None None O
on None None O
the None None O
molecular None None O
mechanisms None None O
underlying None None O
this None None O
effect None None O
, None None O
with None None O
the None None O
expectation None None O
that None None O
a None None O
mechanistic None None O
understanding None None O
may None None O
lead None None O
to None None O
novel None None O
therapeutic None None O
approaches None None O
. None None O

There None None O
is None None O
also None None O
an None None O
implicit None None O
assumption None None O
that None None O
a None None O
mechanistic None None O
understanding None None O
, None None O
although None None O
fundamentally None None O
reductionist None None O
, None None O
will None None O
nonetheless None None O
lead None None O
to None None O
a None None O
more None None O
profound None None O
teleological None None O
understanding None None O
of None None O
the None None O
need None None O
for None None O
altered None None O
metabolism None None O
in None None O
invasive None None O
cancers None None O
. None None O

In None None O
this None None O
communication None None O
, None None O
we None None O
describe None None O
an None None O
alternative None None O
approach None None O
that None None O
begins None None O
with None None O
teleology None None O
; None None O
i None None O
. None None O
e None None O
. None None O
adaptive None None O
landscapes None None O
and None None O
selection None None O
pressures None None O
that None None O
promote None None O
emergence None None O
of None None O
aerobic None None O
glycolysis None None O
during None None O
the None None O
somatic None None O
evolution None None O
of None None O
invasive None None O
cancer None None O
. None None O

Mathematical None None O
models None None O
and None None O
empirical None None O
observations None None O
are None None O
used None None O
to None None O
define None None O
the None None O
adaptive None None O
advantage None None O
of None None O
aerobic None None O
glycolysis None None O
that None None O
would None None O
explain None None O
its None None O
remarkable None None O
prevalence None None O
in None None O
human None None O
cancers None None O
. None None O

These None None O
studies None None O
have None None O
led None None O
to None None O
the None None O
hypothesis None None O
that None None O
increased None None O
consumption None None O
of None None O
glucose None None O
in None None O
metastatic None None O
lesions None None O
is None None O
not None None O
used None None O
for None None O
substantial None None O
energy None None O
production None None O
via None None O
Embden None None O
- None None O
Meyerhoff None None O
glycolysis None None O
, None None O
but None None O
rather None None O
for None None O
production None None O
of None None O
acid None None O
, None None O
which None None O
gives None None O
the None None O
cancer None None O
cells None None O
a None None O
competitive None None O
advantage None None O
for None None O
invasion None None O
. None None O

Alternative None None O
hypotheses None None O
, None None O
wherein None None O
the None None O
glucose None None O
is None None O
used None None O
for None None O
generation None None O
of None None O
reducing None None O
equivalents None None O
( None None O
NADPH None None O
) None None O
or None None O
anabolic None None O
precursors None None O
( None None O
ribose None None O
) None None O
are None None O
also None None O
discussed None None O
. None None O

p21 None None O
delays None None O
tumor None None O
onset None None O
by None None O
preservation None None O
of None None O
chromosomal None None O
stability None None O
. None None O

The None None O
p53 None None O
protein None None O
suppresses None None O
tumorigenesis None None O
by None None O
initiating None None O
cellular None None O
functions None None O
such None None O
as None None O
cell None None O
cycle None None O
arrest None None O
and None None O
apoptosis None None O
in None None O
response None None O
to None None O
DNA None None O
damage None None O
. None None O

A None None O
p53 None None O
mutant None None O
, None None O
p53R172P None None O
, None None O
which None None O
is None None O
deficient None None O
for None None O
apoptosis None None O
but None None O
retains None None O
a None None O
partial None None O
cell None None O
cycle None None O
arrest None None O
function None None O
, None None O
delays None None O
tumor None None O
onset None None O
in None None O
mice None None O
. None None O

Remarkably None None O
, None None O
lymphomas None None O
arising None None O
in None None O
Trp53 None None O
( None None O
515C None None O
/ None None O
515C None None O
) None None O
mice None None O
( None None O
encoding None None O
p53R172P None None O
) None None O
retain None None O
stable None None O
genomes None None O
. None None O

Given None None O
the None None O
dominant None None O
role None None O
of None None O
p21 None None O
in None None O
p53 None None O
cell None None O
cycle None None O
control None None O
, None None O
we None None O
crossed None None O
Trp53 None None O
( None None O
515C None None O
/ None None O
515C None None O
) None None O
mice None None O
onto None None O
a None None O
p21 None None O
- None None O
null None None O
background None None O
to None None O
determine None None O
whether None None O
p21 None None O
was None None O
required None None O
for None None O
maintaining None None O
chromosomal None None O
stability None None O
and None None O
delaying None None O
tumor None None O
onset None None O
. None None O

Loss None None O
of None None O
p21 None None O
completely None None O
abolished None None O
the None None O
cell None None O
cycle None None O
arrest None None O
function None None O
of None None O
p53R172P None None O
and None None O
accelerated None None O
tumor None None O
onset None None O
in None None O
Trp53 None None O
( None None O
515C None None O
/ None None O
515C None None O
) None None O
mice None None O
. None None O

Cytogenetic None None O
examination None None O
of None None O
Trp53 None None O
( None None O
515C None None O
/ None None O
515C None None O
) None None O
p21 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
sarcomas None None O
and None None O
lymphomas None None O
revealed None None O
aneuploidy None None O
and None None O
chromosomal None None O
aberrations None None O
that None None O
were None None O
absent None None O
in None None O
Trp53 None None O
( None None O
515C None None O
/ None None O
515C None None O
) None None O
malignancies None None O
. None None O

Thus None None O
, None None O
p21 None None O
coupled None None O
p53 None None O
- None None O
dependent None None O
checkpoint None None O
control None None O
and None None O
preservation None None O
of None None O
chromosomal None None O
stability None None O
, None None O
and None None O
cooperated None None O
with None None O
apoptosis None None O
in None None O
suppressing None None O
tumor None None O
onset None None O
in None None O
mice None None O
. None None O

Expression None None O
of None None O
thymidylate None None O
synthase None None O
and None None O
dihydropyrimidine None None O
dehydrogenase None None O
in None None O
primary None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
and None None O
corresponding None None O
metastases None None O
in None None O
cervical None None O
lymph None None O
nodes None None O
: None None O
association None None O
with None None O
the None None O
metastasis None None O
suppressor None None O
CD82 None None O
. None None O

Thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
and None None O
dihydropyrimidine None None O
dehydrogenase None None O
( None None O
DPD None None O
) None None O
are None None O
5 None None O
- None None O
fluorouracil None None O
( None None O
5 None None O
- None None O
FU None None O
) None None O
metabolizing None None O
enzymes None None O
and None None O
are None None O
involved None None O
in None None O
the None None O
sensitivity None None O
of None None O
carcinoma None None O
patients None None O
to None None O
5 None None O
- None None O
FU None None O
. None None O

Although None None O
5 None None O
- None None O
FU None None O
is None None O
often None None O
used None None O
for None None O
the None None O
treatment None None O
of None None O
oral None None O
carcinoma None None O
, None None O
there None None O
has None None O
not None None O
been None None O
any None None O
investigation None None O
into None None O
the None None O
expression None None O
of None None O
these None None O
enzymes None None O
in None None O
metastatic None None O
lymph None None O
nodes None None O
or None None O
of None None O
their None None O
roles None None O
in None None O
the None None O
effectiveness None None O
of None None O
5 None None O
- None None O
FU None None O
in None None O
treating None None O
lymph None None O
node None None O
- None None O
metastatic None None O
cancer None None O
. None None O

Oral None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
OSCC None None O
) None None O
often None None O
metastasizes None None O
to None None O
the None None O
lymph None None O
nodes None None O
, None None O
and None None O
these None None O
enzymes None None O
may None None O
be None None O
significant None None O
in None None O
the None None O
survival None None O
of None None O
patients None None O
with None None O
this None None O
disease None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
expression None None O
of None None O
TS None None O
and None None O
DPD None None O
in None None O
cervical None None O
lymph None None O
node None None O
metastases None None O
and None None O
its None None O
relationship None None O
with None None O
primary None None O
OSCC None None O
, None None O
as None None O
well None None O
as None None O
the None None O
interaction None None O
between None None O
these None None O
enzymes None None O
and None None O
Kangai None None O
1 None None O
( None None O
KAI1 None None O
/ None None O
CD82 None None O
) None None O
which None None O
is None None O
a None None O
metastasis None None O
suppressor None None O
protein None None O
. None None O

Surgical None None O
specimens None None O
from None None O
20 None None O
cases None None O
of None None O
OSCC None None O
with None None O
lymph None None O
node None None O
metastasis None None O
, None None O
20 None None O
cases None None O
of None None O
OSCC None None O
without None None O
lymph None None O
node None None O
metastasis None None O
, None None O
and None None O
10 None None O
cases None None O
of None None O
normal None None O
mucosa None None O
were None None O
examined None None O
by None None O
immunohistochemistry None None O
. None None O

The None None O
relationship None None O
between None None O
TS None None O
and None None O
DPD None None O
expression None None O
and None None O
clinicopathological None None O
data None None O
was None None O
analyzed None None O
. None None O

TS None None O
and None None O
DPD None None O
proteins None None O
were None None O
overexpressed None None O
in None None O
primary None None O
OSCC None None O
compared None None O
to None None O
that None None O
in None None O
normal None None O
mucosa None None O
. None None O

TS None None O
expression None None O
of None None O
the None None O
primary None None O
oral None None O
cancer None None O
cells None None O
in None None O
the None None O
group None None O
with None None O
lymph None None O
node None None O
metastasis None None O
was None None O
higher None None O
than None None O
that None None O
of None None O
those None None O
without None None O
. None None O

DPD None None O
expression None None O
did None None O
not None None O
significantly None None O
correlate None None O
with None None O
the None None O
occurrence None None O
of None None O
lymph None None O
node None None O
metastasis None None O
, None None O
nor None None O
was None None O
it None None O
different None None O
between None None O
primary None None O
oral None None O
cancer None None O
cells None None O
and None None O
cervical None None O
metastases None None O
. None None O

CD82 None None O
expression None None O
was None None O
significantly None None O
reduced None None O
in None None O
lymph None None O
node None None O
metastases None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
TS None None O
and None None O
CD82 None None O
may None None O
be None None O
of None None O
great None None O
value None None O
in None None O
assessing None None O
lymph None None O
node None None O
metastasis None None O
of None None O
OSCC None None O
, None None O
and None None O
could None None O
be None None O
taken None None O
as None None O
new None None O
targets None None O
for None None O
therapy None None O
of None None O
metastatic None None O
OSCC None None O
. None None O

Androgen None None O
stimulates None None O
glycolysis None None O
for None None O
de None None O
novo None None O
lipid None None O
synthesis None None O
by None None O
increasing None None O
the None None O
activities None None O
of None None O
hexokinase None None O
2 None None O
and None None O
6 None None O
- None None O
phosphofructo None None O
- None None O
2 None None O
- None None O
kinase None None O
/ None None O
fructose None None O
- None None O
2 None None O
, None None O
6 None None O
- None None O
bisphosphatase None None O
2 None None O
in None None O
prostate None None O
cancer None None O
cells None None O
. None None O

Up None None O
- None None O
regulation None None O
of None None O
lipogenesis None None O
by None None O
androgen None None O
is None None O
one None None O
of None None O
the None None O
most None None O
characteristic None None O
metabolic None None O
features None None O
of None None O
LNCaP None None I-Cell-line-name
prostate None None O
cancer None None O
cells None None O
. None None O

The None None O
present None None O
study None None O
revealed None None O
that None None O
androgen None None O
increases None None O
glucose None None O
utilization None None O
for None None O
de None None O
novo None None O
lipogenesis None None O
in None None O
LNCaP None None I-Cell-line-name
cells None None O
through None None O
the None None O
activation None None O
of None None O
HK2 None None O
( None None O
hexokinase None None O
2 None None O
) None None O
and None None O
activation None None O
of None None O
the None None O
cardiac None None O
isoform None None O
of None None O
PFKFB2 None None O
( None None O
6 None None O
- None None O
phosphofructo None None O
- None None O
2 None None O
- None None O
kinase None None O
/ None None O
fructose None None O
- None None O
2 None None O
, None None O
6 None None O
- None None O
bisphosphatase None None O
) None None O
. None None O

Activation None None O
of None None O
PKA None None O
( None None O
cAMP None None O
- None None O
dependent None None O
protein None None O
kinase None None O
) None None O
by None None O
androgen None None O
increased None None O
phosphorylation None None O
of None None O
CREB None None O
[ None None O
CRE None None O
( None None O
cAMP None None O
- None None O
response None None O
element None None O
) None None O
- None None O
binding None None O
protein None None O
] None None O
, None None O
which None None O
in None None O
turn None None O
bound None None O
to None None O
CRE None None O
on None None O
the None None O
promoter None None O
of None None O
the None None O
HK2 None None O
gene None None O
resulting None None O
in None None O
transcriptional None None O
activation None None O
of None None O
the None None O
HK2 None None O
gene None None O
. None None O

Up None None O
- None None O
regulation None None O
of None None O
PFKFB2 None None O
expression None None O
was None None O
mediated None None O
by None None O
the None None O
direct None None O
binding None None O
of None None O
ligand None None O
- None None O
activated None None O
androgen None None O
receptor None None O
to None None O
the None None O
PFKFB2 None None O
promoter None None O
. None None O

The None None O
activated None None O
PI3K None None O
( None None O
phosphoinositide None None O
3 None None O
- None None O
kinase None None O
) None None O
/ None None O
Akt None None O
signalling None None O
pathway None None O
in None None O
LNCaP None None I-Cell-line-name
cells None None O
contributes None None O
to None None O
the None None O
phosphorylation None None O
of None None O
PFKFB2 None None O
at None None O
Ser466 None None O
and None None O
Ser483 None None O
, None None O
resulting None None O
in None None O
the None None O
constitutive None None O
activation None None O
of None None O
PFK None None O
- None None O
2 None None O
( None None O
6 None None O
- None None O
phosphofructo None None O
- None None O
2 None None O
- None None O
kinase None None O
) None None O
activity None None O
. None None O

Glucose None None O
uptake None None O
and None None O
lipogenesis None None O
were None None O
severely None None O
blocked None None O
by None None O
knocking None None O
- None None O
down None None O
of None None O
PFKFB2 None None O
using None None O
siRNA None None O
( None None O
small None None O
interfering None None O
RNA None None O
) None None O
or None None O
by None None O
inhibition None None O
of None None O
PFK None None O
- None None O
2 None None O
activity None None O
with None None O
LY294002 None None O
treatment None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
the None None O
induction None None O
of None None O
de None None O
novo None None O
lipid None None O
synthesis None None O
by None None O
androgen None None O
requires None None O
the None None O
transcriptional None None O
up None None O
- None None O
regulation None None O
of None None O
HK2 None None O
and None None O
PFKFB2 None None O
, None None O
and None None O
phosphorylation None None O
of None None O
PFKFB2 None None O
generated None None O
by None None O
the None None O
PI3K None None O
/ None None O
Akt None None O
signalling None None O
pathway None None O
to None None O
supply None None O
the None None O
source None None O
for None None O
lipogenesis None None O
from None None O
glucose None None O
in None None O
prostate None None O
cancer None None O
cells None None O
. None None O

The None None O
element None None O
effect None None O
and None None O
nucleophilicity None None O
in None None O
nucleophilic None None O
aromatic None None O
photosubstitution None None O
( None None O
SN2Ar None None O
* None None O
) None None O
. None None O

Local None None O
atom None None O
effects None None O
as None None O
mechanistic None None O
probes None None O
of None None O
very None None O
fast None None O
reactions None None O
. None None O

Photoreactions None None O
of None None O
4 None None O
- None None O
nitroanisole None None O
and None None O
the None None O
2 None None O
- None None O
halo None None O
- None None O
4 None None O
- None None O
nitroanisoles None None O
( None None O
halogen None None O
= None None O
F None None O
, None None O
Cl None None O
, None None O
Br None None O
, None None O
and None None O
I None None O
) None None O
with None None O
the None None O
nucleophiles None None O
hydroxide None None O
ion None None O
and None None O
pyridine None None O
have None None O
been None None O
investigated None None O
quantitatively None None O
to None None O
extend None None O
the None None O
findings None None O
recently None None O
communicated None None O
for None None O
cyanide None None O
ion None None O
. None None O

The None None O
halonitroanisoles None None O
on None None O
excitation None None O
form None None O
triplet None None O
pi None None O
, None None O
pi None None O
* None None O
states None None O
, None None O
which None None O
undergo None None O
substitution None None O
of None None O
the None None O
halogen None None O
by None None O
nucleophiles None None O
. None None O

Chemical None None O
yields None None O
of None None O
photoproducts None None O
, None None O
Stern None None O
- None None O
Volmer None None O
kinetic None None O
plots None None O
, None None O
triplet None None O
lifetimes None None O
, None None O
and None None O
triplet None None O
yields None None O
are None None O
reported None None O
for None None O
the None None O
five None None O
compounds None None O
with None None O
the None None O
three None None O
nucleophiles None None O
. None None O

Following None None O
a None None O
standard None None O
kinetic None None O
treatment None None O
, None None O
73 None None O
rate None None O
constants None None O
are None None O
determined None None O
for None None O
elementary None None O
reactions None None O
of None None O
the None None O
triplets None None O
including None None O
quenching None None O
and None None O
various None None O
nucleophilic None None O
addition None None O
processes None None O
. None None O

The None None O
photoadditions None None O
are None None O
roughly None None O
14 None None O
orders None None O
of None None O
magnitude None None O
faster None None O
than None None O
thermal None None O
counterparts None None O
. None None O

Rate None None O
constants None None O
for None None O
attack None None O
at None None O
the None None O
fluorine None None O
- None None O
bearing None None O
carbon None None O
of None None O
triplet None None O
2 None None O
- None None O
fluoro None None O
- None None O
4 None None O
- None None O
nitroanisole None None O
are None None O
2 None None O
. None None O
9 None None O
x None None O
10 None None O
( None None O
9 None None O
) None None O
, None None O
1 None None O
. None None O
3 None None O
x None None O
10 None None O
( None None O
9 None None O
) None None O
, None None O
and None None O
6 None None O
. None None O
3 None None O
x None None O
10 None None O
( None None O
8 None None O
) None None O
M None None O
( None None O
- None None O
1 None None O
) None None O
s None None O
( None None O
- None None O
1 None None O
) None None O
for None None O
cyanide None None O
ion None None O
, None None O
hydroxide None None O
ion None None O
, None None O
and None None O
pyridine None None O
, None None O
respectively None None O
. None None O

The None None O
relative None None O
rates None None O
for None None O
attack None None O
at None None O
the None None O
halogen None None O
- None None O
bearing None None O
carbons None None O
for None None O
F None None O
/ None None O
Cl None None O
/ None None O
Br None None O
/ None None O
I None None O
are None None O
27 None None O
: None None O
1 None None O
. None None O
9 None None O
: None None O
1 None None O
. None None O
9 None None O
: None None O
1 None None O
( None None O
cyanide None None O
ion None None O
) None None O
, None None O
29 None None O
: None None O
2 None None O
. None None O
6 None None O
: None None O
2 None None O
. None None O
4 None None O
: None None O
1 None None O
( None None O
hydroxide None None O
ion None None O
) None None O
, None None O
and None None O
39 None None O
: None None O
3 None None O
. None None O
9 None None O
: None None O
3 None None O
. None None O
5 None None O
: None None O
1 None None O
( None None O
pyridine None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
relative None None O
nucleophilicities None None O
vary None None O
somewhat None None O
with None None O
the None None O
attack None None O
site None None O
; None None O
they None None O
are None None O
about None None O
5 None None O
: None None O
2 None None O
: None None O
1 None None O
for None None O
cyanide None None O
ion None None O
, None None O
hydroxide None None O
ion None None O
, None None O
and None None O
pyridine None None O
for None None O
attack None None O
at None None O
the None None O
halogen None None O
- None None O
bearing None None O
carbons None None O
. None None O

The None None O
trend None None O
of None None O
the None None O
element None None O
effect None None O
opposes None None O
that None None O
of None None O
aliphatic None None O
substitution None None O
and None None O
elimination None None O
but None None O
is None None O
similar None None O
in None None O
size None None O
and None None O
parallel None None O
to None None O
that None None O
of None None O
thermal None None O
nucleophilic None None O
aromatic None None O
substitution None None O
. None None O

Relative None None O
nucleophilicities None None O
in None None O
the None None O
photoreactions None None O
are None None O
also None None O
similar None None O
to None None O
those None None O
of None None O
comparable None None O
but None None O
vastly None None O
slower None None O
thermal None None O
reactions None None O
. None None O

The None None O
findings None None O
imply None None O
that None None O
the None None O
efficiency None None O
- None None O
determining None None O
step None None O
of None None O
the None None O
halogen None None O
photosubstitution None None O
is None None O
simple None None O
formation None None O
of None None O
a None None O
sigma None None O
- None None O
complex None None O
through None None O
electron None None O
- None None O
paired None None O
bonding None None O
within None None O
the None None O
triplet None None O
manifold None None O
. None None O

Fragmentation None None O
of None None O
the None None O
parent None None O
ion None None O
/ None None O
TCE None None O
- None None O
sulfate None None O
moiety None None O

The None None O
mass None None O
spectrum None None O
of None None O
compound None None O
5 None None O
displays None None O
its None None O
molecular None None O
ion None None O
5a None None O
with None None O
the None None O
typical None None O
isotope None None O
pattern None None O
[ None None O
18 None None O
] None None O
of None None O
a None None O
pentachlorinated None None O
compound None None O
at None None O
m None None O
/ None None O
z None None O
448 None None O
( None None O
relative None None O
abundance None None O
, None None O
15 None None O
% None None O
) None None O
( None None O
Figure None None O
2 None None O
) None None O
. None None O

Scheme None None O
1 None None O
illustrates None None O
the None None O
various None None O
fragmentation None None O
pathways None None O
of None None O
this None None O
precursor None None O
ion None None O
. None None O

The None None O
molecular None None O
ion None None O
5a None None O
loses None None O
a None None O
PCB None None O
sulfate None None O
( None None O
ArOSO3 None None O
- None None O
) None None O
group None None O
, None None O
thus None None O
yielding None None O
TCE None None O
group None None O
- None None O
derived None None O
fragment None None O
ions None None O
. None None O

These None None O
ions None None O
, None None O
[ None None O
CH2CCl3 None None O
] None None O
+ None None O
and None None O
[ None None O
CH None None O
= None None O
CCl2 None None O
] None None O
+ None None O
, None None O
are None None O
observed None None O
at None None O
m None None O
/ None None O
z None None O
131 None None O
( None None O
6 None None O
% None None O
) None None O
and None None O
95 None None O
( None None O
7 None None O
% None None O
) None None O
, None None O
respectively None None O
. None None O

Scheme None None O
1 None None O

Principal None None O
EI None None O
- None None O
MS None None O
fragmentation None None O
pathways None None O
of None None O
sulfuric None None O
acid None None O
2 None None O
' None None O
, None None O
5 None None O
' None None O
- None None O
dichlorobiphenyl None None O
- None None O
4yl None None O
ester None None O
2 None None O
, None None O
2 None None O
, None None O
2 None None O
- None None O
trichloroethyl None None O
ester None None O
5 None None O
. None None O

More None None O
complex None None O
fragmentation None None O
patterns None None O
are None None O
observed None None O
for None None O
the None None O
fragmentation None None O
of None None O
the None None O
- None None O
OSO3 None None O
- None None O
TCE None None O
group None None O
. None None O

The None None O
abundant None None O
fragment None None O
ion None None O
5g None None O
( None None O
m None None O
/ None None O
z None None O
237 None None O
, None None O
28 None None O
% None None O
) None None O
can None None O
be None None O
formed None None O
by None None O
two None None O
fragmentation None None O
pathways None None O
from None None O
precursor None None O
ion None None O
5a None None O
. None None O

One None None O
pathway None None O
involves None None O
the None None O
release None None O
of None None O
HCl None None O
and None None O
Cl None None O
from None None O
precursor None None O
ion None None O
5a None None O
, None None O
leading None None O
to None None O
an None None O
unstable None None O
cyclic None None O
fragment None None O
ion None None O
5b None None O
( None None O
m None None O
/ None None O
z None None O
377 None None O
, None None O
5 None None O
% None None O
) None None O
. None None O

In None None O
turn None None O
, None None O
fragment None None O
ion None None O
5b None None O
produces None None O
the None None O
fragment None None O
ion None None O
5g None None O
after None None O
releasing None None O
chloroethyne None None O
and None None O
SO3 None None O
. None None O

The None None O
other None None O
pathway None None O
resulting None None O
in None None O
the None None O
formation None None O
of None None O
fragment None None O
ion None None O
5g None None O
involves None None O
the None None O
removal None None O
of None None O
two None None O
neutral None None O
molecules None None O
, None None O
HCHO None None O
and None None O
SO2 None None O
, None None O
from None None O
the None None O
daughter None None O
fragment None None O
ion None None O
5c None None O
( None None O
m None None O
/ None None O
z None None O
331 None None O
, None None O
5 None None O
% None None O
) None None O
, None None O
which None None O
is None None O
formed None None O
by None None O
releasing None None O
the None None O
free None None O
radical None None O
group None None O
CCl3 None None O
from None None O
fragment None None O
ion None None O
5a None None O
. None None O

Alternatively None None O
, None None O
the None None O
fragment None None O
ion None None O
5c None None O
can None None O
also None None O
produce None None O
the None None O
daughter None None O
fragment None None O
ion None None O
5e None None O
( None None O
m None None O
/ None None O
z None None O
183 None None O
, None None O
12 None None O
% None None O
) None None O
by None None O
losing None None O
one None None O
molecule None None O
of None None O
SO3 None None O
. None None O

In None None O
addition None None O
, None None O
precursor None None O
ion None None O
5a None None O
yields None None O
the None None O
daughter None None O
ion None None O
5d None None O
by None None O
losing None None O
a None None O
CHCCl3 None None O
fragment None None O
. None None O

The None None O
basic None None O
fragment None None O
ion None None O
5f None None O
at None None O
m None None O
/ None None O
z None None O
238 None None O
is None None O
produced None None O
from None None O
the None None O
daughter None None O
ion None None O
5d None None O
( None None O
m None None O
/ None None O
z None None O
318 None None O
, None None O
20 None None O
% None None O
) None None O
by None None O
releasing None None O
one None None O
molecule None None O
of None None O
SO3 None None O
. None None O

Fragment None None O
ions None None O
5f None None O
and None None O
5g None None O
can None None O
produce None None O
the None None O
important None None O
fragment None None O
ion None None O
5h None None O
at None None O
m None None O
/ None None O
z None None O
209 None None O
with None None O
a None None O
relative None None O
abundance None None O
of None None O
26 None None O
% None None O
by None None O
losing None None O
a None None O
CHO None None O
or None None O
CO None None O
fragment None None O
, None None O
respectively None None O
. None None O

The None None O
same None None O
fragmentation None None O
pathways None None O
are None None O
observed None None O
for None None O
the None None O
TCE None None O
PCB None None O
sulfates None None O
diesters None None O
1 None None O
and None None O
3 None None O
- None None O
10 None None O
. None None O

The None None O
only None None O
exception None None O
is None None O
compound None None O
2 None None O
, None None O
which None None O
has None None O
the None None O
TCE None None O
sulfate None None O
group None None O
in None None O
ortho None None O
position None None O
to None None O
the None None O
other None None O
phenyl None None O
ring None None O
. None None O

The None None O
mass None None O
spectrum None None O
of None None O
compounds None None O
2 None None O
is None None O
distinctively None None O
different None None O
from None None O
the None None O
mass None None O
spectrum None None O
of None None O
its None None O
isomer None None O
, None None O
compound None None O
3 None None O
( None None O
Figures None None O
3 None None O
and None None O
4 None None O
) None None O
. None None O

As None None O
shown None None O
in None None O
Scheme None None O
2 None None O
, None None O
the None None O
basic None None O
fragment None None O
ion None None O
of None None O
compound None None O
2 None None O
is None None O
the None None O
stable None None O
dibenzofuran None None O
ion None None O
2f None None O
. None None O

Fragment None None O
ion None None O
2f None None O
is None None O
formed None None O
from None None O
the None None O
parent None None O
ion None None O
2a None None O
( None None O
m None None O
/ None None O
z None None O
414 None None O
; None None O
relative None None O
abundance None None O
, None None O
21 None None O
% None None O
) None None O
by None None O
sequential None None O
loss None None O
of None None O
CHCCl3 None None O
( None None O
2d None None O
, None None O
m None None O
/ None None O
z None None O
284 None None O
; None None O
relative None None O
abundance None None O
, None None O
10 None None O
% None None O
) None None O
, None None O
SO3 None None O
( None None O
2e None None O
, None None O
m None None O
/ None None O
z None None O
204 None None O
; None None O
relative None None O
abundance None None O
, None None O
28 None None O
% None None O
) None None O
and None None O
HCl None None O
( None None O
2f None None O
, None None O
m None None O
/ None None O
z None None O
168 None None O
; None None O
relative None None O
abundance None None O
, None None O
100 None None O
% None None O
) None None O
. None None O

The None None O
stable None None O
dibenzofuran None None O
cation None None O
2f None None O
is None None O
also None None O
formed None None O
as None None O
the None None O
base None None O
peak None None O
ion None None O
in None None O
the None None O
fragmentation None None O
pathways None None O
of None None O
corresponding None None O
methoxylated None None O
PCB None None O
11 None None O
( None None O
Table None None O
1 None None O
) None None O
. None None O

Similarly None None O
, None None O
other None None O
2 None None O
- None None O
methoxy None None O
PCB None None O
derivatives None None O
also None None O
form None None O
a None None O
stable None None O
dibenzofuran None None O
cation None None O
after None None O
losing None None O
chlorine None None O
atom None None O
and None None O
methyl None None O
group None None O
[ None None O
19 None None O
] None None O
. None None O

Scheme None None O
2 None None O

Principal None None O
EI None None O
- None None O
MS None None O
fragmentation None None O
pathways None None O
of None None O
sulfuric None None O
acid None None O
4 None None O
' None None O
- None None O
dichlorobiphenyl None None O
- None None O
2 None None O
- None None O
yl None None O
ester None None O
2 None None O
, None None O
2 None None O
, None None O
2 None None O
- None None O
trichloroethyl None None O
ester None None O
2 None None O
. None None O

The None None O
relative None None O
abundance None None O
of None None O
several None None O
fragment None None O
ions None None O
depends None None O
on None None O
the None None O
position None None O
of None None O
the None None O
- None None O
OSO3 None None O
- None None O
TCE None None O
group None None O
and None None O
the None None O
chlorine None None O
substitution None None O
pattern None None O
. None None O

The None None O
relative None None O
abundance None None O
of None None O
the None None O
[ None None O
M None None O
- None None O
HCl2 None None O
] None None O
+ None None O
and None None O
[ None None O
M None None O
- None None O
CCl3 None None O
] None None O
+ None None O
fragment None None O
ions None None O
of None None O
compound None None O
2 None None O
, None None O
9 None None O
and None None O
10 None None O
are None None O
lower None None O
compared None None O
to None None O
all None None O
other None None O
TCE None None O
PCB None None O
sulfate None None O
diesters None None O
( None None O
Table None None O
1 None None O
) None None O
. None None O

This None None O
lower None None O
relative None None O
abundance None None O
is None None O
due None None O
to None None O
steric None None O
and None None O
/ None None O
or None None O
electronic None None O
effects None None O
resulting None None O
from None None O
the None None O
ortho None None O
phenyl None None O
substituent None None O
in None None O
compound None None O
2 None None O
or None None O
the None None O
two None None O
ortho None None O
chlorine None None O
substituents None None O
in None None O
compounds None None O
9 None None O
and None None O
10 None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
relative None None O
abundance None None O
of None None O
fragment None None O
ion None None O
[ None None O
ArOSO3H None None O
] None None O
+ None None O
of None None O
the None None O
TCE None None O
PCB None None O
sulfate None None O
diesters None None O
9 None None O
and None None O
10 None None O
is None None O
low None None O
compared None None O
to None None O
the None None O
corresponding None None O
fragment None None O
ion None None O
of None None O
the None None O
other None None O
TCE None None O
PCB None None O
sulfate None None O
diesters None None O
, None None O
with None None O
only None None O
a None None O
trace None None O
of None None O
the None None O
respective None None O
ions None None O
being None None O
observed None None O
( None None O
Table None None O
1 None None O
) None None O
. None None O

For None None O
example None None O
, None None O
the None None O
relative None None O
abundance None None O
of None None O
[ None None O
ArOSO3H None None O
] None None O
+ None None O
5d None None O
is None None O
20 None None O
% None None O
, None None O
whereas None None O
the None None O
abundance None None O
of None None O
the None None O
corresponding None None O
fragment None None O
ions None None O
of None None O
compounds None None O
9 None None O
and None None O
10 None None O
is None None O
< None None O
< None None O
1 None None O
% None None O
. None None O

Since None None O
compounds None None O
9 None None O
and None None O
10 None None O
have None None O
two None None O
chlorine None None O
substituents None None O
in None None O
the None None O
phenyl None None O
ring None None O
with None None O
the None None O
- None None O
OSO3TCE None None O
group None None O
, None None O
the None None O
low None None O
relative None None O
abundance None None O
of None None O
fragment None None O
ion None None O
[ None None O
ArOSO3H None None O
] None None O
+ None None O
suggests None None O
that None None O
the None None O
sulfate None None O
group None None O
of None None O
both None None O
compounds None None O
is None None O
less None None O
stable None None O
, None None O
possibly None None O
because None None O
of None None O
the None None O
comparatively None None O
high None None O
pKa None None O
value None None O
of None None O
the None None O
Ar None None O
- None None O
OH None None O
group None None O
[ None None O
20 None None O
] None None O
. None None O

This None None O
observation None None O
is None None O
in None None O
agreement None None O
with None None O
the None None O
decreasing None None O
chemical None None O
stability None None O
of None None O
aryl None None O
sulfate None None O
monoesters None None O
with None None O
increasing None None O
acidity None None O
of None None O
the None None O
phenolic None None O
aryl None None O
group None None O
[ None None O
21 None None O
] None None O
. None None O

Mechanisms None None O
for None None O
the None None O
magnolol None None O
- None None O
induced None None O
cell None None O
death None None O
of None None O
CGTH None None O
W None None O
- None None O
2 None None O
thyroid None None O
carcinoma None None O
cells None None O
. None None O

Magnolol None None O
, None None O
a None None O
substance None None O
purified None None O
from None None O
the None None O
bark None None O
of None None O
Magnolia None None O
officialis None None O
, None None O
inhibits None None O
cell None None O
proliferation None None O
and None None O
induces None None O
apoptosis None None O
in None None O
a None None O
variety None None O
of None None O
cancer None None O
cells None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
study None None O
the None None O
effects None None O
of None None O
magnolol None None O
on None None O
CGTH None None O
W None None O
- None None O
2 None None O
thyroid None None O
carcinoma None None O
cells None None O
. None None O

After None None O
24 None None O
h None None O
treatment None None O
with None None O
80 None None O
microM None None O
magnolol None None O
in None None O
serum None None O
- None None O
containing None None O
medium None None O
, None None O
about None None O
50 None None O
% None None O
of None None O
the None None O
cells None None O
exhibited None None O
apoptotic None None O
features None None O
and None None O
20 None None O
% None None O
necrotic None None O
features None None O
. None None O

Cytochrome None None O
- None None O
c None None O
staining None None O
was None None O
diffused None None O
in None None O
the None None O
cytoplasm None None O
of None None O
the None None O
apoptotic None None O
cells None None O
, None None O
but None None O
restricted None None O
to None None O
the None None O
mitochondria None None O
in None None O
control None None O
cells None None O
. None None O

Western None None O
blot None None O
analyses None None O
showed None None O
an None None O
increase None None O
in None None O
levels None None O
of None None O
activated None None O
caspases None None O
( None None O
caspase None None O
- None None O
3 None None O
and None None O
- None None O
7 None None O
) None None O
and None None O
of None None O
cleaved None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
( None None O
PARP None None O
) None None O
by None None O
magnolol None None O
. None None O

Concomitantly None None O
, None None O
immunostaining None None O
for None None O
apoptosis None None O
inducing None None O
factor None None O
( None None O
AIF None None O
) None None O
showed None None O
a None None O
time None None O
- None None O
dependent None None O
translocation None None O
from None None O
the None None O
mitochondria None None O
to None None O
the None None O
nucleus None None O
. None None O

Inhibition None None O
of None None O
either None None O
PARP None None O
or None None O
caspase None None O
activity None None O
blocked None None O
magnolol None None O
- None None O
induced None None O
apoptosis None None O
, None None O
supporting None None O
the None None O
involvement None None O
of None None O
the None None O
caspases None None O
and None None O
PARP None None O
. None None O

In None None O
addition None None O
, None None O
magnolol None None O
activated None None O
phosphatase None None O
and None None O
tensin None None O
homolog None None O
deleted None None O
on None None O
chromosome None None O
10 None None O
( None None O
PTEN None None O
) None None O
and None None O
inactivated None None O
Akt None None O
by None None O
decreasing None None O
levels None None O
of None None O
phosphorylated None None O
PTEN None None O
and None None O
phosphorylated None None O
Akt None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
magnolol None None O
promoted None None O
apoptosis None None O
probably None None O
by None None O
alleviating None None O
the None None O
inhibitory None None O
effect None None O
of None None O
Akt None None O
on None None O
caspase None None O
9 None None O
. None None O

Furthermore None None O
, None None O
inhibition None None O
of None None O
PARP None None O
activity None None O
, None None O
but None None O
not None None O
of None None O
caspase None None O
activity None None O
, None None O
completely None None O
prevented None None O
magnolol None None O
- None None O
induced None None O
necrosis None None O
, None None O
suggesting None None O
the None None O
notion None None O
that None None O
it None None O
might None None O
be None None O
caused None None O
by None None O
depletion None None O
of None None O
intracellular None None O
ATP None None O
levels None None O
due None None O
to None None O
PARP None None O
activation None None O
. None None O

These None None O
results None None O
show None None O
that None None O
magnolol None None O
initiates None None O
apoptosis None None O
via None None O
the None None O
cytochrome None None O
- None None O
c None None O
/ None None O
caspase None None O
3 None None O
/ None None O
PARP None None O
/ None None O
AIF None None O
and None None O
PTEN None None O
/ None None O
Akt None None O
/ None None O
caspase None None O
9 None None O
/ None None O
PARP None None O
pathways None None O
and None None O
necrosis None None O
via None None O
PARP None None O
activation None None O
. None None O

Alteration None None O
of None None O
homeobox None None O
gene None None O
expression None None O
by None None O
N None None O
- None None O
ras None None O
transformation None None O
of None None O
PA None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
human None None O
teratocarcinoma None None O
cells None None O
. None None O

We None None O
used None None O
a None None O
series None None O
of None None O
cell None None O
clones None None O
from None None O
a None None O
human None None O
teratocarcinoma None None O
cell None None O
line None None O
, None None O
PA None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
, None None O
to None None O
study None None O
the None None O
effect None None O
of None None O
transformation None None O
by None None O
an None None O
activated None None O
N None None O
- None None O
ras None None O
oncogene None None O
on None None O
the None None O
expression None None O
of None None O
genes None None O
involved None None O
in None None O
retinoic None None O
acid None None O
( None None O
RA None None O
) None None O
- None None O
induced None None O
differentiation None None O
and None None O
growth None None O
regulation None None O
. None None O

Recently None None O
, None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
expression None None O
of None None O
human None None O
HOX None None O
2 None None O
genes None None O
is None None O
sequentially None None O
activated None None O
by None None O
RA None None O
beginning None None O
from None None O
Hox None None O
2 None None O
. None None O
9 None None O
at None None O
the None None O
3 None None O
' None None O
end None None O
of None None O
the None None O
HOX None None O
2 None None O
cluster None None O
( None None O
A None None O
. None None O
Simeone None None O
, None None O
D None None O
. None None O
Acampora None None O
, None None O
L None None O
. None None O
Arcioni None None O
, None None O
P None None O
. None None O
W None None O
. None None O
Andrews None None O
, None None O
E None None O
. None None O
Boncinelli None None O
, None None O
and None None O
F None None O
. None None O
Mavilio None None O
, None None O
Nature None None O
[ None None O
London None None O
] None None O
346 None None O
: None None O
763 None None O
- None None O
766 None None O
, None None O
1990 None None O
) None None O
. None None O

We None None O
now None None O
report None None O
that None None O
six None None O
different None None O
genes None None O
of None None O
the None None O
cluster None None O
HOX None None O
1 None None O
are None None O
sequentially None None O
induced None None O
by None None O
RA None None O
in None None O
a None None O
similar None None O
temporal None None O
pattern None None O
, None None O
beginning None None O
with None None O
genes None None O
at None None O
the None None O
3 None None O
' None None O
end None None O
of None None O
the None None O
cluster None None O
. None None O

However None None O
, None None O
in None None O
N None None O
- None None O
ras None None O
- None None O
transformed None None O
cell None None O
clones None None O
, None None O
RA None None O
- None None O
induced None None O
expression None None O
of None None O
these None None O
homeobox None None O
genes None None O
is None None O
delayed None None O
. None None O

Hox None None O
1 None None O
. None None O
4 None None O
and None None O
Hox None None O
1 None None O
. None None O
3 None None O
, None None O
genes None None O
abundantly None None O
induced None None O
in None None O
nontransformed None None O
clones None None O
after None None O
3 None None O
days None None O
of None None O
RA None None O
treatment None None O
, None None O
are None None O
expressed None None O
in None None O
N None None O
- None None O
ras None None O
- None None O
transformed None None O
cells None None O
only None None O
after None None O
10 None None O
days None None O
of None None O
RA None None O
treatment None None O
. None None O

At None None O
this None None O
time None None O
, None None O
the None None O
cells None None O
' None None O
growth None None O
is None None O
arrested None None O
at None None O
very None None O
high None None O
density None None O
, None None O
and None None O
no None None O
differentiated None None O
morphologic None None O
characteristics None None O
are None None O
observed None None O
. None None O

Constitutive None None O
expression None None O
of None None O
a None None O
transfected None None O
Hox None None O
1 None None O
. None None O
4 None None O
gene None None O
under None None O
the None None O
control None None O
of None None O
a None None O
simian None None O
virus None None O
40 None None O
promotor None None O
leads None None O
to None None O
differentiated None None O
cell None None O
morphology None None O
similar None None O
to None None O
that None None O
of None None O
the None None O
RA None None O
- None None O
induced None None O
phenotype None None O
and None None O
restores None None O
the None None O
growth None None O
- None None O
inhibitory None None O
effects None None O
of None None O
RA None None O
in None None O
N None None O
- None None O
ras None None O
- None None O
transformed None None O
cells None None O
. None None O

These None None O
observations None None O
provide None None O
evidence None None O
that None None O
enhanced None None O
proliferation None None O
in None None O
N None None O
- None None O
ras None None O
- None None O
transformed None None O
cells None None O
compromises None None O
teratocarcinoma None None O
cell None None O
differentiation None None O
by None None O
a None None O
mechanism None None O
that None None O
transiently None None O
suppresses None None O
homeobox None None O
gene None None O
induction None None O
and None None O
implies None None O
a None None O
central None None O
role None None O
for None None O
homeobox None None O
genes None None O
in None None O
RA None None O
- None None O
induced None None O
cell None None O
differentiation None None O
. None None O

We None None O
conclude None None O
that None None O
stimulation None None O
of None None O
a None None O
putative None None O
growth None None O
factor None None O
signal None None O
pathway None None O
, None None O
associated None None O
with None None O
ras None None O
- None None O
induced None None O
proliferation None None O
, None None O
transiently None None O
suppresses None None O
the None None O
induction None None O
of None None O
transcription None None O
factors None None O
functionally None None O
involved None None O
in None None O
cell None None O
growth None None O
and None None O
differentiation None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
in None None O
seizures None None O
: None None O
a None None O
double None None O
- None None O
edged None None O
sword None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
a None None O
vascular None None O
growth None None O
factor None None O
which None None O
induces None None O
angiogenesis None None O
( None None O
the None None O
development None None O
of None None O
new None None O
blood None None O
vessels None None O
) None None O
, None None O
vascular None None O
permeability None None O
, None None O
and None None O
inflammation None None O
. None None O

In None None O
brain None None O
, None None O
receptors None None O
for None None O
VEGF None None O
have None None O
been None None O
localized None None O
to None None O
vascular None None O
endothelium None None O
, None None O
neurons None None O
, None None O
and None None O
glia None None O
. None None O

VEGF None None O
is None None O
upregulated None None O
after None None O
hypoxic None None O
injury None None O
to None None O
the None None O
brain None None O
, None None O
which None None O
can None None O
occur None None O
during None None O
cerebral None None O
ischemia None None O
or None None O
high None None O
- None None O
altitude None None O
edema None None O
, None None O
and None None O
has None None O
been None None O
implicated None None O
in None None O
the None None O
blood None None O
- None None O
brain None None O
barrier None None O
breakdown None None O
associated None None O
with None None O
these None None O
conditions None None O
. None None O

Given None None O
its None None O
recently None None O
- None None O
described None None O
role None None O
as None None O
an None None O
inflammatory None None O
mediator None None O
, None None O
VEGF None None O
could None None O
also None None O
contribute None None O
to None None O
the None None O
inflammatory None None O
responses None None O
observed None None O
in None None O
cerebral None None O
ischemia None None O
. None None O

After None None O
seizures None None O
, None None O
blood None None O
- None None O
brain None None O
barrier None None O
breakdown None None O
and None None O
inflammation None None O
is None None O
also None None O
observed None None O
in None None O
brain None None O
, None None O
albeit None None O
on None None O
a None None O
lower None None O
scale None None O
than None None O
that None None O
observed None None O
after None None O
stroke None None O
. None None O

Recent None None O
evidence None None O
has None None O
suggested None None O
a None None O
role None None O
for None None O
inflammation None None O
in None None O
seizure None None O
disorders None None O
. None None O

We None None O
have None None O
described None None O
striking None None O
increases None None O
in None None O
VEGF None None O
protein None None O
in None None O
both None None O
neurons None None O
and None None O
glia None None O
after None None O
pilocarpine None None O
- None None O
induced None None O
status None None O
epilepticus None None O
in None None O
the None None O
brain None None O
. None None O

Increases None None O
in None None O
VEGF None None O
could None None O
contribute None None O
to None None O
the None None O
blood None None O
- None None O
brain None None O
barrier None None O
breakdown None None O
and None None O
inflammation None None O
observed None None O
after None None O
seizures None None O
. None None O

However None None O
, None None O
VEGF None None O
has None None O
also None None O
been None None O
shown None None O
to None None O
be None None O
neuroprotective None None O
across None None O
several None None O
experimental None None O
paradigms None None O
, None None O
and None None O
hence None None O
could None None O
potentially None None O
protect None None O
vulnerable None None O
cells None None O
from None None O
damage None None O
associated None None O
with None None O
seizures None None O
. None None O

Therefore None None O
, None None O
the None None O
role None None O
of None None O
VEGF None None O
after None None O
seizures None None O
could None None O
be None None O
either None None O
protective None None O
or None None O
destructive None None O
. None None O

Although None None O
only None None O
further None None O
research None None O
will None None O
determine None None O
the None None O
exact None None O
nature None None O
of None None O
VEGF None None O
' None None O
s None None O
role None None O
after None None O
seizures None None O
, None None O
preliminary None None O
data None None O
indicate None None O
that None None O
VEGF None None O
plays None None O
a None None O
protective None None O
role None None O
after None None O
seizures None None O
. None None O

Nicked None None O
{ None None O
beta None None O
} None None O
2 None None O
- None None O
glycoprotein None None O
I None None O
binds None None O
angiostatin None None O
4 None None O
. None None O
5 None None O
( None None O
plasminogen None None O
kringle None None O
1 None None O
- None None O
5 None None O
) None None O
and None None O
attenuates None None O
its None None O
antiangiogenic None None O
property None None O
. None None O

Angiostatin None None O
was None None O
first None None O
discovered None None O
as None None O
a None None O
plasminogen None None O
fragment None None O
with None None O
antitumor None None O
/ None None O
antiangiogenic None None O
property None None O
. None None O

One None None O
of None None O
the None None O
angiostatin None None O
isoforms None None O
, None None O
that None None O
is None None O
, None None O
angiostatin None None O
4 None None O
. None None O
5 None None O
( None None O
AS4 None None O
. None None O
5 None None O
) None None O
, None None O
consisting None None O
of None None O
plasminogen None None O
kringle None None O
1 None None O
to None None O
4 None None O
and None None O
a None None O
most None None O
part None None O
of None None O
kringle None None O
5 None None O
, None None O
is None None O
produced None None O
by None None O
autoproteolysis None None O
and None None O
present None None O
in None None O
human None None O
plasma None None O
. None None O

beta2 None None O
- None None O
glycoprotein None None O
I None None O
( None None O
beta2GPI None None O
) None None O
is None None O
proteolytically None None O
cleaved None None O
by None None O
plasmin None None O
in None None O
its None None O
domain None None O
V None None O
( None None O
nicked None None O
beta2GPI None None O
) None None O
, None None O
resulting None None O
in None None O
binding None None O
to None None O
plasminogen None None O
. None None O

Antiangiogenic None None O
properties None None O
have None None O
been None None O
recently None None O
reported None None O
in None None O
nicked None None O
beta2GPI None None O
as None None O
well None None O
as None None O
in None None O
intact None None O
beta2GPI None None O
at None None O
higher None None O
concentrations None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
found None None O
significant None None O
binding None None O
of None None O
nicked None None O
beta2GPI None None O
to None None O
AS4 None None O
. None None O
5 None None O
( None None O
K None None O
( None None O
D None None O
) None None O
= None None O
3 None None O
. None None O
27 None None O
x None None O
10 None None O
( None None O
6 None None O
) None None O
M None None O
( None None O
- None None O
1 None None O
) None None O
) None None O
. None None O

Via None None O
this None None O
binding None None O
, None None O
nicked None None O
beta2GPI None None O
attenuates None None O
the None None O
antiangiogenic None None O
functions None None O
of None None O
AS4 None None O
. None None O
5 None None O
in None None O
the None None O
proliferation None None O
of None None O
arterial None None O
/ None None O
venous None None O
endothelial None None O
cells None None O
, None None O
in None None O
the None None O
extracellular None None O
matrix None None O
invasion None None O
and None None O
the None None O
tube None None O
formation None None O
of None None O
venous None None O
endothelial None None O
cells None None O
, None None O
and None None O
in None None O
vivo None None O
angiogenesis None None O
. None None O

In None None O
contrast None None O
, None None O
intact None None O
beta2GPI None None O
does None None O
not None None O
bind None None O
to None None O
AS4 None None O
. None None O
5 None None O
or None None O
inhibit None None O
its None None O
antiangiogenic None None O
activity None None O
. None None O

Thus None None O
, None None O
nicked None None O
beta2GPI None None O
exerts None None O
dual None None O
effects None None O
on None None O
angiogenesis None None O
, None None O
that None None O
is None None O
, None None O
nicked None None O
beta2GPI None None O
promotes None None O
angiogenesis None None O
in None None O
the None None O
presence None None O
of None None O
AS4 None None O
. None None O
5 None None O
, None None O
whereas None None O
nicked None None O
beta2GPI None None O
inhibits None None O
angiogenesis None None O
at None None O
concentrations None None O
high None None O
enough None None O
to None None O
neutralize None None O
AS4 None None O
. None None O
5 None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
plasmin None None O
- None None O
nicked None None O
beta2GPI None None O
promotes None None O
angiogenesis None None O
by None None O
interacting None None O
with None None O
plasmin None None O
- None None O
generated None None O
AS4 None None O
. None None O
5 None None O
in None None O
sites None None O
of None None O
increased None None O
fibrinolysis None None O
such None None O
as None None O
thrombus None None O
. None None O

[ None None O
Histophysiology None None O
and None None O
histopathology None None O
of None None O
the None None O
adrenals None None O
in None None O
experimental None None O
hypokinesia None None O
] None None O
. None None O

In None None O
experiments None None O
on None None O
male None None O
rats None None O
in None None O
the None None O
course None None O
of None None O
3 None None O
- None None O
month None None O
hypokinesia None None O
phasic None None O
changes None None O
were None None O
observed None None O
in None None O
the None None O
relative None None O
adrenal None None O
gland None None O
weight None None O
, None None O
in None None O
the None None O
volume None None O
of None None O
the None None O
cell None None O
nuclei None None O
of None None O
the None None O
glomerular None None O
, None None O
fasicular None None O
zones None None O
and None None O
the None None O
medulla None None O
, None None O
in None None O
the None None O
activity None None O
of None None O
the None None O
succinic None None O
dehydrogenase None None O
, None None O
alkaline None None O
and None None O
acid None None O
phosphatases None None O
, None None O
in None None O
the None None O
RNA None None O
and None None O
catecholamine None None O
content None None O
. None None O

These None None O
changes None None O
are None None O
associated None None O
with None None O
variations None None O
in None None O
the None None O
secretion None None O
and None None O
biosynthesis None None O
of None None O
the None None O
hormones None None O
of None None O
the None None O
cortical None None O
and None None O
the None None O
medullary None None O
layer None None O
of None None O
the None None O
adrenal None None O
glands None None O
during None None O
the None None O
hypokinetic None None O
stress None None O
development None None O
. None None O

Comparison None None O
of None None O
the None None O
number None None O
of None None O
known None None O
complexes None None O
matched None None O
by None None O
the None None O
predicted None None O
clusters None None O
generated None None O
by None None O
IPCA None None O
and None None O
other None None O
previous None None O
algorithms None None O

Rate None None O
of None None O
distraction None None O
calculation None None O
( None None O
Figs None None O
. None None O
6 None None O
, None None O
7 None None O
and None None O
8 None None O
) None None O

Ideal None None O
rate None None O
for None None O
new None None O
bone None None O
formation None None O
by None None O
distraction None None O
osteogenesis None None O
is None None O
known None None O
as None None O
1 None None O
mm None None O
/ None None O
day None None O
. None None O
5 None None O
, None None O
6 None None O
The None None O
slower None None O
rates None None O
may None None O
lead None None O
to None None O
premature None None O
consolidation None None O
, None None O
whereas None None O
the None None O
faster None None O
rates None None O
may None None O
result None None O
in None None O
poor None None O
regenerate None None O
bone None None O
formation None None O
. None None O

In None None O
simple None None O
longitudinal None None O
lengthening None None O
, None None O
the None None O
rate None None O
of None None O
distraction None None O
is None None O
equal None None O
at None None O
any None None O
point None None O
of None None O
the None None O
corticotomy None None O
, None None O
however None None O
, None None O
the None None O
rate None None O
of None None O
distraction None None O
at None None O
any None None O
given None None O
portion None None O
of None None O
the None None O
corticotomy None None O
varies None None O
during None None O
angular None None O
correction None None O
. None None O

Usually None None O
, None None O
the None None O
gap None None O
between None None O
corticotomized None None O
bone None None O
ends None None O
is None None O
larger None None O
on None None O
the None None O
concave None None O
side None None O
, None None O
therefore None None O
, None None O
the None None O
rate None None O
of None None O
angular None None O
correction None None O
should None None O
be None None O
adjusted None None O
so None None O
that None None O
the None None O
rate None None O
of None None O
distraction None None O
of None None O
the None None O
concave None None O
side None None O
is None None O
closer None None O
to None None O
1 None None O
mm None None O
/ None None O
day None None O
. None None O

In None None O
cases None None O
with None None O
passive None None O
hinge None None O
system None None O
, None None O
the None None O
amount None None O
of None None O
daily None None O
angular None None O
correction None None O
can None None O
easily None None O
be None None O
calculated None None O
by None None O
the None None O
geometric None None O
methods None None O
using None None O
the None None O
rule None None O
of None None O
similar None None O
triangles None None O
and None None O
the None None O
rule None None O
of None None O
concentric None None O
circles None None O
, None None O
and None None O
can None None O
be None None O
expressed None None O
as None None O
the None None O
amount None None O
of None None O
daily None None O
lengthening None None O
of None None O
motor None None O
system None None O
. None None O

In None None O
passive None None O
hinge None None O
system None None O
, None None O
the None None O
ACA None None O
is None None O
fixed None None O
on None None O
the None None O
frame None None O
in None None O
Ilizarov None None O
system None None O
or None None O
on None None O
the None None O
convex None None O
side None None O
of None None O
corticotomy None None O
in None None O
unilateral None None O
fixator None None O
system None None O
, None None O
and None None O
angular None None O
correction None None O
is None None O
achieved None None O
by None None O
changing None None O
the None None O
length None None O
of None None O
the None None O
motor None None O
( None None O
Ilizarov None None O
system None None O
) None None O
or None None O
the None None O
lengthener None None O
( None None O
unilateral None None O
fixator None None O
) None None O
which None None O
rotates None None O
the None None O
passive None None O
hinge None None O
. None None O

However None None O
, None None O
in None None O
active None None O
hinge None None O
system None None O
, None None O
angulator None None O
directly None None O
corrects None None O
angular None None O
deformity None None O
, None None O
and None None O
the None None O
lengthener None None O
and None None O
translator None None O
adjust None None O
secondary None None O
displacement None None O
. None None O

Therefore None None O
, None None O
the None None O
rate None None O
of None None O
angular None None O
correction None None O
cannot None None O
be None None O
determined None None O
by None None O
the None None O
simple None None O
geometric None None O
methods None None O
used None None O
for None None O
passive None None O
hinge None None O
system None None O
. None None O

Regardless None None O
of None None O
types None None O
of None None O
fixators None None O
, None None O
the None None O
gap None None O
opens None None O
larger None None O
on None None O
the None None O
concave None None O
side None None O
of None None O
the None None O
deformity None None O
after None None O
realignment None None O
. None None O

The None None O
rate None None O
of None None O
angular None None O
correction None None O
also None None O
should None None O
be None None O
adjusted None None O
so None None O
that None None O
the None None O
rate None None O
of None None O
distraction None None O
of None None O
concave None None O
side None None O
is None None O
1 None None O
mm None None O
/ None None O
day None None O
. None None O

Theoretically None None O
, None None O
after None None O
realignment None None O
by None None O
Dyna None None O
- None None O
ATC None None O
with None None O
adjustment None None O
of None None O
secondary None None O
displacement None None O
, None None O
the None None O
convex None None O
side None None O
of None None O
the None None O
corticotomy None None O
does None None O
not None None O
change None None O
in None None O
length None None O
, None None O
but None None O
the None None O
cocave None None O
side None None O
opens None None O
to None None O
correct None None O
angular None None O
deformity None None O
. None None O

The None None O
amount None None O
of None None O
lengthening None None O
on None None O
the None None O
concave None None O
side None None O
can None None O
be None None O
calculated None None O
with None None O
the None None O
thickness None None O
of None None O
the None None O
bone None None O
at None None O
the None None O
corticotomy None None O
site None None O
and None None O
the None None O
amount None None O
of None None O
angular None None O
deformity None None O
( None None O
Fig None None O
. None None O
6 None None O
) None None O
. None None O

If None None O
the None None O
corticotomy None None O
is None None O
performed None None O
on None None O
the None None O
CORA None None O
, None None O
no None None O
translation None None O
deformity None None O
happens None None O
, None None O
however None None O
, None None O
if None None O
not None None O
, None None O
translation None None O
results None None O
at None None O
the None None O
corticotomy None None O
site None None O
after None None O
realignment None None O
is None None O
achieved None None O
. None None O

The None None O
amount None None O
of None None O
translation None None O
can None None O
be None None O
calculated None None O
with None None O
the None None O
distance None None O
from None None O
the None None O
CORA None None O
to None None O
the None None O
corticotomy None None O
over None None O
the None None O
longitudinal None None O
bisecting None None O
line None None O
( None None O
lBL None None O
) None None O
( None None O
Fig None None O
. None None O
6 None None O
) None None O
. None None O

On None None O
the None None O
immediate None None O
post None None O
- None None O
operative None None O
radiographs None None O
, None None O
the None None O
gap None None O
distance None None O
of None None O
concave None None O
side None None O
after None None O
realignment None None O
can None None O
be None None O
calculated None None O
with None None O
the None None O
expected None None O
change None None O
in None None O
length None None O
and None None O
translation None None O
on None None O
the None None O
concave None None O
side None None O
of None None O
the None None O
corticotomy None None O
using None None O
the None None O
Pythaorean None None O
theorem None None O
. None None O

The None None O
rate None None O
of None None O
angular None None O
correction None None O
should None None O
be None None O
given None None O
as None None O
the None None O
amount None None O
of None None O
daily None None O
correction None None O
angle None None O
, None None O
but None None O
not None None O
as None None O
the None None O
amount None None O
of None None O
length None None O
change None None O
of None None O
the None None O
fixator None None O
. None None O

The None None O
angular None None O
change None None O
of None None O
angulator None None O
determines None None O
the None None O
secondary None None O
change None None O
of None None O
length None None O
and None None O
translation None None O
of None None O
the None None O
corticotomy None None O
site None None O
. None None O

The None None O
amount None None O
of None None O
secondary None None O
deformity None None O
during None None O
angular None None O
correction None None O
can None None O
be None None O
calculated None None O
with None None O
the None None O
thickness None None O
of None None O
bone None None O
at None None O
the None None O
corticotomy None None O
site None None O
, None None O
the None None O
distance None None O
between None None O
the None None O
ACA None None O
and None None O
the None None O
corticotomy None None O
, None None O
and None None O
tan None None O
( None None O
a None None O
/ None None O
2 None None O
) None None O
( None None O
a None None O
is None None O
the None None O
amount None None O
of None None O
angular None None O
correction None None O
) None None O
( None None O
Fig None None O
. None None O
6 None None O
) None None O
. None None O

The None None O
thickness None None O
of None None O
the None None O
bone None None O
at None None O
the None None O
corticotomy None None O
site None None O
and None None O
the None None O
distance None None O
between None None O
the None None O
ACA None None O
and None None O
the None None O
corticotomy None None O
do None None O
not None None O
change None None O
, None None O
once None None O
the None None O
corticotomy None None O
is None None O
performed None None O
after None None O
Dyna None None O
- None None O
ATC None None O
is None None O
applied None None O
. None None O

Therefore None None O
, None None O
the None None O
amount None None O
of None None O
secondary None None O
deformities None None O
changes None None O
only None None O
with None None O
tan None None O
( None None O
a None None O
/ None None O
2 None None O
) None None O
value None None O
. None None O

If None None O
tangent None None O
value None None O
varies None None O
proportionally None None O
with None None O
changes None None O
of None None O
angle None None O
, None None O
the None None O
gap None None O
distance None None O
increases None None O
constantly None None O
with None None O
the None None O
given None None O
amount None None O
of None None O
daily None None O
correction None None O
angle None None O
during None None O
angular None None O
correction None None O
. None None O

If None None O
not None None O
, None None O
the None None O
gap None None O
distance None None O
varies None None O
continuously None None O
with None None O
changes None None O
of None None O
the None None O
angle None None O
, None None O
therefore None None O
, None None O
the None None O
amount None None O
of None None O
correction None None O
angle None None O
should None None O
be None None O
readjusted None None O
everyday None None O
to None None O
maintain None None O
1 None None O
mm None None O
/ None None O
day None None O
of None None O
distraction None None O
rate None None O
on None None O
the None None O
concave None None O
side None None O
of None None O
the None None O
corticotomy None None O
. None None O

Fortunately None None O
, None None O
while None None O
the None None O
value None None O
of None None O
tangent None None O
angle None None O
increases None None O
exponentially None None O
especially None None O
over None None O
45 None None O
degrees None None O
, None None O
tangent None None O
function None None O
curve None None O
is None None O
nearly None None O
straight None None O
, None None O
less None None O
than None None O
30 None None O
degrees None None O
( None None O
Fig None None O
. None None O
7 None None O
) None None O
. None None O

Therefore None None O
, None None O
in None None O
cases None None O
with None None O
less None None O
than None None O
60 None None O
degrees None None O
of None None O
angular None None O
deformity None None O
, None None O
the None None O
amount None None O
of None None O
daily None None O
correction None None O
angle None None O
which None None O
permits None None O
1 None None O
mm None None O
/ None None O
day None None O
of None None O
distraction None None O
rate None None O
on None None O
the None None O
concave None None O
side None None O
of None None O
the None None O
corticotomy None None O
can None None O
be None None O
obtained None None O
as None None O
the None None O
rate None None O
of None None O
angular None None O
correction None None O
without None None O
daily None None O
adjustment None None O
during None None O
angular None None O
correction None None O
. None None O

Once None None O
the None None O
amount None None O
of None None O
daily None None O
angular None None O
correction None None O
is None None O
determined None None O
, None None O
the None None O
amount None None O
of None None O
daily None None O
length None None O
and None None O
translation None None O
compensation None None O
can None None O
also None None O
be None None O
calculated None None O
with None None O
the None None O
amount None None O
of None None O
daily None None O
angular None None O
correction None None O
. None None O

Exact None None O
adjustment None None O
of None None O
secondary None None O
changes None None O
in None None O
length None None O
and None None O
translation None None O
at None None O
each None None O
angular None None O
correction None None O
opens None None O
the None None O
concave None None O
side None None O
of None None O
the None None O
corticotomy None None O
1 None None O
mm None None O
per None None O
day None None O
, None None O
but None None O
allows None None O
minimal None None O
gap None None O
on None None O
the None None O
corticotomy None None O
of None None O
convex None None O
side None None O
especially None None O
in None None O
the None None O
early None None O
stage None None O
of None None O
angular None None O
correction None None O
. None None O

Therefore None None O
, None None O
it None None O
is None None O
possible None None O
that None None O
the None None O
corticotomized None None O
bone None None O
ends None None O
of None None O
convex None None O
side None None O
, None None O
may None None O
abut None None O
each None None O
other None None O
and None None O
prevent None None O
angular None None O
correction None None O
or None None O
adjustment None None O
of None None O
secondary None None O
translation None None O
. None None O

For None None O
the None None O
cases None None O
where None None O
the None None O
concomitant None None O
lengthening None None O
is None None O
required None None O
, None None O
longitudinal None None O
lengthening None None O
prior None None O
to None None O
angular None None O
correction None None O
is None None O
recommended None None O
. None None O

Otherwise None None O
, None None O
about None None O
5 None None O
mm None None O
pre None None O
- None None O
lengthening None None O
and None None O
re None None O
- None None O
shortening None None O
after None None O
angular None None O
correction None None O
could None None O
be None None O
helpful None None O
in None None O
avoiding None None O
abutment None None O
on None None O
the None None O
convex None None O
side None None O
of None None O
the None None O
corticotomy None None O
site None None O
. None None O

Inappropriate None None O
sequence None None O
of None None O
angular None None O
correction None None O
and None None O
adjustment None None O
of None None O
secondary None None O
deformities None None O
could None None O
be None None O
one None None O
of None None O
the None None O
causes None None O
of None None O
the None None O
impingement None None O
. None None O

Appropriate None None O
sequence None None O
of None None O
correction None None O
is None None O
lengthening None None O
- None None O
translation None None O
- None None O
angulation None None O
with None None O
Dyna None None O
- None None O
ATC None None O
on None None O
the None None O
concave None None O
side None None O
and None None O
angulation None None O
- None None O
translation None None O
- None None O
shortening None None O
with None None O
Dyna None None O
- None None O
ATC None None O
on None None O
the None None O
convex None None O
side None None O
. None None O

Inducible None None O
nitric None None O
oxide None None O
synthase None None O
modulates None None O
angiogenesis None None O
in None None O
ischemic None None O
hindlimb None None O
of None None O
rat None None O
. None None O

BACKGROUND None None O
: None None O
Angiogenesis None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
maintaining None None O
adequate None None O
oxygen None None O
delivery None None O
, None None O
and None None O
nitric None None O
oxide None None O
( None None O
NO None None O
) None None O
is None None O
a None None O
potential None None O
regulator None None O
of None None O
angiogenesis None None O
. None None O

NO None None O
is None None O
synthesized None None O
through None None O
three None None O
isoforms None None O
of None None O
NO None None O
synthase None None O
( None None O
NOS None None O
) None None O
. None None O

It None None O
is None None O
hypothesized None None O
that None None O
the None None O
NO None None O
derived None None O
from None None O
inducible None None O
NOS None None O
( None None O
iNOS None None O
) None None O
may None None O
promote None None O
survival None None O
of None None O
ischemic None None O
tissue None None O
through None None O
angiogenesis None None O
. None None O

To None None O
test None None O
this None None O
hypothesis None None O
, None None O
we None None O
investigated None None O
the None None O
effect None None O
of None None O
iNOS None None O
deficiency None None O
( None None O
by None None O
L None None O
- None None O
NIL None None O
) None None O
on None None O
angiogenesis None None O
in None None O
a None None O
hindlimb None None O
ischemia None None O
model None None O
. None None O

METHODS None None O
: None None O
Thirty None None O
- None None O
two None None O
male None None O
wistar None None O
rats None None O
randomly None None O
divided None None O
into None None O
four None None O
groups None None O
. None None O

In None None O
groups None None O
1 None None O
& None None O
2 None None O
, None None O
hindlimb None None O
ischemia None None O
was None None O
induced None None O
by None None O
ligation None None O
of None None O
femoral None None O
artery None None O
and None None O
they None None O
received None None O
L None None O
- None None O
NIL None None O
and None None O
saline None None O
respectively None None O
. None None O

The None None O
animals None None O
in None None O
groups None None O
3 None None O
and None None O
4 None None O
also None None O
received None None O
L None None O
- None None O
NIL None None O
and None None O
saline None None O
respectively None None O
without None None O
surgical None None O
procedure None None O
. None None O

After None None O
21 None None O
days None None O
, None None O
the None None O
serum None None O
concentration None None O
of None None O
nitrite None None O
, None None O
capillary None None O
density None None O
and None None O
expression None None O
of None None O
HIF1alpha None None O
were None None O
determined None None O
. None None O

RESULTS None None O
: None None O
Serum None None O
nitrite None None O
levels None None O
were None None O
significantly None None O
lower None None O
in None None O
L None None O
- None None O
NIL None None O
groups None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
capillary None None O
density None None O
in None None O
group None None O
1 None None O
( None None O
ischemia None None O
+ None None O
L None None O
- None None O
NIL None None O
) None None O
was None None O
significantly None None O
different None None O
from None None O
group None None O
2 None None O
( None None O
ischemia None None O
+ None None O
saline None None O
) None None O
; None None O
group None None O
1 None None O
: None None O
360 None None O
. None None O
33 None None O
+ None None O
/ None None O
- None None O
77 None None O
. None None O
02 None None O
, None None O
group None None O
2 None None O
: None None O
549 None None O
+ None None O
/ None None O
- None None O
81 None None O
. None None O
85 None None O
/ None None O
mm2 None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O
In None None O
addition None None O
, None None O
expression None None O
of None None O
HIF1alpha None None O
was None None O
significantly None None O
increased None None O
in None None O
ischemic None None O
groups None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
Selective None None O
inhibition None None O
of None None O
iNOS None None O
by None None O
L None None O
- None None O
NIL None None O
inhibits None None O
angiogenesis None None O
in None None O
a None None O
hindlimb None None O
ischemic None None O
rat None None O
model None None O
. None None O

In None None O
addition None None O
, None None O
ischemia None None O
induces None None O
expression None None O
of None None O
HIF1alpha None None O
in None None O
hypoxic None None O
tissue None None O
. None None O

Human None None O
cytomegalovirus None None O
elevates None None O
levels None None O
of None None O
the None None O
cellular None None O
protein None None O
p53 None None O
in None None O
infected None None O
fibroblasts None None O
. None None O

Human None None O
cytomegalovirus None None O
( None None O
HCMV None None O
) None None O
, None None O
like None None O
other None None O
DNA None None O
tumor None None O
viruses None None O
, None None O
induces None None O
morphological None None O
transformation None None O
of None None O
cells None None O
in None None O
vitro None None O
and None None O
stimulates None None O
host None None O
cell None None O
macromolecular None None O
synthesis None None O
in None None O
infected None None O
cells None None O
. None None O

Since None None O
other None None O
DNA None None O
tumor None None O
viruses None None O
, None None O
such None None O
as None None O
simian None None O
virus None None O
40 None None O
and None None O
adenovirus None None O
, None None O
have None None O
previously None None O
been None None O
shown None None O
to None None O
interact None None O
with None None O
cellular None None O
protein None None O
p53 None None O
, None None O
we None None O
investigated None None O
whether None None O
infection None None O
of None None O
cells None None O
by None None O
HCMV None None O
would None None O
modulate None None O
cellular None None O
p53 None None O
levels None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
HCMV None None O
elevates None None O
cellular None None O
p53 None None O
levels None None O
on None None O
the None None O
order None None O
of None None O
10 None None O
- None None O
to None None O
20 None None O
- None None O
fold None None O
in None None O
infected None None O
fibroblasts None None O
. None None O

The None None O
induction None None O
of None None O
elevated None None O
p53 None None O
levels None None O
was None None O
dependent None None O
upon None None O
the None None O
presence None None O
of None None O
active None None O
virus None None O
and None None O
was None None O
prevented None None O
by None None O
neutralizing None None O
antibody None None O
. None None O

The None None O
induction None None O
of None None O
elevated None None O
p53 None None O
levels None None O
was None None O
determined None None O
not None None O
to None None O
be None None O
due None None O
to None None O
virus None None O
- None None O
receptor None None O
interactions None None O
or None None O
HCMV None None O
late None None O
events None None O
. None None O

The None None O
induction None None O
of None None O
elevated None None O
p53 None None O
levels None None O
commenced None None O
at None None O
immediate None None O
- None None O
early None None O
times None None O
of None None O
the None None O
HCMV None None O
multiplication None None O
cycle None None O
( None None O
6 None None O
h None None O
postinfection None None O
) None None O
and None None O
reached None None O
maximal None None O
levels None None O
by None None O
24 None None O
h None None O
postinfection None None O
, None None O
before None None O
most None None O
of None None O
the None None O
HCMV None None O
DNA None None O
synthesis None None O
was None None O
initiated None None O
. None None O

HCMV None None O
immediate None None O
- None None O
early None None O
proteins None None O
were None None O
clearly None None O
shown None None O
to None None O
be None None O
responsible None None O
for None None O
elevating None None O
p53 None None O
levels None None O
in None None O
infected None None O
fibroblasts None None O
; None None O
expression None None O
of None None O
HCMV None None O
immediate None None O
- None None O
early None None O
region None None O
1 None None O
and None None O
2 None None O
proteins None None O
resulted None None O
in None None O
elevation None None O
of None None O
p53 None None O
levels None None O
in None None O
transfected None None O
human None None O
fibroblasts None None O
. None None O

This None None O
is None None O
the None None O
first None None O
report None None O
of None None O
increased None None O
p53 None None O
levels None None O
caused None None O
by None None O
HCMV None None O
in None None O
infected None None O
fibroblasts None None O
. None None O

Images None None O

Figure None None O
1 None None O

Figure None None O
2 None None O

Figure None None O
3 None None O

Figure None None O
4 None None O

Cloning None None O
and None None O
characterization None None O
of None None O
the None None O
latent None None O
membrane None None O
protein None None O
( None None O
LMP None None O
) None None O
of None None O
a None None O
specific None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
variant None None O
derived None None O
from None None O
the None None O
nasopharyngeal None None O
carcinoma None None O
in None None O
the None None O
Taiwanese None None O
population None None O
. None None O

A None None O
DNA None None O
fragment None None O
containing None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
terminal None None O
fragment None None O
sequence None None O
was None None O
obtained None None O
from None None O
a None None O
genomic None None O
library None None O
of None None O
nasopharyngeal None None O
carcinoma None None O
( None None O
NPC None None O
) None None O
. None None O

One None None O
of None None O
the None None O
clones None None O
( None None O
clone None None O
1510 None None O
) None None O
contained None None O
the None None O
gene None None O
encoding None None O
latent None None O
membrane None None O
protein None None O
( None None O
LMP None None O
) None None O
. None None O

Sequence None None O
analysis None None O
revealed None None O
that None None O
this None None O
gene None None O
had None None O
95 None None O
% None None O
homology None None O
with None None O
the None None O
LMP None None O
sequence None None O
of None None O
the None None O
B95 None None O
- None None O
8 None None O
strain None None O
. None None O

Among None None O
the None None O
sequence None None O
variations None None O
, None None O
there None None O
was None None O
a None None O
change None None O
from None None O
G None None O
to None None O
T None None O
at None None O
nucleotide None None O
position None None O
169 None None O
, None None O
426 None None O
, None None O
resulting None None O
in None None O
the None None O
loss None None O
of None None O
an None None O
XhoI None None O
site None None O
in None None O
exon None None O
1 None None O
of None None O
the None None O
LMP None None O
gene None None O
. None None O

A None None O
pair None None O
of None None O
primers None None O
bracketing None None O
the None None O
XhoI None None O
site None None O
were None None O
designed None None O
to None None O
synthesize None None O
the None None O
EBV None None O
DNA None None O
fragment None None O
from None None O
nucleotides None None O
169 None None O
, None None O
081 None None O
- None None O
169 None None O
, None None O
577 None None O
by None None O
using None None O
the None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
PCR None None O
) None None O
method None None O
. None None O

The None None O
PCR None None O
products None None O
were None None O
then None None O
subject None None O
to None None O
XhoI None None O
digestion None None O
and None None O
to None None O
DNA None None O
sequencing None None O
analysis None None O
. None None O

This None None O
restriction None None O
enzyme None None O
site None None O
polymorphism None None O
along None None O
with None None O
the None None O
sequence None None O
variations None None O
were None None O
also None None O
observed None None O
in None None O
50 None None O
biopsy None None O
tissues None None O
as None None O
well None None O
as None None O
in None None O
the None None O
throat None None O
washings None None O
of None None O
6 None None O
out None None O
of None None O
20 None None O
healthy None None O
individuals None None O
that None None O
we None None O
examined None None O
, None None O
indicating None None O
that None None O
the None None O
EBV None None O
strain None None O
predominantly None None O
existing None None O
in None None O
these None None O
biopsy None None O
tissues None None O
was None None O
different None None O
from None None O
strains None None O
of None None O
B95 None None O
- None None O
8 None None O
, None None O
Jijoye None None O
or None None O
nude None None O
mouse None None O
passaged None None O
cells None None O
( None None O
C15 None None I-Cell-line-name
) None None O
with None None O
an None None O
African None None O
origin None None O
, None None O
but None None O
closely None None O
resembled None None O
other None None O
nude None None O
mouse None None O
passaged None None O
CAO None None I-Cell-line-name
cells None None O
which None None O
were None None O
originally None None O
derived None None O
from None None O
China None None O
. None None O

Balb None None I-Cell-line-name
/ None None I-Cell-line-name
c None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
carrying None None O
this None None O
NPC None None O
- None None O
LMP None None O
gene None None O
showed None None O
a None None O
transformed None None O
cell None None O
morphology None None O
and None None O
were None None O
tumorigenic None None O
in None None O
nude None None O
mice None None O
. None None O

The None None O
relationship None None O
between None None O
this None None O
unique None None O
type None None O
of None None O
EBV None None O
and None None O
NPC None None O
has None None O
yet None None O
to None None O
be None None O
established None None O
. None None O

Results None None O

Table None None O
1 None None O
shows None None O
the None None O
predicted None None O
new None None O
case None None O
detection None None O
rates None None O
at None None O
25 None None O
years None None O
after None None O
the None None O
initiation None None O
of None None O
the None None O
interventions None None O
. None None O

Under None None O
the None None O
baseline None None O
control None None O
program None None O
, None None O
the None None O
different None None O
mechanisms None None O
that None None O
determined None None O
susceptibility None None O
showed None None O
up None None O
to None None O
three None None O
- None None O
fold None None O
differences None None O
in None None O
the None None O
predicted None None O
number None None O
of None None O
cases None None O
per None None O
100 None None O
, None None O
000 None None O
people None None O
. None None O

In None None O
Figure None None O
1 None None O
, None None O
the None None O
trends None None O
in None None O
the None None O
new None None O
case None None O
detection None None O
rates None None O
over None None O
50 None None O
years None None O
are None None O
shown None None O
for None None O
all None None O
seven None None O
interventions None None O
. None None O

All None None O
susceptibility None None O
mechanisms None None O
give None None O
qualitatively None None O
comparable None None O
trends None None O
. None None O

When None None O
the None None O
intervention None None O
scenarios None None O
were None None O
ordered None None O
after None None O
50 None None O
years None None O
by None None O
the None None O
amount None None O
of None None O
reduction None None O
in None None O
new None None O
case None None O
detection None None O
rates None None O
, None None O
the None None O
order None None O
was None None O
as None None O
good None None O
as None None O
identical None None O
for None None O
all None None O
mechanisms None None O
; None None O
i None None O
. None None O
e None None O
. None None O
early None None O
diagnosis None None O
lowest None None O
; None None O
then None None O
no None None O
BCG None None O
& None None O
early None None O
diagnosis None None O
; None None O
then None None O
chemoprophylaxis None None O
; None None O
then None None O
baseline None None O
; None None O
then None None O
no None None O
BCG None None O
& None None O
chemoprophylaxis None None O
together None None O
with None None O
no None None O
contact None None O
tracing None None O
; None None O
and None None O
finally None None O
no None None O
BCG None None O
had None None O
the None None O
highest None None O
new None None O
case None None O
detection None None O
rate None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pntd None None O
. None None O
0001330 None None O
. None None O
g001 None None O
Figure None None O
1 None None O

Predicted None None O
decline None None O
of None None O
the None None O
new None None O
case None None O
detection None None O
rate None None O
with None None O
seven None None O
intervention None None O
scenarios None None O
and None None O
six None None O
mechanisms None None O
of None None O
leprosy None None O
susceptiblity None None O
since None None O
start None None O
of None None O
intervention None None O
strategy None None O
. None None O

The None None O
baseline None None O
program None None O
( None None O
black None None O
line None None O
) None None O
included None None O
passive None None O
detection None None O
, None None O
multidrug None None O
therapy None None O
, None None O
contact None None O
tracing None None O
, None None O
and None None O
an None None O
infant None None O
leprosy None None O
- None None O
preventative None None O
BCG None None O
vaccination None None O
given None None O
at None None O
the None None O
population None None O
level None None O
. None None O

The None None O
other None None O
six None None O
intervention None None O
strategies None None O
included None None O
the None None O
baseline None None O
program None None O
and None None O
, None None O
introduction None None O
of None None O
a None None O
new None None O
tuberculosis None None O
vaccine None None O
ineffective None None O
against None None O
leprosy None None O
replacing None None O
BCG None None O
( None None O
red None None O
) None None O
; None None O
no None None O
tracing None None O
of None None O
household None None O
contacts None None O
( None None O
orange None None O
) None None O
; None None O
a None None O
single None None O
chemoprophylactic None None O
dose None None O
of None None O
rifampicin None None O
that None None O
cured None None O
50 None None O
% None None O
of None None O
subclinically None None O
infected None None O
contacts None None O
( None None O
yellow None None O
) None None O
; None None O
early None None O
diagnosis None None O
of None None O
70 None None O
% None None O
of None None O
subclinically None None O
infected None None O
contacts None None O
in None None O
each None None O
of None None O
3 None None O
consecutive None None O
annual None None O
examinations None None O
( None None O
green None None O
) None None O
; None None O
chemoprophylaxis None None O
plus None None O
introduction None None O
of None None O
a None None O
tuberculosis None None O
vaccine None None O
ineffective None None O
against None None O
leprosy None None O
( None None O
blue None None O
) None None O
; None None O
and None None O
detection None None O
of None None O
subclinically None None O
infected None None O
contacts None None O
plus None None O
introduction None None O
of None None O
a None None O
tuberculosis None None O
vaccine None None O
ineffective None None O
against None None O
le None None O
- None None O
pro None None O
- None None O
sy None None O
( None None O
purple None None O
) None None O
. None None O

Results None None O
are None None O
the None None O
average None None O
of None None O
100 None None O
runs None None O
of None None O
the None None O
simulation None None O
model None None O
for None None O
each None None O
scenario None None O
and None None O
susceptibilty None None O
mechanism None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pntd None None O
. None None O
0001330 None None O
. None None O
t001 None None O
Table None None O
1 None None O

Predicted None None O
new None None O
case None None O
detection None None O
rates None None O
( None None O
per None None O
100 None None O
, None None O
000 None None O
) None None O
at None None O
25 None None O
years None None O
after None None O
the None None O
introduction None None O
of None None O
the None None O
indicated None None O
intervention None None O
scenario None None O
for None None O
six None None O
mechanisms None None O
of None None O
leprosy None None O
susceptibility None None O
as None None O
described None None O
in None None O
[ None None O
9 None None O
] None None O
. None None O

Intervention None None O
Mechanism None None O
determining None None O
susceptibilty None None O

Random None None O
Household None None O
Dominant None None O
Recessive None None O
Household None None O
& None None O
dominant None None O
Household None None O
& None None O
recessive None None O

Baseline None None O
control None None O
3 None None O
. None None O
4 None None O
4 None None O
. None None O
0 None None O
10 None None O
. None None O
4 None None O
8 None None O
. None None O
2 None None O
5 None None O
. None None O
6 None None O
4 None None O
. None None O
6 None None O

No None None O
BCG None None O
4 None None O
. None None O
6 None None O
5 None None O
. None None O
5 None None O
15 None None O
. None None O
0 None None O
11 None None O
. None None O
9 None None O
7 None None O
. None None O
6 None None O
6 None None O
. None None O
4 None None O

No None None O
contact None None O
tracing None None O
3 None None O
. None None O
8 None None O
4 None None O
. None None O
1 None None O
10 None None O
. None None O
5 None None O
8 None None O
. None None O
5 None None O
5 None None O
. None None O
5 None None O
4 None None O
. None None O
8 None None O

Chemoprophylaxis None None O
2 None None O
. None None O
8 None None O
3 None None O
. None None O
2 None None O
6 None None O
. None None O
9 None None O
5 None None O
. None None O
9 None None O
4 None None O
. None None O
1 None None O
3 None None O
. None None O
4 None None O

Early None None O
diagnosis None None O
1 None None O
. None None O
1 None None O
2 None None O
. None None O
1 None None O
2 None None O
. None None O
7 None None O
2 None None O
. None None O
6 None None O
2 None None O
. None None O
1 None None O
2 None None O
. None None O
0 None None O

No None None O
BCG None None O
& None None O
chemoprophylaxis None None O
3 None None O
. None None O
6 None None O
4 None None O
. None None O
0 None None O
10 None None O
. None None O
5 None None O
8 None None O
. None None O
5 None None O
5 None None O
. None None O
9 None None O
5 None None O
. None None O
1 None None O

No None None O
BCG None None O
& None None O
early None None O
diagnosis None None O
1 None None O
. None None O
2 None None O
2 None None O
. None None O
5 None None O
3 None None O
. None None O
7 None None O
3 None None O
. None None O
7 None None O
2 None None O
. None None O
9 None None O
2 None None O
. None None O
8 None None O

The None None O
results None None O
are None None O
average None None O
of None None O
100 None None O
runs None None O
of None None O
the None None O
simulation None None O
model None None O
. None None O

Both None None O
the None None O
cessation None None O
of None None O
contact None None O
tracing None None O
and None None O
the None None O
replacement None None O
of None None O
BCG None None O
vaccine None None O
by None None O
a None None O
tuberculosis None None O
vaccine None None O
ineffective None None O
for None None O
leprosy None None O
( None None O
no None None O
BCG None None O
) None None O
would None None O
have None None O
detrimental None None O
effects None None O
on None None O
the None None O
rate None None O
of None None O
decline None None O
in None None O
leprosy None None O
( None None O
Figure None None O
2 None None O
) None None O
. None None O

Twenty None None O
- None None O
five None None O
years None None O
after None None O
introduction None None O
of None None O
the None None O
ineffective None None O
vaccine None None O
( None None O
no None None O
BCG None None O
) None None O
, None None O
the None None O
new None None O
case None None O
detection None None O
of None None O
leprosy None None O
was None None O
approximately None None O
1 None None O
. None None O
5 None None O
times None None O
higher None None O
than None None O
the None None O
baseline None None O
( None None O
Table None None O
1 None None O
) None None O
. None None O

The None None O
cessation None None O
of None None O
contact None None O
tracing None None O
was None None O
predicted None None O
to None None O
have None None O
a None None O
smaller None None O
impact None None O
, None None O
with None None O
a None None O
marked None None O
drop None None O
in None None O
detection None None O
of None None O
new None None O
leprosy None None O
cases None None O
during None None O
the None None O
first None None O
few None None O
years None None O
. None None O

This None None O
sudden None None O
drop None None O
was None None O
due None None O
to None None O
the None None O
reduced None None O
number None None O
of None None O
examinations None None O
of None None O
people None None O
in None None O
contact None None O
with None None O
patients None None O
; None None O
thus None None O
, None None O
these None None O
cases None None O
would None None O
not None None O
be None None O
detected None None O
until None None O
later None None O
, None None O
through None None O
passive None None O
detection None None O
( None None O
self None None O
- None None O
reporting None None O
) None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pntd None None O
. None None O
0001330 None None O
. None None O
g002 None None O
Figure None None O
2 None None O

Predicted None None O
new None None O
case None None O
detection None None O
rates None None O
for None None O
six None None O
intervention None None O
scenarios None None O
relative None None O
to None None O
the None None O
baseline None None O
control None None O
program None None O
. None None O

For None None O
each None None O
intervention None None O
scenario None None O
simulations None None O
with None None O
different None None O
mechanisms None None O
of None None O
susceptibility None None O
to None None O
leprosy None None O
, None None O
as None None O
defined None None O
in None None O
our None None O
previous None None O
paper None None O
[ None None O
9 None None O
] None None O
are None None O
performed None None O
. None None O

For None None O
each None None O
intervention None None O
scenario None None O
, None None O
the None None O
two None None O
dotted None None O
lines None None O
show None None O
the None None O
smallest None None O
and None None O
largest None None O
deviations None None O
from None None O
the None None O
baseline None None O
control None None O
program None None O
. None None O

The None None O
solid None None O
line None None O
shows None None O
the None None O
median None None O
of None None O
all None None O
susceptibility None None O
mechanisms None None O
. None None O

Results None None O
are None None O
the None None O
average None None O
of None None O
100 None None O
runs None None O
of None None O
the None None O
simulation None None O
model None None O
. None None O

Both None None O
chemoprophylaxis None None O
and None None O
early None None O
diagnosis None None O
were None None O
predicted None None O
to None None O
have None None O
substantial None None O
effects None None O
on None None O
the None None O
new None None O
case None None O
detection None None O
of None None O
leprosy None None O
( None None O
Figure None None O
2 None None O
) None None O
. None None O

With None None O
no None None O
BCG None None O
, None None O
chemoprophylaxis None None O
would None None O
partially None None O
compensate None None O
for None None O
the None None O
predicted None None O
increase None None O
in None None O
new None None O
case None None O
detection None None O
rates None None O
. None None O

Furthermore None None O
, None None O
early None None O
diagnosis None None O
was None None O
predicted None None O
to None None O
more None None O
than None None O
compensate None None O
for None None O
the None None O
adverse None None O
effects None None O
of None None O
a None None O
leprosy None None O
- None None O
ineffective None None O
tuberculosis None None O
vaccine None None O
, None None O
and None None O
reduce None None O
the None None O
rate None None O
of None None O
new None None O
case None None O
detection None None O
compared None None O
to None None O
the None None O
baseline None None O
. None None O

The None None O
effects None None O
were None None O
more None None O
promising None None O
with None None O
the None None O
ongoing None None O
presence None None O
of None None O
the None None O
BCG None None O
vaccine None None O
. None None O

Under None None O
those None None O
conditions None None O
, None None O
at None None O
25 None None O
years None None O
after None None O
the None None O
introduction None None O
of None None O
chemoprophylaxis None None O
, None None O
the None None O
new None None O
case None None O
detection None None O
rate None None O
was None None O
predicted None None O
to None None O
be None None O
25 None None O
% None None O
lower None None O
than None None O
baseline None None O
control None None O
. None None O

Moreover None None O
, None None O
with None None O
the None None O
introduction None None O
of None None O
early None None O
diagnosis None None O
, None None O
the None None O
new None None O
case None None O
detection None None O
rate None None O
was None None O
predicted None None O
to None None O
halve None None O
the None None O
baseline None None O
incidence None None O
after None None O
25 None None O
years None None O
( None None O
Table None None O
1 None None O
) None None O
. None None O

Early None None O
diagnosis None None O
of None None O
infection None None O
allows None None O
the None None O
detection None None O
of None None O
subclinical None None O
cases None None O
, None None O
of None None O
which None None O
part None None O
would None None O
be None None O
detected None None O
later None None O
or None None O
never None None O
at None None O
all None None O
. None None O

These None None O
subclinical None None O
cases None None O
are None None O
added None None O
to None None O
the None None O
number None None O
of None None O
detected None None O
cases None None O
. None None O

This None None O
is None None O
seen None None O
in None None O
the None None O
results None None O
of None None O
this None None O
intervention None None O
. None None O

The None None O
introduction None None O
of None None O
early None None O
diagnosis None None O
would None None O
increase None None O
the None None O
total None None O
number None None O
of None None O
detected None None O
cases None None O
in None None O
the None None O
first None None O
18 None None O
years None None O
, None None O
simply None None O
because None None O
of None None O
the None None O
detection None None O
of None None O
previously None None O
undetectable None None O
subclinical None None O
cases None None O
. None None O

Over None None O
time None None O
however None None O
, None None O
the None None O
total None None O
number None None O
of None None O
new None None O
cases None None O
( None None O
subclinical None None O
and None None O
clinical None None O
) None None O
would None None O
finally None None O
drop None None O
below None None O
the None None O
number None None O
detected None None O
in None None O
the None None O
baseline None None O
control None None O
program None None O
( None None O
Figure None None O
3 None None O
) None None O
. None None O

In None None O
Figure None None O
3 None None O
, None None O
we None None O
show None None O
that None None O
the None None O
new None None O
cases None None O
detected None None O
under None None O
the None None O
chemoprophylaxis None None O
intervention None None O
strategy None None O
drop None None O
immediately None None O
below None None O
the None None O
level None None O
of None None O
the None None O
baseline None None O
control None None O
program None None O
. None None O

The None None O
additional None None O
effect None None O
of None None O
chemoprophylaxis None None O
is None None O
that None None O
additional None None O
new None None O
infections None None O
are None None O
prevented None None O
on None None O
top None None O
of None None O
the None None O
cure None None O
of None None O
subclinical None None O
infections None None O
. None None O

These None None O
additional None None O
prevented None None O
infections None None O
are None None O
due None None O
to None None O
a None None O
shorter None None O
infectious None None O
period None None O
of None None O
the None None O
cured None None O
subclinical None None O
infections None None O
. None None O

To None None O
illustrate None None O
this None None O
effect None None O
we None None O
show None None O
in None None O
Figure None None O
3 None None O
the None None O
clinical None None O
and None None O
the None None O
subclinical None None O
cases None None O
that None None O
were None None O
cured None None O
by None None O
the None None O
chemoprophylactic None None O
intervention None None O
. None None O

During None None O
the None None O
first None None O
10 None None O
years None None O
, None None O
this None None O
total None None O
number None None O
of None None O
newly None None O
detected None None O
cases None None O
plus None None O
cured None None O
cases None None O
is None None O
equal None None O
to None None O
the None None O
number None None O
of None None O
newly None None O
detected None None O
cases None None O
under None None O
the None None O
baseline None None O
control None None O
program None None O
, None None O
but None None O
afterwards None None O
the None None O
number None None O
of None None O
cases None None O
plus None None O
cured None None O
subclinical None None O
cases None None O
in None None O
the None None O
chemoprophylaxis None None O
intervention None None O
group None None O
drops None None O
under None None O
the None None O
baseline None None O
control None None O
program None None O
, None None O
indicating None None O
the None None O
prevention None None O
of None None O
new None None O
infections None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pntd None None O
. None None O
0001330 None None O
. None None O
g003 None None O
Figure None None O
3 None None O

Cumulative None None O
New None None O
cases None None O
detected None None O
of None None O
leprosy None None O
per None None O
person None None O
- None None O
year None None O
since None None O
start None None O
of None None O
the None None O
interventions None None O
. None None O

Results None None O
are None None O
the None None O
average None None O
of None None O
100 None None O
runs None None O
of None None O
the None None O
simulation None None O
model None None O
. None None O

Imaging None None O
techniques None None O
for None None O
the None None O
assessment None None O
of None None O
body None None O
composition None None O
. None None O

Three None None O
imaging None None O
methods None None O
, None None O
ultrasound None None O
imaging None None O
( None None O
UI None None O
) None None O
, None None O
computer None None O
- None None O
assisted None None O
axial None None O
tomography None None O
( None None O
CAT None None O
) None None O
and None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
MRI None None O
) None None O
, None None O
are None None O
widely None None O
used None None O
in None None O
medicine None None O
. None None O

Their None None O
application None None O
to None None O
the None None O
assessment None None O
of None None O
body None None O
composition None None O
in None None O
nutrition None None O
research None None O
is None None O
still None None O
being None None O
explored None None O
and None None O
developed None None O
. None None O

Ultrasound None None O
imaging None None O
yields None None O
poor None None O
image None None O
quality None None O
but None None O
, None None O
because None None O
it None None O
is None None O
cheap None None O
and None None O
safe None None O
, None None O
deserves None None O
further None None O
exploration None None O
. None None O

Both None None O
CAT None None O
and None None O
MRI None None O
can None None O
produce None None O
images None None O
with None None O
good None None O
discrimination None None O
among None None O
bone None None O
, None None O
muscle None None O
and None None O
adipose None None O
tissue None None O
. None None O

Movement None None O
artifacts None None O
tend None None O
to None None O
be None None O
more None None O
serious None None O
in None None O
MRI None None O
than None None O
in None None O
CAT None None O
due None None O
to None None O
the None None O
longer None None O
imaging None None O
time None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
X None None O
- None None O
ray None None O
exposure None None O
in None None O
CAT None None O
is None None O
likely None None O
to None None O
limit None None O
its None None O
use None None O
in None None O
human None None O
nutrition None None O
research None None O
. None None O

Repeated None None O
measurements None None O
of None None O
tissue None None O
volumes None None O
by None None O
CAT None None O
and None None O
MRI None None O
give None None O
similar None None O
CV None None O
. None None O

In None None O
both None None O
CAT None None O
and None None O
MRI None None O
, None None O
intra None None O
- None None O
abdominal None None O
adipose None None O
tissue None None O
presents None None O
greater None None O
problems None None O
of None None O
measurement None None O
than None None O
subcutaneous None None O
adipose None None O
tissue None None O
. None None O

Validation None None O
studies None None O
with None None O
77 None None O
- None None O
kg None None O
pigs None None O
of None None O
MRI None None O
, None None O
using None None O
13 None None O
slices None None O
, None None O
predicted None None O
total None None O
body None None O
lipid None None O
with None None O
residual None None O
standard None None O
deviation None None O
of None None O
1 None None O
. None None O
9 None None O
% None None O
. None None O

In None None O
validating None None O
any None None O
of None None O
these None None O
methods None None O
, None None O
account None None O
should None None O
be None None O
take None None O
of None None O
the None None O
extent None None O
to None None O
which None None O
the None None O
information None None O
they None None O
give None None O
can None None O
augment None None O
that None None O
given None None O
by None None O
more None None O
simple None None O
measures None None O
like None None O
age None None O
and None None O
weight None None O
. None None O

Toward None None O
a None None O
theory None None O
regarding None None O
the None None O
pathogenesis None None O
of None None O
the None None O
systemic None None O
inflammatory None None O
response None None O
syndrome None None O
: None None O
what None None O
we None None O
do None None O
and None None O
do None None O
not None None O
know None None O
about None None O
cytokine None None O
regulation None None O
. None None O

OBJECTIVES None None O
: None None O

The None None O
systemic None None O
inflammatory None None O
response None None O
syndrome None None O
( None None O
SIRS None None O
) None None O
is None None O
the None None O
massive None None O
inflammatory None None O
reaction None None O
resulting None None O
from None None O
systemic None None O
mediator None None O
release None None O
that None None O
may None None O
lead None None O
to None None O
multiple None None O
organ None None O
dysfunction None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
review None None O
article None None O
is None None O
to None None O
analyze None None O
the None None O
roles None None O
of None None O
cytokines None None O
, None None O
cytokine None None O
production None None O
, None None O
and None None O
the None None O
relationship None None O
of None None O
cytokine None None O
production None None O
to None None O
the None None O
development None None O
of None None O
SIRS None None O
. None None O

DATA None None O
SOURCES None None O
: None None O

Previous None None O
research None None O
and None None O
clinical None None O
studies None None O
related None None O
to None None O
cytokines None None O
and None None O
their None None O
relationship None None O
to None None O
SIRS None None O
. None None O

STUDY None None O
SELECTION None None O
: None None O

From None None O
the None None O
studies None None O
reviewed None None O
, None None O
three None None O
critical None None O
questions None None O
are None None O
addressed None None O
. None None O

First None None O
, None None O
what None None O
is None None O
the None None O
definition None None O
of None None O
increased None None O
cytokine None None O
concentrations None None O
? None None O

Second None None O
, None None O
what None None O
other None None O
systemic None None O
illnesses None None O
besides None None O
sepsis None None O
can None None O
alter None None O
cytokine None None O
concentrations None None O
? None None O

Third None None O
, None None O
what None None O
are None None O
the None None O
right None None O
cytokines None None O
to None None O
measure None None O
? None None O

DATA None None O
SYNTHESIS None None O
: None None O

This None None O
article None None O
postulates None None O
a None None O
three None None O
- None None O
stage None None O
development None None O
of None None O
SIRS None None O
, None None O
in None None O
which None None O
stage None None O
1 None None O
is None None O
a None None O
local None None O
production None None O
of None None O
cytokines None None O
in None None O
response None None O
to None None O
an None None O
injury None None O
or None None O
infection None None O
. None None O

Stage None None O
2 None None O
is None None O
the None None O
protective None None O
release None None O
of None None O
a None None O
small None None O
amount None None O
of None None O
cytokines None None O
into None None O
the None None O
body None None O
' None None O
s None None O
circulation None None O
. None None O

Stage None None O
3 None None O
is None None O
the None None O
massive None None O
systemic None None O
reaction None None O
where None None O
cytokines None None O
turn None None O
destructive None None O
by None None O
compromising None None O
the None None O
integrity None None O
of None None O
the None None O
capillary None None O
walls None None O
and None None O
flooding None None O
end None None O
organs None None O
. None None O

CONCLUSIONS None None O
: None None O

While None None O
cytokines None None O
are None None O
generally None None O
viewed None None O
as None None O
a None None O
destructive None None O
development None None O
in None None O
the None None O
patient None None O
that None None O
generally None None O
leads None None O
to None None O
multiple None None O
organ None None O
dysfunction None None O
, None None O
cytokines None None O
also None None O
protect None None O
the None None O
body None None O
when None None O
localized None None O
. None None O

It None None O
will None None O
be None None O
necessary None None O
to None None O
study None None O
the None None O
positive None None O
effects None None O
of None None O
cytokines None None O
while None None O
also None None O
studying None None O
their None None O
role None None O
in None None O
causing None None O
SIRS None None O
. None None O

It None None O
will None None O
also None None O
be None None O
important None None O
to None None O
investigate None None O
the None None O
relationship None None O
between None None O
cytokines None None O
and None None O
their None None O
blockers None None O
in None None O
SIRS None None O
. None None O

Disk None None O
preparation None None O
phase None None O

o None None O
Adoption None None O
of None None O
a None None O
two None None O
- None None O
stage None None O
sampling None None O
scheme None None O
. None None O

o None None O
Careful None None O
planning None None O
and None None O
choice None None O
of None None O
representative None None O
sampling None None O
groups None None O
and None None O
sites None None O
according None None O
to None None O
the None None O
adopted None None O
network None None O
sampling None None O
technique None None O
, None None O
and None None O
determining None None O
certain None None O
criteria None None O
such None None O
as None None O
control None None O
sites None None O
where None None O
major None None O
sampling None None O
groups None None O
exist None None O
( None None O
i None None O
. None None O
e None None O
. None None O
surface None None O
water None None O
points None None O
, None None O
valleys None None O
, None None O
and None None O
wells None None O
) None None O
, None None O
impact None None O
sites None None O
where None None O
contamination None None O
is None None O
expected None None O
, None None O
such None None O
as None None O
polygons None None O
, None None O
and None None O
outlets None None O
( None None O
e None None O
. None None O
g None None O
. None None O
treated None None O
water None None O
discharges None None O
site None None O
) None None O
to None None O
maximise None None O
understanding None None O
the None None O
quality None None O
of None None O
urban None None O
water None None O
sources None None O
, None None O
and None None O
with None None O
the None None O
least None None O
risk None None O
of None None O
missing None None O
the None None O
correct None None O
representative None None O
sampling None None O
groups None None O
and None None O
sites None None O
. None None O

o None None O
Attention None None O
paid None None O
to None None O
ensure None None O
inclusion None None O
in None None O
the None None O
sampling None None O
frame None None O
of None None O
all None None O
groups None None O
and None None O
locations None None O
( None None O
sites None None O
, None None O
roads None None O
, None None O
venues None None O
, None None O
and None None O
so None None O
on None None O
) None None O
via None None O
screening None None O
, None None O
browsing None None O
, None None O
and None None O
delineation None None O
from None None O
a None None O
satellite None None O
digital None None O
map None None O
of None None O
the None None O
Khamis None None O
Mushait None None O
Governorate None None O
zone None None O
, None None O
because None None O
local None None O
pre None None O
- None None O
knowledge None None O
was None None O
preferred None None O
with None None O
regard None None O
to None None O
accessibility None None O
, None None O
safety None None O
, None None O
and None None O
permission None None O
. None None O

o None None O
Approximation None None O
of None None O
the None None O
number None None O
of None None O
the None None O
target None None O
study None None O
population None None O
in None None O
each None None O
group None None O
and None None O
sampling None None O
location None None O
. None None O

o None None O
Determination None None O
of None None O
the None None O
proportional None None O
allocation None None O
of None None O
samples None None O
between None None O
different None None O
groups None None O
and None None O
locations None None O
. None None O

o None None O
Training None None O
of None None O
interviewers None None O
\ None None O
sample None None O
collectors None None O
to None None O
follow None None O
and None None O
to None None O
use None None O
the None None O
sampling None None O
strategy None None O
and None None O
procedures None None O
. None None O

o None None O
Implementation None None O
of None None O
ways None None O
to None None O
boost None None O
participation None None O
rates None None O
in None None O
the None None O
screening None None O
and None None O
core None None O
interviews None None O
and None None O
sample None None O
collection None None O
. None None O

o None None O
Planning None None O
of None None O
logistic None None O
needs None None O
of None None O
timing None None O
, None None O
gathering None None O
, None None O
handling None None O
samples None None O
, None None O
and None None O
laboratory None None O
. None None O

o None None O
Producing None None O
sampling None None O
cards None None O
to None None O
be None None O
completed None None O
to None None O
record None None O
observations None None O
at None None O
scene None None O
( None None O
sample None None O
ID None None O
and None None O
data None None O
/ None None O
information None None O
: None None O
date None None O
, None None O
time None None O
, None None O
temperature None None O
, None None O
group None None O
, None None O
locality None None O
, None None O
problems None None O
in None None O
the None None O
area None None O
, None None O
sketch None None O
map None None O
) None None O
. None None O

o None None O
Selection None None O
of None None O
an None None O
appropriate None None O
major None None O
sampling None None O
method None None O
[ None None O
52 None None O
] None None O
( None None O
i None None O
. None None O
e None None O
. None None O
simple None None O
random None None O
sample None None O
; None None O
network None None O
sampling None None O
) None None O
. None None O

o None None O
Planning None None O
of None None O
pilot None None O
visits None None O
to None None O
samples None None O
of None None O
each None None O
group None None O
in None None O
the None None O
field None None O
to None None O
review None None O
strategy None None O
. None None O

Endosialin None None O
/ None None O
TEM None None O
1 None None O
/ None None O
CD248 None None O
is None None O
a None None O
pericyte None None O
marker None None O
of None None O
embryonic None None O
and None None O
tumor None None O
neovascularization None None O
. None None O

The None None O
formation None None O
of None None O
functional None None O
, None None O
mature None None O
blood None None O
vessels None None O
depends None None O
on None None O
the None None O
interaction None None O
between None None O
endothelial None None O
cells None None O
and None None O
pericytes None None O
. None None O

Commonality None None O
exists None None O
in None None O
the None None O
processes None None O
involved None None O
in None None O
vasculature None None O
development None None O
between None None O
tissues None None O
whether None None O
healthy None None O
or None None O
diseased None None O
. None None O

Endosialin None None O
/ None None O
TEM None None O
1 None None O
is None None O
a None None O
cell None None O
membrane None None O
protein None None O
that None None O
is None None O
expressed None None O
in None None O
blood None None O
vessels None None O
during None None O
embryogenesis None None O
and None None O
tumorigenesis None None O
but None None O
not None None O
in None None O
normal None None O
mature None None O
vessels None None O
. None None O

Antibodies None None O
developed None None O
to None None O
human None None O
endosialin None None O
were None None O
used None None O
to None None O
investigate None None O
endosialin None None O
expression None None O
and None None O
function None None O
in None None O
human None None O
prenatal None None O
brain None None O
pericytes None None O
and None None O
pericytes None None O
residing None None O
in None None O
tumors None None O
. None None O

Anti None None O
- None None O
endosialin None None O
was None None O
capable None None O
of None None O
preventing None None O
pericyte None None O
tube None None O
formation None None O
in None None O
culture None None O
and None None O
inhibited None None O
migration None None O
. None None O

Brain None None O
pericytes None None O
in None None O
culture None None O
had None None O
higher None None O
levels None None O
of None None O
endosialin None None O
/ None None O
TEM None None O
1 None None O
than None None O
TEMs None None O
- None None O
2 None None O
, None None O
- None None O
3 None None O
, None None O
- None None O
4 None None O
, None None O
- None None O
5 None None O
, None None O
- None None O
7 None None O
, None None O
and None None O
- None None O
8 None None O
. None None O

Immunocytochemistry None None O
revealed None None O
that None None O
endosialin None None O
was None None O
present None None O
in None None O
the None None O
cytoplasmic None None O
body None None O
and None None O
in None None O
the None None O
elongated None None O
extensions None None O
essential None None O
to None None O
pericyte None None O
function None None O
. None None O

Transgenic None None O
mice None None O
engineered None None O
to None None O
express None None O
human None None O
endosialin None None O
bred None None O
on None None O
an None None O
immunocompromised None None O
background None None O
allowed None None O
the None None O
growth None None O
of None None O
human None None O
tumor None None O
xenografts None None O
. None None O

In None None O
human None None O
colon None None O
carcinoma None None O
Colo205 None None O
and None None O
HT29 None None I-Cell-line-name
xenografts None None O
grown None None O
in None None O
human None None O
endosialin None None O
- None None O
transgenic None None O
mice None None O
, None None O
endosialin None None O
expression None None O
was None None O
largely None None O
confined None None O
to None None O
NG2 None None O
- None None O
expressing None None O
perivascular None None O
cells None None O
and None None O
not None None O
CD31 None None O
- None None O
positive None None O
endothelial None None O
cells None None O
. None None O

Similar None None O
methods None None O
applied None None O
to None None O
human None None O
ovarian None None O
and None None O
colon None None O
tumors None None O
confirmed None None O
endosialin None None O
expression None None O
by None None O
pericytes None None O
. None None O

The None None O
data None None O
indicate None None O
that None None O
endosialin None None O
is None None O
strongly None None O
expressed None None O
by None None O
pericytes None None O
during None None O
periods None None O
of None None O
active None None O
angiogenesis None None O
during None None O
embryonic None None O
and None None O
tumor None None O
development None None O
. None None O

Anti None None O
- None None O
endosialin None None O
antibodies None None O
may None None O
have None None O
value None None O
in None None O
identifying None None O
vasculature None None O
in None None O
malignant None None O
tissues None None O
. None None O

With None None O
the None None O
appropriate None None O
agent None None O
, None None O
targeting None None O
endosialin None None O
may None None O
interfere None None O
with None None O
blood None None O
vessel None None O
growth None None O
during None None O
tumor None None O
development None None O
. None None O

INTRODUCTION None None O

For None None O
several None None O
years None None O
now None None O
, None None O
virtual None None O
microscopy None None O
has None None O
been None None O
utilized None None O
in None None O
medical None None O
teaching None None O
, None None O
research None None O
, None None O
proficiency None None O
testing None None O
, None None O
American None None O
Board None None O
of None None O
Pathology None None O
examinations None None O
, None None O
pathology None None O
meetings None None O
and None None O
conferences None None O
, None None O
and None None O
quality None None O
assurance None None O
programs None None O
. None None O

In None None O
diagnostic None None O
practice None None O
, None None O
it None None O
is None None O
most None None O
widely None None O
and None None O
routinely None None O
used None None O
in None None O
image None None O
analysis None None O
. None None O

Some None None O
practices None None O
are None None O
beginning None None O
to None None O
use None None O
it None None O
internally None None O
( None None O
within None None O
their None None O
group None None O
) None None O
for None None O
frozen None None O
section None None O
intraoperative None None O
consultations None None O
and None None O
subspecialty None None O
consultations None None O
due None None O
to None None O
geographic None None O
and None None O
time None None O
constrains None None O
. None None O

Although None None O
diagnostic None None O
consultation None None O
for None None O
expert None None O
second None None O
opinion None None O
is None None O
a None None O
well None None O
- None None O
established None None O
practice None None O
in None None O
pathology None None O
for None None O
glass None None O
slides None None O
, None None O
similar None None O
consultation None None O
via None None O
virtual None None O
microscopy None None O
poses None None O
multiple None None O
controversial None None O
issues None None O
such None None O
as None None O
licensing None None O
, None None O
liability None None O
, None None O
security None None O
, None None O
reimbursement None None O
, None None O
and None None O
scanning None None O
quality None None O
and None None O
its None None O
validation None None O
. None None O

Regulations None None O
and None None O
standardization None None O
are None None O
not None None O
yet None None O
in None None O
place None None O
that None None O
pathologists None None O
can None None O
use None None O
to None None O
allay None None O
these None None O
fears None None O
. None None O

Nevertheless None None O
, None None O
if None None O
the None None O
virtual None None O
microscopy None None O
scans None None O
are None None O
of None None O
optimal None None O
quality None None O
, None None O
these None None O
can None None O
be None None O
simply None None O
substituted None None O
for None None O
glass None None O
slides None None O
and None None O
a None None O
microscope None None O
while None None O
maintaining None None O
all None None O
other None None O
practice None None O
guidelines None None O
for None None O
second None None O
opinion None None O
consultation None None O
. None None O

Additionally None None O
, None None O
the None None O
cost None None O
and None None O
maintenance None None O
of None None O
scanning None None O
equipment None None O
is None None O
not None None O
currently None None O
affordable None None O
to None None O
most None None O
practitioners None None O
and None None O
consultants None None O
. None None O

A None None O
practice None None O
model None None O
that None None O
offers None None O
tertiary None None O
consultation None None O
in None None O
gastrointestinal None None O
( None None O
GI None None O
) None None O
and None None O
liver None None O
pathology None None O
is None None O
presented None None O
that None None O
eliminates None None O
the None None O
cost None None O
and None None O
maintenance None None O
of None None O
scanners None None O
by None None O
the None None O
consultants None None O
and None None O
clients None None O
, None None O
minimizes None None O
the None None O
need None None O
for None None O
review None None O
of None None O
glass None None O
slides None None O
, None None O
facilitates None None O
clinicopathological None None O
and None None O
radiological None None O
correlation None None O
and None None O
serves None None O
the None None O
need None None O
of None None O
clients None None O
who None None O
need None None O
timely None None O
help None None O
with None None O
challenging None None O
liver None None O
and None None O
GI None None O
cases None None O
and None None O
to None None O
obtain None None O
expert None None O
opinion None None O
for None None O
dysplasia None None O
in None None O
Barrett None None O
' None None O
s None None O
and None None O
ulcerative None None O
colitis None None O
surveillance None None O
biopsies None None O
required None None O
by None None O
the None None O
American None None O
Gastroenterology None None O
Association None None O
( None None O
AGA None None O
) None None O
. None None O

This None None O
model None None O
has None None O
been None None O
practiced None None O
for None None O
3 None None O
years None None O
and None None O
applied None None O
to None None O
over None None O
2000 None None O
cases None None O
by None None O
small None None O
pathology None None O
practices None None O
in None None O
the None None O
50 None None O
United None None O
States None None O
and None None O
a None None O
single None None O
consultant None None O
GI None None O
and None None O
liver None None O
pathologist None None O
. None None O

Impact None None O
of None None O
tumor None None O
cell None None O
VEGF None None O
expression None None O
on None None O
the None None O
in None None O
vivo None None O
efficacy None None O
of None None O
vandetanib None None O
( None None O
ZACTIMA None None O
; None None O
ZD6474 None None O
) None None O
. None None O

VEGF None None O
is None None O
the None None O
key None None O
player None None O
in None None O
tumor None None O
angiogenesis None None O
. None None O

In None None O
the None None O
current None None O
study None None O
, None None O
the None None O
impact None None O
of None None O
VEGF None None O
expression None None O
on None None O
the None None O
response None None O
of None None O
tumors None None O
to None None O
the None None O
VEGFR2 None None O
associated None None O
tyrosine None None O
kinase None None O
inhibitor None None O
vandetanib None None O
was None None O
evaluated None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
Human None None O
colon None None O
carcinoma None None O
( None None O
HT29 None None I-Cell-line-name
) None None O
and None None O
murine None None O
squamous None None O
carcinoma None None O
( None None O
SCCVII None None I-Cell-line-name
) None None O
clonal None None O
cell None None O
lines None None O
expressing None None O
varying None None O
levels None None O
of None None O
VEGF None None O
were None None O
established None None O
and None None O
their None None O
response None None O
to None None O
vandetanib None None O
was None None O
assessed None None O
in None None O
tissue None None O
culture None None O
and None None O
as None None O
solid None None O
tumors None None O
. None None O

RESULTS None None O
: None None O
Vandetanib None None O
treatment None None O
had None None O
no None None O
effect None None O
on None None O
tumor None None O
cell None None O
clonogenic None None O
cell None None O
survival None None O
in None None O
vitro None None O
but None None O
doses None None O
> None None O
or None None O
= None None O
10 None None O
nM None None O
significantly None None O
reduced None None O
endothelial None None O
cell None None O
migration None None O
. None None O

In None None O
vivo None None O
, None None O
tumors None None O
derived None None O
from None None O
cell None None O
clones None None O
expressing None None O
high None None O
levels None None O
of None None O
VEGF None None O
displayed None None O
significantly None None O
enhanced None None O
angiogenesis None None O
and None None O
more None None O
aggressive None None O
growth None None O
. None None O

An None None O
intradermal None None O
angiogenesis None None O
assay None None O
was None None O
used None None O
to None None O
demonstrate None None O
that None None O
a None None O
4 None None O
- None None O
day None None O
treatment None None O
with None None O
vandetanib None None O
( None None O
50 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
) None None O
was None None O
able None None O
to None None O
significantly None None O
inhibit None None O
blood None None O
vessel None None O
growth None None O
induced None None O
by None None O
both None None O
parental None None O
and None None O
high None None O
VEGF None None O
- None None O
expressing None None O
tumor None None O
cell None None O
clones None None O
. None None O

In None None O
the None None O
HT29 None None I-Cell-line-name
tumor None None O
model None None O
, None None O
treatment None None O
response None None O
to None None O
vandetanib None None O
( None None O
50 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
, None None O
Monday None None O
- None None O
Friday None None O
for None None O
2 None None O
weeks None None O
) None None O
was None None O
greatest None None O
in None None O
xenografts None None O
derived None None O
from None None O
the None None O
highest None None O
VEGF None None O
- None None O
expressing None None O
cell None None O
clones None None O
. None None O

A None None O
similar None None O
trend None None O
was None None O
noted None None O
in None None O
the None None O
SCCVII None None I-Cell-line-name
tumor None None O
model None None O
. None None O

The None None O
present None None O
findings None None O
indicate None None O
that None None O
vandetanib None None O
therapy None None O
effectively None None O
counteracted None None O
the None None O
aggressive None None O
feature None None O
of None None O
tumor None None O
growth None None O
resulting None None O
from None None O
VEGF None None O
over None None O
- None None O
expressing None None O
tumor None None O
cells None None O
and None None O
suggest None None O
that None None O
such None None O
tumors None None O
may None None O
be None None O
particularly None None O
well None None O
suited None None O
for None None O
anti None None O
- None None O
VEGF None None O
interventions None None O
. None None O

Step None None O
- None None O
wise None None O
logistic None None O
regression None None O
( None None O
STEPLOG None None O
) None None O

The None None O
group None None O
variable None None O
was None None O
considered None None O
as None None O
an None None O
ordinal None None O
( None None O
or None None O
binary None None O
) None None O
dependent None None O
variable None None O
and None None O
the None None O
feature None None O
vector None None O
( None None O
multiple None None O
marker None None O
IBD None None O
estimates None None O
and None None O
covariates None None O
) None None O
as None None O
the None None O
independent None None O
variables None None O
. None None O

A None None O
nonlinear None None O
relationship None None O
( None None O
logit None None O
) None None O
between None None O
the None None O
dependent None None O
and None None O
independent None None O
variables None None O
was None None O
taken None None O
. None None O

For None None O
binary None None O
data None None O
( None None O
collapsing None None O
concordantly None None O
affected None None O
or None None O
unaffected None None O
sib None None O
pair None None O
into None None O
one None None O
group None None O
) None None O
, None None O
a None None O
conventional None None O
logistic None None O
regression None None O
was None None O
used None None O
. None None O

For None None O
ordinal None None O
data None None O
, None None O
the None None O
SAS None None O
LOGISTIC None None O
[ None None O
8 None None O
] None None O
procedure None None O
fits None None O
a None None O
parallel None None O
lines None None O
regression None None O
model None None O
based None None O
on None None O
the None None O
cumulative None None O
distribution None None O
probabilities None None O
of None None O
response None None O
categories None None O
, None None O
rather None None O
than None None O
on None None O
their None None O
individual None None O
probabilities None None O
. None None O

The None None O
statistical None None O
P None None O
- None None O
value None None O
for None None O
each None None O
( None None O
selected None None O
) None None O
independent None None O
variable None None O
was None None O
obtained None None O
from None None O
the None None O
final None None O
model None None O
fitting None None O
with None None O
only None None O
selected None None O
variables None None O
included None None O
via None None O
an None None O
asymptotic None None O
chi None None O
- None None O
squared None None O
statistic None None O
. None None O

Results None None O

In None None O
the None None O
established None None O
adult None None O
rat None None O
NSC None None O
culture None None O
, None None O
FGF None None O
- None None O
2 None None O
promotes None None O
self None None O
- None None O
renewal None None O
by None None O
increasing None None O
proliferation None None O
and None None O
inhibiting None None O
spontaneous None None O
differentiation None None O
of None None O
adult None None O
NSCs None None O
, None None O
accompanied None None O
with None None O
activation None None O
of None None O
MAPK None None O
and None None O
PLC None None O
pathways None None O
. None None O

Using None None O
a None None O
molecular None None O
genetic None None O
approach None None O
, None None O
we None None O
demonstrate None None O
that None None O
activation None None O
of None None O
FGF None None O
receptor None None O
1 None None O
( None None O
FGFR1 None None O
) None None O
, None None O
largely None None O
through None None O
two None None O
key None None O
cytoplasmic None None O
amino None None O
acid None None O
residues None None O
that None None O
are None None O
linked None None O
to None None O
MAPK None None O
and None None O
PLC None None O
activation None None O
, None None O
suffices None None O
to None None O
promote None None O
adult None None O
NSC None None I-Cell-line-name
self None None O
- None None O
renewal None None O
. None None O

The None None O
canonical None None O
MAPK None None O
, None None O
Erk1 None None O
/ None None O
2 None None O
activation None None O
, None None O
is None None O
both None None O
required None None O
and None None O
sufficient None None O
for None None O
the None None O
NSC None None I-Cell-line-name
expansion None None O
and None None O
anti None None O
- None None O
differentiation None None O
effects None None O
of None None O
FGF None None O
- None None O
2 None None O
. None None O

In None None O
contrast None None O
, None None O
PLC None None O
activation None None O
is None None O
integral None None O
to None None O
the None None O
maintenance None None O
of None None O
adult None None O
NSC None None I-Cell-line-name
characteristics None None O
, None None O
including None None O
the None None O
full None None O
capacity None None O
for None None O
neuronal None None O
and None None O
oligodendroglial None None O
differentiation None None O
. None None O

Reagents None None O

CNQX None None O
, None None O
colchicine None None O
, None None O
forskolin None None O
, None None O
and None None O
carbenoxolone None None O
were None None O
purchased None None O
from None None O
Sigma None None O
. None None O

DCG None None O
- None None O
IV None None O
, None None O
ZD7288 None None O
, None None O
CGP55845 None None O
and None None O
DPCPX None None O
were None None O
obtained None None O
from None None O
Tocris None None O
Cookson None None O
( None None O
Ellisville None None O
, None None O
MO None None O
) None None O
. None None O

MDM2 None None O
as None None O
a None None O
predictor None None O
of None None O
prostate None None O
carcinoma None None O
outcome None None O
: None None O
an None None O
analysis None None O
of None None O
Radiation None None O
Therapy None None O
Oncology None None O
Group None None O
Protocol None None O
8610 None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
MDM2 None None O
oncoprotein None None O
promotes None None O
p53 None None O
degradation None None O
via None None O
ubiquitin None None O
, None None O
establishing None None O
negative None None O
feedback None None O
control None None O
of None None O
p53 None None O
and None None O
consequently None None O
affecting None None O
cell None None O
cycle None None O
arrest None None O
and None None O
apoptosis None None O
. None None O

The None None O
authors None None O
evaluated None None O
the None None O
association None None O
between None None O
MDM2 None None O
expression None None O
and None None O
local None None O
failure None None O
, None None O
distant None None O
metastasis None None O
( None None O
DM None None O
) None None O
, None None O
cause None None O
- None None O
specific None None O
mortality None None O
, None None O
and None None O
overall None None O
mortality None None O
in None None O
men None None O
treated None None O
in None None O
Radiation None None O
Therapy None None O
Oncology None None O
Group None None O
8610 None None O
with None None O
radiotherapy None None O
, None None O
with None None O
or None None O
without None None O
androgen None None O
deprivation None None O
. None None O

METHODS None None O
: None None O
Of None None O
the None None O
456 None None O
eligible None None O
and None None O
analyzable None None O
patients None None O
( None None O
parent None None O
cohort None None O
) None None O
, None None O
adequate None None O
archival None None O
diagnostic None None O
tissue None None O
specimens None None O
from None None O
108 None None O
patients None None O
were None None O
available None None O
for None None O
MDM2 None None O
analysis None None O
( None None O
MDM2 None None O
cohort None None O
) None None O
. None None O

Cox None None O
proportional None None O
hazards None None O
multivariate None None O
analysis None None O
( None None O
MVA None None O
) None None O
was None None O
used None None O
to None None O
determine None None O
the None None O
relation None None O
of None None O
MDM2 None None O
to None None O
the None None O
endpoints None None O
. None None O

MDM2 None None O
overexpression None None O
was None None O
manually None None O
classified None None O
as None None O
> None None O
5 None None O
% None None O
nuclear None None O
staining None None O
. None None O

An None None O
image None None O
analysis None None O
system None None O
was None None O
also None None O
used None None O
to None None O
quantify None None O
the None None O
proportion None None O
of None None O
tumor None None O
nuclei None None O
with None None O
MDM2 None None O
staining None None O
( None None O
ACIS None None O
index None None O
) None None O
and None None O
staining None None O
intensity None None O
. None None O

RESULTS None None O
: None None O
Overexpression None None O
of None None O
MDM2 None None O
by None None O
manual None None O
counts None None O
was None None O
seen None None O
in None None O
44 None None O
% None None O
( None None O
n None None O
= None None O
47 None None O
) None None O
of None None O
the None None O
patients None None O
. None None O

In None None O
the None None O
manual None None O
count None None O
analysis None None O
, None None O
there None None O
was None None O
no None None O
significant None None O
relation None None O
between None None O
MDM2 None None O
overexpression None None O
and None None O
outcome None None O
. None None O

The None None O
ACIS None None O
index None None O
, None None O
using None None O
a None None O
cutoff None None O
point None None O
defined None None O
by None None O
the None None O
median None None O
value None None O
, None None O
< None None O
or None None O
= None None O
3 None None O
% None None O
versus None None O
> None None O
3 None None O
% None None O
, None None O
was None None O
related None None O
to None None O
5 None None O
- None None O
year None None O
DM None None O
rates None None O
in None None O
univariate None None O
analyses None None O
( None None O
32 None None O
. None None O
6 None None O
% None None O
vs None None O
. None None O
45 None None O
. None None O
8 None None O
% None None O
; None None O
P None None O
= None None O
0 None None O
. None None O
057 None None O
) None None O
and None None O
MVA None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
06 None None O
) None None O
. None None O

The None None O
intensity None None O
of None None O
MDM2 None None O
staining None None O
was None None O
not None None O
significant None None O
. None None O

CONCLUSIONS None None O
: None None O
MDM2 None None O
expression None None O
quantified None None O
by None None O
image None None O
analysis None None O
was None None O
weakly None None O
associated None None O
with None None O
DM None None O
. None None O

The None None O
cohort None None O
examined None None O
was None None O
relatively None None O
small None None O
and None None O
with None None O
larger None None O
patient None None O
numbers None None O
, None None O
MDM2 None None O
overexpression None None O
may None None O
emerge None None O
as None None O
a None None O
more None None O
significant None None O
covariate None None O
. None None O

Efficient None None O
inhibition None None O
of None None O
ovarian None None O
cancer None None O
growth None None O
and None None O
prolonged None None O
survival None None O
by None None O
transfection None None O
with None None O
a None None O
novel None None O
pro None None O
- None None O
apoptotic None None O
gene None None O
, None None O
hPNAS None None O
- None None O
4 None None O
, None None O
in None None O
a None None O
mouse None None O
model None None O
. None None O

In None None O
vivo None None O
and None None O
in None None O
vitro None None O
results None None O
. None None O

OBJECTIVE None None O
: None None O
We None None O
transfected None None O
ovarian None None O
cancer None None O
cells None None O
and None None O
administered None None O
recombinant None None O
plasmid None None O
encoding None None O
hPNAS None None O
- None None O
4 None None O
to None None O
nude None None O
mice None None O
bearing None None O
ovarian None None O
cancer None None O
, None None O
aiming None None O
to None None O
evaluate None None O
the None None O
effect None None O
of None None O
hPNAS None None O
- None None O
4 None None O
against None None O
ovarian None None O
cancer None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

METHODS None None O
: None None O
Ovarian None None O
cancer None None O
SKOV3 None None I-Cell-line-name
cells None None O
were None None O
transfected None None O
with None None O
hPNAS None None O
- None None O
4 None None O
- None None O
plasmid None None O
, None None O
and None None O
cell None None O
proliferation None None O
was None None O
evaluated None None O
by None None O
MTT None None O
assay None None O
; None None O
apoptosis None None O
was None None O
examined None None O
by None None O
DNA None None O
ladder None None O
, None None O
Hoechst33258 None None O
staining None None O
and None None O
flow None None O
- None None O
cytometric None None O
assays None None O
. None None O

Nude None None O
mice None None O
bearing None None O
ovarian None None O
cancers None None O
were None None O
treated None None O
with None None O
hPNAS None None O
- None None O
4 None None O
- None None O
p None None O
/ None None O
liposome None None O
. None None O

Tumor None None O
growth None None O
was None None O
determined None None O
and None None O
survival None None O
was None None O
recorded None None O
. None None O

TUNEL None None O
assay None None O
and None None O
microvessel None None O
density None None O
was None None O
assessed None None O
to None None O
evaluate None None O
apoptosis None None O
and None None O
angiogenesis None None O
. None None O

RESULTS None None O
: None None O
Both None None O
inhibition None None O
of None None O
proliferation None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
and None None O
induction None None O
of None None O
apoptosis None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
were None None O
observed None None O
in None None O
SKOV3 None None I-Cell-line-name
cells None None O
transfected None None O
with None None O
hPNAS None None O
- None None O
4 None None O
- None None O
p None None O
in None None O
vitro None None O
. None None O

In None None O
hPNAS None None O
- None None O
4 None None O
- None None O
p None None O
- None None O
treated None None O
tumor None None O
cells None None O
in None None O
vivo None None O
, None None O
tumor None None O
growth None None O
significantly None None O
decreased None None O
, None None O
while None None O
the None None O
survival None None O
time None None O
of None None O
tumor None None O
- None None O
bearing None None O
mice None None O
was None None O
prolonged None None O
compared None None O
with None None O
control None None O
groups None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Increased None None O
apoptosis None None O
of None None O
tumor None None O
cells None None O
and None None O
decreased None None O
angiogenesis None None O
in None None O
tumor None None O
tissue None None O
were None None O
also None None O
observed None None O
. None None O

CONCLUSIONS None None O
: None None O
Our None None O
promising None None O
results None None O
on None None O
the None None O
potential None None O
antitumor None None O
effects None None O
of None None O
hPNAS None None O
- None None O
4 None None O
on None None O
ovarian None None O
cancer None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
may None None O
be None None O
explained None None O
, None None O
in None None O
part None None O
, None None O
by None None O
the None None O
induction None None O
of None None O
apoptosis None None O
and None None O
inhibition None None O
of None None O
angiogenesis None None O
. None None O

Consequently None None O
, None None O
hPNAS None None O
- None None O
4 None None O
has None None O
potential None None O
as None None O
a None None O
new None None O
gene None None O
therapy None None O
for None None O
human None None O
ovarian None None O
cancer None None O
. None None O

NSPCs None None O
protect None None O
against None None O
30 None None O
minute None None O
MCAO None None O
. None None O

( None None O
A None None O
- None None O
D None None O
) None None O
Coronal None None O
histological None None O
sections None None O
through None None O
the None None O
ischemic None None O
striatum None None O
3 None None O
days None None O
following None None O
MCAO None None O
, None None O
stained None None O
for None None O
TUNEL None None O
( None None O
A None None O
, None None O
B None None O
) None None O
or None None O
NeuN None None O
( None None O
C None None O
, None None O
D None None O
) None None O
. None None O

Mice None None O
received None None O
intrastriatal None None O
injections None None O
of None None O
exogenous None None O
PBS None None O
( None None O
A None None O
, None None O
C None None O
) None None O
or None None O
EGFP None None O
+ None None O
NSPCs None None O
( None None O
B None None O
, None None O
D None None O
, None None O
E None None O
) None None O
72 None None O
hr None None O
prior None None O
to None None O
MCAO None None O
. None None O

Inset None None O
in None None O
( None None O
B None None O
) None None O
shows None None O
40x None None O
magnified None None O
view None None O
of None None O
the None None O
injection None None O
site None None O
. None None O

( None None O
E None None O
) None None O
Monochrome None None O
conversion None None O
of None None O
image None None O
shown None None O
in None None O
B None None O
to None None O
demonstrate None None O
concentric None None O
ring None None O
structures None None O
used None None O
for None None O
Sholl None None O
analysis None None O
. None None O

( None None O
F None None O
) None None O
Quantification None None O
of None None O
TUNEL None None O
+ None None O
cells None None O
using None None O
Sholl None None O
analysis None None O
performed None None O
on None None O
fluorescent None None O
images None None O
. None None O

* None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
, None None O
n None None O
= None None O
5 None None O
mice None None O
per None None O
group None None O
. None None O

Scale None None O
bar None None O
: None None O
A None None O
, None None O
B None None O
= None None O
20 None None O
microm None None O
; None None O
C None None O
, None None O
D None None O
= None None O
10 None None O
microm None None O
. None None O

The None None O
in None None O
vivo None None O
properties None None O
of None None O
STX243 None None O
: None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
in None None O
breast None None O
cancer None None O
. None None O

The None None O
steroidal None None O
- None None O
based None None O
drug None None O
2 None None O
- None None O
ethyloestradiol None None O
- None None O
3 None None O
, None None O
17 None None O
- None None O
O None None O
, None None O
O None None O
- None None O
bis None None O
- None None O
sulphamate None None O
( None None O
STX243 None None O
) None None O
has None None O
been None None O
developed None None O
as None None O
a None None O
potent None None O
antiangiogenic None None O
and None None O
antitumour None None O
compound None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
ascertain None None O
whether None None O
STX243 None None O
is None None O
more None None O
active None None O
in None None O
vivo None None O
than None None O
the None None O
clinically None None O
relevant None None O
drug None None O
2 None None O
- None None O
methoxyoestradiol None None O
( None None O
2 None None O
- None None O
MeOE2 None None O
) None None O
and None None O
the None None O
structurally None None O
similar None None O
compound None None O
2 None None O
- None None O
MeOE2 None None O
- None None O
3 None None O
, None None O
17 None None O
- None None O
O None None O
, None None O
O None None O
- None None O
bis None None O
- None None O
sulphamate None None O
( None None O
STX140 None None O
) None None O
. None None O

The None None O
tumour None None O
growth None None O
inhibition None None O
efficacy None None O
, None None O
antiangiogenic None None O
potential None None O
and None None O
pharmacokinetics None None O
of None None O
STX243 None None O
were None None O
examined None None O
using None None O
four None None O
in None None O
vivo None None O
models None None O
. None None O

Both None None O
STX243 None None O
and None None O
STX140 None None O
were None None O
capable None None O
of None None O
retarding None None O
the None None O
growth None None O
of None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
xenograft None None O
tumours None None O
( None None O
72 None None O
and None None O
63 None None O
% None None O
, None None O
respectively None None O
) None None O
, None None O
whereas None None O
no None None O
inhibition None None O
was None None O
observed None None O
for None None O
animals None None O
treated None None O
with None None O
2 None None O
- None None O
MeOE2 None None O
. None None O

Further None None O
tumour None None O
inhibition None None O
studies None None O
showed None None O
that None None O
STX243 None None O
was None None O
also None None O
active None None O
against None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
paclitaxel None None O
- None None O
resistant None None O
tumours None None O
. None None O

Using None None O
a None None O
Matrigel None None O
plug None None O
- None None O
based None None O
model None None O
, None None O
in None None O
vivo None None O
angiogenesis None None O
was None None O
restricted None None O
with None None O
STX243 None None O
and None None O
STX140 None None O
( None None O
50 None None O
and None None O
72 None None O
% None None O
, None None O
respectively None None O
, None None O
using None None O
a None None O
10 None None O
mg None None O
kg None None O
( None None O
- None None O
1 None None O
) None None O
oral None None O
dose None None O
) None None O
, None None O
thereby None None O
showing None None O
the None None O
antiangiogenic None None O
activity None None O
of None None O
both None None O
compounds None None O
. None None O

The None None O
pharmacokinetics None None O
of None None O
STX243 None None O
were None None O
examined None None O
at None None O
two None None O
different None None O
doses None None O
using None None O
adult None None O
female None None O
rats None None O
. None None O

The None None O
compound None None O
was None None O
orally None None O
bioavailable None None O
( None None O
31 None None O
% None None O
after None None O
a None None O
single None None O
10 None None O
mg None None O
kg None None O
( None None O
- None None O
1 None None O
) None None O
dose None None O
) None None O
and None None O
resistant None None O
to None None O
metabolism None None O
. None None O

These None None O
results None None O
show None None O
that None None O
STX243 None None O
is None None O
a None None O
potent None None O
in None None O
vivo None None O
drug None None O
and None None O
could None None O
be None None O
clinically None None O
effective None None O
at None None O
treating None None O
a None None O
number None None O
of None None O
oncological None None O
conditions None None O
. None None O

Analysis None None O
of None None O
molecular None None O
aberrations None None O
of None None O
Wnt None None O
pathway None None O
gladiators None None O
in None None O
colorectal None None O
cancer None None O
in None None O
the None None O
Kashmiri None None O
population None None O
. None None O

The None None O
development None None O
and None None O
progression None None O
of None None O
colorectal None None O
cancer None None O
( None None O
CRC None None O
) None None O
is None None O
a None None O
multi None None O
- None None O
step None None O
process None None O
, None None O
and None None O
the None None O
Wnt None None O
pathways None None O
with None None O
its None None O
two None None O
molecular None None O
gladiators None None O
adenomatous None None O
polyposis None None O
coli None None O
( None None O
APC None None O
) None None O
and None None O
beta None None O
- None None O
catenin None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
transforming None None O
a None None O
normal None None O
tissue None None O
into None None O
a None None O
malignant None None O
one None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
aimed None None O
to None None O
investigate None None O
the None None O
role None None O
of None None O
aberrations None None O
in None None O
the None None O
APC None None O
and None None O
beta None None O
- None None O
catenin None None O
genes None None O
in None None O
the None None O
pathogenesis None None O
of None None O
CRC None None O
in None None O
the None None O
Kashmir None None O
valley None None O
, None None O
and None None O
to None None O
correlate None None O
it None None O
with None None O
various None None O
clinicopathological None None O
variables None None O
. None None O

We None None O
examined None None O
the None None O
paired None None O
tumour None None O
and None None O
normal None None O
- None None O
tissue None None O
specimens None None O
of None None O
86 None None O
CRC None None O
patients None None O
for None None O
the None None O
occurrence None None O
of None None O
aberrations None None O
in None None O
the None None O
mutation None None O
cluster None None O
region None None O
( None None O
MCR None None O
) None None O
of None None O
the None None O
APC None None O
gene None None O
and None None O
exon None None O
3 None None O
of None None O
the None None O
beta None None O
- None None O
catenin None None O
gene None None O
by None None O
polymerase None None O
chain None None O
reaction None None O
- None None O
single None None O
- None None O
strand None None O
conformation None None O
polymorphism None None O
( None None O
PCR None None O
- None None O
SSCP None None O
) None None O
and None None O
/ None None O
or None None O
PCR None None O
- None None O
direct None None O
sequencing None None O
. None None O

Analysis None None O
of None None O
promoter None None O
hypermethylation None None O
of None None O
the None None O
APC None None O
gene None None O
was None None O
also None None O
carried None None O
out None None O
using None None O
methylation None None O
- None None O
specific None None O
PCR None None O
( None None O
MS None None O
- None None O
PCR None None O
) None None O
. None None O

The None None O
overall None None O
mutation None None O
rate None None O
of None None O
the None None O
MCR None None O
of None None O
the None None O
APC None None O
gene None None O
among None None O
86 None None O
CRC None None O
cases None None O
was None None O
12 None None O
. None None O
8 None None O
per None None O
cent None None O
( None None O
11 None None O
of None None O
86 None None O
) None None O
. None None O

Promoter None None O
hypermethylation None None O
of None None O
APC None None O
was None None O
observed None None O
in None None O
54 None None O
. None None O
65 None None O
per None None O
cent None None O
( None None O
47 None None O
of None None O
86 None None O
) None None O
of None None O
cases None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
a None None O
significant None None O
association None None O
between None None O
tumour None None O
location None None O
, None None O
tumour None None O
grade None None O
and None None O
node None None O
status None None O
and None None O
the None None O
methylation None None O
status None None O
of None None O
the None None O
APC None None O
gene None None O
( None None O
p None None O
< None None O
= None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Although None None O
the None None O
number None None O
of None None O
mutations None None O
in None None O
the None None O
APC None None O
and None None O
beta None None O
- None None O
catenin None None O
genes None None O
in None None O
our None None O
CRC None None O
cases None None O
was None None O
very None None O
low None None O
, None None O
the None None O
study None None O
confirms None None O
the None None O
role None None O
of None None O
epigenetic None None O
gene None None O
silencing None None O
of None None O
the None None O
pivotal None None O
molecular None None O
gladiator None None O
, None None O
APC None None O
, None None O
of None None O
the None None O
Wnt None None O
pathway None None O
in None None O
the None None O
development None None O
of None None O
CRC None None O
in None None O
the None None O
Kashmiri None None O
population None None O
. None None O

Grape None None O
seed None None O
extract None None O
inhibits None None O
angiogenesis None None O
via None None O
suppression None None O
of None None O
the None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
signaling None None O
pathway None None O
. None None O

Blockade None None O
of None None O
angiogenesis None None O
is None None O
an None None O
important None None O
approach None None O
for None None O
cancer None None O
treatment None None O
and None None O
prevention None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
one None None O
of None None O
the None None O
most None None O
critical None None O
factors None None O
that None None O
induce None None O
angiogenesis None None O
and None None O
has None None O
thus None None O
become None None O
an None None O
attractive None None O
target None None O
for None None O
antiangiogenesis None None O
treatment None None O
. None None O

However None None O
, None None O
most None None O
current None None O
anti None None O
- None None O
VEGF None None O
agents None None O
often None None O
cause None None O
some None None O
side None None O
effects None None O
when None None O
given None None O
chronically None None O
. None None O

Identification None None O
of None None O
naturally None None O
occurring None None O
VEGF None None O
inhibitors None None O
derived None None O
from None None O
diet None None O
would None None O
be None None O
one None None O
alternative None None O
approach None None O
with None None O
an None None O
advantage None None O
of None None O
known None None O
safety None None O
. None None O

Grape None None O
seed None None O
extract None None O
( None None O
GSE None None O
) None None O
, None None O
a None None O
widely None None O
used None None O
dietary None None O
supplement None None O
, None None O
is None None O
known None None O
to None None O
have None None O
antitumor None None O
activity None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
explored None None O
the None None O
activity None None O
of None None O
GSE None None O
on None None O
VEGF None None O
receptor None None O
and None None O
angiogenesis None None O
. None None O

We None None O
found None None O
that None None O
GSE None None O
could None None O
directly None None O
inhibit None None O
the None None O
kinase None None O
activity None None O
of None None O
purified None None O
VEGF None None O
receptor None None O
2 None None O
, None None O
a None None O
novel None None O
activity None None O
of None None O
GSE None None O
that None None O
has None None O
not None None O
been None None O
characterized None None O
. None None O

GSE None None O
could None None O
also None None O
inhibit None None O
the None None O
VEGF None None O
receptor None None O
/ None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
- None None O
mediated None None O
signaling None None O
pathway None None O
in None None O
endothelial None None O
cells None None O
. None None O

As None None O
a None None O
result None None O
, None None O
GSE None None O
could None None O
inhibit None None O
VEGF None None O
- None None O
induced None None O
endothelial None None O
cell None None O
proliferation None None O
and None None O
migration None None O
as None None O
well None None O
as None None O
sprout None None O
formation None None O
from None None O
aorta None None O
ring None None O
. None None O

In None None O
vivo None None O
assay None None O
further None None O
showed None None O
that None None O
GSE None None O
could None None O
inhibit None None O
tumor None None O
growth None None O
and None None O
tumor None None O
angiogenesis None None O
of None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
in None None O
mice None None O
. None None O

Consistent None None O
with None None O
the None None O
in None None O
vitro None None O
data None None O
, None None O
GSE None None O
treatment None None O
of None None O
tumor None None O
- None None O
bearing None None O
mice None None O
led None None O
to None None O
concomitant None None O
reduction None None O
of None None O
blood None None O
vessel None None O
density None None O
and None None O
phosphorylation None None O
of None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
. None None O

Depletion None None O
of None None O
polyphenol None None O
with None None O
polyvinylpyrrolidone None None O
abolished None None O
the None None O
antiangiogenic None None O
activity None None O
of None None O
GSE None None O
, None None O
suggesting None None O
a None None O
water None None O
- None None O
soluble None None O
fraction None None O
of None None O
polyphenol None None O
in None None O
GSE None None O
is None None O
responsible None None O
for None None O
the None None O
antiangiogenic None None O
activity None None O
. None None O

Taken None None O
together None None O
, None None O
this None None O
study None None O
indicates None None O
that None None O
GSE None None O
is None None O
a None None O
well None None O
- None None O
tolerated None None O
and None None O
inexpensive None None O
natural None None O
VEGF None None O
inhibitor None None O
and None None O
could None None O
potentially None None O
be None None O
useful None None O
in None None O
cancer None None O
prevention None None O
or None None O
treatment None None O
. None None O

The None None O
Down None None O
syndrome None None O
critical None None O
region None None O
gene None None O
1 None None O
short None None O
variant None None O
promoters None None O
direct None None O
vascular None None O
bed None None O
- None None O
specific None None O
gene None None O
expression None None O
during None None O
inflammation None None O
in None None O
mice None None O
. None None O

Down None None O
syndrome None None O
critical None None O
region None None O
gene None None O
1 None None O
( None None O
DSCR None None O
- None None O
1 None None O
) None None O
short None None O
variant None None O
( None None O
DSCR None None O
- None None O
1s None None O
) None None O
is None None O
an None None O
inhibitor None None O
of None None O
calcineurin None None O
/ None None O
NFAT None None O
signaling None None O
encoded None None O
by None None O
exons None None O
4 None None O
- None None O
7 None None O
of None None O
DSCR1 None None O
. None None O

We None None O
previously None None O
reported None None O
that None None O
VEGF None None O
induces None None O
DSCR None None O
- None None O
1s None None O
expression None None O
in None None O
endothelial None None O
cells None None O
, None None O
which None None O
in None None O
turn None None O
negatively None None O
feeds None None O
back None None O
to None None O
attenuate None None O
endothelial None None O
cell None None O
activation None None O
. None None O

Here None None O
, None None O
in None None O
order None None O
to None None O
characterize None None O
the None None O
role None None O
of None None O
the None None O
promoter None None O
that None None O
drives None None O
DSCR None None O
- None None O
1s None None O
expression None None O
in None None O
mediating None None O
inducible None None O
expression None None O
in None None O
vivo None None O
and None None O
to None None O
determine None None O
the None None O
functional None None O
relevance None None O
of None None O
DSCR None None O
- None None O
1s None None O
in None None O
inflammation None None O
, None None O
we None None O
targeted None None O
a None None O
DNA None None O
construct None None O
containing None None O
1 None None O
. None None O
7 None None O
kb None None O
of None None O
the None None O
human None None O
DSCR1s None None O
promoter None None O
coupled None None O
to None None O
the None None O
lacZ None None O
reporter None None O
to None None O
the None None O
hypoxanthine None None O
guanine None None O
phosphoribosyl None None O
transferase None None O
( None None O
Hprt None None O
) None None O
locus None None O
of None None O
mice None None O
. None None O

We None None O
determined None None O
that None None O
lacZ None None O
was None None O
uniformly None None O
expressed None None O
in None None O
the None None O
endothelium None None O
of None None O
transgenic None None O
embryos None None O
but None None O
was None None O
markedly None None O
downregulated None None O
postnatally None None O
. None None O

Systemic None None O
administration None None O
of None None O
VEGF None None O
or None None O
LPS None None O
in None None O
adult None None O
mice None None O
resulted None None O
in None None O
cyclosporine None None O
A None None O
- None None O
sensitive None None O
reactivation None None O
of None None O
the None None O
DSCR1s None None O
promoter None None O
and None None O
endogenous None None O
gene None None O
expression None None O
in None None O
a None None O
subset None None O
of None None O
organs None None O
, None None O
including None None O
the None None O
heart None None O
and None None O
brain None None O
. None None O

The None None O
DSCR1s None None O
promoter None None O
was None None O
similarly None None O
induced None None O
in None None O
the None None O
endothelium None None O
of None None O
tumor None None O
xenografts None None O
. None None O

In None None O
a None None O
mouse None None O
model None None O
of None None O
endotoxemia None None O
, None None O
DSCR None None O
- None None O
1s None None O
- None None O
deficient None None O
mice None None O
demonstrated None None O
increased None None O
sepsis None None O
mortality None None O
, None None O
whereas None None O
adenovirus None None O
- None None O
mediated None None O
DSCR None None O
- None None O
1s None None O
overexpression None None O
protected None None O
against None None O
LPS None None O
- None None O
induced None None O
lethality None None O
. None None O

Collectively None None O
, None None O
these None None O
data None None O
suggest None None O
that None None O
the None None O
DSCR1s None None O
promoter None None O
directs None None O
vascular None None O
bed None None O
- None None O
specific None None O
expression None None O
in None None O
activated None None O
endothelium None None O
and None None O
that None None O
DSCR None None O
- None None O
1s None None O
serves None None O
to None None O
dampen None None O
the None None O
host None None O
response None None O
to None None O
infection None None O
. None None O

Overexpression None None O
of None None O
Glut None None O
- None None O
1 None None O
glucose None None O
transporter None None O
in None None O
human None None O
breast None None O
cancer None None O
. None None O

An None None O
immunohistochemical None None O
study None None O
. None None O

BACKGROUND None None O
: None None O
Breast None None O
cancers None None O
have None None O
higher None None O
than None None O
normal None None O
glucose None None O
metabolism None None O
, None None O
but None None O
the None None O
mechanism None None O
of None None O
glucose None None O
entry None None O
into None None O
these None None O
tumors None None O
is None None O
not None None O
well None None O
understood None None O
. None None O

METHODS None None O
: None None O
The None None O
expression None None O
of None None O
five None None O
facilitative None None O
glucose None None O
transporters None None O
, None None O
Glut None None O
- None None O
1 None None O
( None None O
erythrocyte None None O
type None None O
) None None O
, None None O
Glut None None O
- None None O
2 None None O
( None None O
liver None None O
type None None O
) None None O
, None None O
Glut None None O
- None None O
3 None None O
( None None O
brain None None O
type None None O
) None None O
, None None O
Glut None None O
- None None O
4 None None O
( None None O
muscle None None O
/ None None O
fat None None O
type None None O
) None None O
, None None O
and None None O
Glut None None O
- None None O
5 None None O
( None None O
small None None O
intestine None None O
type None None O
) None None O
, None None O
was None None O
studied None None O
by None None O
immunohistochemistry None None O
of None None O
paraffin None None O
sections None None O
from None None O
12 None None O
primary None None O
human None None O
breast None None O
cancers None None O
and None None O
8 None None O
lymph None None O
node None None O
metastases None None O
from None None O
2 None None O
patients None None O
. None None O

Rat None None O
tissues None None O
known None None O
to None None O
express None None O
these None None O
glucose None None O
transporters None None O
were None None O
used None None O
as None None O
controls None None O
. None None O

RESULTS None None O
: None None O
All None None O
the None None O
primary None None O
breast None None O
cancers None None O
and None None O
the None None O
lymph None None O
node None None O
metastases None None O
were None None O
positive None None O
for None None O
Glut None None O
- None None O
1 None None O
. None None O

This None None O
transporter None None O
was None None O
expressed None None O
on None None O
the None None O
cell None None O
membrane None None O
and None None O
in None None O
the None None O
cytoplasm None None O
of None None O
the None None O
tumor None None O
cells None None O
, None None O
but None None O
exhibited None None O
marked None None O
intratumoral None None O
and None None O
intertumoral None None O
variability None None O
in None None O
the None None O
proportions None None O
of None None O
positive None None O
cells None None O
and None None O
the None None O
intensity None None O
of None None O
staining None None O
. None None O

Staining None None O
of None None O
the None None O
normal None None O
mammary None None O
epithelium None None O
, None None O
if None None O
present None None O
, None None O
was None None O
much None None O
lower None None O
than None None O
observed None None O
in None None O
tumor None None O
cells None None O
from None None O
the None None O
same None None O
patient None None O
. None None O

Glut None None O
- None None O
2 None None O
was None None O
expressed None None O
in None None O
all None None O
of None None O
the None None O
tumors None None O
, None None O
but None None O
the None None O
intensity None None O
of None None O
staining None None O
was None None O
not None None O
consistently None None O
stronger None None O
than None None O
that None None O
seen None None O
in None None O
healthy None None O
breast None None O
. None None O

Clusters None None O
of None None O
Glut None None O
- None None O
4 None None O
- None None O
positive None None O
granule None None O
were None None O
observed None None O
in None None O
cells None None O
in None None O
six None None O
of None None O
the None None O
tumors None None O
. None None O

None None None O
of None None O
the None None O
tumors None None O
or None None O
the None None O
healthy None None O
breast None None O
in None None O
the None None O
tissues None None O
studied None None O
expressed None None O
Glut None None O
- None None O
3 None None O
or None None O
Glut None None O
- None None O
5 None None O
. None None O

CONCLUSIONS None None O
: None None O
Higher None None O
expression None None O
of None None O
the None None O
glucose None None O
transporter None None O
Glut None None O
- None None O
1 None None O
by None None O
breast None None O
cancer None None O
cells None None O
compared None None O
with None None O
the None None O
healthy None None O
breast None None O
tissue None None O
is None None O
common None None O
. None None O

Increased None None O
glucose None None O
transporter None None O
protein None None O
expression None None O
may None None O
contribute None None O
to None None O
the None None O
increased None None O
uptake None None O
of None None O
2 None None O
- None None O
[ None None O
18F None None O
] None None O
- None None O
fluoro None None O
- None None O
2 None None O
- None None O
deoxy None None O
- None None O
D None None O
- None None O
glucose None None O
( None None O
FDG None None O
) None None O
by None None O
these None None O
tumors None None O
observed None None O
by None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
imaging None None O
. None None O

Comparative None None O
NMR None None O
study None None O
of None None O
a None None O
differentiated None None O
rat None None O
hepatoma None None O
and None None O
its None None O
dedifferentiated None None O
subclone None None O
cultured None None O
as None None O
spheroids None None O
and None None O
as None None O
implanted None None O
tumors None None O
. None None O

H4IIEC3 None None I-Cell-line-name
( None None O
H4 None None I-Cell-line-name
) None None O
, None None O
a None None O
differentiated None None O
rat None None O
hepatoma None None O
line None None O
and None None O
H5 None None I-Cell-line-name
, None None O
its None None O
dedifferentiated None None O
subclone None None O
, None None O
were None None O
investigated None None O
as None None O
proliferating None None O
spheroids None None O
and None None O
as None None O
implanted None None O
subcutaneous None None O
tumors None None O
in None None O
juvenile None None O
rats None None O
. None None O

H4 None None I-Cell-line-name
cells None None O
formed None None O
tight None None O
, None None O
round None None O
spheroids None None O
whereas None None O
H5 None None I-Cell-line-name
cells None None O
formed None None O
loose None None O
, None None O
grape None None O
- None None O
like None None O
structures None None O
. None None O

31P None None O
MR None None O
spectra None None O
showed None None O
that None None O
phosphocreatine None None O
was None None O
present None None O
in None None O
H5 None None I-Cell-line-name
spheroids None None O
but None None O
not None None O
in None None O
H4 None None I-Cell-line-name
spheroids None None O
or None None O
tumors None None O
. None None O

[ None None O
13C None None O
] None None O
Lactate None None O
production None None O
from None None O
[ None None O
13C None None O
] None None O
glucose None None O
, None None O
with None None O
no None None O
detectable None None O
uptake None None O
of None None O
[ None None O
13C None None O
] None None O
alanine None None O
, None None O
indicated None None O
that None None O
energy None None O
production None None O
in None None O
H5 None None I-Cell-line-name
spheroids None None O
was None None O
primarily None None O
via None None O
glycolysis None None O
. None None O

No None None O
[ None None O
13C None None O
] None None O
glucose None None O
utilization None None O
was None None O
detected None None O
in None None O
H4 None None I-Cell-line-name
spheroids None None O
, None None O
but None None O
uptake None None O
of None None O
alanine None None O
and None None O
accumulation None None O
of None None O
labeled None None O
lactate None None O
, None None O
glutamate None None O
and None None O
glutamine None None O
indicated None None O
oxidation None None O
via None None O
the None None O
tricarboxylic None None O
acid None None O
( None None O
TCA None None O
) None None O
cycle None None O
. None None O

Tumors None None O
of None None O
H4 None None I-Cell-line-name
cells None None O
were None None O
well None None O
perfused None None O
, None None O
unlike None None O
tumors None None O
of None None O
H5 None None I-Cell-line-name
cells None None O
which None None O
were None None O
highly None None O
necrotic None None O
. None None O

Following None None O
i None None O
. None None O
v None None O
. None None O
infusion None None O
with None None O
[ None None O
13C None None O
] None None O
alanine None None O
, None None O
[ None None O
13C None None O
] None None O
lactate None None O
and None None O
glutamate None None O
, None None O
evidence None None O
of None None O
oxidation None None O
via None None O
the None None O
TCA None None O
cycle None None O
, None None O
were None None O
observed None None O
in None None O
H4 None None I-Cell-line-name
tumors None None O
. None None O

Thus None None O
the None None O
results None None O
obtained None None O
by None None O
31P None None O
and None None O
13C None None O
MRS None None O
correlated None None O
with None None O
the None None O
differentiation None None O
state None None O
of None None O
H4 None None I-Cell-line-name
and None None O
H5 None None I-Cell-line-name
spheroids None None O
and None None O
tumors None None O
. None None O

RESULTS None None O

Forty None None O
Caucasians None None O
( None None O
19 None None O
females None None O
) None None O
with None None O
essential None None O
hypertension None None O
were None None O
enrolled None None O
in None None O
the None None O
study None None O
. None None O

Their None None O
mean None None O
age None None O
was None None O
57 None None O
years None None O
. None None O

Most None None O
of None None O
them None None O
were None None O
overweight None None O
, None None O
17 None None O
had None None O
metabolic None None O
syndrome None None O
according None None O
to None None O
the None None O
updated None None O
AHA None None O
NHLBI None None O
statement None None O
( None None O
defined None None O
as None None O
3 None None O
or None None O
more None None O
of None None O
the None None O
following None None O
: None None O
waist None None O
circumference None None O
> None None O
102 None None O
cm None None O
in None None O
men None None O
and None None O
> None None O
88 None None O
cm None None O
in None None O
women None None O
, None None O
blood None None O
pressure None None O
> None None O
= None None O
130 None None O
/ None None O
85 None None O
mmHg None None O
, None None O
triglycerides None None O
> None None O
150 None None O
mg None None O
/ None None O
dl None None O
, None None O
HDL None None O
- None None O
C None None O
< None None O
40 None None O
mg None None O
/ None None O
dl None None O
in None None O
men None None O
and None None O
< None None O
50 None None O
mg None None O
/ None None O
dl None None O
in None None O
women None None O
, None None O
and None None O
fasting None None O
glucose None None O
> None None O
= None None O
100 None None O
mg None None O
/ None None O
dl None None O
) None None O
, None None O
8 None None O
had None None O
type None None O
2 None None O
diabetes None None O
and None None O
18 None None O
were None None O
smokers None None O
( None None O
Table None None O
1 None None O
) None None O
. None None O

Eprosartan None None O
reduced None None O
SBP None None O
by None None O
8 None None O
% None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
DBP None None O
by None None O
13 None None O
% None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
while None None O
it None None O
had None None O
a None None O
neutral None None O
effect None None O
on None None O
the None None O
lipid None None O
profile None None O
and None None O
apolipoprotein None None O
levels None None O
( None None O
Table2 None None O
) None None O
. None None O

Eprosartan None None O
did None None O
not None None O
affect None None O
plasma None None O
8 None None O
- None None O
epiPGF2a None None O
levels None None O
, None None O
whereas None None O
it None None O
significantly None None O
increased None None O
by None None O
24 None None O
% None None O
the None None O
lag None None O
time None None O
of None None O
total None None O
serum None None O
oxidation None None O
( None None O
145 None None O
+ None None O
/ None None O
- None None O
54 None None O
min None None O
vs None None O
180 None None O
+ None None O
/ None None O
- None None O
58 None None O
min None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
( None None O
Table2 None None O
) None None O
. None None O

Eprosartan None None O
reduced None None O
by None None O
14 None None O
% None None O
the None None O
aspartate None None O
aminotransferase None None O
( None None O
form None None O
21 None None O
to None None O
18 None None O
U None None O
/ None None O
L None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
04 None None O
) None None O
and None None O
by None None O
21 None None O
% None None O
the None None O
alanine None None O
aminotransferase None None O
( None None O
from None None O
24 None None O
to None None O
19 None None O
U None None O
/ None None O
L None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
05 None None O
) None None O
activity None None O
( None None O
Table2 None None O
) None None O
. None None O

The None None O
administration None None O
of None None O
eprosartan None None O
had None None O
no None None O
influence None None O
on None None O
glucose None None O
homeostasis None None O
, None None O
as None None O
well None None O
as None None O
on None None O
creatinine None None O
and None None O
uric None None O
acid None None O
levels None None O
( None None O
Table2 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
eprosartan None None O
did None None O
not None None O
affect None None O
clotting None None O
or None None O
fibrinolytic None None O
activity None None O
as None None O
this None None O
was None None O
estimated None None O
by None None O
PAI None None O
- None None O
1 None None O
, None None O
tPA None None O
and None None O
a2 None None O
- None None O
antiplasmin None None O
( None None O
Table2 None None O
) None None O
. None None O

The None None O
enzymatic None None O
activity None None O
of None None O
Lp None None O
- None None O
PLA2 None None O
and None None O
PON1 None None O
were None None O
not None None O
altered None None O
significantly None None O
following None None O
eprosartan None None O
treatment None None O
( None None O
Table2 None None O
) None None O
. None None O

Membrane None None O
- None None O
anchored None None O
Cbl None None O
suppresses None None O
Hck None None O
protein None None O
- None None O
tyrosine None None O
kinase None None O
mediated None None O
cellular None None O
transformation None None O
. None None O

The None None O
mammalian None None O
proto None None O
- None None O
oncogene None None O
Cbl None None O
and None None O
its None None O
cellular None None O
homologues None None O
in None None O
Caenorhabditis None None O
elegans None None O
( None None O
Sli None None O
- None None O
1 None None O
) None None O
and None None O
Drosophila None None O
( None None O
D None None O
- None None O
Cbl None None O
) None None O
are None None O
negative None None O
regulators None None O
of None None O
some None None O
growth None None O
factor None None O
receptor None None O
signaling None None O
pathways None None O
. None None O

Herein None None O
we None None O
show None None O
that None None O
Cbl None None O
can None None O
negatively None None O
regulate None None O
another None None O
signaling None None O
molecule None None O
, None None O
namely None None O
theSrc None None O
- None None O
family None None O
kinase None None O
Hck None None O
by None None O
targeting None None O
it None None O
for None None O
degradation None None O
. None None O

Hck None None O
- None None O
mediated None None O
cellular None None O
transformation None None O
of None None O
murine None None O
fibroblasts None None O
is None None O
reverted None None O
by None None O
ectopic None None O
expression None None O
of None None O
a None None O
membrane None None O
- None None O
anchored None None O
allele None None O
of None None O
Cbl None None O
as None None O
assessed None None O
by None None O
the None None O
cellular None None O
morphology None None O
, None None O
suppression None None O
of None None O
anchorage None None O
independent None None O
growth None None O
, None None O
and None None O
an None None O
overall None None O
reduction None None O
in None None O
the None None O
total None None O
tyrosine None None O
phosphorylation None None O
levels None None O
within None None O
the None None O
cells None None O
. None None O

The None None O
expression None None O
of None None O
Cbl None None O
at None None O
the None None O
plasma None None O
membrane None None O
targets None None O
both None None O
Hck None None O
and None None O
itself None None O
for None None O
ubiquitination None None O
and None None O
degradation None None O
, None None O
requiring None None O
an None None O
intact None None O
RING None None O
finger None None O
. None None O

Pharmacological None None O
inhibition None None O
of None None O
the None None O
proteasome None None O
prevents None None O
the None None O
degradation None None O
of None None O
Hck None None O
correlating None None O
with None None O
an None None O
increase None None O
in None None O
the None None O
phosphotyrosine None None O
levels None None O
within None None O
the None None O
cells None None O
. None None O

Activated None None O
Hck None None O
and None None O
membrane None None O
- None None O
anchored None None O
Cbl None None O
are None None O
present None None O
in None None O
similar None None O
subcellular None None O
localizations None None O
and None None O
co None None O
- None None O
immunoprecipitate None None O
, None None O
suggesting None None O
that None None O
their None None O
interaction None None O
is None None O
required None None O
for None None O
subsequent None None O
ubiquitination None None O
and None None O
degradation None None O
. None None O

Interestingly None None O
, None None O
both None None O
constitutively None None O
active None None O
and None None O
kinase None None O
- None None O
inactive None None O
Hck None None O
interact None None O
with None None O
and None None O
are None None O
targeted None None O
for None None O
degradation None None O
by None None O
Cbl None None O
. None None O

This None None O
work None None O
illustrates None None O
alternate None None O
means None None O
to None None O
regulate None None O
Src None None O
- None None O
family None None O
kinases None None O
, None None O
and None None O
suggests None None O
that None None O
Cbl None None O
may None None O
be None None O
able None None O
to None None O
suppress None None O
many None None O
signaling None None O
pathways None None O
that None None O
are None None O
activated None None O
in None None O
various None None O
proliferative None None O
syndromes None None O
including None None O
cancer None None O
. None None O

Materials None None O
and None None O
Methods None None O

[ None None O
The None None O
clinical None None O
and None None O
laboratory None None O
features None None O
of None None O
acute None None O
promyelocytic None None O
leukemia None None O
: None None O
an None None O
analysis None None O
of None None O
513 None None O
cases None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
investigate None None O
the None None O
clinical None None O
and None None O
laboratory None None O
features None None O
of None None O
acute None None O
promyelocytic None None O
leukemia None None O
( None None O
APL None None O
) None None O
. None None O

METHODS None None O
: None None O

513 None None O
APL None None O
patients None None O
in None None O
the None None O
last None None O
two None None O
decades None None O
were None None O
retrospectively None None O
analyzed None None O
in None None O
this None None O
research None None O
. None None O

We None None O
investigated None None O
the None None O
clinical None None O
features None None O
including None None O
age None None O
, None None O
sex None None O
, None None O
abnormality None None O
of None None O
peripheral None None O
hemogram None None O
before None None O
treatment None None O
, None None O
therapeutic None None O
effect None None O
and None None O
follow None None O
- None None O
up None None O
and None None O
laboratory None None O
data None None O
such None None O
as None None O
morphology None None O
, None None O
immunology None None O
, None None O
cytogenetics None None O
and None None O
molecular None None O
biology None None O
( None None O
MICM None None O
) None None O
. None None O

RESULTS None None O
: None None O

The None None O
median None None O
age None None O
of None None O
the None None O
APL None None O
patients None None O
was None None O
33 None None O
years None None O
old None None O
and None None O
the None None O
ratio None None O
of None None O
male None None O
and None None O
female None None O
was None None O
1 None None O
. None None O
21 None None O
: None None O
1 None None O
. None None O

Before None None O
treatment None None O
, None None O
the None None O
median None None O
level None None O
of None None O
WBC None None O
was None None O
4 None None O
. None None O
3 None None O
x None None O
10 None None O
( None None O
9 None None O
) None None O
/ None None O
L None None O
and None None O
the None None O
detection None None O
rate None None O
of None None O
abnormal None None O
promyelocyte None None O
on None None O
blood None None O
film None None O
was None None O
85 None None O
. None None O
8 None None O
% None None O
; None None O
with None None O
immunophenotypic None None O
detection None None O
, None None O
the None None O
expression None None O
levels None None O
of None None O
CD117 None None O
, None None O
CD34 None None O
, None None O
HLA None None O
- None None O
DR None None O
, None None O
CD7 None None O
, None None O
CD14 None None O
and None None O
CD19 None None O
in None None O
APL None None O
were None None O
found None None O
to None None O
be None None O
lower None None O
and None None O
the None None O
expression None None O
levels None None O
of None None O
CD2 None None O
, None None O
CD33 None None O
and None None O
MPO None None O
higher None None O
than None None O
those None None O
in None None O
other None None O
subtypes None None O
of None None O
acute None None O
myelocytic None None O
leukemia None None O
( None None O
AML None None O
) None None O
( None None O
both None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Specific None None O
abnormal None None O
chromosome None None O
t None None O
( None None O
15 None None O
; None None O
17 None None O
) None None O
was None None O
detected None None O
in None None O
91 None None O
. None None O
7 None None O
% None None O
of None None O
the None None O
patients None None O
, None None O
of None None O
whom None None O
75 None None O
. None None O
9 None None O
% None None O
had None None O
standard None None O
translocation None None O
of None None O
t None None O
( None None O
15 None None O
; None None O
17 None None O
) None None O
, None None O
being None None O
the None None O
most None None O
common None None O
one None None O
and None None O
15 None None O
. None None O
8 None None O
% None None O
of None None O
the None None O
patients None None O
had None None O
t None None O
( None None O
15 None None O
; None None O
17 None None O
) None None O
with None None O
additional None None O
abnormal None None O
chromosome None None O
. None None O

There None None O
was None None O
only None None O
7 None None O
. None None O
5 None None O
% None None O
of None None O
the None None O
patients None None O
with None None O
normal None None O
karyotype None None O
. None None O

However None None O
, None None O
the None None O
presence None None O
of None None O
both None None O
simple None None O
translocation None None O
and None None O
complex None None O
translocation None None O
was None None O
seldom None None O
seen None None O
. None None O

With None None O
molecular None None O
biological None None O
detection None None O
, None None O
PML None None O
/ None None O
RARalpha None None O
fusion None None O
gene None None O
positive None None O
rate None None O
was None None O
99 None None O
. None None O
6 None None O
% None None O
. None None O

In None None O
a None None O
relatively None None O
long None None O
clinical None None O
follow None None O
- None None O
up None None O
, None None O
we None None O
found None None O
that None None O
the None None O
complete None None O
remission None None O
( None None O
CR None None O
) None None O
rate None None O
in None None O
APL None None O
patients None None O
was None None O
84 None None O
. None None O
7 None None O
% None None O
, None None O
incidence None None O
of None None O
DIC None None O
was None None O
13 None None O
. None None O
4 None None O
% None None O
and None None O
five None None O
- None None O
year None None O
survival None None O
rate None None O
was None None O
30 None None O
. None None O
7 None None O
% None None O
. None None O

The None None O
median None None O
count None None O
of None None O
WBC None None O
in None None O
CR None None O
group None None O
was None None O
lower None None O
than None None O
that None None O
non None None O
- None None O
remission None None O
group None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

There None None O
were None None O
no None None O
significant None None O
differences None None O
on None None O
expressions None None O
of None None O
CD34 None None O
and None None O
CD2 None None O
and None None O
changes None None O
of None None O
cytogenetics None None O
between None None O
the None None O
two None None O
groups None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

Comprehensive None None O
evaluation None None O
of None None O
MICM None None O
could None None O
be None None O
of None None O
important None None O
significance None None O
in None None O
the None None O
diagnosis None None O
and None None O
prognosis None None O
judgment None None O
for None None O
APL None None O
patients None None O
. None None O

The None None O
CR None None O
rate None None O
in None None O
these None None O
patients None None O
with None None O
high None None O
WBC None None O
count None None O
was None None O
considerable None None O
low None None O
. None None O

Percentage None None O
reported None None O
purchasing None None O
intentions None None O
, None None O
comparing None None O
ITN None None O
- None None O
owning None None O
to None None O
non None None O
- None None O
owning None None O
households None None O

Conservative None None O
treatment None None O
of None None O
endometriosis None None O
: None None O
the None None O
effects None None O
of None None O
limited None None O
surgery None None O
and None None O
hormonal None None O
pseudopregnancy None None O
. None None O

This None None O
study None None O
compares None None O
the None None O
effects None None O
of None None O
limited None None O
surgery None None O
or None None O
hormonal None None O
pseudopregnancy None None O
, None None O
or None None O
a None None O
combination None None O
of None None O
these None None O
two None None O
, None None O
upon None None O
fertility None None O
and None None O
the None None O
need None None O
for None None O
subsequent None None O
surgery None None O
with None None O
respect None None O
to None None O
the None None O
extent None None O
of None None O
the None None O
disease None None O
at None None O
the None None O
time None None O
of None None O
initial None None O
diagnosis None None O
in None None O
patients None None O
with None None O
endometriosis None None O
externa None None O
. None None O

Of None None O
the None None O
61 None None O
patients None None O
who None None O
desired None None O
to None None O
enhance None None O
or None None O
preserve None None O
reproductive None None O
capacity None None O
, None None O
20 None None O
patients None None O
became None None O
pregnant None None O
, None None O
for None None O
a None None O
pregnancy None None O
rate None None O
of None None O
33 None None O
% None None O
. None None O

The None None O
pregnancy None None O
rate None None O
in None None O
all None None O
categories None None O
, None None O
that None None O
is None None O
, None None O
those None None O
patients None None O
treated None None O
with None None O
pseudopregnancy None None O
, None None O
conservative None None O
surgery None None O
, None None O
and None None O
combined None None O
pseudopregnancy None None O
and None None O
surgery None None O
, None None O
was None None O
found None None O
to None None O
be None None O
in None None O
direct None None O
relationship None None O
to None None O
the None None O
initial None None O
extent None None O
of None None O
disease None None O
. None None O

In None None O
such None None O
patients None None O
, None None O
conservative None None O
surgery None None O
alone None None O
seemed None None O
to None None O
give None None O
the None None O
best None None O
results None None O
in None None O
the None None O
achievement None None O
of None None O
pregnancy None None O
. None None O

There None None O
seemed None None O
to None None O
be None None O
little None None O
difference None None O
between None None O
pseudopregnancy None None O
alone None None O
and None None O
conservative None None O
surgery None None O
in None None O
regard None None O
to None None O
the None None O
need None None O
for None None O
subsequent None None O
surgery None None O
after None None O
initial None None O
therapy None None O
, None None O
although None None O
there None None O
seemed None None O
to None None O
be None None O
a None None O
significantly None None O
greater None None O
chance None None O
for None None O
the None None O
need None None O
for None None O
subsequent None None O
surgery None None O
in None None O
patients None None O
receiving None None O
a None None O
combination None None O
of None None O
the None None O
two None None O
forms None None O
of None None O
therapy None None O
. None None O

The None None O
need None None O
for None None O
subsequent None None O
surgery None None O
after None None O
initial None None O
therapy None None O
in None None O
80 None None O
patients None None O
increased None None O
in None None O
direct None None O
relationship None None O
to None None O
the None None O
initial None None O
extent None None O
of None None O
disease None None O
present None None O
, None None O
despite None None O
the None None O
form None None O
of None None O
therapy None None O
used None None O
. None None O

Fifty None None O
- None None O
nine None None O
other None None O
patients None None O
with None None O
endometriosis None None O
, None None O
who None None O
did None None O
not None None O
desire None None O
to None None O
preserve None None O
fertility None None O
and None None O
presented None None O
for None None O
relief None None O
of None None O
other None None O
symptoms None None O
, None None O
underwent None None O
initial None None O
" None None O
radical None None O
" None None O
therapy None None O
. None None O

Forty None None O
- None None O
six None None O
patients None None O
underwent None None O
complete None None O
operation None None O
, None None O
including None None O
removal None None O
of None None O
uterus None None O
, None None O
tubes None None O
and None None O
ovaries None None O
, None None O
and None None O
none None None O
required None None O
subsequent None None O
reoperation None None O
. None None O

Of None None O
the None None O
13 None None O
remaining None None O
patients None None O
, None None O
who None None O
underwent None None O
incomplete None None O
surgical None None O
removal None None O
, None None O
leaving None None O
one None None O
or None None O
both None None O
ovaries None None O
in None None O
situ None None O
, None None O
11 None None O
required None None O
subsequent None None O
reoperation None None O
for None None O
recurrent None None O
pelvic None None O
endometriosis None None O
. None None O

Adaptor None None O
protein None None O
Crk None None O
is None None O
required None None O
for None None O
ephrin None None O
- None None O
B1 None None O
- None None O
induced None None O
membrane None None O
ruffling None None O
and None None O
focal None None O
complex None None O
assembly None None O
of None None O
human None None O
aortic None None O
endothelial None None O
cells None None O
. None None O

Endothelial None None O
cell None None O
migration None None O
is None None O
an None None O
essential None None O
step None None O
in None None O
vasculogenesis None None O
and None None O
angiogenesis None None O
, None None O
in None None O
which None None O
receptor None None O
tyrosine None None O
kinases None None O
play None None O
a None None O
pivotal None None O
role None None O
. None None O

We None None O
investigated None None O
the None None O
mechanism None None O
by None None O
which None None O
ephrin None None O
- None None O
B1 None None O
promotes None None O
membrane None None O
ruffling None None O
in None None O
human None None O
aortic None None O
endothelial None None O
cells None None O
, None None O
because None None O
membrane None None O
ruffling None None O
heralds None None O
cell None None O
body None None O
migration None None O
. None None O

We None None O
especially None None O
focused None None O
on None None O
the None None O
role None None O
of None None O
Crk None None O
adaptor None None O
protein None None O
in None None O
EphB None None O
- None None O
mediated None None O
signaling None None O
. None None O

Using None None O
DsRed None None O
- None None O
tagged None None O
Crk None None O
and None None O
a None None O
fluorescent None None O
time None None O
- None None O
lapse None None O
microscope None None O
, None None O
we None None O
showed None None O
that None None O
Crk None None O
was None None O
recruited None None O
to None None O
the None None O
nascent None None O
focal None None O
complex None None O
after None None O
ephrin None None O
- None None O
B1 None None O
stimulation None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
p130 None None O
( None None O
Cas None None O
) None None O
, None None O
but None None O
not None None O
paxillin None None O
, None None O
recruited None None O
Crk None None O
to None None O
the None None O
nascent None None O
focal None None O
complex None None O
. None None O

The None None O
necessity None None O
of None None O
Crk None None O
in None None O
ephrin None None O
- None None O
B1 None None O
- None None O
induced None None O
membrane None None O
ruffling None None O
was None None O
shown None None O
both None None O
by None None O
the None None O
overexpression None None O
of None None O
dominant None None O
negative None None O
Crk None None O
mutants None None O
and None None O
by None None O
the None None O
depletion None None O
of None None O
Crk None None O
by None None O
using None None O
RNA None None O
interference None None O
. None None O

Then None None O
, None None O
we None None O
examined None None O
the None None O
role None None O
of None None O
two None None O
major None None O
downstream None None O
molecules None None O
of None None O
Crk None None O
, None None O
Rac1 None None O
and None None O
Rap1 None None O
. None None O

The None None O
dominant None None O
negative None None O
mutant None None O
of None None O
Rac1 None None O
completely None None O
inhibited None None O
ephrin None None O
- None None O
B1 None None O
- None None O
induced None None O
membrane None None O
ruffling None None O
and None None O
focal None None O
complex None None O
assembly None None O
. None None O

In None None O
contrast None None O
, None None O
rap1GAPII None None O
, None None O
a None None O
negative None None O
regulator None None O
of None None O
Rap1 None None O
, None None O
did None None O
not None None O
inhibit None None O
ephrin None None O
- None None O
B1 None None O
- None None O
induced None None O
membrane None None O
ruffling None None O
. None None O

However None None O
, None None O
in None None O
rap1GAPII None None O
- None None O
expressing None None O
cells None None O
, None None O
ephrin None None O
- None None O
B1 None None O
did None None O
not None None O
induce None None O
membrane None None O
spreading None None O
, None None O
probably None None O
due None None O
to None None O
instability None None O
of None None O
the None None O
focal None None O
complex None None O
. None None O

These None None O
results None None O
indicated None None O
that None None O
Crk None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
Rac1 None None O
- None None O
induced None None O
membrane None None O
ruffling None None O
and None None O
Rap1 None None O
- None None O
mediated None None O
nascent None None O
focal None None O
complex None None O
stabilization None None O
contributing None None O
to None None O
ephrin None None O
- None None O
B1 None None O
- None None O
induced None None O
human None None O
aortic None None O
endothelial None None O
cells None None O
migration None None O
. None None O

Lack None None O
of None None O
developmental None None O
and None None O
reproductive None None O
toxicity None None O
of None None O
2 None None O
, None None O
3 None None O
, None None O
3 None None O
' None None O
, None None O
4 None None O
, None None O
4 None None O
' None None O
- None None O
pentachlorobiphenyl None None O
( None None O
PCB None None O
105 None None O
) None None O
in None None O
ring None None O
- None None O
necked None None O
pheasants None None O
. None None O

Mono None None O
- None None O
ortho None None O
PCBs None None O
are None None O
global None None O
contaminants None None O
of None None O
wildlife None None O
with None None O
the None None O
potential None None O
to None None O
produce None None O
toxicity None None O
by None None O
an None None O
aryl None None O
hydrocarbon None None O
receptor None None O
( None None O
AhR None None O
) None None O
- None None O
mediated None None O
mechanism None None O
. None None O

To None None O
determine None None O
the None None O
potency None None O
of None None O
2 None None O
, None None O
3 None None O
, None None O
3 None None O
' None None O
, None None O
4 None None O
, None None O
4 None None O
' None None O
- None None O
pentachlorobiphenyl None None O
( None None O
PCB None None O
105 None None O
) None None O
for None None O
producing None None O
reproductive None None O
and None None O
developmental None None O
toxicity None None O
, None None O
adult None None O
ring None None O
- None None O
necked None None O
pheasant None None O
hens None None O
( None None O
Phasianus None None O
colchicus None None O
) None None O
were None None O
orally None None O
dosed None None O
with None None O
0 None None O
, None None O
0 None None O
. None None O
06 None None O
, None None O
0 None None O
. None None O
6 None None O
, None None O
or None None O
6 None None O
mg None None O
PCB None None O
105 None None O
/ None None O
kg None None O
hen None None O
/ None None O
week None None O
for None None O
10 None None O
weeks None None O
to None None O
achieve None None O
cumulative None None O
doses None None O
of None None O
0 None None O
, None None O
0 None None O
. None None O
6 None None O
, None None O
6 None None O
, None None O
or None None O
60 None None O
mg None None O
PCB None None O
105 None None O
/ None None O
kg None None O
hen None None O
after None None O
which None None O
hens None None O
were None None O
bred None None O
with None None O
untreated None None O
roosters None None O
once None None O
per None None O
week None None O
for None None O
8 None None O
weeks None None O
. None None O

Except None None O
at None None O
week None None O
6 None None O
of None None O
the None None O
egg None None O
- None None O
laying None None O
period None None O
when None None O
cumulative None None O
egg None None O
production None None O
in None None O
the None None O
6 None None O
mg None None O
PCB None None O
105 None None O
/ None None O
kg None None O
hen None None O
group None None O
was None None O
greater None None O
than None None O
controls None None O
, None None O
fertilized None None O
egg None None O
production None None O
was None None O
not None None O
significantly None None O
different None None O
between None None O
treatment None None O
groups None None O
. None None O

Embryo None None O
mortality None None O
and None None O
chick None None O
mortality None None O
were None None O
not None None O
significantly None None O
different None None O
between None None O
treatment None None O
groups None None O
. None None O

Total None None O
body None None O
and None None O
heart None None O
weights None None O
of None None O
all None None O
chicks None None O
1 None None O
day None None O
posthatch None None O
( None None O
dph None None O
) None None O
were None None O
not None None O
different None None O
between None None O
groups None None O
, None None O
however None None O
, None None O
liver None None O
weights None None O
of None None O
chicks None None O
from None None O
the None None O
60 None None O
mg None None O
/ None None O
kg None None O
treatment None None O
group None None O
were None None O
greater None None O
than None None O
controls None None O
at None None O
1 None None O
dph None None O
. None None O

The None None O
first None None O
chick None None O
to None None O
hatch None None O
from None None O
each None None O
hen None None O
was None None O
reared None None O
to None None O
21 None None O
dph None None O
and None None O
among None None O
these None None O
birds None None O
, None None O
the None None O
total None None O
body None None O
, None None O
liver None None O
, None None O
and None None O
heart None None O
weights None None O
were None None O
not None None O
different None None O
between None None O
groups None None O
. None None O

There None None O
were None None O
no None None O
dose None None O
- None None O
related None None O
malformations None None O
of None None O
the None None O
beak None None O
or None None O
limbs None None O
, None None O
and None None O
no None None O
signs None None O
of None None O
subcutaneous None None O
edema None None O
, None None O
ascites None None O
, None None O
or None None O
pericardial None None O
edema None None O
in None None O
chicks None None O
at None None O
1 None None O
or None None O
21 None None O
dph None None O
. None None O

Hepatic None None O
microsomal None None O
monooxygenase None None O
activities None None O
[ None None O
ethoxyresorufin None None O
- None None O
O None None O
- None None O
dealkylase None None O
( None None O
EROD None None O
) None None O
, None None O
benzyloxyresorufin None None O
- None None O
O None None O
- None None O
dealkylase None None O
( None None O
BROD None None O
) None None O
, None None O
and None None O
methyloxyresorufin None None O
- None None O
O None None O
- None None O
dealkylase None None O
( None None O
MROD None None O
) None None O
] None None O
were None None O
significantly None None O
elevated None None O
in None None O
chicks None None O
at None None O
1 None None O
dph None None O
from None None O
hens None None O
given None None O
a None None O
cumulative None None O
PCB None None O
105 None None O
dose None None O
of None None O
6 None None O
mg None None O
/ None None O
kg None None O
and None None O
in None None O
chicks None None O
at None None O
21 None None O
dph None None O
from None None O
hens None None O
given None None O
a None None O
cumulative None None O
PCB None None O
dose None None O
of None None O
60 None None O
mg None None O
/ None None O
kg None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
a None None O
cumulative None None O
PCB None None O
105 None None O
dose None None O
up None None O
to None None O
60 None None O
mg None None O
/ None None O
kg None None O
hen None None O
does None None O
not None None O
decrease None None O
the None None O
production None None O
of None None O
fertilized None None O
eggs None None O
or None None O
increase None None O
embryo None None O
or None None O
chick None None O
mortality None None O
in None None O
ring None None O
- None None O
necked None None O
pheasants None None O
, None None O
but None None O
does None None O
increase None None O
chick None None O
hepatic None None O
monooxygenase None None O
activity None None O
. None None O

N None None O
- None None O
myc None None O
augments None None O
death None None O
and None None O
attenuates None None O
protective None None O
effects None None O
of None None O
Bcl None None O
- None None O
2 None None O
in None None O
trophically None None O
stressed None None O
neuroblastoma None None O
cells None None O
. None None O

N None None O
- None None O
myc None None O
has None None O
proapoptotic None None O
functions None None O
, None None O
yet None None O
it None None O
acts None None O
as None None O
an None None O
oncogene None None O
in None None O
neuroblastoma None None O
. None None O

Thus None None O
, None None O
antiapoptotic None None O
mechanisms None None O
have None None O
to None None O
be None None O
operative None None O
in None None O
neuroblastoma None None O
cells None None O
that None None O
antagonize None None O
the None None O
proapoptotic None None O
effects None None O
of None None O
N None None O
- None None O
myc None None O
. None None O

We None None O
conditionally None None O
activated None None O
N None None O
- None None O
myc None None O
in None None O
SH None None I-Cell-line-name
- None None I-Cell-line-name
EP None None I-Cell-line-name
neuroblastoma None None O
cells None None O
subjected None None O
to None None O
the None None O
trophic None None O
stress None None O
of None None O
serum None None O
or None None O
nutrient None None O
deprivation None None O
while None None O
changing None None O
the None None O
expression None None O
of None None O
Bcl None None O
- None None O
2 None None O
, None None O
survivin None None O
and None None O
FLIP None None O
( None None O
L None None O
) None None O
, None None O
antiapoptotic None None O
molecules None None O
often None None O
overexpressed None None O
in None None O
poor None None O
prognosis None None O
neuroblastomas None None O
. None None O

Bcl None None O
- None None O
2 None None O
protected None None O
SH None None I-Cell-line-name
- None None I-Cell-line-name
EP None None I-Cell-line-name
cells None None O
from None None O
death None None O
during None None O
nutritional None None O
deprivation None None O
by None None O
activating None None O
energetically None None O
advantageous None None O
oxidative None None O
phosphorylation None None O
. None None O

N None None O
- None None O
myc None None O
overrode None None O
the None None O
metabolic None None O
protection None None O
provided None None O
by None None O
Bcl None None O
- None None O
2 None None O
- None None O
induced None None O
oxidative None None O
phosphorylation None None O
by None None O
reestablishing None None O
the None None O
glycolytic None None O
phenotype None None O
and None None O
attenuated None None O
the None None O
antiapoptotic None None O
effect None None O
of None None O
Bcl None None O
- None None O
2 None None O
during None None O
metabolic None None O
stress None None O
. None None O

Survivin None None O
partially None None O
antagonized None None O
the None None O
growth None None O
suppressive None None O
function None None O
of None None O
N None None O
- None None O
myc None None O
in None None O
SH None None I-Cell-line-name
- None None I-Cell-line-name
EP None None I-Cell-line-name
neuroblastoma None None O
cells None None O
during None None O
serum None None O
deprivation None None O
whereas None None O
FLIP None None O
( None None O
L None None O
) None None O
did None None O
not None None O
. None None O

These None None O
findings None None O
advance None None O
our None None O
understanding None None O
of None None O
the None None O
functions None None O
of None None O
N None None O
- None None O
myc None None O
in None None O
neuroblastoma None None O
cells None None O
. None None O

School None None O
environment None None O

At None None O
the None None O
majority None None O
of None None O
the None None O
schools None None O
a None None O
soft None None O
drink None None O
vending None None O
machine None None O
( None None O
91 None None O
% None None O
, None None O
n None None O
= None None O
446 None None O
) None None O
and None None O
/ None None O
or None None O
a None None O
vending None None O
machine None None O
containing None None O
sweets None None O
and None None O
candy None None O
bars None None O
( None None O
81 None None O
% None None O
, None None O
n None None O
= None None O
413 None None O
) None None O
is None None O
present None None O
( None None O
Table None None O
2 None None O
) None None O
. None None O

At None None O
78 None None O
% None None O
( None None O
n None None O
= None None O
393 None None O
) None None O
of None None O
the None None O
schools None None O
there None None O
is None None O
a None None O
supermarket None None O
, None None O
gas None None O
station None None O
or None None O
a None None O
fast None None O
food None None O
restaurant None None O
in None None O
the None None O
neighbourhood None None O
( None None O
within None None O
1 None None O
km None None O
of None None O
the None None O
school None None O
) None None O
. None None O

At None None O
68 None None O
% None None O
( None None O
n None None O
= None None O
345 None None O
) None None O
of None None O
the None None O
schools None None O
there None None O
are None None O
facilities None None O
at None None O
or None None O
around None None O
the None None O
school None None O
property None None O
where None None O
the None None O
students None None O
can None None O
be None None O
physically None None O
active None None O
, None None O
for None None O
example None None O
a None None O
soccer None None O
field None None O
or None None O
a None None O
basketball None None O
field None None O
. None None O

Table None None O
2 None None O

The None None O
school None None O
environment None None O

Total None None O
School None None O
level None None O

Vocational None None O
education None None O
schools None None O
Mixed None None O
schools None None O
Higher None None O
education None None O
schools None None O
Vocational None None O
education None None O
schools None None O
versus None None O
higher None None O
education None None O
schools None None O
# None None O
Mixed None None O
schools None None O
versus None None O
higher None None O
education None None O
schools None None O
# None None O

n None None O
= None None O
515 None None O
n None None O
= None None O
216 None None O
n None None O
= None None O
232 None None O
n None None O
= None None O
67 None None O

% None None O
( None None O
n None None O
) None None O
% None None O
( None None O
n None None O
) None None O
% None None O
( None None O
n None None O
) None None O
% None None O
( None None O
n None None O
) None None O
OR None None O
( None None O
95 None None O
% None None O
CI None None O
) None None O
OR None None O
( None None O
95 None None O
% None None O
CI None None O
) None None O

Soft None None O
drink None None O
vending None None O
machine None None O
present None None O
at None None O
school None None O
91 None None O
. None None O
4 None None O
( None None O
466 None None O
) None None O
90 None None O
. None None O
2 None None O
( None None O
194 None None O
) None None O
91 None None O
. None None O
3 None None O
( None None O
209 None None O
) None None O
95 None None O
. None None O
5 None None O
( None None O
63 None None O
) None None O
1 None None O
. None None O
0 None None O
( None None O
0 None None O
. None None O
9 None None O
; None None O
1 None None O
. None None O
1 None None O
) None None O
1 None None O
. None None O
0 None None O
( None None O
0 None None O
. None None O
9 None None O
; None None O
1 None None O
. None None O
0 None None O
) None None O

Percentage None None O
of None None O
soft None None O
drink None None O
vending None None O
machines None None O
present None None O
at None None O
school None None O
that None None O
contain None None O
light None None O
soft None None O
drinks None None O
79 None None O
. None None O
8 None None O
( None None O
372 None None O
) None None O
75 None None O
. None None O
4 None None O
( None None O
147 None None O
) None None O
82 None None O
. None None O
2 None None O
( None None O
171 None None O
) None None O
85 None None O
. None None O
7 None None O
( None None O
54 None None O
) None None O
0 None None O
. None None O
9 None None O
( None None O
0 None None O
. None None O
8 None None O
; None None O
1 None None O
. None None O
0 None None O
) None None O
1 None None O
. None None O
0 None None O
( None None O
0 None None O
. None None O
9 None None O
; None None O
1 None None O
. None None O
1 None None O
) None None O

Soft None None O
drink None None O
vending None None O
machines None None O
contain None None O
more None None O
unhealthy None None O
drinks None None O
than None None O
healthy None None O
drinks None None O
57 None None O
. None None O
9 None None O
( None None O
268 None None O
) None None O
61 None None O
. None None O
9 None None O
( None None O
120 None None O
) None None O
58 None None O
. None None O
5 None None O
( None None O
121 None None O
) None None O
43 None None O
. None None O
6 None None O
( None None O
27 None None O
) None None O
1 None None O
. None None O
4 None None O
( None None O
1 None None O
. None None O
0 None None O
; None None O
1 None None O
. None None O
9 None None O
) None None O
1 None None O
. None None O
4 None None O
( None None O
1 None None O
. None None O
0 None None O
; None None O
1 None None O
. None None O
9 None None O
) None None O
* None None O

Vending None None O
machine None None O
present None None O
at None None O
school None None O
that None None O
contains None None O
sweets None None O
/ None None O
candy None None O
bars None None O
80 None None O
. None None O
7 None None O
( None None O
413 None None O
) None None O
75 None None O
. None None O
6 None None O
( None None O
161 None None O
) None None O
84 None None O
. None None O
9 None None O
( None None O
197 None None O
) None None O
82 None None O
. None None O
1 None None O
( None None O
55 None None O
) None None O
1 None None O
. None None O
1 None None O
( None None O
0 None None O
. None None O
9 None None O
; None None O
1 None None O
. None None O
2 None None O
) None None O
1 None None O
. None None O
1 None None O
( None None O
1 None None O
. None None O
0 None None O
; None None O
1 None None O
. None None O
2 None None O
) None None O

Sweets None None O
/ None None O
candy None None O
bars None None O
vending None None O
machines None None O
contain None None O
more None None O
unhealthy None None O
than None None O
healthy None None O
foods None None O
63 None None O
. None None O
7 None None O
( None None O
260 None None O
) None None O
70 None None O
. None None O
6 None None O
( None None O
113 None None O
) None None O
64 None None O
. None None O
4 None None O
( None None O
125 None None O
) None None O
40 None None O
. None None O
7 None None O
( None None O
22 None None O
) None None O
1 None None O
. None None O
7 None None O
( None None O
1 None None O
. None None O
2 None None O
; None None O
2 None None O
. None None O
4 None None O
) None None O
* None None O
1 None None O
. None None O
6 None None O
( None None O
1 None None O
. None None O
1 None None O
; None None O
2 None None O
. None None O
3 None None O
) None None O
* None None O

There None None O
is None None O
a None None O
supermarket None None O
, None None O
gas None None O
station None None O
, None None O
or None None O
fast None None O
food None None O
restaurant None None O
in None None O
the None None O
neighbourhood None None O
of None None O
the None None O
school None None O
78 None None O
. None None O
3 None None O
( None None O
393 None None O
) None None O
76 None None O
. None None O
7 None None O
( None None O
161 None None O
) None None O
79 None None O
. None None O
7 None None O
( None None O
181 None None O
) None None O
78 None None O
. None None O
5 None None O
( None None O
51 None None O
) None None O
1 None None O
. None None O
1 None None O
( None None O
0 None None O
. None None O
9 None None O
; None None O
1 None None O
. None None O
2 None None O
) None None O
1 None None O
. None None O
1 None None O
( None None O
0 None None O
. None None O
9 None None O
; None None O
1 None None O
. None None O
2 None None O
) None None O

The None None O
students None None O
are None None O
allowed None None O
to None None O
leave None None O
the None None O
school None None O
property None None O
during None None O
school None None O
hours None None O
57 None None O
. None None O
4 None None O
( None None O
295 None None O
) None None O
42 None None O
. None None O
6 None None O
( None None O
92 None None O
) None None O
65 None None O
. None None O
8 None None O
( None None O
152 None None O
) None None O
76 None None O
. None None O
1 None None O
( None None O
51 None None O
) None None O
0 None None O
. None None O
6 None None O
( None None O
0 None None O
. None None O
5 None None O
; None None O
0 None None O
. None None O
8 None None O
) None None O
* None None O
0 None None O
. None None O
9 None None O
( None None O
0 None None O
. None None O
8 None None O
; None None O
1 None None O
. None None O
0 None None O
) None None O

There None None O
are None None O
facilities None None O
at None None O
and None None O
around None None O
the None None O
school None None O
property None None O
where None None O
the None None O
students None None O
can None None O
be None None O
physically None None O
active None None O
68 None None O
. None None O
1 None None O
( None None O
345 None None O
) None None O
63 None None O
. None None O
1 None None O
( None None O
135 None None O
) None None O
70 None None O
. None None O
3 None None O
( None None O
161 None None O
) None None O
76 None None O
. None None O
6 None None O
( None None O
49 None None O
) None None O
0 None None O
. None None O
8 None None O
( None None O
0 None None O
. None None O
7 None None O
; None None O
1 None None O
. None None O
0 None None O
) None None O
0 None None O
. None None O
9 None None O
( None None O
0 None None O
. None None O
8 None None O
; None None O
1 None None O
. None None O
1 None None O
) None None O

# None None O
Associations None None O
are None None O
adjusted None None O
for None None O
school None None O
size None None O

* None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O

The None None O
vocational None None O
education None None O
schools None None O
did None None O
not None None O
differ None None O
from None None O
the None None O
higher None None O
education None None O
schools None None O
with None None O
regard None None O
to None None O
the None None O
presence None None O
of None None O
vending None None O
machines None None O
and None None O
a None None O
canteen None None O
, None None O
but None None O
the None None O
vending None None O
machines None None O
and None None O
the None None O
canteen None None O
contained None None O
a None None O
less None None O
favourable None None O
selection None None O
of None None O
foods None None O
and None None O
drinks None None O
. None None O

The None None O
vocational None None O
education None None O
schools None None O
indicated None None O
more None None O
often None None O
that None None O
the None None O
vending None None O
machines None None O
and None None O
the None None O
canteen None None O
contained None None O
more None None O
unhealthy None None O
foods None None O
and None None O
drinks None None O
than None None O
healthy None None O
foods None None O
and None None O
drinks None None O
. None None O

Vocational None None O
education None None O
schools None None O
had None None O
fewer None None O
facilities None None O
at None None O
and None None O
around None None O
the None None O
school None None O
property None None O
to None None O
be None None O
physical None None O
than None None O
the None None O
higher None None O
education None None O
schools None None O
. None None O

Most None None O
associations None None O
were None None O
attenuated None None O
after None None O
adjustment None None O
for None None O
school None None O
size None None O
. None None O

For None None O
example None None O
, None None O
the None None O
association None None O
between None None O
school None None O
level None None O
and None None O
content None None O
of None None O
the None None O
soft None None O
drink None None O
vending None None O
machines None None O
was None None O
OR None None O
= None None O
1 None None O
. None None O
42 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
1 None None O
. None None O
05 None None O
- None None O
1 None None O
. None None O
93 None None O
in None None O
the None None O
crude None None O
analysis None None O
and None None O
OR None None O
= None None O
1 None None O
. None None O
35 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
0 None None O
. None None O
99 None None O
- None None O
1 None None O
. None None O
85 None None O
in None None O
the None None O
adjusted None None O
analysis None None O
. None None O

Phenolic None None O
fraction None None O
of None None O
tobacco None None O
smoke None None O
condensate None None O
potentiates None None O
benzo None None O
[ None None O
a None None O
] None None O
pyerene None None O
diol None None O
epoxide None None O
- None None O
induced None None O
cell None None O
transformation None None O
: None None O
role None None O
of None None O
protein None None O
kinase None None O
C None None O
. None None O

In None None O
this None None O
study None None O
we None None O
separated None None O
weakly None None O
acidic None None O
phenolic None None O
components None None O
from None None O
other None None O
neutral None None O
, None None O
acidic None None O
and None None O
basic None None O
components None None O
of None None O
tobacco None None O
smoke None None O
condensate None None O
( None None O
TSC None None O
) None None O
and None None O
observed None None O
that None None O
phenolic None None O
fraction None None O
of None None O
TSC None None O
significantly None None O
increased None None O
the None None O
number None None O
of None None O
colonies None None O
of None None O
promotion None None O
- None None O
sensitive None None O
JB6 None None I-Cell-line-name
Cl41 None None I-Cell-line-name
cells None None O
that None None O
showed None None O
anchorage None None O
- None None O
independent None None O
growth None None O
on None None O
soft None None O
agar None None O
in None None O
response None None O
to None None O
BPDE None None O
( None None O
an None None O
ultimate None None O
carcinogen None None O
produced None None O
by None None O
metabolic None None O
activation None None O
of None None O
the None None O
PAH None None O
benzo None None O
[ None None O
a None None O
] None None O
pyrene None None O
) None None O
. None None O

Anchorage None None O
- None None O
independent None None O
cell None None O
growth None None O
is None None O
indicative None None O
of None None O
cell None None O
transformation None None O
resulting None None O
in None None O
acquisition None None O
of None None O
tumorigenic None None O
potential None None O
. None None O

In None None O
order None None O
to None None O
understand None None O
the None None O
underlying None None O
mechanism None None O
by None None O
which None None O
TSC None None O
phenolic None None O
fraction None None O
potentiates None None O
BPDE None None O
- None None O
induced None None O
tumorigenicity None None O
, None None O
we None None O
examined None None O
its None None O
effect None None O
on None None O
the None None O
activation None None O
of None None O
two None None O
transcription None None O
factors None None O
AP None None O
- None None O
1 None None O
and None None O
NF None None O
- None None O
kappaB None None O
which None None O
are None None O
known None None O
to None None O
be None None O
influenced None None O
by None None O
established None None O
tumor None None O
promoter None None O
TPA None None O
. None None O

BPDE None None O
treatment None None O
caused None None O
induction None None O
of None None O
both None None O
AP None None O
- None None O
1 None None O
and None None O
NF None None O
- None None O
kappaB None None O
activity None None O
as None None O
determined None None O
by None None O
luciferase None None O
reporter None None O
assay None None O
and None None O
only None None O
NF None None O
- None None O
kappaB None None O
induction None None O
in None None O
response None None O
to None None O
BPDE None None O
was None None O
significantly None None O
attenuated None None O
by None None O
TSC None None O
phenolic None None O
fraction None None O
whereas None None O
AP None None O
- None None O
1 None None O
induction None None O
remains None None O
unaltered None None O
. None None O

Attenuation None None O
of None None O
NF None None O
- None None O
kappaB None None O
activation None None O
by None None O
TSC None None O
phenolic None None O
fraction None None O
was None None O
associated None None O
with None None O
significant None None O
decrease None None O
of None None O
intracellular None None O
PKC None None O
substrate None None O
phosphorylation None None O
in None None O
BPDE None None O
treated None None O
cells None None O
. None None O

Non None None O
- None None O
specific None None O
PKC None None O
inhibitors None None O
staurosporine None None O
and None None O
bisindolylmaleimide None None O
II None None O
as None None O
well None None O
as None None O
inhibitors None None O
specific None None O
to None None O
conventional None None O
PKCs None None O
( None None O
Go6976 None None O
) None None O
and None None O
PKC None None O
- None None O
delta None None O
( None None O
rottlerin None None O
) None None O
attenuated None None O
NF None None O
- None None O
kappaB None None O
activation None None O
in None None O
BPDE None None O
treated None None O
cells None None O
to None None O
a None None O
varying None None O
degree None None O
indicating None None O
a None None O
possible None None O
link None None O
between None None O
PKC None None O
down None None O
- None None O
regulation None None O
and None None O
the None None O
attenuation None None O
of None None O
NF None None O
- None None O
kappaB None None O
activity None None O
by None None O
TSC None None O
phenolic None None O
fraction None None O
. None None O

Treatment None None O
of None None O
cells None None O
with None None O
PKC None None O
inhibitors None None O
also None None O
potentiated None None O
anchorage None None O
- None None O
independent None None O
growth None None O
of None None O
BPDE None None O
treated None None O
cells None None O
on None None O
soft None None O
agar None None O
. None None O

Our None None O
data None None O
suggest None None O
a None None O
possible None None O
role None None O
of None None O
PKC None None O
down None None O
- None None O
regulation None None O
in None None O
potentiation None None O
of None None O
BPDE None None O
- None None O
induced None None O
tumorogenicity None None O
by None None O
TSC None None O
phenolic None None O
fraction None None O
. None None O

The None None O
patterns None None O
of None None O
internal None None O
migration None None O
in None None O
Maharashtra None None O
: None None O
an None None O
analysis None None O
of None None O
1971 None None O
census None None O
data None None O
. None None O

Patterns None None O
of None None O
internal None None O
migration None None O
in None None O
the None None O
state None None O
of None None O
Maharashtra None None O
, None None O
India None None O
, None None O
for None None O
the None None O
period None None O
1961 None None O
- None None O
1971 None None O
are None None O
analyzed None None O
using None None O
1971 None None O
census None None O
data None None O
. None None O

The None None O
nature None None O
, None None O
volume None None O
, None None O
and None None O
direction None None O
of None None O
migration None None O
are None None O
examined None None O
. None None O

Migrants None None O
are None None O
characterized None None O
according None None O
to None None O
factors None None O
including None None O
age None None O
, None None O
sex None None O
, None None O
marital None None O
status None None O
, None None O
occupation None None O
, None None O
and None None O
areas None None O
of None None O
origin None None O
and None None O
destination None None O
. None None O

[ None None O
An None None O
experimental None None O
study None None O
on None None O
angiogenesis None None O
of None None O
non None None O
- None None O
vascularized None None O
autogenous None None O
bone None None O
graft None None O
with None None O
vascular None None O
bundle None None O
implantation None None O
] None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
effect None None O
of None None O
vascular None None O
bundle None None O
implantation None None O
in None None O
autogenous None None O
bone None None O
graft None None O
on None None O
angiogenesis None None O
. None None O

METHODS None None O
: None None O
Thirty None None O
- None None O
six None None O
New None None O
Zealand None None O
white None None O
rabbits None None O
were None None O
evaluated None None O
in None None O
this None None O
study None None O
. None None O

A None None O
portion None None O
of None None O
bilateral None None O
radial None None O
bones None None O
of None None O
a None None O
rabbit None None O
were None None O
removed None None O
as None None O
free None None O
bone None None O
grafts None None O
, None None O
whose None None O
periostea None None O
were None None O
peeled None None O
off None None O
. None None O

In None None O
test None None O
group None None O
, None None O
the None None O
external None None O
maxillary None None O
artery None None O
bundle None None O
was None None O
passed None None O
through None None O
the None None O
marrow None None O
cavity None None O
of None None O
the None None O
bone None None O
. None None O

In None None O
control None None O
group None None O
, None None O
there None None O
was None None O
no None None O
vascular None None O
bundle None None O
implantation None None O
. None None O

Each None None O
bone None None O
was None None O
placed None None O
in None None O
masseter None None O
muscle None None O
separately None None O
. None None O

The None None O
rabbits None None O
were None None O
sacrificed None None O
and None None O
the None None O
specimens None None O
were None None O
procured None None O
at None None O
3 None None O
days None None O
, None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
, None None O
4 None None O
and None None O
6 None None O
weeks None None O
after None None O
surgery None None O
for None None O
histological None None O
observation None None O
, None None O
Chinese None None O
ink None None O
perfusion None None O
and None None O
CD34 None None O
immunohistochemistry None None O
. None None O

Microvessel None None O
density None None O
( None None O
MVD None None O
) None None O
was None None O
assessed None None O
in None None O
order None None O
to None None O
evaluate None None O
angiogenesis None None O
of None None O
autogenous None None O
bone None None O
grafts None None O
. None None O

RESULTS None None O
: None None O
The None None O
bone None None O
grafts None None O
were None None O
found None None O
revascularization None None O
in None None O
3 None None O
days None None O
after None None O
surgery None None O
in None None O
the None None O
test None None O
group None None O
, None None O
whereas None None O
at None None O
2 None None O
weeks None None O
in None None O
the None None O
control None None O
group None None O
. None None O

In None None O
3 None None O
days None None O
, None None O
1 None None O
week None None O
, None None O
2 None None O
weeks None None O
, None None O
3 None None O
weeks None None O
and None None O
4 None None O
weeks None None O
after None None O
surgery None None O
, None None O
the None None O
MVD None None O
of None None O
test None None O
group None None O
was None None O
significantly None None O
higher None None O
than None None O
that None None O
of None None O
control None None O
group None None O
. None None O

In None None O
4 None None O
weeks None None O
after None None O
surgery None None O
, None None O
angiogenesis None None O
of None None O
test None None O
group None None O
reached None None O
to None None O
peak None None O
. None None O

CONCLUSION None None O
: None None O
Vascular None None O
bundle None None O
implantation None None O
improved None None O
angiogenesis None None O
in None None O
non None None O
- None None O
vascularized None None O
autogenous None None O
bone None None O
graft None None O
in None None O
this None None O
study None None O
. None None O

Photodynamic None None O
therapy None None O
with None None O
verteporfin None None O
for None None O
subfoveal None None O
choroidal None None O
neovascularization None None O
secondary None None O
to None None O
pathologic None None O
myopia None None O
: None None O
long None None O
- None None O
term None None O
study None None O
. None None O

PURPOSE None None O
: None None O
To None None O
assess None None O
the None None O
safety None None O
and None None O
effectiveness None None O
of None None O
photodynamic None None O
therapy None None O
( None None O
PDT None None O
) None None O
with None None O
verteporfin None None O
for None None O
subfoveal None None O
choroidal None None O
neovascularization None None O
( None None O
CNV None None O
) None None O
secondary None None O
to None None O
pathologic None None O
myopia None None O
( None None O
PM None None O
) None None O
. None None O

METHODS None None O
: None None O
Sixty None None O
- None None O
two None None O
patients None None O
( None None O
62 None None O
eyes None None O
) None None O
with None None O
PM None None O
underwent None None O
PDT None None O
according None None O
to None None O
the None None O
guidelines None None O
of None None O
the None None O
Verteporfin None None O
in None None O
Photodynamic None None O
Therapy None None O
Study None None O
. None None O

Clinical None None O
evaluations None None O
performed None None O
at None None O
all None None O
study None None O
visits None None O
included None None O
measurement None None O
of None None O
best None None O
- None None O
corrected None None O
Snellen None None O
visual None None O
acuity None None O
, None None O
slit None None O
- None None O
lamp None None O
biomicroscopy None None O
, None None O
and None None O
fundus None None O
fluorescein None None O
angiography None None O
. None None O

Patients None None O
were None None O
followed None None O
up None None O
at None None O
1 None None O
month None None O
and None None O
3 None None O
months None None O
after None None O
treatment None None O
and None None O
thereafter None None O
at None None O
3 None None O
- None None O
month None None O
intervals None None O
. None None O

RESULTS None None O
: None None O
The None None O
final None None O
visual None None O
acuity None None O
of None None O
the None None O
study None None O
patients None None O
, None None O
after None None O
a None None O
median None None O
follow None None O
- None None O
up None None O
of None None O
31 None None O
months None None O
, None None O
improved None None O
by None None O
greater None None O
than None None O
or None None O
= None None O
1 None None O
Snellen None None O
lines None None O
in None None O
8 None None O
patients None None O
( None None O
13 None None O
% None None O
) None None O
, None None O
deteriorated None None O
in None None O
20 None None O
( None None O
32 None None O
% None None O
) None None O
, None None O
and None None O
remained None None O
stable None None O
in None None O
34 None None O
( None None O
55 None None O
% None None O
) None None O
. None None O

The None None O
baseline None None O
visual None None O
acuity None None O
was None None O
similar None None O
in None None O
the None None O
various None None O
study None None O
groups None None O
. None None O

The None None O
final None None O
mean None None O
visual None None O
acuity None None O
in None None O
group None None O
A None None O
( None None O
55 None None O
years None None O
of None None O
age None None O
or None None O
younger None None O
) None None O
was None None O
20 None None O
/ None None O
80 None None O
and None None O
significantly None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
006 None None O
) None None O
better None None O
than None None O
that None None O
( None None O
20 None None O
/ None None O
138 None None O
) None None O
in None None O
group None None O
B None None O
( None None O
older None None O
than None None O
55 None None O
years None None O
of None None O
age None None O
) None None O
. None None O

The None None O
mean None None O
final None None O
visual None None O
acuity None None O
in None None O
eyes None None O
with None None O
higher None None O
refractive None None O
error None None O
at None None O
baseline None None O
( None None O
greater None None O
than None None O
- None None O
17 None None O
diopters None None O
) None None O
was None None O
significantly None None O
better None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
014 None None O
) None None O
than None None O
that None None O
in None None O
eyes None None O
with None None O
lower None None O
refractive None None O
error None None O
( None None O
- None None O
6 None None O
to None None O
- None None O
10 None None O
diopters None None O
) None None O
. None None O

CNV None None O
size None None O
did None None O
not None None O
affect None None O
visual None None O
outcomes None None O
. None None O

CONCLUSION None None O
: None None O
PDT None None O
preserves None None O
vision None None O
in None None O
patients None None O
with None None O
CNV None None O
associated None None O
with None None O
PM None None O
. None None O

Younger None None O
patients None None O
and None None O
eyes None None O
with None None O
higher None None O
refractive None None O
error None None O
appear None None O
more None None O
likely None None O
to None None O
benefit None None O
from None None O
PDT None None O
with None None O
verteporfin None None O
. None None O

Potential None None O
roles None None O
for None None O
focal None None O
adhesion None None O
kinase None None O
in None None O
development None None O
. None None O

Focal None None O
adhesion None None O
kinase None None O
( None None O
pp125FAK None None O
or None None O
FAK None None O
) None None O
is None None O
a None None O
protein None None O
tyrosine None None O
kinase None None O
which None None O
is None None O
associated None None O
with None None O
intracellular None None O
signalling None None O
cascades None None O
which None None O
are None None O
initiated None None O
when None None O
the None None O
integrin None None O
family None None O
of None None O
cell None None O
adhesion None None O
molecules None None O
engage None None O
extracellular None None O
matrix None None O
molecules None None O
. None None O

In None None O
cultured None None O
cells None None O
, None None O
this None None O
molecule None None O
is None None O
physically None None O
associated None None O
with None None O
focal None None O
adhesions None None O
, None None O
which None None O
are None None O
well None None O
- None None O
defined None None O
regions None None O
of None None O
intimate None None O
cell None None O
- None None O
to None None O
- None None O
substratum None None O
adhesion None None O
. None None O

In None None O
this None None O
location None None O
, None None O
it None None O
interacts None None O
with None None O
other None None O
proteins None None O
of None None O
the None None O
focal None None O
adhesion None None O
to None None O
activate None None O
intracellular None None O
signalling None None O
events None None O
associated None None O
with None None O
cell None None O
adhesion None None O
. None None O

The None None O
in None None O
vitro None None O
expression None None O
of None None O
FAK None None O
and None None O
its None None O
level None None O
of None None O
phosphorylation None None O
appear None None O
to None None O
be None None O
related None None O
to None None O
several None None O
physiological None None O
phenomena None None O
, None None O
including None None O
cell None None O
spreading None None O
, None None O
cell None None O
differentiation None None O
, None None O
cell None None O
locomotion None None O
and None None O
cell None None O
death None None O
. None None O

Because None None O
these None None O
phenomena None None O
are None None O
all None None O
of None None O
critical None None O
importance None None O
during None None O
morphogenesis None None O
, None None O
and None None O
because None None O
FAK None None O
is None None O
expressed None None O
in None None O
embryonic None None O
cells None None O
, None None O
evidence None None O
has None None O
been None None O
accumulating None None O
to None None O
indicate None None O
that None None O
FAK None None O
may None None O
be None None O
an None None O
important None None O
modulator None None O
of None None O
developmental None None O
processes None None O
. None None O

In None None O
this None None O
review None None O
, None None O
this None None O
evidence None None O
is None None O
surveyed None None O
together None None O
with None None O
evidence None None O
from None None O
analogous None None O
situations None None O
, None None O
such None None O
as None None O
tumour None None O
cell None None O
migration None None O
and None None O
invasiveness None None O
. None None O

Although None None O
evidence None None O
suggesting None None O
a None None O
role None None O
for None None O
FAK None None O
in None None O
morphogenesis None None O
is None None O
accumulating None None O
, None None O
current None None O
uncertainties None None O
regarding None None O
its None None O
cytoplasmic None None O
location None None O
and None None O
its None None O
molecular None None O
interactions None None O
in None None O
vivo None None O
make None None O
it None None O
difficult None None O
to None None O
reach None None O
definitive None None O
conclusions None None O
regarding None None O
the None None O
significance None None O
of None None O
its None None O
contributions None None O
to None None O
developmental None None O
processes None None O
. None None O

Antiapoptotic None None O
effect None None O
of None None O
coagulation None None O
factor None None O
VIIa None None O
. None None O

Binding None None O
of None None O
factor None None O
VIIa None None O
( None None O
FVIIa None None O
) None None O
to None None O
its None None O
cellular None None O
receptor None None O
tissue None None O
factor None None O
( None None O
TF None None O
) None None O
was None None O
previously None None O
shown None None O
to None None O
induce None None O
various None None O
intracellular None None O
signaling None None O
events None None O
, None None O
which None None O
were None None O
thought None None O
to None None O
be None None O
responsible None None O
for None None O
TF None None O
- None None O
mediated None None O
biologic None None O
effects None None O
, None None O
including None None O
angiogenesis None None O
, None None O
tumor None None O
metastasis None None O
, None None O
and None None O
restenosis None None O
. None None O

To None None O
understand None None O
the None None O
mechanisms None None O
behind None None O
these None None O
processes None None O
, None None O
we None None O
have None None O
examined None None O
the None None O
effect None None O
of None None O
FVIIa None None O
on None None O
apoptosis None None O
. None None O

Serum None None O
deprivation None None O
- None None O
induced None None O
apoptosis None None O
of None None O
BHK None None I-Cell-line-name
( None None O
+ None None O
TF None None O
) None None O
cells None None O
was None None O
characterized None None O
by None None O
apoptotic None None O
blebs None None O
, None None O
nuclei None None O
with None None O
chromatin None None O
- None None O
condensed None None O
bodies None None O
, None None O
DNA None None O
degradation None None O
, None None O
and None None O
activation None None O
of None None O
caspase None None O
3 None None O
. None None O

FVIIa None None O
markedly None None O
decreased None None O
the None None O
number None None O
of None None O
cells None None O
with None None O
apoptotic None None O
morphology None None O
and None None O
prevented None None O
the None None O
DNA None None O
degradation None None O
as None None O
measured None None O
by None None O
means None None O
of None None O
TdT None None O
- None None O
mediated None None O
dUTP None None O
nick None None O
end None None O
labeling None None O
( None None O
TUNEL None None O
) None None O
. None None O

The None None O
antiapoptotic None None O
effect None None O
of None None O
FVIIa None None O
was None None O
confirmed None None O
by None None O
the None None O
observation None None O
that None None O
FVIIa None None O
attenuated None None O
caspase None None O
3 None None O
activation None None O
. None None O

FVIIa None None O
- None None O
induced None None O
antiapoptotic None None O
effect None None O
was None None O
dependent None None O
on None None O
its None None O
proteolytic None None O
activity None None O
and None None O
TF None None O
but None None O
independent None None O
of None None O
factor None None O
Xa None None O
and None None O
thrombin None None O
. None None O

FVIIa None None O
- None None O
induced None None O
cell None None O
survival None None O
correlated None None O
with None None O
the None None O
activation None None O
of None None O
Akt None None O
and None None O
was None None O
inhibited None None O
markedly None None O
by None None O
the None None O
specific None None O
PI3 None None O
- None None O
kinase None None O
inhibitor None None O
, None None O
LY294002 None None O
. None None O

Blocking None None O
the None None O
activation None None O
of None None O
p44 None None O
/ None None O
42 None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
by None None O
the None None O
specific None None O
mitogen None None O
- None None O
induced None None O
extracellular None None O
kinase None None O
( None None O
MEK None None O
) None None O
inhibitor None None O
, None None O
U0126 None None O
, None None O
impaired None None O
modestly None None O
the None None O
ability None None O
of None None O
FVIIa None None O
to None None O
promote None None O
cell None None O
survival None None O
. None None O

In None None O
conclusion None None O
, None None O
FVIIa None None O
binding None None O
to None None O
TF None None O
provided None None O
protection None None O
against None None O
apoptosis None None O
induced None None O
by None None O
growth None None O
factor None None O
deprivation None None O
, None None O
primarily None None O
through None None O
activation None None O
of None None O
PI3 None None O
- None None O
kinase None None O
/ None None O
Akt None None O
pathway None None O
, None None O
and None None O
to None None O
a None None O
lesser None None O
extent None None O
, None None O
p44 None None O
/ None None O
42 None None O
MAPK None None O
pathway None None O
. None None O

Metastasis None None O
- None None O
associated None None O
5T4 None None O
antigen None None O
disrupts None None O
cell None None O
- None None O
cell None None O
contacts None None O
and None None O
induces None None O
cellular None None O
motility None None O
in None None O
epithelial None None O
cells None None O
. None None O

The None None O
5T4 None None O
antigen None None O
is None None O
defined None None O
by None None O
a None None O
monoclonal None None O
antibody None None O
( None None O
MAb None None O
) None None O
specific None None O
for None None O
human None None O
trophoblast None None O
. None None O

It None None O
is None None O
also None None O
expressed None None O
by None None O
many None None O
types None None O
of None None O
tumour None None O
cell None None O
and None None O
has None None O
been None None O
associated None None O
with None None O
metastasis None None O
and None None O
poor None None O
clinical None None O
outcome None None O
in None None O
a None None O
number None None O
of None None O
cancers None None O
. None None O

This None None O
pattern None None O
of None None O
expression None None O
is None None O
consistent None None O
with None None O
a None None O
mechanistic None None O
involvement None None O
of None None O
5T4 None None O
molecules None None O
in None None O
the None None O
spread None None O
of None None O
cancer None None O
cells None None O
. None None O

The None None O
5T4 None None O
antigen None None O
is None None O
a None None O
transmembrane None None O
glycoprotein None None O
with None None O
a None None O
310 None None O
amino None None O
acid None None O
extracellular None None O
domain None None O
and None None O
a None None O
44 None None O
amino None None O
acid None None O
cytoplasmic None None O
domain None None O
. None None O

Transfection None None O
of None None O
full None None O
- None None O
length None None O
5T4 None None O
cDNA None None O
into None None O
epithelial None None O
cells None None O
alters None None O
cell None None O
- None None O
cell None None O
contacts None None O
and None None O
cellular None None O
motility None None O
. None None O

Thus None None O
, None None O
in None None O
5T4 None None O
- None None O
transfected None None O
CL None None I-Cell-line-name
- None None I-Cell-line-name
S1 None None I-Cell-line-name
murine None None O
mammary None None O
cells None None O
, None None O
5T4 None None O
expression None None O
is None None O
associated None None O
with None None O
dendritic None None O
morphology None None O
, None None O
accompanied None None O
by None None O
abrogation None None O
of None None O
actin None None O
/ None None O
cadherin None None O
- None None O
containing None None O
contacts None None O
and None None O
increased None None O
motility None None O
. None None O

In None None O
transfected None None O
MDCK None None O
canine None None O
kidney None None O
epithelial None None O
cells None None O
, None None O
5T4 None None O
over None None O
- None None O
expression None None O
also None None O
results None None O
in None None O
increased None None O
motility None None O
, None None O
but None None O
disruption None None O
of None None O
cell None None O
- None None O
cell None None O
contacts None None O
, None None O
either None None O
by None None O
culturing None None O
cells None None O
in None None O
low None None O
calcium None None O
medium None None O
or None None O
by None None O
addition None None O
of None None O
HGF None None O
/ None None O
SF None None O
, None None O
is None None O
needed None None O
. None None O

The None None O
effects None None O
of None None O
5T4 None None O
expression None None O
on None None O
morphology None None O
and None None O
motility None None O
are None None O
separable None None O
since None None O
cells None None O
transfected None None O
with None None O
a None None O
truncated None None O
form None None O
of None None O
5T4 None None O
cDNA None None O
in None None O
which None None O
the None None O
cytoplasmic None None O
domain None None O
is None None O
deleted None None O
reveal None None O
that None None O
the None None O
latter None None O
is None None O
necessary None None O
to None None O
abrogate None None O
actin None None O
/ None None O
cadherin None None O
- None None O
containing None None O
contacts None None O
but None None O
does None None O
not None None O
influence None None O
the None None O
effects None None O
on None None O
motility None None O
. None None O

Thus None None O
, None None O
5T4 None None O
molecules None None O
can None None O
deliver None None O
signals None None O
through None None O
both None None O
the None None O
extracellular None None O
and None None O
intracellular None None O
domains None None O
, None None O
and None None O
the None None O
resultant None None O
effects None None O
are None None O
consistent None None O
with None None O
a None None O
role None None O
for None None O
5T4 None None O
molecules None None O
in None None O
invasion None None O
processes None None O
. None None O

Development None None O
and None None O
validation None None O
of None None O
an None None O
approach None None O
to None None O
produce None None O
large None None O
- None None O
scale None None O
quantities None None O
of None None O
CpG None None O
- None None O
methylated None None O
plasmid None None O
DNA None None O
. None None O

The None None O
prokaryotic None None O
CpG None None O
- None None O
specific None None O
DNA None None O
methylase None None O
from None None O
Spiroplasma None None O
, None None O
SssI None None O
methylase None None O
, None None O
has None None O
been None None O
extensively None None O
used None None O
to None None O
methylate None None O
plasmid None None O
DNA None None O
in None None O
vitro None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
methylation None None O
in None None O
vertebrate None None O
systems None None O
. None None O

Currently None None O
available None None O
methods None None O
to None None O
produce None None O
CpG None None O
- None None O
methylated None None O
plasmid None None O
DNA None None O
have None None O
certain None None O
limitations None None O
and None None O
cannot None None O
generate None None O
large None None O
quantities None None O
of None None O
methylated None None O
DNA None None O
without None None O
cost None None O
or None None O
problems None None O
of None None O
purity None None O
. None None O

Here None None O
we None None O
describe None None O
an None None O
approach None None O
in None None O
which None None O
the None None O
SssI None None O
methylase None None O
gene None None O
has None None O
been None None O
introduced None None O
into None None O
the None None O
Escherichia None None O
coli None None O
bacterial None None O
genome None None O
under None None O
the None None O
control None None O
of None None O
an None None O
inducible None None O
promoter None None O
. None None O

Plasmid None None O
DNA None None O
propagated None None O
in None None O
this None None O
bacterium None None O
under None None O
conditions None None O
which None None O
induce None None O
the None None O
methylase None None O
gene None None O
result None None O
in None None O
significant None None O
( None None O
> None None O
90 None None O
% None None O
) None None O
CpG None None O
methylation None None O
. None None O

Methylated None None O
DNA None None O
produced None None O
by None None O
this None None O
approach None None O
behaves None None O
similarly None None O
to None None O
methylated None None O
DNA None None O
produced None None O
in None None O
vitro None None O
using None None O
the None None O
purified None None O
methylase None None O
. None None O

The None None O
approach None None O
is None None O
scalable None None O
allowing None None O
for None None O
the None None O
production None None O
of None None O
milligram None None O
quantities None None O
of None None O
methylated None None O
plasmid None None O
DNA None None O
. None None O

8 None None O
. None None O
2 None None O
. None None O

Species None None O
Differences None None O
in None None O
PPARalpha None None O
- None None O
Associated None None O
Signaling None None O

The None None O
PPARalpha None None O
isotype None None O
has None None O
prime None None O
importance None None O
for None None O
studies None None O
with None None O
animal None None O
models None None O
to None None O
predict None None O
the None None O
effects None None O
of None None O
hepatic None None O
PPs None None O
in None None O
humans None None O
, None None O
because None None O
PPARalpha None None O
agonists None None O
induce None None O
seemingly None None O
quite None None O
different None None O
actions None None O
in None None O
rodents None None O
and None None O
humans None None O
[ None None O
53 None None O
] None None O
. None None O

Originally None None O
, None None O
as None None O
the None None O
name None None O
indicates None None O
, None None O
PPARs None None O
were None None O
studied None None O
because None None O
of None None O
their None None O
ability None None O
to None None O
bind None None O
PPs None None O
and None None O
consequently None None O
induce None None O
PP None None O
- None None O
metabolizing None None O
enzymes None None O
. None None O

In None None O
rats None None O
and None None O
mice None None O
, None None O
but None None O
not None None O
in None None O
humans None None O
, None None O
PPs None None O
such None None O
as None None O
hypolipidemic None None O
drugs None None O
, None None O
industrial None None O
plasticizers None None O
, None None O
and None None O
herbicides None None O
are None None O
non None None O
- None None O
genotoxic None None O
carcinogens None None O
that None None O
cause None None O
liver None None O
tumors None None O
[ None None O
54 None None O
] None None O
. None None O

In None None O
humans None None O
, None None O
these None None O
drugs None None O
function None None O
to None None O
maintain None None O
lipid None None O
homeostasis None None O
and None None O
do None None O
not None None O
induce None None O
peroxisome None None O
proliferation None None O
. None None O

Thus None None O
, None None O
the None None O
toxicity None None O
and None None O
carcinogenicity None None O
of None None O
PPs None None O
are None None O
highly None None O
species None None O
specific None None O
[ None None O
55 None None O
] None None O
. None None O

The None None O
species None None O
differences None None O
may None None O
be None None O
attributable None None O
to None None O
lower None None O
PPAR None None O
mRNA None None O
expression None None O
levels None None O
in None None O
h None None O
- None None O
hepatocytes None None O
compared None None O
with None None O
rodent None None O
cells None None O
[ None None O
56 None None O
, None None O
57 None None O
] None None O
. None None O

Alternatively None None O
, None None O
or None None O
additionally None None O
, None None O
species None None O
differences None None O
may None None O
be None None O
the None None O
result None None O
of None None O
different None None O
sensitivities None None O
of None None O
the None None O
genes None None O
associated None None O
with None None O
the None None O
peroxisome None None O
proliferation None None O
response None None O
to None None O
low None None O
levels None None O
of None None O
PPs None None O
, None None O
owing None None O
to None None O
structural None None O
differences None None O
in None None O
PPARalpha None None O
[ None None O
54 None None O
] None None O
. None None O

There None None O
are None None O
both None None O
similarities None None O
and None None O
differences None None O
in None None O
responses None None O
to None None O
xenobiotics None None O
among None None O
not None None O
only None None O
different None None O
species None None O
( None None O
interspecies None None O
) None None O
but None None O
also None None O
individuals None None O
of None None O
the None None O
same None None O
species None None O
( None None O
intraspecies None None O
) None None O
. None None O

Interspecific None None O
PPARalpha None None O
diversity None None O
between None None O
rodents None None O
and None None O
humans None None O
is None None O
well None None O
known None None O
and None None O
has None None O
been None None O
studied None None O
with None None O
respect None None O
to None None O
drug None None O
metabolism None None O
. None None O

NR None None O
subfamily None None O
1 None None O
members None None O
have None None O
at None None O
least None None O
two None None O
functions None None O
in None None O
mammals None None O
. None None O

One None None O
is None None O
to None None O
regulate None None O
peroxisome None None O
proliferation None None O
through None None O
binding None None O
to None None O
PPAR None None O
response None None O
elements None None O
( None None O
PPREs None None O
) None None O
in None None O
the None None O
promoters None None O
of None None O
genes None None O
such None None O
as None None O
ACO None None O
[ None None O
58 None None O
, None None O
59 None None O
] None None O
, None None O
bifunctional None None O
dehydrogenase None None O
/ None None O
hydratase None None O
( None None O
BFE None None O
) None None O
[ None None O
60 None None O
] None None O
, None None O
and None None O
microsomal None None O
CYP4A1 None None O
[ None None O
61 None None O
] None None O
. None None O

The None None O
other None None O
is None None O
to None None O
modulate None None O
the None None O
serum None None O
cholesterol None None O
level None None O
by None None O
targeting None None O
genes None None O
such None None O
as None None O
the None None O
lipoprotein None None O
lipase None None O
gene None None O
[ None None O
62 None None O
] None None O
and None None O
the None None O
apolipoprotein None None O
regulating None None O
genes None None O
AI None None O
, None None O
AII None None O
, None None O
and None None O
CII None None O
[ None None O
63 None None O
] None None O
. None None O

The None None O
former None None O
mechanism None None O
appears None None O
to None None O
function None None O
in None None O
rodents None None O
, None None O
but None None O
not None None O
in None None O
humans None None O
, None None O
and None None O
is None None O
responsible None None O
for None None O
the None None O
induction None None O
of None None O
peroxisome None None O
proliferation None None O
and None None O
hepatocarcinogenesis None None O
, None None O
whereas None None O
the None None O
latter None None O
mechanism None None O
controls None None O
basic None None O
lipid None None O
metabolism None None O
in None None O
both None None O
rodents None None O
and None None O
humans None None O
[ None None O
56 None None O
] None None O
. None None O

This None None O
species None None O
difference None None O
in None None O
xenobiotic None None O
receptor None None O
/ None None O
ligand None None O
signaling None None O
may None None O
be None None O
attributable None None O
to None None O
differences None None O
in None None O
the None None O
expression None None O
level None None O
of None None O
a None None O
receptor None None O
, None None O
or None None O
to None None O
differences None None O
in None None O
receptor None None O
/ None None O
ligand None None O
binding None None O
affinity None None O
, None None O
and None None O
causes None None O
difficulty None None O
in None None O
determining None None O
responses None None O
in None None O
humans None None O
based None None O
on None None O
rodent None None O
data None None O
[ None None O
56 None None O
] None None O
. None None O

Comparison None None O
of None None O
image None None O
( None None O
CAS None None O
200 None None O
) None None O
and None None O
flow None None O
cytometry None None O
determined None None O
DNA None None O
content None None O
of None None O
paraffin None None O
- None None O
embedded None None O
Hodgkin None None O
' None None O
s None None O
disease None None O
tissue None None O
. None None O

To None None O
assess None None O
the None None O
reliability None None O
of None None O
DNA None None O
estimation None None O
using None None O
image None None O
cytometry None None O
, None None O
deparaffinized None None O
lymph None None O
nodes None None O
from None None O
70 None None O
patients None None O
with None None O
Hodgkin None None O
' None None O
s None None O
disease None None O
were None None O
examined None None O
and None None O
the None None O
results None None O
obtained None None O
were None None O
compared None None O
with None None O
those None None O
from None None O
flow None None O
cytometry None None O
. None None O

Image None None O
analysis None None O
without None None O
discriminating None None O
between None None O
the None None O
various None None O
cell None None O
types None None O
, None None O
as None None O
found None None O
in None None O
Hodgkin None None O
' None None O
s None None O
disease None None O
, None None O
revealed None None O
no None None O
separate None None O
aneuploid None None O
peak None None O
. None None O

Selecting None None O
on None None O
morphologically None None O
defined None None O
nuclear None None O
types None None O
DNA None None O
aneuploidy None None O
was None None O
detected None None O
in None None O
20 None None O
% None None O
of None None O
the None None O
cases None None O
( None None O
14 None None O
/ None None O
70 None None O
) None None O
. None None O

The None None O
aneuploid None None O
populations None None O
were None None O
limited None None O
to None None O
the None None O
population None None O
of None None O
nuclei None None O
defined None None O
as None None O
Reed None None O
- None None O
Sternberg None None O
( None None O
RS None None O
) None None O
- None None O
like None None O
or None None O
medium None None O
- None None O
sized None None O
lymphocytes None None O
. None None O

Benign None None O
lymph None None O
nodes None None O
DNA None None O
aneuploidy None None O
was None None O
not None None O
found None None O
in None None O
any None None O
of None None O
the None None O
controls None None O
. None None O

Comparison None None O
of None None O
DNA None None O
histograms None None O
obtained None None O
by None None O
image None None O
and None None O
flow None None O
cytometry None None O
showed None None O
aneuploid None None O
peaks None None O
using None None O
image None None O
cytometry None None O
in None None O
4 None None O
of None None O
30 None None O
diploid None None O
and None None O
10 None None O
of None None O
40 None None O
aneuploid None None O
flow None None O
histograms None None O
. None None O

In None None O
conclusion None None O
, None None O
image None None O
analysis None None O
using None None O
the None None O
CAS None None O
200 None None O
system None None O
as None None O
compared None None O
to None None O
flow None None O
cytometry None None O
is None None O
more None None O
time None None O
- None None O
consuming None None O
and None None O
less None None O
sensitive None None O
to None None O
assess None None O
ploidy None None O
status None None O
, None None O
although None None O
it None None O
may None None O
provide None None O
extra None None O
information None None O
in None None O
some None None O
selected None None O
cases None None O
. None None O

Evidence None None O
is None None O
obtained None None O
that None None O
DNA None None O
aneuploidy None None O
in None None O
Hodgkin None None O
' None None O
s None None O
disease None None O
is None None O
preferentially None None O
expressed None None O
by None None O
cells None None O
with None None O
the None None O
RS None None O
/ None None O
H None None O
- None None O
like None None O
and None None O
medium None None O
- None None O
sized None None O
lymphocyte None None O
morphology None None O
. None None O

Actin None None O
- None None O
sequestering None None O
protein None None O
, None None O
thymosin None None O
beta None None O
- None None O
4 None None O
, None None O
is None None O
a None None O
novel None None O
hypoxia None None O
responsive None None O
regulator None None O
. None None O

Angiogenesis None None O
is None None O
induced None None O
by None None O
soluble None None O
factors None None O
such None None O
as None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
released None None O
from None None O
tumor None None O
cells None None O
in None None O
hypoxia None None O
. None None O

It None None O
enhances None None O
solid None None O
tumor None None O
growth None None O
and None None O
provides None None O
an None None O
ability None None O
to None None O
establish None None O
metastasis None None O
at None None O
peripheral None None O
sites None None O
by None None O
tumor None None O
cell None None O
migration None None O
. None None O

Thymosin None None O
beta None None O
- None None O
4 None None O
( None None O
TB4 None None O
) None None O
is None None O
an None None O
actin None None O
- None None O
sequestering None None O
protein None None O
to None None O
control None None O
cytoskeletal None None O
reorganization None None O
. None None O

Here None None O
, None None O
we None None O
investigated None None O
whether None None O
angiogenesis None None O
and None None O
tumor None None O
metastasis None None O
are None None O
dependent None None O
on None None O
hypoxia None None O
conditioning None None O
- None None O
induced None None O
TB4 None None O
expression None None O
in None None O
B16F10 None None I-Cell-line-name
melanoma None None O
cells None None O
. None None O

TB4 None None O
expression None None O
in None None O
B16F10 None None I-Cell-line-name
cells None None O
was None None O
increased None None O
by None None O
hypoxia None None O
conditioning None None O
in None None O
a None None O
time None None O
- None None O
dependent None None O
manner None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
found None None O
an None None O
increase None None O
of None None O
angiogenesis None None O
and None None O
HIF None None O
- None None O
1alpha None None O
expression None None O
in None None O
TB4 None None O
- None None O
transgenic None None O
( None None O
Tg None None O
) None None O
mice None None O
as None None O
compared None None O
to None None O
wildtype None None O
mice None None O
. None None O

When None None O
wound None None O
healing None None O
assay None None O
was None None O
used None None O
to None None O
assess None None O
in None None O
vitro None None O
tumor None None O
cell None None O
migration None None O
, None None O
hypoxia None None O
conditioning None None O
for None None O
1 None None O
h None None O
enhanced None None O
B16F10 None None I-Cell-line-name
cell None None O
migration None None O
. None None O

When None None O
TB4 None None O
expression None None O
in None None O
B16F10 None None I-Cell-line-name
cells None None O
was None None O
inhibited None None O
by None None O
the None None O
infection None None O
with None None O
small None None O
hairpin None None O
( None None O
sh None None O
) None None O
RNA None None O
of None None O
TB4 None None O
cloned None None O
in None None O
lentiviral None None O
vector None None O
, None None O
tumor None None O
cell None None O
migration None None O
was None None O
retarded None None O
. None None O

In None None O
addition None None O
, None None O
hypoxia None None O
conditioning None None O
- None None O
induced None None O
tumor None None O
cell None None O
migration None None O
was None None O
reduced None None O
by None None O
the None None O
infection None None O
of None None O
lentiviral None None O
shRNA None None O
of None None O
TB4 None None O
. None None O

HIF None None O
- None None O
1alpha None None O
stabilization None None O
and None None O
the None None O
expression None None O
of None None O
VEGF None None O
isoform None None O
165 None None O
and None None O
121 None None O
in None None O
hypoxia None None O
were None None O
also None None O
reduced None None O
by None None O
the None None O
infection None None O
of None None O
lentiviral None None O
shRNA None None O
of None None O
TB4 None None O
in None None O
B16F10 None None I-Cell-line-name
cells None None O
. None None O

We None None O
also None None O
found None None O
an None None O
increase None None O
of None None O
tumor None None O
growth None None O
and None None O
lung None None O
metastasis None None O
count None None O
in None None O
TB4 None None O
- None None O
Tg None None O
mice None None O
as None None O
compared None None O
to None None O
wildtype None None O
mice None None O
. None None O

Collectively None None O
, None None O
hypoxia None None O
conditioning None None O
induced None None O
tumor None None O
cell None None O
migration None None O
by None None O
TB4 None None O
expression None None O
- None None O
dependent None None O
HIF None None O
- None None O
1alpha None None O
stabilization None None O
. None None O

It None None O
suggests None None O
that None None O
TB4 None None O
could None None O
be None None O
a None None O
hypoxia None None O
responsive None None O
regulator None None O
to None None O
control None None O
tumor None None O
cell None None O
migration None None O
in None None O
angiogenesis None None O
and None None O
tumor None None O
metastasis None None O
. None None O

The None None O
right None None O
eye None None O
of None None O
a None None O
50 None None O
- None None O
year None None O
- None None O
old None None O
patient None None O
with None None O
severe None None O
hypertension None None O
at None None O
the None None O
first None None O
visit None None O
. None None O

( None None O
a None None O
) None None O
Fundus None None O
photograph None None O
shows None None O
serous None None O
retinal None None O
detachment None None O
. None None O

The None None O
optic None None O
disc None None O
is None None O
pale None None O
at None None O
the None None O
temporal None None O
side None None O
. None None O

( None None O
b None None O
) None None O
Optical None None O
coherence None None O
tomography None None O
( None None O
OCT None None O
) None None O
shows None None O
retinal None None O
detachment None None O
involving None None O
the None None O
fovea None None O
and None None O
cystic None None O
change None None O
of None None O
inner None None O
retina None None O
. None None O

( None None O
c None None O
) None None O
Early None None O
phase None None O
images None None O
of None None O
fluorescein None None O
angiography None None O
( None None O
FA None None O
) None None O
( None None O
left None None O
) None None O
and None None O
indocyanine None None O
green None None O
angiography None None O
( None None O
IA None None O
) None None O
( None None O
right None None O
) None None O
. None None O

( None None O
d None None O
) None None O
Late None None O
phase None None O
images None None O
of None None O
FA None None O
( None None O
left None None O
) None None O
and None None O
IA None None O
( None None O
right None None O
) None None O
. None None O

FA None None O
shows None None O
window None None O
defect None None O
associated None None O
with None None O
macular None None O
cystic None None O
change None None O
. None None O

Note None None O
that None None O
no None None O
active None None O
leakage None None O
is None None O
observed None None O
in None None O
the None None O
area None None O
with None None O
serous None None O
retinal None None O
detachment None None O
or None None O
cystoid None None O
edema None None O
. None None O

IA None None O
shows None None O
decreased None None O
perfusion None None O
of None None O
the None None O
choroid None None O
at None None O
the None None O
macula None None O
and None None O
window None None O
defect None None O
with None None O
the None None O
damaged None None O
RPE None None O
. None None O

Hypofluorescence None None O
( None None O
arrow None None O
) None None O
along None None O
the None None O
retinal None None O
artery None None O
are None None O
observed None None O
. None None O

These None None O
are None None O
unique None None O
findings None None O
. None None O

Titration None None O
of None None O
Ab None None O
- None None O
01 None None O
inhibition None None O
of None None O
ex None None O
vivo None None O
response None None O
to None None O
rhIL21 None None O

Samples None None O
from None None O
4 None None O
individual None None O
healthy None None O
human None None O
donors None None O
were None None O
pre None None O
- None None O
incubated None None O
for None None O
2 None None O
hours None None O
at None None O
the None None O
indicated None None O
concentration None None O
of None None O
Ab None None O
- None None O
01 None None O
or None None O
the None None O
control None None O
IgG1TM None None O
prior None None O
to None None O
addition None None O
of None None O
10 None None O
ng None None O
/ None None O
mL None None O
rhIL21 None None O
and None None O
2 None None O
hr None None O
incubation None None O
, None None O
and None None O
the None None O
effect None None O
on None None O
the None None O
6 None None O
biomarkers None None O
was None None O
then None None O
assessed None None O
( None None O
Figures None None O
4 None None O
and None None O
5 None None O
) None None O
. None None O

For None None O
the None None O
first None None O
2 None None O
donors None None O
tested None None O
, None None O
even None None O
the None None O
lowest None None O
concentration None None O
of None None O
Ab None None O
- None None O
01 None None O
( None None O
0 None None O
. None None O
1 None None O
mug None None O
/ None None O
mL None None O
, None None O
0 None None O
. None None O
66 None None O
nM None None O
) None None O
resulted None None O
in None None O
complete None None O
inhibition None None O
of None None O
the None None O
rhIL21 None None O
response None None O
, None None O
therefore None None O
the None None O
two None None O
subsequent None None O
donors None None O
were None None O
tested None None O
at None None O
increasing None None O
concentrations None None O
of None None O
Ab None None O
- None None O
01 None None O
starting None None O
at None None O
0 None None O
. None None O
003 None None O
mug None None O
/ None None O
mL None None O
. None None O

Ab None None O
- None None O
01 None None O
inhibited None None O
the None None O
response None None O
of None None O
all None None O
6 None None O
genes None None O
in None None O
all None None O
4 None None O
donors None None O
. None None O

IC50 None None O
values None None O
ranged None None O
between None None O
0 None None O
. None None O
003 None None O
and None None O
0 None None O
. None None O
015 None None O
mug None None O
/ None None O
mL None None O
Ab None None O
- None None O
01 None None O
( None None O
Figure None None O
5 None None O
) None None O
. None None O

Control None None O
IgG1TM None None O
had None None O
no None None O
significant None None O
effect None None O
on None None O
rhIL21 None None O
response None None O
( None None O
Figure4B None None O
) None None O
. None None O

Figure None None O
4 None None O

Average None None O
percent None None O
inhibition None None O
of None None O
the None None O
expression None None O
level None None O
of None None O
6 None None O
IL21 None None O
- None None O
responsive None None O
genes None None O
. None None O

Percent None None O
inhibition None None O
values None None O
were None None O
calculated None None O
based None None O
on None None O
RQ None None O
( None None O
relative None None O
quantification None None O
) None None O
values None None O
of None None O
untreated None None O
control None None O
and None None O
rhIL21 None None O
- None None O
treated None None O
samples None None O
for None None O
each None None O
of None None O
the None None O
4 None None O
donors None None O
, None None O
and None None O
subsequently None None O
the None None O
mean None None O
and None None O
standard None None O
deviation None None O
were None None O
determined None None O
for None None O
each None None O
gene None None O
shown None None O
. None None O

A None None O
: None None O
Percent None None O
inhibition None None O
in None None O
presence None None O
of None None O
Ab None None O
- None None O
01 None None O
. None None O

B None None O
: None None O
Percent None None O
inhibition None None O
in None None O
presence None None O
of None None O
control None None O
IgG1TM None None O
. None None O

Data None None O
for None None O
the None None O
0 None None O
. None None O
1 None None O
mug None None O
/ None None O
mL None None O
, None None O
0 None None O
. None None O
3 None None O
mug None None O
/ None None O
mL None None O
and None None O
1 None None O
mug None None O
/ None None O
mL None None O
concentrations None None O
were None None O
generated None None O
using None None O
4 None None O
donors None None O
. None None O

Data None None O
for None None O
the None None O
higher None None O
and None None O
the None None O
lower None None O
concentrations None None O
were None None O
generated None None O
using None None O
2 None None O
donors None None O
. None None O

Figure None None O
5 None None O

Inhibition None None O
by None None O
Ab None None O
- None None O
01 None None O
at None None O
the None None O
indicated None None O
concentration None None O
is None None O
shown None None O
for None None O
6 None None O
IL21 None None O
- None None O
responsive None None O
genes None None O
. None None O

IC50 None None O
values None None O
of None None O
inhibition None None O
curves None None O
shown None None O
in None None O
Figure None None O
4A None None O
were None None O
calculated None None O
using None None O
curve None None O
fit None None O
( None None O
XLfit None None O
) None None O
program None None O
for None None O
each None None O
of None None O
the None None O
referred None None O
biomarker None None O
genes None None O
. None None O

Values None None O
for None None O
the None None O
0 None None O
. None None O
1 None None O
mug None None O
/ None None O
mL None None O
, None None O
0 None None O
. None None O
3 None None O
mug None None O
/ None None O
mL None None O
and None None O
1 None None O
mug None None O
/ None None O
mL None None O
concentrations None None O
were None None O
generated None None O
using None None O
4 None None O
donors None None O
. None None O

Data None None O
for None None O
the None None O
higher None None O
and None None O
the None None O
lower None None O
concentrations None None O
were None None O
generated None None O
using None None O
2 None None O
donors None None O
each None None O
. None None O

[ None None O
Decreased None None O
stimulation None None O
of None None O
glycosaminoglycan None None O
synthesis None None O
by None None O
human None None O
skin None None O
fibroblasts None None O
by None None O
interleukin None None O
6 None None O
within None None O
the None None O
scope None None O
of None None O
in None None O
vitro None None O
aging None None O
] None None O
. None None O

Addition None None O
of None None O
human None None O
recombinant None None O
interleukin None None O
6 None None O
( None None O
IL None None O
- None None O
6 None None O
) None None O
to None None O
culture None None O
medium None None O
( None None O
supplemented None None O
MEM None None O
without None None O
or None None O
with None None O
10 None None O
% None None O
fetal None None O
calf None None O
serum None None O
( None None O
FCS None None O
) None None O
) None None O
of None None O
human None None O
skin None None O
fibroblasts None None O
exerted None None O
a None None O
stimulating None None O
effect None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
on None None O
glycosaminoglycan None None O
( None None O
GAG None None O
) None None O
synthesis None None O
, None None O
including None None O
hyaluronic None None O
acid None None O
( None None O
hyaluronan None None O
) None None O
synthesis None None O
, None None O
of None None O
young None None O
( None None O
phase None None O
- None None O
II None None O
) None None O
skin None None O
fibroblasts None None O
in None None O
concentrations None None O
of None None O
1 None None O
ng None None O
/ None None O
ml None None O
and None None O
10 None None O
ng None None O
/ None None O
ml None None O
. None None O

Stimulation None None O
was None None O
mainly None None O
due None None O
to None None O
an None None O
increase None None O
in None None O
extracellular None None O
GAGs None None O
( None None O
secreted None None O
into None None O
culture None None O
medium None None O
) None None O
, None None O
and None None O
to None None O
a None None O
lesser None None O
extent None None O
to None None O
an None None O
increase None None O
in None None O
peri None None O
- None None O
and None None O
intracellular None None O
GAGs None None O
. None None O

Stimulation None None O
with None None O
1 None None O
ng None None O
/ None None O
ml None None O
and None None O
10 None None O
ng None None O
/ None None O
ml None None O
IL None None O
- None None O
6 None None O
led None None O
to None None O
an None None O
increase None None O
in None None O
hyaluronic None None O
acid None None O
from None None O
48 None None O
% None None O
to None None O
61 None None O
% None None O
( None None O
- None None O
FCS None None O
) None None O
and None None O
from None None O
77 None None O
% None None O
to None None O
90 None None O
% None None O
( None None O
+ None None O
10 None None O
% None None O
FCS None None O
) None None O
, None None O
respectively None None O
. None None O

Maximum None None O
stimulation None None O
, None None O
with None None O
and None None O
without None None O
FCS None None O
, None None O
was None None O
achieved None None O
by None None O
10 None None O
ng None None O
/ None None O
ml None None O
IL None None O
- None None O
6 None None O
. None None O

Compared None None O
to None None O
young None None O
( None None O
phase None None O
- None None O
II None None O
) None None O
cells None None O
, None None O
senescent None None O
( None None O
phase None None O
- None None O
III None None O
) None None O
cells None None O
, None None O
showed None None O
no None None O
significant None None O
stimulation None None O
of None None O
total None None O
GAG None None O
( None None O
including None None O
hyaluronic None None O
acid None None O
) None None O
synthesis None None O
by None None O
IL None None O
- None None O
6 None None O
. None None O

The None None O
diminished None None O
response None None O
of None None O
GAG None None O
- None None O
and None None O
hyaluronic None None O
acid None None O
synthesis None None O
during None None O
aging None None O
of None None O
these None None O
in None None O
vitro None None O
cultured None None O
fibroblasts None None O
should None None O
motivate None None O
further None None O
research None None O
if None None O
similar None None O
processes None None O
occur None None O
during None None O
aging None None O
in None None O
an None None O
organism None None O
. None None O

Defective None None O
biliary None None O
copper None None O
excretion None None O
in None None O
Wilson None None O
' None None O
s None None O
disease None None O
: None None O
the None None O
role None None O
of None None O
caeruloplasmin None None O
. None None O

Previous None None O
studies None None O
have None None O
failed None None O
to None None O
explain None None O
the None None O
link None None O
between None None O
copper None None O
accumulation None None O
and None None O
abnormal None None O
caeruloplasmin None None O
expression None None O
in None None O
Wilson None None O
' None None O
s None None O
disease None None O
. None None O

Furthermore None None O
, None None O
despite None None O
the None None O
isolation None None O
of None None O
a None None O
candidate None None O
gene None None O
for None None O
Wilson None None O
' None None O
s None None O
disease None None O
, None None O
which None None O
predicts None None O
a None None O
defective None None O
copper None None O
transport None None O
protein None None O
, None None O
the None None O
localization None None O
of None None O
this None None O
putative None None O
protein None None O
and None None O
its None None O
relationship None None O
to None None O
the None None O
pathway None None O
involved None None O
in None None O
copper None None O
excretion None None O
and None None O
to None None O
caeruloplasmin None None O
remain None None O
unknown None None O
. None None O

We None None O
now None None O
present None None O
evidence None None O
that None None O
caeruloplasmin None None O
, None None O
the None None O
major None None O
plasma None None O
copper None None O
- None None O
carrying None None O
protein None None O
, None None O
is None None O
present None None O
in None None O
the None None O
liver None None O
in None None O
Wilson None None O
' None None O
s None None O
disease None None O
, None None O
and None None O
thus None None O
that None None O
reduced None None O
circulating None None O
levels None None O
of None None O
the None None O
protein None None O
result None None O
from None None O
a None None O
post None None O
- None None O
translational None None O
defect None None O
in None None O
the None None O
secretory None None O
pathway None None O
. None None O

We None None O
have None None O
also None None O
identified None None O
a None None O
novel None None O
form None None O
of None None O
caeruloplasmin None None O
, None None O
molecular None None O
weight None None O
125 None None O
kD None None O
, None None O
which None None O
we None None O
propose None None O
may None None O
act None None O
as None None O
the None None O
carrier None None O
for None None O
excretory None None O
copper None None O
into None None O
bile None None O
, None None O
since None None O
it None None O
is None None O
normally None None O
present None None O
in None None O
both None None O
liver None None O
and None None O
bile None None O
, None None O
although None None O
largely None None O
absent None None O
from None None O
serum None None O
, None None O
and None None O
undetectable None None O
in None None O
bile None None O
from None None O
Wilson None None O
' None None O
s None None O
disease None None O
patients None None O
. None None O

The None None O
presence None None O
of None None O
this None None O
form None None O
of None None O
caeruloplasmin None None O
in None None O
Wilson None None O
' None None O
s None None O
disease None None O
liver None None O
suggests None None O
that None None O
a None None O
related None None O
post None None O
- None None O
translational None None O
defect None None O
may None None O
also None None O
be None None O
responsible None None O
for None None O
its None None O
absence None None O
from None None O
bile None None O
in None None O
Wilson None None O
' None None O
s None None O
disease None None O
. None None O

This None None O
study None None O
thus None None O
provides None None O
the None None O
first None None O
plausible None None O
explanation None None O
of None None O
a None None O
link None None O
between None None O
the None None O
defective None None O
copper None None O
excretion None None O
and None None O
the None None O
reduced None None O
plasma None None O
caeruloplasmin None None O
, None None O
which None None O
characterize None None O
Wilson None None O
' None None O
s None None O
disease None None O
. None None O

Cone None None O
beam None None O
geometry None None O

A None None O
pancreatic None None O
beta None None O
- None None O
cell None None O
- None None O
specific None None O
enhancer None None O
in None None O
the None None O
human None None O
PDX None None O
- None None O
1 None None O
gene None None O
is None None O
regulated None None O
by None None O
hepatocyte None None O
nuclear None None O
factor None None O
3beta None None O
( None None O
HNF None None O
- None None O
3beta None None O
) None None O
, None None O
HNF None None O
- None None O
1alpha None None O
, None None O
and None None O
SPs None None O
transcription None None O
factors None None O
. None None O

The None None O
PDX None None O
- None None O
1 None None O
transcription None None O
factor None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
pancreas None None O
development None None O
. None None O

Although None None O
expressed None None O
in None None O
all None None O
cells None None O
at None None O
the None None O
early None None O
stages None None O
, None None O
in None None O
the None None O
adult None None O
it None None O
is None None O
mainly None None O
restricted None None O
to None None O
the None None O
beta None None O
- None None O
cell None None O
. None None O

To None None O
characterize None None O
the None None O
regulatory None None O
elements None None O
and None None O
potential None None O
transcription None None O
factors None None O
necessary None None O
for None None O
human None None O
PDX None None O
- None None O
1 None None O
gene None None O
expression None None O
in None None O
beta None None O
- None None O
cells None None O
, None None O
we None None O
constructed None None O
a None None O
series None None O
of None None O
5 None None O
' None None O
and None None O
3 None None O
' None None O
deletion None None O
fragments None None O
of None None O
the None None O
5 None None O
' None None O
- None None O
flanking None None O
region None None O
of None None O
the None None O
gene None None O
, None None O
fused None None O
to None None O
the None None O
luciferase None None O
reporter None None O
gene None None O
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
identify None None O
by None None O
transient None None O
transfections None None O
in None None O
beta None None O
- None None O
and None None O
non None None O
- None None O
beta None None O
- None None O
cells None None O
a None None O
novel None None O
beta None None O
- None None O
cell None None O
- None None O
specific None None O
distal None None O
enhancer None None O
element None None O
located None None O
between None None O
- None None O
3 None None O
. None None O
7 None None O
and None None O
- None None O
3 None None O
. None None O
45 None None O
kilobases None None O
. None None O

DNase None None O
I None None O
footprinting None None O
analysis None None O
revealed None None O
two None None O
protected None None O
regions None None O
, None None O
one None None O
binding None None O
the None None O
transcription None None O
factors None None O
SP1 None None O
and None None O
SP3 None None O
and None None O
the None None O
other None None O
hepatocyte None None O
nuclear None None O
factor None None O
3beta None None O
( None None O
HNF None None O
- None None O
3beta None None O
) None None O
and None None O
HNF None None O
- None None O
1alpha None None O
. None None O

Cotransfection None None O
experiments None None O
suggest None None O
that None None O
HNF None None O
- None None O
3beta None None O
, None None O
HNF None None O
- None None O
1alpha None None O
, None None O
and None None O
SP1 None None O
are None None O
positive None None O
regulators None None O
of None None O
the None None O
herein None None O
- None None O
described None None O
human None None O
PDX None None O
- None None O
1 None None O
enhancer None None O
element None None O
. None None O

Furthermore None None O
, None None O
mutations None None O
within None None O
each None None O
motif None None O
abolished None None O
the None None O
binding None None O
of None None O
the None None O
corresponding None None O
factor None None O
( None None O
s None None O
) None None O
and None None O
dramatically None None O
impaired None None O
the None None O
enhancer None None O
activity None None O
, None None O
therefore None None O
suggesting None None O
cooperativity None None O
between None None O
these None None O
factors None None O
. None None O

Genetic None None O
differences None None O
in None None O
susceptibility None None O
to None None O
ulcerative None None O
enteritis None None O
in None None O
Japanese None None O
quail None None O
. None None O

Six None None O
lines None None O
of None None O
Japanese None None O
quail None None O
were None None O
derived None None O
from None None O
a None None O
single None None O
foundation None None O
population None None O
. None None O

Four None None O
of None None O
the None None O
lines None None O
were None None O
selected None None O
on None None O
the None None O
basis None None O
of None None O
family None None O
mean None None O
three None None O
week None None O
body None None O
weight None None O
, None None O
two None None O
were None None O
unselected None None O
and None None O
all None None O
lines None None O
were None None O
randomly None None O
mated None None O
. None None O

Quail None None O
were None None O
housed None None O
in None None O
wire None None O
batteries None None O
during None None O
the None None O
brooding None None O
, None None O
rearing None None O
and None None O
laying None None O
periods None None O
. None None O

During None None O
the None None O
brooding None None O
period None None O
, None None O
hover None None O
temperature None None O
and None None O
floor None None O
space None None O
per None None O
chick None None O
were None None O
similar None None O
from None None O
line None None O
to None None O
line None None O
. None None O

For None None O
the None None O
rearing None None O
and None None O
laying None None O
periods None None O
, None None O
floor None None O
space None None O
per None None O
chick None None O
was None None O
approximately None None O
the None None O
same None None O
from None None O
line None None O
to None None O
line None None O
. None None O

During None None O
an None None O
outbreak None None O
of None None O
ulcerative None None O
enteritis None None O
( None None O
diagnosed None None O
on None None O
the None None O
basis None None O
of None None O
gross None None O
and None None O
histopathology None None O
) None None O
in None None O
generation None None O
31 None None O
and None None O
again None None O
in None None O
generation None None O
34 None None O
, None None O
mortality None None O
ranged None None O
from None None O
zero None None O
for None None O
males None None O
of None None O
one None None O
control None None O
line None None O
to None None O
approximately None None O
50 None None O
percent None None O
for None None O
females None None O
of None None O
one None None O
selected None None O
line None None O
. None None O

Analysis None None O
of None None O
variance None None O
showed None None O
that None None O
incidence None None O
of None None O
mortality None None O
differed None None O
significantly None None O
among None None O
lines None None O
and None None O
between None None O
sexes None None O
. None None O

Mortality None None O
was None None O
generally None None O
higher None None O
in None None O
selected None None O
than None None O
in None None O
control None None O
lines None None O
and None None O
in None None O
females None None O
than None None O
in None None O
males None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
susceptibility None None O
to None None O
ulcerative None None O
enteritis None None O
in None None O
quail None None O
may None None O
be None None O
a None None O
polygenically None None O
inherited None None O
trait None None O
and None None O
that None None O
the None None O
breeding None None O
which None None O
accompanied None None O
selection None None O
for None None O
body None None O
size None None O
may None None O
have None None O
made None None O
some None None O
loci None None O
homozygous None None O
for None None O
susceptibility None None O
alleles None None O
. None None O

Hedgehog None None O
signaling None None O
: None None O
networking None None O
to None None O
nurture None None O
a None None O
promalignant None None O
tumor None None O
microenvironment None None O
. None None O

In None None O
addition None None O
to None None O
its None None O
role None None O
in None None O
embryonic None None O
development None None O
, None None O
the None None O
Hedgehog None None O
pathway None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
an None None O
active None None O
participant None None O
in None None O
cancer None None O
development None None O
, None None O
progression None None O
, None None O
and None None O
metastasis None None O
. None None O

Although None None O
this None None O
pathway None None O
is None None O
activated None None O
by None None O
autocrine None None O
signaling None None O
by None None O
Hedgehog None None O
ligands None None O
, None None O
it None None O
can None None O
also None None O
initiate None None O
paracrine None None O
signaling None None O
with None None O
cells None None O
in None None O
the None None O
microenvironment None None O
. None None O

This None None O
creates None None O
a None None O
network None None O
of None None O
Hedgehog None None O
signaling None None O
that None None O
determines None None O
the None None O
malignant None None O
behavior None None O
of None None O
the None None O
tumor None None O
cells None None O
. None None O

As None None O
a None None O
result None None O
of None None O
paracrine None None O
signal None None O
transmission None None O
, None None O
the None None O
effects None None O
of None None O
Hedgehog None None O
signaling None None O
most None None O
profoundly None None O
influence None None O
the None None O
stromal None None O
cells None None O
that None None O
constitute None None O
the None None O
tumor None None O
microenvironment None None O
. None None O

The None None O
stromal None None O
cells None None O
in None None O
turn None None O
produce None None O
factors None None O
that None None O
nurture None None O
the None None O
tumor None None O
. None None O

Thus None None O
, None None O
such None None O
a None None O
resonating None None O
cross None None O
- None None O
talk None None O
can None None O
amplify None None O
Hedgehog None None O
signaling None None O
, None None O
resulting None None O
in None None O
molecular None None O
chatter None None O
that None None O
overall None None O
promotes None None O
tumor None None O
progression None None O
. None None O

Inhibitors None None O
of None None O
Hedgehog None None O
signaling None None O
have None None O
been None None O
the None None O
subject None None O
of None None O
intense None None O
research None None O
. None None O

Several None None O
of None None O
these None None O
inhibitors None None O
are None None O
currently None None O
being None None O
evaluated None None O
in None None O
clinical None None O
trials None None O
. None None O

Here None None O
, None None O
we None None O
review None None O
the None None O
role None None O
of None None O
the None None O
Hedgehog None None O
pathway None None O
in None None O
the None None O
signature None None O
characteristics None None O
of None None O
cancer None None O
cells None None O
that None None O
determine None None O
tumor None None O
development None None O
, None None O
progression None None O
, None None O
and None None O
metastasis None None O
. None None O

This None None O
review None None O
condenses None None O
the None None O
latest None None O
findings None None O
on None None O
the None None O
signaling None None O
pathways None None O
that None None O
are None None O
activated None None O
and None None O
/ None None O
or None None O
regulated None None O
by None None O
molecules None None O
generated None None O
from None None O
Hedgehog None None O
signaling None None O
in None None O
cancer None None O
and None None O
cites None None O
promising None None O
clinical None None O
interventions None None O
. None None O

Finally None None O
, None None O
we None None O
discuss None None O
future None None O
directions None None O
for None None O
identifying None None O
the None None O
appropriate None None O
patients None None O
for None None O
therapy None None O
, None None O
developing None None O
reliable None None O
markers None None O
of None None O
efficacy None None O
of None None O
treatment None None O
, None None O
and None None O
combating None None O
resistance None None O
to None None O
Hedgehog None None O
pathway None None O
inhibitors None None O
. None None O

Results None None O

Contrary None None O
to None None O
previous None None O
reports None None O
that None None O
PON1 None None O
activities None None O
plateau None None O
by None None O
2 None None O
years None None O
of None None O
age None None O
, None None O
we None None O
observed None None O
an None None O
age None None O
- None None O
dependent None None O
increase None None O
in None None O
all None None O
three None None O
PON1 None None O
measures None None O
from None None O
birth None None O
through None None O
7 None None O
years None None O
of None None O
age None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

The None None O
PON1192 None None O
genotype None None O
significantly None None O
modified None None O
the None None O
effect None None O
of None None O
age None None O
on None None O
paraoxonase None None O
( None None O
POase None None O
) None None O
activity None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
such None None O
that None None O
increases None None O
in None None O
enzyme None None O
activity None None O
with None None O
age None None O
were None None O
influenced None None O
by None None O
the None None O
number None None O
of None None O
R None None O
alleles None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
. None None O

Children None None O
with None None O
the None None O
PON1 None None O
- None None O
108CC192RR None None O
diplotype None None O
had None None O
significantly None None O
higher None None O
mean None None O
PON1 None None O
activities None None O
and None None O
also None None O
experienced None None O
steeper None None O
increases None None O
of None None O
POase None None O
activity None None O
over None None O
time None None O
compared None None O
with None None O
children None None O
with None None O
the None None O
PON1 None None O
- None None O
108TT192QQ None None O
diplotype None None O
. None None O

Bovine None None O
papillomavirus None None O
E7 None None O
transformation None None O
function None None O
correlates None None O
with None None O
cellular None None O
p600 None None O
protein None None O
binding None None O
. None None O

The None None O
E7 None None O
oncoprotein None None O
of None None O
bovine None None O
papillomavirus None None O
type None None O
1 None None O
( None None O
BPV None None O
- None None O
1 None None O
) None None O
is None None O
required None None O
for None None O
the None None O
full None None O
transformation None None O
activity None None O
of None None O
the None None O
virus None None O
. None None O

However None None O
, None None O
the None None O
mechanism None None O
by None None O
which None None O
E7 None None O
contributes None None O
to None None O
cellular None None O
transformation None None O
is None None O
unknown None None O
. None None O

To None None O
address None None O
this None None O
question None None O
, None None O
we None None O
used None None O
the None None O
proteomic None None O
approach None None O
of None None O
tandem None None O
affinity None None O
purification None None O
to None None O
identify None None O
cellular None None O
proteins None None O
that None None O
are None None O
in None None O
complex None None O
with None None O
E7 None None O
, None None O
and None None O
identified None None O
the None None O
600 None None O
- None None O
kDa None None O
protein None None O
, None None O
p600 None None O
, None None O
as None None O
a None None O
binding None None O
partner None None O
of None None O
E7 None None O
. None None O

The None None O
ability None None O
of None None O
E7 None None O
to None None O
complex None None O
with None None O
p600 None None O
correlated None None O
with None None O
its None None O
ability None None O
to None None O
enhance None None O
anchorage None None O
independence None None O
of None None O
BPV None None O
- None None O
1 None None O
E6 None None O
- None None O
expressing None None O
cells None None O
. None None O

Furthermore None None O
, None None O
E7 None None O
mutant None None O
proteins None None O
impaired None None O
in None None O
their None None O
ability None None O
to None None O
bind None None O
p600 None None O
were None None O
transformation None None O
defective None None O
. None None O

Additionally None None O
, None None O
knockdown None None O
of None None O
p600 None None O
reduced None None O
transformation None None O
of None None O
cells None None O
expressing None None O
both None None O
BPV None None O
- None None O
1 None None O
E6 None None O
and None None O
E7 None None O
, None None O
as None None O
well None None O
as None None O
E6 None None O
alone None None O
, None None O
suggesting None None O
that None None O
the None None O
ability None None O
of None None O
E7 None None O
to None None O
transformed None None O
cells None None O
is None None O
mediated None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
through None None O
its None None O
ability None None O
to None None O
bind None None O
p600 None None O
. None None O

These None None O
data None None O
complement None None O
work None None O
that None None O
shows None None O
that None None O
HPV16 None None O
E7 None None O
also None None O
interacts None None O
with None None O
p600 None None O
, None None O
and None None O
that None None O
this None None O
interaction None None O
correlates None None O
with None None O
the None None O
ability None None O
of None None O
HPV16 None None O
E7 None None O
to None None O
transform None None O
cells None None O
. None None O

These None None O
studies None None O
thus None None O
identify None None O
p600 None None O
as None None O
a None None O
shared None None O
target None None O
of None None O
the None None O
E7 None None O
proteins None None O
of None None O
multiple None None O
papillomaviruses None None O
. None None O

Images None None O

FIGURE None None O
2 None None O
. None None O

Detection None None O
of None None O
lymphovascular None None O
invasion None None O
in None None O
early None None O
breast None None O
cancer None None O
by None None O
D2 None None O
- None None O
40 None None O
( None None O
podoplanin None None O
) None None O
: None None O
a None None O
clinically None None O
useful None None O
predictor None None O
for None None O
axillary None None O
lymph None None O
node None None O
metastases None None O
. None None O

PURPOSE None None O
: None None O
The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
use None None O
of None None O
D2 None None O
- None None O
40 None None O
for None None O
the None None O
detection None None O
of None None O
lymphovascular None None O
invasion None None O
( None None O
LVI None None O
) None None O
in None None O
node None None O
positive None None O
and None None O
negative None None O
early None None O
breast None None O
cancer None None O
. None None O

LVI None None O
is None None O
associated None None O
with None None O
axillary None None O
lymph None None O
node None None O
metastases None None O
( None None O
ALNM None None O
) None None O
and None None O
a None None O
long None None O
- None None O
term None None O
prognostic None None O
factor None None O
. None None O

A None None O
precise None None O
identification None None O
of None None O
LVI None None O
would None None O
have None None O
a None None O
strong None None O
clinical None None O
impact None None O
for None None O
breast None None O
cancer None None O
patients None None O
. None None O

METHODS None None O
: None None O
Immunohistochemical None None O
staining None None O
with None None O
D2 None None O
- None None O
40 None None O
and None None O
CD34 None None O
was None None O
performed None None O
on None None O
formalin None None O
- None None O
fixed None None O
, None None O
paraffin None None O
- None None O
embedded None None O
tissue None None O
sections None None O
of None None O
254 None None O
invasive None None O
breast None None O
tumors None None O
of None None O
247 None None O
patients None None O
with None None O
node None None O
negative None None O
and None None O
node None None O
positive None None O
early None None O
breast None None O
cancer None None O
. None None O

All None None O
slides None None O
were None None O
screened None None O
for None None O
the None None O
presence None None O
of None None O
LVI None None O
. None None O

Correlation None None O
with None None O
clinico None None O
- None None O
pathological None None O
factors None None O
including None None O
LVI None None O
as None None O
retrieved None None O
by None None O
routine None None O
haematoxylin None None O
and None None O
eosin None None O
( None None O
H None None O
. None None O
E None None O
. None None O
) None None O
stained None None O
sections None None O
and None None O
the None None O
eligibility None None O
for None None O
the None None O
prediction None None O
of None None O
ALNM None None O
was None None O
assessed None None O
. None None O

RESULTS None None O
: None None O
Using None None O
the None None O
D2 None None O
- None None O
40 None None O
antibody None None O
for None None O
immunostaining None None O
, None None O
our None None O
results None None O
demonstrate None None O
a None None O
significant None None O
higher None None O
detection None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
of None None O
LVI None None O
as None None O
compared None None O
with None None O
routine None None O
H None None O
. None None O
E None None O
. None None O
- None None O
staining None None O
in None None O
early None None O
breast None None O
cancer None None O
. None None O

LVI None None O
was None None O
correctly None None O
identified None None O
by None None O
D2 None None O
- None None O
40 None None O
( None None O
D2 None None O
- None None O
40 None None O
+ None None O
) None None O
in None None O
70 None None O
out None None O
of None None O
254 None None O
tumors None None O
( None None O
28 None None O
% None None O
) None None O
as None None O
compared None None O
to None None O
40 None None O
tumors None None O
( None None O
16 None None O
% None None O
) None None O
by None None O
routine None None O
HE None None O
staining None None O
( None None O
HE None None O
+ None None O
) None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
between None None O
D2 None None O
- None None O
40 None None O
+ None None O
LVI None None O
and None None O
age None None O
, None None O
t None None O
- None None O
stage None None O
, None None O
nodal None None O
status None None O
, None None O
grading None None O
and None None O
hormonreceptor None None O
- None None O
status None None O
. None None O

Correlation None None O
between None None O
D2 None None O
- None None O
40 None None O
+ None None O
LVI None None O
and None None O
menopausal None None O
- None None O
status None None O
, None None O
HER2 None None O
- None None O
status None None O
and None None O
histological None None O
type None None O
was None None O
not None None O
significant None None O
, None None O
while None None O
there None None O
was None None O
a None None O
significant None None O
correlation None None O
of None None O
D2 None None O
- None None O
40 None None O
and None None O
so None None O
called None None O
" None None O
triple None None O
negative None None O
" None None O
tumors None None O
( None None O
ER None None O
/ None None O
PR None None O
and None None O
HER2neu None None O
- None None O
negative None None O
) None None O
. None None O

In None None O
a None None O
multivariate None None O
analysis None None O
D2 None None O
- None None O
40 None None O
+ None None O
was None None O
the None None O
strongest None None O
predictor None None O
for None None O
ALNM None None O
with None None O
an None None O
odds None None O
ratio None None O
of None None O
3 None None O
. None None O
489 None None O
and None None O
a None None O
P None None O
- None None O
value None None O
of None None O
P None None O
= None None O
0 None None O
. None None O
0003 None None O
, None None O
followed None None O
only None None O
by None None O
T None None O
- None None O
stage None None O
and None None O
grading None None O
with None None O
odds None None O
ratios None None O
of None None O
3 None None O
. None None O
167 None None O
and None None O
1 None None O
. None None O
953 None None O
and None None O
P None None O
- None None O
values None None O
P None None O
= None None O
0 None None O
. None None O
0003 None None O
and None None O
P None None O
= None None O
0 None None O
. None None O
0352 None None O
. None None O

CONCLUSION None None O
: None None O
Immunostaining None None O
with None None O
D2 None None O
- None None O
40 None None O
significantly None None O
increased None None O
the None None O
frequency None None O
of None None O
detection None None O
of None None O
lymphatic None None O
invasion None None O
compared None None O
to None None O
conventional None None O
H None None O
. None None O
E None None O
. None None O
- None None O
staining None None O
in None None O
early None None O
breast None None O
cancer None None O
. None None O

As None None O
LVI None None O
is None None O
a None None O
strong None None O
predictive None None O
and None None O
prognostic None None O
marker None None O
, None None O
the None None O
monoclonal None None O
antibody None None O
D2 None None O
- None None O
40 None None O
has None None O
the None None O
potential None None O
to None None O
play None None O
a None None O
significant None None O
role None None O
in None None O
pathological None None O
routine None None O
workup None None O
of None None O
breast None None O
tumors None None O
. None None O

Further None None O
prospective None None O
studies None None O
are None None O
needed None None O
to None None O
prove None None O
the None None O
clinical None None O
impact None None O
of None None O
D2 None None O
- None None O
40 None None O
. None None O

Detection None None O
of None None O
total None None O
assist None None O
and None None O
sucking None None O
points None None O
based None None O
on None None O
the None None O
pulsatility None None O
of None None O
a None None O
continuous None None O
flow None None O
artificial None None O
heart None None O
: None None O
in None None O
vivo None None O
evaluation None None O
. None None O

Our None None O
novel None None O
control None None O
strategy None None O
for None None O
a None None O
continuous None None O
flow None None O
artificial None None O
heart None None O
by None None O
detecting None None O
the None None O
total None None O
assist None None O
and None None O
sucking None None O
points None None O
based None None O
on None None O
pump None None O
pulsatility None None O
was None None O
evaluated None None O
in None None O
acute None None O
animal None None O
experiments None None O
using None None O
beagle None None O
dogs None None O
and None None O
our None None O
mixed None None O
flow None None O
pump None None O
. None None O

The None None O
pump None None O
was None None O
installed None None O
as None None O
a None None O
left None None O
ventricular None None O
( None None O
LV None None O
) None None O
bypass None None O
through None None O
a None None O
left None None O
thoracotomy None None O
. None None O

To None None O
change None None O
LV None None O
contractility None None O
, None None O
the None None O
left None None O
coronary None None O
arteries None None O
were None None O
occluded None None O
for None None O
30 None None O
min None None O
, None None O
followed None None O
by None None O
a None None O
120 None None O
min None None O
reperfusion None None O
. None None O

To None None O
change None None O
LV None None O
end None None O
diastolic None None O
pressure None None O
( None None O
LVEDP None None O
) None None O
, None None O
dextran None None O
solution None None O
was None None O
rapidly None None O
infused None None O
. None None O

To None None O
estimate None None O
the None None O
pump None None O
pulsatility None None O
without None None O
any None None O
specific None None O
sensor None None O
, None None O
we None None O
calculated None None O
the None None O
index None None O
of None None O
current None None O
amplitude None None O
( None None O
ICA None None O
) None None O
, None None O
which None None O
was None None O
obtained None None O
from None None O
the None None O
amplitude None None O
of None None O
the None None O
motor None None O
current None None O
waveform None None O
divided None None O
by None None O
the None None O
simultaneous None None O
mean None None O
value None None O
. None None O

To None None O
investigate None None O
the None None O
basic None None O
characteristics None None O
of None None O
the None None O
ICA None None O
, None None O
the None None O
pump None None O
speed None None O
was None None O
changed None None O
temporarily None None O
from None None O
2 None None O
, None None O
300 None None O
rpm None None O
to None None O
5 None None O
, None None O
000 None None O
rpm None None O
. None None O

In None None O
92 None None O
% None None O
of None None O
all None None O
measurements None None O
, None None O
the None None O
ICA None None O
plotted None None O
against None None O
the None None O
pump None None O
speed None None O
had None None O
a None None O
peak None None O
point None None O
( None None O
t None None O
- None None O
point None None O
) None None O
that None None O
corresponded None None O
highly None None O
with None None O
the None None O
turning None None O
point None None O
from None None O
partial None None O
to None None O
total None None O
assistance None None O
. None None O

The None None O
ICA None None O
also None None O
had None None O
a None None O
trough None None O
( None None O
s None None O
- None None O
point None None O
) None None O
that None None O
corresponded None None O
with None None O
the None None O
beginning None None O
of None None O
severe None None O
sucking None None O
in None None O
most None None O
cases None None O
. None None O

Only None None O
preload None None O
significantly None None O
influenced None None O
pump None None O
flow None None O
rate None None O
at None None O
the None None O
t None None O
- None None O
point None None O
from None None O
among None None O
preload None None O
( None None O
LVEDP None None O
) None None O
, None None O
afterload None None O
( None None O
SAoP None None O
) None None O
, None None O
and None None O
contractility None None O
( None None O
max None None O
LV None None O
dP None None O
/ None None O
dt None None O
) None None O
, None None O
by None None O
which None None O
we None None O
can None None O
simulate None None O
Starling None None O
' None None O
s None None O
law None None O
of None None O
the None None O
natural None None O
heart None None O
. None None O

We None None O
concluded None None O
that None None O
a None None O
continuous None None O
flow None None O
artificial None None O
heart None None O
could None None O
be None None O
well None None O
controlled None None O
by None None O
detecting None None O
the None None O
t None None O
- None None O
point None None O
and None None O
s None None O
- None None O
point None None O
. None None O

[ None None O
Effects None None O
of None None O
carcinostatic None None O
agents None None O
in None None O
the None None O
hematogenous None None O
metastasis None None O
of None None O
cancer None None O
] None None O
. None None O

The None None O
experimental None None O
studies None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
were None None O
performed None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
carcinostatic None None O
agents None None O
in None None O
the None None O
adhesion None None O
of None None O
cancer None None O
cells None None O
to None None O
endothelial None None O
cells None None O
. None None O

Certain None None O
carcinostatic None None O
agents None None O
induce None None O
the None None O
expression None None O
of None None O
E None None O
- None None O
selectin None None O
on None None O
endothelial None None O
cells None None O
and None None O
enhance None None O
the None None O
expression None None O
of None None O
carbohydrate None None O
ligands None None O
on None None O
cancer None None O
cells None None O
. None None O

Consequently None None O
, None None O
increased None None O
adhesion None None O
of None None O
cancer None None O
cells None None O
to None None O
endothelial None None O
cells None None O
was None None O
observed None None O
by None None O
the None None O
treatment None None O
of None None O
carcinostatic None None O
agents None None O
. None None O

In None None O
the None None O
trans None None O
- None None O
splenic None None O
hepatic None None O
metastasis None None O
model None None O
using None None O
nude None None O
mice None None O
, None None O
the None None O
augmentation None None O
of None None O
cancer None None O
metastasis None None O
was None None O
observed None None O
by None None O
the None None O
treatment None None O
of None None O
carcinostatic None None O
agents None None O
. None None O

From None None O
the None None O
above None None O
, None None O
we None None O
concluded None None O
that None None O
carcinostatic None None O
agents None None O
may None None O
increase None None O
the None None O
metastatic None None O
ability None None O
of None None O
cancer None None O
cells None None O
in None None O
patients None None O
with None None O
cancer None None O
. None None O

Background None None O

Over None None O
the None None O
past None None O
decades None None O
, None None O
extensive None None O
comparative None None O
mapping None None O
research None None O
has None None O
been None None O
performed None None O
in None None O
the None None O
plant None None O
family None None O
Solanaceae None None O
. None None O

The None None O
recent None None O
identification None None O
of None None O
a None None O
large None None O
set None None O
of None None O
single None None O
- None None O
copy None None O
conserved None None O
orthologous None None O
( None None O
COSII None None O
) None None O
markers None None O
has None None O
greatly None None O
accelerated None None O
comparative None None O
mapping None None O
studies None None O
among None None O
major None None O
solanaceous None None O
species None None O
including None None O
tomato None None O
, None None O
potato None None O
, None None O
eggplant None None O
, None None O
pepper None None O
and None None O
diploid None None O
Nicotiana None None O
species None None O
( None None O
as None None O
well None None O
as None None O
tetraploid None None O
tobacco None None O
) None None O
. None None O

The None None O
large None None O
amount None None O
of None None O
comparative None None O
data None None O
now None None O
available None None O
for None None O
these None None O
species None None O
provides None None O
the None None O
opportunity None None O
to None None O
describe None None O
the None None O
overall None None O
patterns None None O
of None None O
chromosomal None None O
evolution None None O
in None None O
this None None O
important None None O
plant None None O
family None None O
. None None O

The None None O
results None None O
of None None O
this None None O
investigation None None O
are None None O
described None None O
herein None None O
. None None O

Protection None None O
from None None O
experimental None None O
ocular None None O
herpetic None None O
keratitis None None O
by None None O
a None None O
heat None None O
- None None O
killed None None O
virus None None O
vaccine None None O
. None None O

New None None O
Zealand None None O
white None None O
rabbits None None O
were None None O
given None None O
limbal None None O
inoculations None None O
of None None O
a None None O
heat None None O
- None None O
killed None None O
suspension None None O
of None None O
herpes None None O
simplex None None O
virus None None O
( None None O
HSV None None O
) None None O
in None None O
a None None O
lysate None None O
of None None O
human None None O
embryonic None None O
kidney None None O
cells None None O
. None None O

At None None O
intervals None None O
of None None O
four None None O
to None None O
14 None None O
days None None O
, None None O
the None None O
animals None None O
were None None O
challenged None None O
by None None O
intrastromal None None O
inoculation None None O
with None None O
10 None None O
, None None O
000 None None O
plaque None None O
- None None O
forming None None O
units None None O
of None None O
viable None None O
HSV None None O
. None None O

Epithelial None None O
keratitis None None O
, None None O
disciform None None O
edema None None O
, None None O
and None None O
necrotizing None None O
keratitis None None O
with None None O
neovascularization None None O
of None None O
the None None O
cornea None None O
developed None None O
in None None O
control None None O
animals None None O
. None None O

Epithelial None None O
keratitis None None O
and None None O
corneal None None O
edema None None O
also None None O
developed None None O
in None None O
the None None O
immunized None None O
animals None None O
during None None O
the None None O
first None None O
week None None O
after None None O
virus None None O
challenge None None O
, None None O
but None None O
these None None O
symptoms None None O
rapidly None None O
resolved None None O
during None None O
the None None O
following None None O
weeks None None O
. None None O

The None None O
absence None None O
of None None O
iritis None None O
, None None O
neovascularization None None O
, None None O
and None None O
necrotizing None None O
keratitis None None O
in None None O
the None None O
corneas None None O
of None None O
the None None O
immunized None None O
animals None None O
was None None O
particularly None None O
striking None None O
. None None O
